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S Y N O P S I S
3
Gas chromatography/mass spectrometry profiling methods 
for the identification and accurate quantitation of organic 
acid metabolites in urine, amniotic fluid and serum have 
been developed. These methods allow quantitation of organic 
acids in body fluid samples with a lower limit of detection of 
0.3 yg/ml and a precision of 0.1 yg/ml, with less than 4% 
variation between duplicate samples. An isotope dilution 
method was developed to validate the profiling method for 
methylmalonic acid.
The methods were applied to prenatal diagnosis of genetic 
diseases. Three pregnancies at risk for methylmalonic acidemia 
were monitored. In all three the normal amniotic fluid levels 
of MMA allowed prediction of normal foetuses, a result confirmed 
by enzyme measurements on cell cultures and by perinatal studies 
of the infants. Results obtained during one pregnancy showed 
raised levels of maternal MMA excretion which are at variance 
with literature reports that the genotype of the foetus rather 
than the mother determines maternal MMA excretion during preg­
nancy.
In a pregnancy at risk for glutaric aciduria, amniotic 
fluid studies showed an increase in glutaric acid concentrat­
ion of fifteen times normal at fifteen weeks gestation . As a 
result an affected foetus was predicted and the prediction was 
confirmed by enzyme studies on cultured cells. At termination 
the AF glutaric acid level had risen to forty times normal.
These results suggest that the quantitation of relevant met­
abolites in amniotic fluids in appropriate cases is a reliable 
method of prenatal diagnosis, in those pregnancies where the 
foetus is at risk for an organic acidemia.
Gas chromatographic/mass spectrometric profiling and 
quantitation of metabolites has also been applied to the peri­
natal diagnosis of genetic diseases. Urines of three children 
who presented with an episode of a disease resembling Reye's 
syndrome were found to contain large quantities of the di-
k
carboxylic acids, adipic and suberic acid as well as the 
glycine conjugate of suberic acid, suberylglycine. A variety 
of other dicarboxylic acids, both saturated and unsaturated, 
were also found in the urine during the acute clinical stage. 
The glycine conjugate of hexanoic acid, hexanoylglycine, was 
also elevated when the children were sick. The excretion of 
these metabolites could be markedly increased by fasting the 
patients for periods of greater than ten hours. These 
results indicate that the children may have a defect in fatty 
acid 3-oxidation which becomes clinically significant during 
periods of prolonged fasting when fatty acid oxidation be­
comes the major source of energy.
Two abnormal metabolites, 3-keto-2-methylvaleric acid and 
3-hydroxy-2-methylvaleric acid, have been identified and 
quantitated in the urine of a child with propionic acidemia. 
These metabolites may have been produced as a result of self­
condensation of propionyl-CoA. Data is presented to show that 
the unusual ketone 3-pentanone, which has been observed 
previously in the urine of patients with propionic acidemia, 
is produced as a result of the decarboxylation of 3-keto-2- 
methylvaleric acid. The identification of these and other 
characteristic metabolites enabled the post-mortem diagnosis of 
propionic acidemia in a child who had died following a disease 
characterised by acidotic episodes.
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I N T R O D U C T I O N
Individual variation, health and disease are controlled in large 
part by genetic mechanisms. This touchstone of modern human biology 
and medicine has its roots in the medical studies of the eighteenth 
and nineteenth centuries but has assumed its present position of 
eminence only during the last thirty years. From studies of molecular 
biology and of causes and courses of disease have begun to emerge a 
scientific basis of diagnosis and treatment.
The study of human genetics has been responsible for and dependent 
on three related subdisciplines :-
(a) Population genetics in which studies are made of the 
frequency, distribution and effects of specific genetic 
defects.
(b) Cytogenetics which studies the location and organisation of 
genes on the forty six human chromosomes.
(c) Biochemical genetics which studies the chemical identity of the 
gene and its products, the mechanisms of control of cellular 
metabolism by genes and the disturbances of cellular metab­
olism caused by lack of expression of genes.
The term "inborn error of metabolism", introduced by Garrod at the 
turn of the century applies to the group of diseases studied by bio­
chemical genetics in which we can define the inborn errors as genetic­
ally determined biochemical disorders due to specific congenital 
defects in the structure or function of protein molecules. Many of 
the inborn errors have clinical and pathological consequences which 
are a direct result of the specific biochemical disorder. However the 
importance of these conditions go far beyond their clinical impact. The 
treatment of an individual patient must always remain the prime concern 
of medicine but studies of patients with specific inborn metabolic 
errors have been instrumental in elucidating normal biochemical path­
ways, in establishing the structure and function of various species of
macromolecules and in illuminating genetic concepts and mechanisms.
2Thus the definition of the enzymic defect in phenylketonuria, albinism
and alkaptonuria^ provided important information about the pathway of
aromatic amino acid metabolism. Similarly studies of haemoglobin 
cvariants provided insight into the structures and functions of the
7
normal haemoglobin molecule and much of our current thinking on carbo-
Q
hydrate metabolism is based on studies of galactosemia, the glyco­
genoses and pentosuria.^
GOALS AND LIMITATIONS OF STUDY OF GENETIC DISEASES 
Investigations of inborn errors of metabolism have two independent 
goals. The first is to define the diagnostic, therapeutic and prog­
nostic implications of the disease for the affected subject and for . 
others suffering from a similar defect. The second is to investigate 
the biochemical and genetic events which are responsible for the 
clinical disturbance and to relate these to the normal patterns of 
metabolism. The closer we come to this second goal the more rational 
we become about the first. Thus the identification that the enzymic 
defect in isovaleric acidemia is on the path of leucine catabolism, 
gives rise to the premise that the isovaleric acid is solely (or at 
least predominantly) derived from dietary leucine and restriction of 
this amino acid will decrease isovaleric acid accumulation. Treatment
of the patient with low leucine diets lead to normal physical and
9 .mental development. Similarly the identification of the enzymatic
($ .defect in patients with galactosemia provided the chemical basis for 
the accumulation of galactose-l-phosphate in body tissue. This fact 
provided not only the rationale for dietary treatment of the condition 
which prevents and reverses cerebral symptoms but also has provided a 
method of detection of carriers of the mutant gene.
This situation does not exist for all genetic diseases. In some 
diseases such as sickle cell anaemia we have a reasonable amount of 
information about the biochemical defect but this gives little basis 
for treatment. Conversely for some diseases such as organic acidurias 
we have effective dietary therapy but have little information on the 
structural defects in the enzymes involved. In Tay-Sachs disease we 
know that certain glycolipids accumulate in cells owing to a specific 
catabolic enzyme deficiency but we have no effective means of reversing 
the condition. Finally for many diseases such as Huntington's Chorea, 
family studies and morphologic changes suggest a specific inborn metab­
olic disturbance but we have no "biochemical handle" with which to
is
advances which one may expect in the future. They also suggest the 
need to think of inborn errors of metabolism as signposts on the road 
to an understanding of the ways in which genetic variation and sub­
sequent protein structure influence our individual variation and normal 
physiology. Thus the study of genetic diseases is of major importance 
in understanding the biochemical reations in health and disease and not 
a study of rare defects which only affect a few individuals.
GENETIC MUTATION AND MACROMOLECULES 
Genetic diseases are caused by a variation in the nucleotide sequence 
of the chromosomes in the nucleus of the cell. This variation, known as 
a mutation, may be expressed as a change in the structure or function of 
macromolecules such as enzymes in a cell. Such mutations may be express­
ed as a clinical or chemical disturbance, or they may remain unknown 
either because they cause no significant functional disturbance or be­
cause they are incompatible with life. Such genetically controlled
10 11structural variation is found for all proteins studied 3 and may
be responsible for the variant forms of a given inborn error which ex­
. . . . ■ 12 hibits biochemical and genetic heterogeneity e.g. phenylketonuria
and cystinuria.^
FUNCTIONAL DERANGEMENT DUE TO GENETIC VARIATION —  ---------------- ---—
Although Garrod stressed enzymatic defects which produce a block in 
an anabolic or catabolic pathway, inborn errors have been described for 
all types of protein. Mutations have been described affecting function 
of cell membranes in the intestine, kidney and other organs which lead 
to diminuation in the transport of sugars, amino acids, phosphates, 
vitamins, cations and water.^”^
These mutations may reflect the malfunction, absence or alteration of 
specific membrane carrier protein or an abnormality in the membrane
receptor sites for hormones or other mediators. Other mutations involve
. . 1? . .. . 1 8 , .  ^ . 19 . 20serum proteins such as albumin, lipoprotein, immunoglobulins or
. 10transferrins and may have important clinical consequences or none at 
all.
or absence of an intracellular enzyme function. The functional conse­
quences of this loss of enzyme activity are of greatest interest and 
concern. The loss of functional activity may be produced by complete 
cessation of enzyme synthesis or by production of a mutant protein 
which has lost the ability to carry out its usual function. It is 
¿often difficult to distinguish between these two possibilities but 
immunological and enzymatic studies may allow the distinction between 
lack of synthesis and production of an antigenically similar but
functionless protein to be made. Such studies have been carried out for
21a small number of inborn errors of metabolism such as galactosemia,
, 22 23Lesch-Nyhan syndrome and muscle phosphorylase deficiency but many
diseases remain to be studied in this fashion.
Other disorders are characterised by only a partial loss of enzymic
activity, which may be expressed in several ways. Firstly the mutant
enzyme may have a markedly reduced affinity for its substrate. This
24defect has been demonstrated in citrullinemia and some defects of
glucose-6-phosphate dehydrogenase activity. Secondly the mutant
enzyme may have increased thermo-lability which may explain the reduced 
•26, 27 Similarly instability or increased rate of destruction
26, 28, 29
activity. . . . . .2  ,of a mutant enzyme may give lowered activity. In some cases the
mutant enzyme binds essential cofactors abnormally. Thus in cystathion- 
inuria patients the cysathioninase activity of an in vitro liver homogen­
ate is markedly increased when pyridoxyl phosphate is added to the 
incubation medium and nearly normal activity can be restored by the 
presence of large amounts of this co-factor. This alteration of
activity is paralleled in vivo by a reduction in cystathionine excretion. , . 30in these patients when treated with large amounts of pyndoxme.
Similarly in one variant of methylmalonic acidemia, Baumgartner, Bach- 
31mann and Wick have demonstrated that activity of methylmalonyl-CoA
mutase enzyme can be restored to normal activity in vitro and in vivo
by the addition of large amounts of 5* - deoxyadenosylcobalamin which
is the specific co-factor for the mutase apoenzyme. Other vitamin. . 32dependent inborn errors have been described for several vitamins 
including vitamin Studies of patients with B12 responsive
methylmalonic aciduria have shown that the defect may be in the path­
way of B. metabolism which produces the active coenzyme as well asJL m
A , B , C , D  Substrate and products of major reaction pathway, 
F . G  Products of minor reaction pathway.
Transport system for A
F E  . E  ~ E„r- E„ Enzymes catalysing conversion of A to B, ‘"AB' BC'^CD* AF'*“FG J
B to C,C to D,A to F and F to G-
Cell Membrane
FIGURE 1. Schematic representation of biochemical sequence in a cell.
in the mutase enzyme. ZZ3Z4
Two other mechanisms of reduced enzymatic activity are of importance. 
Mutations could affect polypeptide sub-units in such a way that when 
these are assembled into functional enzymes the activity is impaired.
A parallel situation exists where the globin chain of haemoglobin M 
interferes with the redox state of iron in the haemoglobin complex 
causing methaemoglobinemia.̂  Such a defect has not yet been described 
for an enzymic or membrance protein. Finally we must consider the case 
in which the same reaction is catalysed by more than one enzyme in the 
one cell. Total deficiency of one enzyme could lead to partial red­
uction of net activity. This situation has been described in Fabry's 
' Z 5 3 Qdisease and for Tay-Sachs disease and may be much more common 
than previously recognised as an explanation of genetic heterogeneity.
Although the known inborn errors of metabolism are usually caused
by a decrease or loss of activity the converse may also apply. In acute
intermittent porphyria hepatic framinotevulinie acid synthetase activity is 
. Z7-Z9increased several fold and increased enzyme activity is character­
istic of several other diseases.
CONSEQUENCES OF ENZYME DEFECTS'
The intracellular effect of a genetic alteration of a protein will 
depend on factors such as its function and the severity of the defect. 
However it is possible to make generalisations of the consequences of 
the enzyme defects. If we consider the sequence of reactions in Fig. I 
we can define five possible consequences.
(a) Precursor Deficiency
If the specific transport system for a substance A across 
a membrane is defective the intracellular concentration of A 
may be too low to saturate the enzyme E^. This can then 
slow the entire sequence and lead to a deficiency of all 
products B, C and D. This mechanism is evident in Hartnup 
disease where tryptophan transport is defective and leads to 
an intracellular deficiency of nicotinamide. It is also 
evident in pernicious anaemia where transport of vitamin 
across the intestinal wall is defective, leading to a
deficiency of the cofactor for methylmalonyl-CoA mutase.
(b) Precursor Accumulation
If the enzyme is defective then the precursors A, B, C 
may accumulate in the cell. This has been shown for methyl­
malonic aciduria where a defect in the methylmalonyl-CoA 
raeemase or mutase causes the intracellular accumulation of 
methylmalonyl-CoA and the excretion of large amounts of 
methylmalonic acid.
(c) Alternative Pathway Utilisation.
If the conversion of substance A to substance B is impaired 
by a defect in the enzyme an accessory pathway to F and 
G may become prominent. Thus in phenylketonuria the lack of 
phenylalanine hydroxylase activity leads to overproduction 
and excretion of phenylpyruvic, phenyllactic and phenylacetic 
acids.
(d) Product Deficit.
If product D is the physiologically active product of the 
reaction sequence, a block in any of the steps leading to 
its formation may result in inadequate production of D.
This is illustrated in vitamin responsive methylmalonic 
acidemia where a defect in B^2 metabolism causes a deficit 
of co-factor for the methylmalonyl-CoA mutase enzyme and 
thus accumulation of methylmalonic acid. Similarly in 
albinism melanin is not formed because of lack of tyrosinase 
activity. *
(e) Lack of Feedback Control
The end product of the reaction sequence D may regulate the 
activity of the first enzyme in the pathway E^g This control
regulates the flux of material through the pathway. This 
process has been extensively studied in microbial systems and 
is of importance in man. Thus in the Lesch-Nyhan syndrome 
the enzyme defect in hypoxanthine-guanine phosphoribosyl 
transferase results in the failure to regulate synthesis
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of uric acid and leads to marked over production of the 
end product.
CLINICAL MANIFESTATION OF ENZYME DEFECTS
The clinical expression of enzyme defects may vary tremendously.
Some defects such as pentosuria, iminoglycinuria and (3-aminoisobutyric 
aciduria are harmless; others such as branched chain ketoaciduria 
propionic aciduria and phenylketonuria lead to severe metabolic disturb­
ances early in infancy which may result in early death or profound mental 
and physical handicaps. Although the mutations responsible for the in­
born errors are already in the gamete at conception they may not be ex­
pressed until many years after birth. For example acute intermittent 
Porphyria rarely manifests autonomic nervous system involvement before 
puberty and Huntington's Chorea rarely shows clinical symptoms before 
the age of forty.
Sex may also play a large role in clinical expression of disease.
Some inborn errors are sex linked (generally only expressed in the male) 
and may be inherited as dominant or recessive traits. In other diseases 
the role of sex is more subtle e.g. the unusual occurrence of gouty 
arthritis in the pre-menopausal female.
Organ involvement may relate directly to the tissue in which the 
defect is expressed, but in many disorders this is not true. In 
cystinuria the defective resorbtion of cystine leads to the formation 
of cystine calculi and in hepatic glycogenoses the enzymatic liver 
defects are responsible for the accumulation of liver glycogen. In 
phenylketonuria and acute intermittent porphyria however specific 
enzymatic liver defects lead to manifestation in the central or auton­
omic nervous system, possibly due to the accumulation in the circulation 
of toxic metabolites.
DIAGNOSIS OF METABOLIC DEFECTS
The earliest recognition of the concept of inborn errors of metab­
olism by Garrod grew out of his interest in and studies of alka­
ptonuria, albinism, cystinuria and pentosuria. He noted that in alka­
ptonuria, patients excreted large amounts of homogentisic acid in their 
urine almost from birth and this excretion could be increased by admin­
istration of protein or the amino acids phenylalanine and tyrosine.
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FIGURE 2. Growth of knowledge about Inborn errors of amino acid 
metabolism.
The open circles indicate findings made in the pre-partition chromatography era;filled 
circles reflect findings derived from the use of partition chromatography on filter 
paper and the ninhydrin stain to locate amino acids in biological fluids;the squares 
represent at least a dozen diseases identified through the application of GC-MS methods 
to biological fluids.
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These observations, together with his studies of the families of the 
affected patients lead to his postulation that alkaptonuria resulted 
from the deficiency of a normal enzyme responsible for the catabolism 
of homogentisic acid, such deficiency being inherited as a recessive 
trait. The identification of the homogentisic acid depended on the 
qualitative chemical tests available and on the preparation of deriv­
atives which could be characterised by physical or chemical tests.
This pattern of identification of accumulated or missing metabolites 
is fundamental to the diagnosis of inborn errors of metabolism. For the 
first half of this century the identification of specific metabolites 
depended exclusively on either a few qualitative chemical tests or on 
the preparation of derivatives which could be characterised by physico­
chemical means. Included in these tests were the ferric chloride 
test for the detection of phenols, the cyanide-nitroprusside reagent 
for the detection of disulphides and the use of phenylhydrazine for 
the detection of keto acids. The limits of detection and the limited 
range of tests accounted for the few known inborn errors of metabolism.
4 t  42In 1946 Dent 3 published his papers on partition chromatography 
of amino acids in urine and serum. This technique, coupled with the 
sensitive and specific ninhydrin stain for amino acids was then applied 
to the investigation of human disease. Two decades later, the expo­
nential growth of knowledge fostered by this technology had given birth
to some fifty "ninhydrin positive" characterised diseases. (See Fig. 2,
43 ... .after Scriver and Rosenberg ). The sensitivity and effectiveness of 
Dent's techniques compared to the other techniques in use at that time 
however produced the false impression that most errors of metabolism were 
due to aberrant, metabolism of amino acids. By 1970 the rate of increase 
of new discoveries had begun to decline because most ninhydrin positive 
compounds which accumulate in genetic diseases had been discovered.
The first paper on gas chromatography appeared in the literature in
44 . •1952, and the method was quickly put to use in the petroleum industry
where it mushroomed into a major analytical tool in the 1950's. As the 
technique developed and commercial equipment became available the tech­
nique was soon applied in other fields such as biology and chemistry.
TABLE 1
SOME ENZYME DEFECTS LEADING TO ORGANIC ACIDURIAS
Defective Pathway Major Organic Acids Metabolic Pathway
a - M e t h y l a c e t o a c e t y l  C o A - f i - k e t o -  
t h i o l a s e
a-Methylacetoacetic 
a-Methyl-8-hydroxylutyric
Isoleucine catabolism
I s o v a l e r y l  C o A  d e h y d r o g e n a s e Isovaleric Leucine catabolism
$ - M e t h y l c r o t o n y l  C o A  c a r b o x y ­
l a s e
8-methylcrotonic
3 - h y d r o x y - 3 - m e t h y l g l u t a r y l  
C o A  l y a s e
3-hydroxy-3-methylglutaric
B r a n c h e d  chain a m i n o  a c i d  
d e c a r b o x y l a s e
a-ketoisocaproic 
o-keto-3-methyl valeric 
a-keto-isovaleric
Leucine, isoleucine and 
valine catabolism
G l u t a r y l - C o A  d e h y d r o g e n a s e Glutaric ' Lysine catabolism
N o t  k n o w n Glutaric and other acids "Acyl-CoA" metabolism
a - K e t o a d i p i c  d e h y d r o g e n a s e a-ketoadipic Lysine and tryptophan catabolism
G l u t a t h i o n e  s y n t h e t a s e Pyroglutamic Glutathione
P r o p i o n y l  C o A  c a r b o x y l a s e Propionic Propionate catabolism
M e t h y l - m a l o n y l  r a c e m a s e Methylmalonic Methylmalonate catabolism
M e t h y l - m a l o n y l  C o A  m u t a s e Methylmalonic Methylmalonate catabolism
T e r m i n a l  e n z y m e  f o r  A d e n o s y l  
B 1 2  s y n t h e s i s
Methylmalonic " Methylmalonate catabolism
P r o x i m a l  e n z y m e  f o r  A d e n o s y l  .• 
B 1 2  s y n t h e s i s
Methylmalonic Methylmalonate catabolism
B l o c k  i n  M e t h y l  B 1 2  a n d  
A d e n o s y l  B 1 2  s y n t h e s i s
Methylmalonic Methylmalonate catabolism
P y r u v a t e  d e c a r b o x y l a s e Pyruvic Pyruvate metabolism
P y r u v a t e  d e h y d r o g e n a s e Pyruvic Pyruvate metabolism
S u c c i n y l - C 0 4  : 3 - k e t o a c i d - 
C o A  t r a n s f e r a s e
Pyruvic
Succinic
"Ketone Body metabolism
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The discovery of the basic principles and the initial development
45of the mass spectrometer were largely due to physicists and in 
1913 J.J. Thompson carried out his classic studies on the isotopes 
of the elements. By the 1950's this area of instrumentation had 
advanced to the stage where a commercial system became readily 
available. During the early 1960's the gas chromatograph and mass 
spectrometer were coupled to give a very powerful analytical tool 
which was capable of separating and uniquely identifying a wide range 
of organic compounds. The application of this technique to the 
diagnosis and study of inborn errors of metabolism allowed the exam­
ination of non-ninhydrin positive compounds with a sensitivity com­
parable to that of the ninhydrin technique for amino acids. This 
47has lead to an increase in the pace of discovery of new inborn 
errors.
ORGANIC ACIDEMIAS
Several inborn errors of amino acids or carbohydrate metabolism 
have now been described in which the major metabolites accumulating 
in the blood and urine are organic acids or organic acid derivatives 
(see Table 1). All have symptoms of central nervous system involve­
ment and if untreated lead to severe mental retardation or death.
For most of these a biochemical aetiology has been established by 
enzyme studies, although an understanding of the exact structural 
defects is often incomplete. Similarly our knowledge of the complete 
clinical spectrum or range of metabolic derangement is limited at 
present but as further studies are made and results of treatment assess­
ed our understanding of the group of diseases will be widened. The mode 
of inheritance of most of these diseases seems to be by autosomal recessive 
genes.
This group of diseases have presented many problems in diagnosis. 
Acidoses and central nervous system dysfunction are characteristic of 
organic acidemias. Since most severe cases present in the neonatal 
period, central nervous system dysfunction may be difficult to 
assess owing to the limited range of responses available to the neonate.
In addition some of the symptoms are also characteristic of such common 
neonatal conditions as anoxia during birth, cardiorespiratory disease,
18
renal disease or infection.
Three common presentations have been observed:
1. A previously well newborn or young infant becomes rapidly ill, 
usually with persistent vomiting. There may be a rapid pro­
gression to coma, apneic spells and death. In milder situations 
clearing of symptoms is likely but further attacks may be 
triggered by protein feeding or mild infection.
2. An infant or child fails to achieve normal growth and develop­
ment potential. These children often have a history of periods 
of lethargy, failure to feed, irritability and mild vomiting 
and may have neurological defects.
3. An infant may present with acute neonatal central nervous 
system signs such as local or generalised seizures, staring 
spells or myoclonus. Their electroencephalographic patterns 
may include a variety of abnormalites.
Biochemical studies show a metabolic acidosis, often with an 
accompanying lactic acidosis. Ketosis may or may not be present. 
Hyperglycinemia, hyperammonemia and hypoglycemia are other laboratory 
findings frequently present. Plasma and urine amino acids are usually 
normal or manifest non specific elevations.
Treatment rationale is similar in all these diseases and is based on 
restriction of the substrate to the affected enzyme. Initial treatment 
begins by stopping the accumulation of the toxic metabolites by 
removing the precursors, control of the acidosis and fluid balance, 
and provision of an energy source such as glucose until the accumulated 
toxins are excreted. Attempts are then made to enhance the enzyme 
activity by supplying large amounts of cofactors.
Successful treatment of a large number of cases has shown that early 
diagnosis of infants with organic acidurias is essential if permanent 
neurological damage is to be prevented. Long term management emphasizes 
the limitation of toxic metabolites by the use of low protein or artif­
icial diets and this usually controls the acute attacks. Since amino
19
acids are needed for growth and metabolism a careful balance must be . 
maintained between toxic accumulation of metabolites and an adequate 
supply of amino acids. Thus accurate analytical methods are required 
for quantitation of acid excretion and other biochemical parameters to 
ensure the balance between restricting intake and adequate supply of 
amino acids for growth and development.
* DIAGNOSIS OF ORGANIC ACIDEMIAS
The diagnosis of organic acidemias and their genetic aetiology 
depends on the definition of the enzyme defects responsible for the 
accumulation of organic acids. However, the identification of the 
acids, together with a knowledge of normal metabolic pathways, in most 
cases allows one to postulate the location of the defect. The diagnostic 
problem then becomes the identification and quantitation of the organic 
acid accumulating in the cells. The ultimate proof of the diagnosis 
however relies on enzyme studies in isolated tissue or cultures. The 
buildup of acids within the tissues usually leads to an accumulation of 
the metabolites in blood and then in the urine. Thus the diagnostic 
problem becomes the identification of the organic acids or their 
derivatives in serum or urine.
The identification of the acids of intermediary metabolism however 
presents considerable analytical difficulties since the physico­
chemical differences between them are often small. Consequently the 
analytical techniques used have been based on chromatography since 
small quantities of similar or isomeric compounds can be separated. 
Techniques which have been applied successfully include electro­
phoresis, paper, thin layer, liquid partition and gas chromatography. 
Whilst each method has certain advantages the final choice often depends 
on the interests of the investigator, the technical capabilities of the 
laboratory and the particular compounds being investigated.
Since the diagnosis of metabolic errors might require the identific­
ation of many classes of organic acids such as ketoacids, hydroxyacids, 
mono and poly-carboxylic acids and glycine conjugates the analytical 
method of choice must be able to detect all these classes of compounds. 
The most useful techniques which have been found to be suitable are 
liquid partition chromatography, gas chromatography (GC) and gas
chromatography-mass spectrometry (GC-MS). Most workers have favoured 
the use of GC-MS for urinary organic acid analysis. However GC-MS has 
one major limitation: it can only handle volatile constituents or com­
pounds which can be readily converted into volatile derivatives. It 
has been estimated that because of this limitation, analytical methods
based on GC detect only about 20% of the total number of substances
. . 48 49present in a complex biological mixture. ■*
Techniques for examination of highly polar molecules, thermally
unstable and high molecular weight compounds have provided the impetus
for the development of alternative techniques to complement GC-MS. The
development and application of high pressure liquid chromatography
(HPLC) in clinical chemistry ^  ^  and the recent development of micro 
52HPLC-MS interfaces to the analysis of organic acids may well lead to 
the detection of a new group of inborn errors of metabolism.
At present it is clear that GC and GC-MS are the major techniques 
of multicomponent analyses of body fluids in use today and in this 
thesis only the application of GC-MS for organic acid profiling will
be considered. A number of excellent reviews of this area have
.« . 53-58recently appeared.
The use of high resolution MS has not become widespread in bio­
chemical profiling but it may be used to advantage if it is available.
57 60~62Advances in column technology * and the more common use of high
63-66
59
resolution capillary columns together with the wider use of altern-
57 50 io 1ative modes of MS ionisation {especially chemical ionisation
(CI)} have increased both the sensitivity and the number of components
which can be identified in an analysis of a body fluid. The application
of computer technology to GC-MS has enabled not only the collection,
storage, manipulation and display of large amounts of data from a single
experiment but also the concurrent computer control of the GC-MS system,
the ability to identify a component by comparison of its low resolution
mass spectrum to library spectra (either during or after the data
collection) and the measurement of relative concentration of each 
76-78component.
Z1
FIGURE 3. Cl and El mass spectra of the TMS derivative of MMA and 
2 H 3 -MMA •
Note the minor fragmentation of the molecular ion in Cl-MS and the low intensities of 
the ions at m/c 250 and 221 which retain the label in the El-MS.
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METHODS OF QUANTITATION OF METABOLITES
The methods of quantitation of metabolites by GC have been known for 
79many years but the use of GC-MS computer systems has allowed new
80techniques to be developed. The simplest of these techniques is to use
72 81the total ion current plot of the MS 9 alone or in conjunction with
8 2an FID trace produced by sample splitting.
The commercial availability of compounds labelled with stable iso­
topes of hydrogen, carbon, nitrogen, oxygen, suplhur eto. has increased 
the use of such compounds as internal standards, with the increasing 
demand causing a fall in prices. These standards are ideal for quantit­
ive MS investigations, since they are clearly distinguishable by MS 
from the unlabelled compound but are chemically practically identical 
with it. The use of stable isotopic labelled internal standards also 
enhances the extraction efficiency as the standard effectively increases
the total concentration of material in the biological fluid. Compounds 
13 83containing C are the preferred standards as there are no detectable 
isotope effects in the GC separations, absorption losses, extraction 
losses, rates of derivative formation or production of ions in the MS 
source. The use of deuterium labelled compounds usually offers a cheaper 
and more easily synthesised alternative but deuterium labelled compounds 
may show alterations in GC retention and the label may also be chemically 
exchangable during the analysis. The use of such standards should be 
checked using calibration curves.
A major increase in sensitivity may be achieved by the use of chem­
ical ionisation MS (CI-MS). The appropriate choice of reagent gas 
(usually isobutane or methane) and source conditions leads to the 
production of very few product ions, the major one being the protonated 
molecular ion (MH+). This ion retains any isotopic label which may be 
present which is not necessarily true for the fragment ions in the El 
spectrum (see Fig. 3). The increased sensitivity of negative ion 
will give further advances in this area.
The choice of derivatives for quantitative work is governed by 
absorption behaviour and stability but these may be modified for MS 
considerations. Thus trimethylsilyl(TMS) derivatives of acids are easily
a. Addition of internal standard.
b. Hydrolysis of conjugates of acids.
c. Chemical modification of acids ecf formation of keto acid oximes
d. Extraction of basic and neutral compounds.
e. Acidification and extraction of organic acids.
f. Further purification.
g. Drying of extracts
h. Concentration of extracts
i. Derivatisation
j. Separation of components (G-C)
k. Analysis and identification of components of interest
FIGURE 4. Steps in the analysis of organic acids.
Vote that not all steps may be used in a particular analysis.
hydro Lysed but are very helpful for identification and quantitation as 
they usuaii^ give-^tj^se-irfib^ra.cteristic M-15 ions in the mass spectrum.
The general method of workup of samples (see Fig. 4) includes the 
addition of internal standards, possible hydrolysis of conjugates, 
extraction and concentration of the extract. Frequently a number of 
purification, separation and derivatisation steps are needed before 
measurement by the MS and consequently an internal standard method 
is the method of choice. A suitably labelled internal standard may not 
be available and an analog or homolog may then be chosen. The assumpt­
ion made in this method is that the ratio of internal standard to analyte 
is not changed during any chemical or physical operations and thus the 
yields of each sample treatment or extraction step need not be determined. 
A single measurement of the concentration ratio of the analyte to the 
internal standard is all that is necessary. The usefulness of the method 
can be checked by investigation of calibration mixtures. In some 
instances the use of labelled internal standards allows procedures to 
be simplified. For example it may be adequate to carry out only one 
solvent extraction of a biological fluid since further extractions may 
increase the amount of material and of interfering substances but the 
ratio of labelled to unlabelled material will not change. Purification 
of extracts may however be needed since some impurities may contribute 
to the MS measurements.
^ ^ ^ ^ ^ 7 3 ,8 0 ,8 7 -9 1Three major methods of MS measurement have emerged.
First the repetitive scanning of a preselected mass range during the
gas chromatographic run gives the optimum in the versatility of mass
spectral information collection. This method allows the processing of
data to generate individual ion current profiles referred to as Mass
92 .Chromatograms which can be used for comparison of unknown and internal
standard. This technique is statistically inefficient for the quantit­
ation of ion intensity since much of the time is spent measuring masses 
of no particular value to the analysis as well as the time spent in 
regions of the scan between masses. The method does however accommodate 
complex samples, as all eluting peaks will have representative mass 
spectra recorded, and the presence of a compound need not be known prior 
to its elution from the GC. Improvements to the accuracy and sensitivity
may be obtained by limiting the range scanned, high speed scanning, 
threshold sensitivities and mathematical treatment of data.
The technique of detection of a limited number of ions (multiple 
ion selection - MIS) has been found to extend the sensitivity and the 
accuracy of analyses. The focus of the mass spectrometer must be 
alternated between two or more m/e values in a time sequence. This is 
easily accomplished in a quadrupole instrument by altering the DC 
voltages. In a magnetic instrument the magnetic field cannot respond 
fast enough and the accelerating voltage is usually switched.
The best sensitivity is obtained when the whole time is spent 
monitoring a single ion (SIM). Instrumentally this is usually implement­
ed by the use of closed loop feed back control to ensure the instrument 
is always on the top of the peak. An extension of this technique is the 
provision of two detectors to allow for instrumental variations. This 
specialised hardware requirement is not usually available with GC-MS 
but is used for specific applications requiring the highest accuracy.
The major disadvantages of MIS and SIM include the limited number of 
compounds that can be analysed per GC experiment, the difficulties in - 
verifying peak identity (especially at low levels), the need for 
appropriate labelled internal standards, the inability to demonstrate 
the presence of unexpected compounds and the instrumental difficulties 
associated with the implementation of such an analysis especially on 
magnetic instruments.
DIRECT Cl-MS
Most results available at this time have been obtained by GC or
93GC-MS studies but a recent report by Issacher and Yinon has taken 
advantage of the lower fragmentation obtainable with CI-MS. They have 
examined crude urine extracts using solid probe CI-MS and have identif­
ied the acids present by their protonated molecular ions. Patterns 
are obtained at different probe temperatures to examine both low and 
high volatility carboxylic acids. The method does not give quantitative 
results but diagnostic patterns were obtained with some gross metabolic 
defects. This technique may possibly be developed into a screening 
procedure for gross abnormalities but needs much more work to enable 
the identification of more subtle changes in excretion patterns.
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FIGURE 5. Early demonstration of biochemical individuality by metabolic 
profiling(after Williams)
The metabolic patterns of 4 subjects were obtained by measurement of the taste threshold 
1 (Numbers 1-17) and urinary metabolites(Numbers 18-31). The lengths of the lines are 
indicative of the amounts of compounds measured.
Following the development of GC methods for amino acids Summons 
95 96 97et al and others ■* developed methods for analysis of amino acids
which eliminated the need for complete chromatographic resolution of
mixture by monitoring the characteristic ions in the mass spectrum of
98—102the GC column effluent. Halpern and others have developed this
idea using a combination of specific extractions of classes of compounds 
labelled internal standards, derivatisation, differences in volatility 
and the increased intensity of the protonated molecular ion in CI-MS to 
enable quantitative measurements of metabolites without prior chromat-' 
ographic separations. This method has been shown to be applicable to a 
variety of classes of compounds including amino acids, fatty acids, 
steroids, drugs and free and bound cholesterol. The methods can be 
used to analyse mixtures in a fast reproducible manner with minimum 
pretreatment. Good agreement with other methods is obtained and the 
method is applicable to microsamples collected on filter paper. However 
analyses using these techniques must be checked for the possibilities 
of interferences in MS and for specificity and sensitivity.
METABOLIC PROFILING
The concept that individuals might have a "metabolic pattern" that 
would be reflected in the constituents of their biological fluids was 
first developed and tested by Williams et in the late 1940's
and early 1950's.
Utilising data from 200,000 paper chromatograms he was able to show
that the excretion patterns for a variety of substances varied greatly
from individual to individual, but that these patterns were relatively
constant for a given individual, (see Fig. 5 after Gates and 
88Sweeley ). Williams then studied samples from a variety of groups 
including alcoholics, schizophrenics and mental hospital patients and 
produced suggestive evidence for characteristic metabolic patterns 
associated with each group. This work was not repeated by others due 
to the technical complexity of the programme and the ideas of the 
utility of this approach lay dormant until the late 1960's when ad­
vances in gas and liquid chromatography enabled similar studies to be
.  ̂ 105-107carried out.
The term "metabolic profile" was introduced by the Hornings in 
1971 ^ 9 who originally defined it to mean "multicomponent GC
analyses that define or describe metabolic patterns for a group of
109metabolically or analytically related metabolites" . This definition 
has been modified and broadened so that quantitative information is 
often included as well as results obtained by techniques other than GC.
Initially the metabolic profiles obtained were qualitative in nature 
i.e. the identity of the metabolites was the major consideration,^"^ 
but in the last few years the emphasis has been on the development of
quantitative methods for the analysis of components of biological
.. .. 7 6 ,7 8 ,1 1 6 -1 1 8fluids.
TREATMENT OF SAMPLES PRIOR TO SEPARATION 
AND IDENTIFICATION
A. Collection, Storage and Transport.
Most clinical laboratories do not have direct access to GC-MS-
computer systems and thus the initial organic acid screening of
samples is usually carried out by GC alone. In the case of a positive
screening result the samples may then be transported to a specialised
centre for further investigations. Collection, transport and storage
of specimens is rarely under the control of the specialised laboratory
and changes may occur in specimens before receipt by the specialised
laboratory. Fasting blood and the first morning urine specimens are
119the preferred samples and these should be stored at low temperat­
ures to prevent decomposition of metabolites. Information about dietary 
habits and drug intakes by the patient is of vaiue and help
eliminate false positive results. Further samples may be requested 
or studies of twenty-four hour excretion of metabolites may be re­
quired. In some cases follow up studies on other samples from the same 
patient may be required to confirm the presence of an unusual metabolite.
B. Isolation of Organic Acids
Three principal methods for the isolation of acidic constituents
of urine prior to derivatisation and GC are currently in use. These
124 .methods and their relevant merits have been reviewed and their
125efficiencies have been compared. The first is based on solvent
extraction using a variety of solvents, such as ether and ethyl
acetate. The extraction efficiencies may be increased by saturating the
126urine with sodium chloride. A recent variation of this technique
uses the absorbtion of the urine onto a solid phase cellulose resin and
elution of the hydrophobic acids and neutrals with organic solvents.
This variation yields better results in terms of recovery and precision. 
118Fitch et al have shown that small aliphatic molecules and aromatic 
acids are satisfactorily quantitated using solvent extraction. Whilst 
tricarboxylic acids are also isolated the reproducability and their 
recoveries are poor.
The second method is based on ion exchange chromatography. This was
first suggested by H o r n i n g ^ ^ ^ a n d  intensively studied by Chalmers 
127,128and Watts. There have been conflicting reports of the merits of
this approach, and problems have been encountered with the
high concentration of sulphate and phosphate which are present in urine.
This interference may be overcome by the use of a barium hydroxide
125preprecipitation step but this may lead to the possibility of co-
120precipitation or even decomposition of some organic acids. DEAE-
Sephacfex is the most widely used ion exchange resin but others such as
131Dowex-3 have also been used. Following absorbtion of the acids on
the resin and washing to separate neutral molecules the acids are
eluted with aqueous pyridinium acetate and the solution lyophilised. To
counter losses of the more volatile acids during the lyophilisation step
some workers use an elution with hydrochloric acid followed by neutral-
132isation of the eluate with sodium bicarbonate. The ion exchange
. . . . , 118method gives reproducible results with the majority of organic acids,
and is the only technique available that isolates polyhydroxy acids such
as glyceric acid but poor recoveries are obtained for the tricarboxylic
acids which are co-precipitated by the initial barium hydroxide treatment,
Further complications are caused by the partial lactonisation of aldonic
acids. The third method is limited to the isolation of more volatile
es use c 
136,137
. . 131-135acids and mak of either steam distillation or vacuum
distillation.
The choice of which extraction method is to be used will be based on 
the requirements of the analysis. The ion exchange methods are more 
laborious and time consuming but are the best for studies of very 
polar or highly water soluble molecules. In most metabolic diseases
30
however the the deviations from normality are usually so large that the 
use of ion exchange methods are not justified as the use of solvent 
extraction methods together with recovery studies can give accurate fast 
results both for qualitative and quantitative studies.
The use of other chromatographic pre-treatments for class separation
of compounds such as alumina or charcoal absorbtion , XAD-2 hydrophobic
polystyrene resin, or silica gel which have been of great use in drug,
catecholamine, oestrogen and lipid analysis have not been particularly
124useful in the isolation of organic acids and have not been used.
Urine is the only body fluid which is normally devoid of protein. All 
other fluids contain small (amniotic fluid, spinal fluid) or large amounts
of protein (serum, seminal fluid, synovial fluid). It has been suggested
138 131 139-140 .that spinal fluid and amniotic fluid 5 can be treated in the
same way as urine but no recovery studies have been reported to test this 
assumption. Other physiological fluids have to be deproteinised to avoid 
interference by protein. If non destructive methods such as gel filtra­
tion, dialysis or membrane filtration are used, some compounds which are 
tightly bound to protein and water insoluble low molecular weight sub­
stances such as long chain fatty acids may be lost. This is not a problem 
with other classes of metabolites such as carbohydrates and amino acids. 
Protein precipitation1 agents such as sulphosalicylic acid followed by
extraction or ion exchange have been recommended, but it is known that
. , . 141,142 . .some acids may be co-precipitated with the protein. Direct
extraction of serum with ion-solvent pairs such as ammonium carbonate-
ethyl acetate have been widely used for drug extractions but this method
does not extract organic acids.
7 A ?Mamer has suggested that precipitation of protein using ethanol 
after which the ethanol is removed in V c l c c u o  and the extract is treated 
in the same way as urine. Other authors have reported success using 
variations of this method and acetone and methanol
have also been used. Recovery studies have not been reported for these 
methods.
A number of the above techniques have been adapted to the measurement
149 152of methylmalonic acid in serum and amniotic fluid. 3 For measurement 
of this metabolite Hang et al^^ and other groups'^*  ̂ have ignored
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protein effects and measured serum levels with the same methods as are
commonly used for urine methylmalonic acid (MMA). Oberholzer and
other co-workers developed a method in which the protein of diluted
acidified serum was coagulated by heat before the colourimetric estim- 
162ation of MMA was done. The scarcity of results reported for serum 
levels of metabolites and the wide variety of methods reported indicate 
the difficulties of reproducible extraction methods for organic acids from 
protein containing fluids.
The difficulties of extraction of fatty acids and other lipids from
protein containing fluids have generally been overcome by the development
163of special methods such as the Folch or Dade extraction.
C. Derivatisation of the Organic Acids
The acids obtained by extraction or ion exchange are in general too 
involatile for direct GC analysis. The aim of derivatisation is to en­
hance volatility and suppress the absorbtion and decomposition of the 
acids on the surface of the chromatographic packing. To be of value the 
derivatisation step must be chemically simple and it must proceed 
quantitatively.
The urinary acid fraction contains a complex mixture of mono and 
poly-carboxylic acids, hydroxy and keto-acids, phenols, phenolic acids 
and conjugates of these compounds with glycine and glucuronic acids.
The two most useful reactions which have been used for derivatisation are
- 164 165 166 167silylation 3 and esterification (especially methylation ).
Trimethylsilyl (TMS) ethers and esters are the most popular deriv­
atives for the GC of organic acids since they are easy to prepare 
quantitatively and conveniently, are safe to handle and have good 
chromatographic properties. (Table 2). The silyl derivatives are partic­
ularly suitable for GC-MS and commercially available deuterium labelled 
TMS reagents may be used to obtain derivatives with different molecular 
weights. The silyl derivatives give characteristic fragmentation patterns 
innEIMS>and usually have a strong {M—15} ion in the spectrum to indicate 
the molecular weight. Reference spectra of a large number of organic acid 
silyl derivatives are also readily available.
The reagent of choice is N,0-bis(trimethylsilyl)trifluoroacetamide
2 yQ
(b s tfa) which is one of the most potent silylating reagents avail­
able. It has the added advantage that the reaction by-products are 
highly volatile and elute with the solvent and any excess reagent.
The reagent is often used in conjunction with catalytic amounts of 
trimethylchlorosilane or pyridine.
172
Sodium salts of acids are generally more difficult to silylate than
. 171free acids, but recent investigations have shown that bis(tri­
methyl silyl) acetamide (BSA) in the presence of trimethylchlorosilane 
and/or hydroxylamine converts these salts directly into volatile TMS 
derivatives. The TMS_ derivatives of organic acids are highly water 
sensitive, in particular the di-TMS derivatives of dicarboxylic acids 
are readily hydrolysed by even traces of water. However by strict 
exclusion of moisture during preparation and the use of molecular sieve 
and septum sealed containers the derivatives may be kept for several
months without decomposition. The silylation of N-acylglycines may
173give rise to multiple GC peaks from the presence of incompletely
derivatised material. However, when longer silylating times and stronger
_ 173-175 ^   ̂ 176 . .reagents, or methyl esters are chosen as derivatives a single
GC peak is obtained. The two structural isomers of the IMS derivative
of keto acids may also have different GC elution times and these acids
are usually determined when the keto group is first derivatised with
hydroxylamine (or a substituted hydroxylamine )
before silylation. Combined silylation and methylation yields deriv-
108 179atives with good chromatographic properties 3 and combined ethyl-
180ation and silylation has been preferred for some SIM studies.
The methyl esters of organic acids have excellent chromatographic
properties and can be prepared with diazomethane. The mass spectra of
methyl esters are usually simple and easier to interpret than those of
the corresponding silyl compounds. Despite the hazards associated with
diazomethane, its use gives esters in quantitative yield in a simple
smooth and rapid procedure. The method may also lead to certain by-
181 182products, artifacts and unexpected results, 3 but it is still
the method of choice for esterfication. Other diazo alkanes have been
166used to prepare higher molecular weight esters.
Many alternative methods of esterification have been used. These
TABLE 3
SHORT CHAIN FATTY ACIDS AND GLYCINE CONJUGATES 
ASSOCIATED WITH METABOLIC DISEASE
Acid Disease' Refs. |
Propionic Acid Propionic Acidemia 134 jMethylmalonic Acidemia 189 !
Butyric Acid Glutaric Aciduria Type 2 190
2-Methyl propionic 
Acid (Isobutyric)
Glutaric Aciduria Type 2 190
Hexanoic Acid Glutaric Aciduria Type 2 190
Tiglic Acid Propionic Acidemia 191
2-Methyl butyric Jamaican Vomiting Sickness 192
Acid Glutaric Aciduria Type 2 190
3-Methyl crotonic 
Acid
3-Methylcrotonyl glycinuria 193
Isovaleric Acid Isovaleric Acidemia 133
Jamaican Vomiting Sickness 192
Glutaric Aciduria Type 2 190
Propionylglycine. Propionic Acidemia 194
2-Methylbutyryl-
glycine
Propionic Acidemia 195
3-Methylcrotonyl 3-Methylcrotonyl Glycinuria 193
cflycine 3-Methylcrotonyl Glycinuria 
Biotin Responsive
196
Tiglylglycine Propionic Acidemia 
3-Methylcrotonyl Glycinuria
197
Biotin Responsive 
2-Methyl Acetoacetyl CoA
196
Thiolase Deficiency 19 8
Isovalerylglycine Isovaleric Acidemia 188
Jamaican Vomiting Sickness 192
Hexanoylglyeine - Glutaric Aciduria Type 2 190
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. , _ 166.167 , .include an acid/alcohol combination such as methanol/hydrochloric
acid, methanol/boron trifluoride, methanol/thionyl. chloride, the reaction
183 184of silver salts with alkyl halides, 3 the use of crown ethers or other
dehydration catalysts, and the injection port pyrolysis of tetraalkyl­
. - .. 185,186ammonium salts of acids.
There have been a wide variety of derivatives and methods developed
for specialised separations and specific combinations of derivatising
166 167 187agents employed for poly-functional compounds. 3 3 These
specialised methods are not generally applicable to the profiling of 
organic' acids.
D. Special Methods required for Short Chain Acids .
Short chain ( "  Cg) monocarboxylic acids are volatile and therefore
require no derivatisation for GC. These acids as well as their glycine 
. 188conjugates have some value for the diagnosis of human metabolic 
diseases (See Table 3). The presence of these acids may sometimes be 
detected by smell, but the proper diagnosis of disease depends on
quantitative measurement of the acid. Methods for sample preparation
131 135 136have included steam distillation, vacuum distillation and
. * 4. 4.- 188,199-203 204-7,. . .solvent extraction. In some cases ' minimum
sample treatment may even include injection of raw urine, ethanol
deproteinised serum^^J or urine from which the metal ions have been
removed by ion exchange resins?*^ GC separations on such phases
199 201as Porapak, FFAP (Carbowax 20M-nitroterephthalic acid),
204 208Chromosorb 105^ SP 1200/orthophosphoric acid on Chromosorb W and
, 210 210 . many others have been used. One recommended method uses carrier
gas saturated with formic acid and gives analyses with a relative stand­
ard deviation of less than 4%. ‘
Alternative approaches to short chain fatty acid analyses have included
derivatisation to improve the gas chromatographic properties. These have
211 - -included formation of benzyl esters, p-bromophenacyl esters and
212 . . p-phenylphenacyl esters and the use of TMS esters prepared via tri-
2 4 5methylsilylimidazole. The derivatisation techniques are not popular
and despite the problems associated with the GC of free acids the latter 
approach is generally used.
TABLE 4
SOME ARTEFACT METABOLITES DETECTED BY GAS LIQUID 
CHROMATOGRAPHY OF ORGANIC ACID EXTRACTS
Metabolite Probable Source Refs.
Adipic acid Medium chain triglyceride feed 213
N. Acetyltryptophan Protein solution stabiliser 213
Benzoic acid Bacterial metabolite 214Soft drinks, berries, jams, coffee 215
Benzyl alcohol Heparin . 215I.V. Phenobarb 215
Chloral glucronide Chloral ■ 213
Chlorocresol Heparin 213
Citric acid homologue "Lemon" drinks 213
Citric acid "Lemon" drinks 213
p-Cresol Anticoagulant 213Gut flora 216
di-Buty1ph thalate Plasticiser 213
di-Ethylphthalate Plasticiser 213
di-Ethylene glycol Carbitol 215
Ethosuximide metabolites Zarontin 2134-Ethylphenol Gut flora 217
2-5-Furandicarboxylic acid Cooked food 218Sterilised I.V. fructose 219
2-Furoylglycine Cooked food 219Sterilised I.V. fructose 219
Hippuric acid Berries, jams, soft drinks 215I.V. Benzoate 213
4-Hydroxyphenyl acetic acid Strep, faecal is overgrowth 215Cheese, wines, beer 215
5-Hydroxycoumaran• * Homogentesic acid hydrolysis 219
4-Hydroxyphenyl hydracrylic acid Dietary origin 220
5-Hydroxymethyl-2-furoic acid Sterilised I.V. fructose 220
Levulinic acid Diet, calcium levulinate 213N-methylpyroglutamic acid Methylated pyroglutamic acid 213
2-Mercaptobonzthiazide Rubber artefact . 213
3,4-Methylcnehexanedioifc acid Cheese 213
Oxalic acid Anticoagulant 215
3-Oxodipropylacetic acid Epilim 222
Pantothenic acid Pantothenic acid 213
Phenol' • Gut flora 217
Antipruritic lotion ' 215Phenylacetic acid Gut flora 213
Decomposition of phenylpyruvic acid 222Phenylpropionic acid Gut flora 213Phcnoxyacetic acid Penicillin V 213Phenylisobutyric acid "Mylesinum" 213
Phthalic acid Drug capsules 213Propylene glycol I.V. drug diluent 213Pyroglutamic acid Nutramigen feed 223Phenyle tnylmalonamide metabolites Primidone 213
2-(N-propyl)glutaric acid Epilim metabolite 221Salicylic acid Aspirin 108
Salicyluric acid Aspirin 108Sebacic acid Medium chain triglyceride feed 213
Suberic acid Medium chain triglyceride feed 213Tributoxyethyl phosphate B-D vacutainer rubber stopper 213Trichloracetic acid Chloral 213Thymol Urine preservative 215Acetic acid ■ Bacterial metabolite 214Crotonic acid . P-hydroxybutyric acid 224Dipropylacetic acid Epilim metabolite 221Isovaleric acid Bacterial metabolite 2143-Methylcrotonic acid 3-Hydroxyisovaleric acid 225Trans-3-methyl-2-hexenoic acid Polythene bags 215Propionic acid Decarboxylation of methylmalonic acid 206Bacterial metabolite 214Epilim metabolite 221
ARTIFACTS AND PITFALLS
A variety of artifacts and pitfalls may occur during the profiling 
of physiological fluids (See Table 4 after Hammond ), The presence 
of a particular component in a fluid extract may easily be misinterpreted 
as an unusual metabolite which bears a casual relationship to the patient's 
state of health although the origin of the component may be due .to 
contamination. Conversely the absence of a component, the presence of 
which is considered diagnostic, may cause the diagnosis of a condition 
to be missed.
Instrumental problems such as loss of resolution and sensitivity 
which may go unnoticed for periods of time without adequate quality 
control may cause metabolites to be missed. This is especially true of
intermittent faults in equipment. The problem of ghost peaks may also
. . . 210arise especially in short chain fatty acid analysis.
Chemical contamination of the extract is common. It may be
aggravated by the concentration effect of solvent removal and may arise
* , . . 215,226 . . ,  ̂ 215,226 „ 215from sample containers, anticoagulants, solvents,
. 213 . . . . 215,227,228reagents or plasticisers.
Bacterial contamination especially of urine specimens may give rise
to serious problems.214, 215,229,230 213Hammond has shown that
about 45% of samples received showed moderate or profuse bacterial growth
. . 214on arrival m  the laboratory and Hansen et al have shown that many
common bacteria can produce organic acids in short time spans. Bacteria
or faulty storage of sample may also lead to the disappearance of metabolites
from the samples.
Numerous problems may be introduced during sample work up and 
derivatisation. Artifacts may be formed by processes such as the de­
hydration of hydroxy a c i d s , d e c a r b o x y l a t i o n , t r a n s - e s t e r i f i c -  
. 231ation or acid or base catalysed decomposition of compounds such as 
232glucose. Similarly GC may be responsible for the unexpected form­
ation of compounds such b-hydraxycouraaodn from homcgentisic acid.^^J^ ^
Perhaps the most serious problems arise from the ingestion of dietary
TABLE 5
METABOLITES IDENTIFIED IN AMNIOTIC FLUID
Refs. | ___________ 1
2-Ketoisovaleric acid
2- Ketoisocaproic acid 
Maleic acid 
P“Hydroxybenzoic acid 
Laurie acid 
Myristic acid 
Palmitic acid 
Stearic acid
Oleic acid 
Salicylic acid 
Glycolic acid
3- Hydroxyisobutyric acid 
3-ifydroxyisovaleric acid 
Urea
2-Kstocaproic acid 
Glycerol Phosphoric acid 
Glyceric acid
2-Methyl-3-hydroxybutyric acid 
2-iHydroxybenzoic acid
2- Ifydroxyglutaric acid -
3- ;H7droxy~3~methylglutaric acid4- Ifydroxybenzoic ac£d
3- Ifydroxyphenylacetic acid 
Gentisic acid 
Homovanillic acid
4- %droxyphenyllactic acid 
Hexadecanol
Pentose alcohol 
Heptadecanoic acid 
Linoleic acid 
Cholesterol
139 j 257, 139 j 
257, 139 139, 475 
139 
139
257, 139
257, 139
257, 139
139
257
257
257
257
257
257
257
257
257
257
257
257
257
257
257
257
257
257 •
257
257
257
257
21 £ 215 •factors and drugs 3 by the patients. Many patients may be on a wide
variety of drugs as well as intravenous alimentation. Particular attention 
must be paid to acidic drug metabolites which could be mistaken for 
endogenous metabolites. All classes of drugs must be considered as 
Jellum et al have shown that even skin ointments containing salicylic 
acid can lead to interferences in urine profiles. Similarly a restricted 
diet may cause distorted excretion patterns of metabolites, especially 
in very sick patients who may be receiving little or no protein in their 
3-1 ini®1* tat ion and so produce only small amounts of diagnostic metabolites.
ORGANIC ACID PROFILE STUDIES
233Since Markey et al published their table of urinary organic acids 
in 1974 many new metabolites have been discovered by GC-MS methods 120 3
219,234-244
aäults112’116’120’245
Later listings have included urinary studies of normal
and newborns112 and have covered diet and
. .. ., n _  120-122 . . individual variation on organic acid excretion.
Most papers have dealt with urine and very little information exists 
on the organic composition of other body fluids. Some quantitative 
results on serum from patients with organic acidurias have been reported.
Since no recoveries have been reported for these studies the results must
• 1 ̂Rremain suspect. Cerebrospinal fluid has been examined especially for
l^R 94ft 947the presence of acidic catecholamine metabolites. 3 3 Variations
of profiles due to neurological disease have been found but further
investigation is required to determine if this can be used as a diagnostic
. 248 249 53 250criteria. Saliva, seminal fluid and synovial fluid have been
p r i  or O
examined for organic acids as has dialysis fluid 3 from nephrectom- 
ised patients. Amniotic fluid is of interest because of the possibility
of antenatal diagnosis, however only a few papers have dealt with the
. .J39,140,253-257 .organic acid content and concentration (Tables 5,6) m
contrast to the number reported for lipid profiles which are of clinical
value in assessing foetal lung maturation.
There has been a report on the organic acid profile of tissue homo- 
65genates where both differences and similarities between organs are 
shown. . Sensitivity was such that samples obtained by needle biopsy could 
be examined but the usefulness of such studies remain to be established.
In all studies of other fluids the profiles obtained are similar to
40
TABLE 6
METABOLITES IDENTIFIED AND QUANTITATED IN AMNIOTIC FLUID
Metabolite
Concentration 
mM/1 (mean^SD) Refs.
Mean Range
Lactate 6.7 2.9 4.1-14.2 139 ;*759 212 253
Pyruvate 0.13 0.04 0.06-0.20 139*8.2 4.0 253
0.046 0.021 0.013-0.097 1390.12 0.06-0.24 140
3 - hy d r o xybutyrate 0.1142 0.0159 256
2-hydroxybutyrate 0.05 0.03-0.10 140
Succinate 0.009 0.007 0.004-0.027 139
2-ketogluty.rate *7.4 3.3 2530.013 0.008 0.004-0.035 139
Citrate *55.5 12.7 253<f>6.62 0.41 4.6-7.72 254
* Values are in mg/L
<j) Values are in mg/100 ml
those obtained from urine although individual components may differ in 
concentration. The levels reported in serum are generally very much 
lower than those present in urine. The definition of the normal organic 
acid patterns in body and in other fluids provides the basis for the
identification of ahnormal patterns which may be present in the disease 
state.
COMPUTERS IN THE IDENTIFICATION OF COMPOUNDS
The widespread use of GC-MS for the examination of biological fluids
has brought with it a number of problems. The most notable of these is
the amount of data generated in a typical experiment where several thousand
mass spectra may be recorded. Apart from pattern recognition techniques
which have been of great value in analysis of volatiles^ 325&-260 and in
261. 26 2the pyrolysis GC-MS of bacteria and cells most of the work on GC-MS 
Profiling of body fluids ultimately ends up with the problem of identify­
ing certain peaks on the gas chromatogram from their corresponding mass 
spectra. Manual interpretation of the relevant mass spectra is often 
difficult and time consuming. The visual comparison of the unknown 
spectrum with a catalogue of known mass spectra often gives valuable
clues with regard to structure. A number of such collections of spectra 
. . , _. , 263-266 . . .have been published, containing up to 40,000 spectra and details
267of these and other data bases are available.
The development of computing facilities has allowed this process of 
matching and interpreting spectra to be automated. Three general 
approaches have been made to computer applications.
(a) The development of methods in which a file or library of encoded 
reference spectra is searched to find the best match with a similarly 
encoded unknown spectrum.
(b) The use of a pattern recognition approach in which the features 
determined from known mass spectra are used to provide classification of 
unknown spectra of compounds which are not in the data base used to deter­
mine the features.
(c) The use of data systems to elucidate structures of unknowns using 
fragmentation rules and known fragmentation patterns. This approach 
attempts to automate that taken by an organic chemist when he manually 
attempts to interpret a spectrum.
h2
The aim of the first approach is to retrieve an identical spectrum to the 
reference spectrum. However any practical .system should be able to retrieve 
spectra of the same compound even when distorted by instrumental variation. 
Many library systems will retrieve the spectra of structurally similar com­
pounds if no matching spectrum is in the library. This approach has received 
the widest attention because of its innate simplicity, generality and 
the availability of large spectral libraries.
In file searching the spectra in the library are coded, typically
by extracting from the complete spectrum some subset of the total data.
This selection generally transforms the spectrum into a code directly
suitable for computer searching thereby reducing both computer storage
and search time requirements. The similarly coded unknown spectrum is
then compared with either the complete set of library codes or some
subset of these to find known spectra which "best fit" the unknown.
A wide variety of algorithms have been used to determine matching of 
. 73library and unknown spectra. The algorithm used will depend on the 
encoding method used and usually gives an output of the M best matching 
compounds with some measure of similarity.
268—271The pattern recognition approach addresses a general problem:
can an obscure property of a collection of objects (in this case compounds)
be predicted and/or detected using indirect measurements (in this case
mass spectra) made on the object, which are known to be related to the
272property via some unknown relationship? The assumption is made in this
approach that if measurements are made of this obscure property then
objects having properties in common will have similar measurements. In most
73,273-288applications to mass spectra interpretation non parametric
statistical methods are used, in which no assumptions are made about under­
lying statistical relationships. This type of mass spectral interpretation 
is useful for identifying certain features in a mass spectrum even if the 
compound is not in the.library and has demonstrated high reliability in 
answering suitable problems. It also has advantages of speed in execution 
once the relevant factors are determined. However most systems based on 
pattern recognition are generally inferior for the unique identification of 
unknowns, may require large amounts of computational effort to
determine the factors to be recognised, and may be very sensitive to the
libraries used to determine the factors.6 - Factor analysis has been 
used to determine the relationships * used to identify the spectrum 
of the unknown. The best use of pattern recognition appears to be in the 
prediction of the mass spectrum where predictive abilities of 70 — 90% 
have been obtained. .
The application of our knowledge of fragmentation patterns appropriate
to various compound types and sub-structures gives the basis of the third
approach to the interpretation of mass spectrum. Such knowledge, although
imperfect, is considerable (e.g. refs. 295-297). However, it cannot
always be formulated into rules for ready use in computer programmes. It
is likely that with the application of computer techniques to large 
■ • % i 3 0 0 m ■libraries to find these associations of known structural and
spectral features, this problem will be decreased.
These techniques have been applied by many workers to analyse
simple monofunctional molecules, to suggest molecular weights or for the
312—316sequencing of peptides "* are often used in conjunction with high 
317-322 .resolution MS. ~ The best known application of mass spectral theory
to mass spectral interpretation is the application of heuristic programming
73 323-327approach by the Stanford group * ' This programme recognises
features in the mass spectrum of the unknown, generates all possible
structures and their predicted mass spectra and tests the generated
spectra against that of the unknown. The programme has.been applied to a
wide range of compounds and mixtures and can make use of
metastable ion data and high resolution MS if available. The programme
has some interactive intervention during execution to save time by
326 327discarding some intermediate structures. The programme is es-
specially useful for isomeric and structurally related compounds. The 
artificial intelligence approach suffers from the Large computer storage 
and execution time requirements, as well as the difficulty of programming 
and has not been generally applied or developed.
The simple search techniques offer a very useful treatment of a 
large data base and together with the use of specialised libraries can 
give many clues to the identification of unknown compounds. Many of 
these library researching techniques are being applied to small spec­
ialised libraries of mass spectra which can be searched quickly, 
often Using the micro or mini computer that controls the GC-MS system.
TABLE 7
NEW METABOLIC DISORDERS DISCOVERED BY GC/MS PROFILING
Disease Metabolites Detected Year Refs*
Refsum's disease**
(phytanic acid storage disease)
Isovaleric acidemia
Methylmalonic aciduria 
Type I 
Type II 
Type III Type IV
Type IV? Methylmalonic and 3-hydroxy-n-valeric acidemia
Propionic acidemiaType I: biotin-unresponsive 
Type II: biotin-responsive
3-Methylcrotonyl-CoA carboxylase 
deficiencyType I: biotin-unresponsive 
Type II» biotin-responsive***
Type III:?
pyroglutamic aciduria 
(5-0xoprolinuriay glutathione, 
synthetase deficiency)
Acyl CoA-dehydrogenase deficinccy? 
(congenital dicarboxylic aciduria)
2- Methylacetoacetic and 2-methyl-3- hydroxybutyric aciduria
D-Glyceric acidemia 
Type I
Type II
2-Ketoadipic aciduria
Glutaric aciduria 
Type I
Type II
Carnitine deficiency
Non-ketotic dicarboxylic aciduria 
(carnitine deficiency?)
3-Hydroxy-3-methylglutaric aciduria
Glyceroluria
Phytanic acid
Isovaleric acid, isovalerylglycine, 3-hydroxyisovaleric acid
Methylmalonic and propionic acids, 
homocystine and occasionally methylcitric 
acid
Methylmalonic, propionic, 3-hydroxy-n- 
valeric and odd-chain fatty acids
Propionic, 3-hydroxypropionic, methyl- 
citric, 3-hydroxy-3-methylglutaric and 3-hydroxybutyric acids and propionyl- 
glycine
3-Methylerotonylglycine, 3-hydroxyiso- 
valeric acid3-Methylcrotonylglycine, tiglylglycine, 
3-hydroxyisovaleric, 3-methylerotonic, 
methylcitric and 3-hydroxypropionic acids 
2-0xoglutaric and 3-hydroxyisovaleric 
acids, not 3-mcthylcrotonylglycine
Pryoglutamic acid (2-oxoproline)
Saturated C»-Cji, dicarboyxlic acids, 
Cto-Cn cis-5-monounsaturated 
dicarboxylic acids and Cio and Cij trans- 3-monounsaturate^ dicarboxylic acids
2-Methylacetoacetic, 2-me thy1-3-hydroxy­
butyric acids and tiglylglycine
D-Glyceric acid and glycine
D-Glyceric acid
2-Ketoadipic, 2-hydroxyadipic and2- aminoadipic acids
Glutaric, 3-hydroxyglutaric and glutaconic 
acidsGlutaric, (no glutaconic), lactic, iso­
butyric, isovaleric, propionic, 2-methyl- 
butyric, ethylmalonic and 3-hydroxybutyric 
acids and several metabolites associated 
with lactic- and keto-acidoscs
Adipic, pimelic and suberic acids
Adipic, suberic and sebacic acids and 
suberylglycine
3- Hydroxy-3-methylglutaric, 3-methy1- 
glutaconic, 3-hydroxyisovaleric and 
3-methylglutaric acids (not 3-methyl- 
crotonic acid)
Glycerol
1963
1965
1965
1967
1967 
19701972
1973
1968 
1970 
1970
1971
1974
333
367
368
1966 133
161152
369
370
371
134
372
373
1970 374
1970
1974
1973
1976
1973
1972
1974
1976
1974
1975 
1975
1975 
1977
1976
1975
1976
1976
1976
1976
193
374
1976 376
377
378
379
239
198
380
381,
382, 
144
383
384
385
386
387 
190
388
347
355
209
225
1977 358
* Only the first published references on the first patients are cited.•* Classified and described clinically by Refsum (334 ) many years before GC and MS methods were 
Used to discover the accumulated metabolite.
**• A recent investigation ( 37<) ) indicates that some of the patients with biotin-responsive
propionic acidemia and 3 methylcrotonyl-CoA carboxylase deficiency may suffer from a combined 
carboxylase deficiency due to a defect in the transport and/or metabolism of biotin rather 
than the synthesis of the apoenzymes.
I
RESULTS OF GC-MS PROFILING
333Since Klenk and Kahlke used GC-MS methods to separate and identify
334an unknown metabolite (phytanic acid) in Refsum's disease, gas phase 
analytical methods have become increasingly important in the diagnosis 
and study of metabolic diseases. Since that time about 25 new diseases 
(Table 7, after Jellum ) have been discovered and about 50 to 60 previous 
ly described inborn errors of metabolism can also be diagnosed and7 C 77f 'Z 'Z Q
studied using this technique 3 ” (Table 8 )* In general these
diseases are recognised because of the occurrence of new or pathological 
metabolites or large increases in normal metabolites, identifiable by 
means of GC-MS. Subsequent biochemical work, such as enzyme studies on 
cells grown in tissue culture and metabolic studies using stable and/or 
radio isotopes and dietary loading studies are needed to confirm the 
diagnosis and to monitor treatment.
The major problem is to find appropriate cases for GC-MS study by
defining the clinical criteria used in the initial screening of cases.
33 7 .Nyhan discussed some of the problems of selecting patients for screen­
ing and points out a number of cases where a misdiagnosis of pyloric' 9
stenosis was made and an operation was carried out before genetic disease 
was properly diagnosed. • .
Organic acid profiling has also been used to study other disease
, . 115,236,340-346 . ^ . 346-350states such as ketoacidosis, lactic acidosis,
. 199,351 , 352 _ . . . . ... 239mental retardation, 3 stroke, congenital dicarboxylic aciduria,
Jamacian vomiting sickness, 
356-357
192,348,353-354 gastro intestinal disordersj217,
disease related to catecholamine metabolism,
.  ̂ 362-365atory distress syndrome
„ 366Reyes Syndrome.
im, 359-361
bacterial and viral infections261
respir-
and
PRENATAL DIAGNOSIS OF GENETIC DISEASE
Examination of the newborn population shows that two to four per
cent have some type of birth defect which can be considered genetic in 
t o oorigin. The term "birth defect" is used in a general sense to en­
compass all types of structural, metabolic and other abnormalities which 
derive from genetic or other prenatal causes. The birtn defects detected 
postnatally represent only a small fraction of all abnormalities that 
result from genetic aberrations because most result in early spontaneous
TABLE 8
SOME METABOLIC DISORDERS OF ORGANIC ACIDS AMENABLE TO STUDY BY GC/MS
Disorder Metabolites Detectable by GC/MS Abnormal 
Amino Acids
Alkaptonuria Homogentisic acid No
Argininosuccinic aciduria Argininisuccinic acid • Yes
Alanir.uria Lactic, pyruvic acids Yes
Carnitine deficiency Adipic, pimelic, suberic acids No
Dicarboxylic aciduria Lactic, adipic, suberic, suberylglycine, 
sebacic, C 10- C m  cia-Sunsaturated dicarboxylic 
C n ~ C i 2 trans-3-unsaturated dicarboxylic acids
No
Diabetes mellitus Glucose, B hydroxybutyric acid, acetoactic acid No
Essential fructosuria Fructose NO
Essential pentosuria L-xylulose YesFructose 1-6 diphospnatase Lactic, pyruvic, 2-oxoglutaric acids
deficiency
Galactosemia Galactose, amino acids Yes
Glucaric aciduria Glucaric, glucuronic acids, glucaric-1, 4-lactone No
Glyceric acidemia (Type I) Glyceric acid Yes
Glyceric acidemia (Type 2) Glyceric acid NO
Glucose-6-phosphatase deficiency Lactic, pyruvic acids No
Glutaric acidemia Glutaric, glutaconic, 3-hydroxyglutaric acids No
Glutaric acidemia Type 2 Butyric, ethylmalonic, glutaric acids ‘
Glutathione synthetase deficiency Pryoglutamic acid NO
Glycogenosis Type I Lactic, zoxoglutaric acids N.
Glycogen storage disease Type I, 2-oxoglutaric, acetoacetic, adipic, suberic, NO
11 sebacic acids
Glycogen synthetase deficiency Lactic acid NO
Glyceroluria Glycerol YesHartnup disease Neutral amino acids
Hawkinsuria 4-hydroxycyclohexylacetic acid Yes
Histidinemia Imidazole lactic, imidazole pyruvic, imidazole 
lactic acid
Homocytstinuria with methyl- Methylmalonic acid Yes
malonic aciduria
Hydroxymethyl-CoA lyase 3-hydroxy-3-methylglutaric acid, 3-methyl- No
deficiency glutaconic, 3-methylglutaric, 3-hydroxy- 
isovaleric acid •
Hydroxykynuren inuria Xanthurenic NO
Hypermethionaemia 2-oxo-4-methiolbutyric acid Yes
Hyperoxaluria Type 1 Oxalic, glycollic, glyoxylic acids No
Hyperoxaluria Type 2 Oxalic, L-glyceric acid No
Hyper-pipecolatemia Pipecolic (pipcridine-2-carboxylic) acid Yes
Hyper-prolincmia l-pyrrolidinc-5-carboxylic acid Yes
Indolylacroylglycinuria Indolylacroyl glycine No
Isovaleric acidemia Isovalerylglycine, 3-hydroxyisovaleric, 
Isovaleric, acetoacetic acids
No
Jamaican vomiting sickness Adipic, C*-Ci2 diunsaturated, ethylmalonic No
(hypoglycin A toxicity) glutaric, 3-hydroxyisovaleric, isovaleric, 
2-methyl succinic methylene cyclopropylacetic, 
2-methylbutyric, sebacic, suberic acids, . 
hexanoyl glycine, isovaleryl glycine
Xetoacidosis Acetoacetic, 3-hydroxybutyric, 3-hydroxy-iso­
butyric, 3-hydroxyisovaleric, 2-methyl-3-hydroxy­
butyric, adipic, sebacic, suberic acids
NO
2-ketoadipic aciduria 2-ketoadipic, 2-hydroxyadinic, 2-amino adipic Yes
Lactic acidosis Lactic, 2-hydroxybutyric acids NO
Lesch Nyhan syndrome Uric acid NO
2-methylcrotonyl CoA carboxylase 
deficiency Type I (biotin
3-methylcrotonylglycine 3-hydroxyisovaleric 
acid
NO
unresponsive)
3-methylcrotony1 CoA carboxylase 
deficiency Type 2 (biotin 
responsive)
2- ethylhydracrylic acid, 3-hydroxyisovaleric,
3- hydroxy-3-methylglutaric, 3-hydroxypropionic, 
methylcitric, 3-methylcrotonic acids, 3-methyl­
crotonyl glycine, tiglylglycine
NO
3-methylcrotonyl CoA carboxylase 2-oxoglutaric, 3-hydroxyisovaleric acids NO
deficiency Type 3
2-methylacetoacetic, 2-methyl- 2-methylacetoacetic, 2-methyl-3-hydroxybutyric NO
3-hydroxybutyric aciduria
Maple syrup urine disease
Methylmalonic aciduria (Types 
I-IV)
2-oxoisocaproic, 2-oxo-3-methylvaleric,
2- oxoisovaleric, 2-hydroxyisocaproic, 2-hydroxy-
3- methylvaleric, 2-hydroxyisovaleric, acetoacetic
3- hydroxybutyric, pyruvic acids.
Methylmalonic, propionic, 3-hydroxybutyric 
acetoacetic, 3- hydru::y-n-vaieric acids, 
and odd chain fatty acids
NO
'Neuroblastoma 3-methoxy-4-hycroxyphenylacetic acid, 
3-methoxy-4-hy<'.roxyinur.aelic acid, 
catecholamines and metabolites
NO
Oat house disease 2-hydroxybutync, phenylpyruvic, branches 
chain ketoacids
Yes
Orotic aciduria Orotic acid NoPhenylketonuria Phenylpyruvic, phenyl-lactic, 2-hydroxy- 
phenylacetic, mandelic, 4-hydroxyphenyl- 
pyruvic,4-hydroxyphenyl-lactic acids.
Yes
Phosphatase dehydrogenase Lactic, pyruvic acids Yesdeficiency
Propionic acidemia Propionic, 3-hydroxypropionic, methylatric 
3-hydroxy-3-methylglutaric, 3-hydroxybutyric, 
acetoacetic, 3-kctovaloric, tiglic acids, 
propionyl glycine, tiglyl glycine
No
Pyruvic decarboxylase deficiency Lactic, pyruvic acids Yes(various forms)
Pheochromocytoma 3-hydroxy-4-hydroxymandelic acid, 
catecholamines and metabolites
NO
Refsum's disease Phytanic acid . NORenal glycosuria Glucose NoSaccharopinuria Saccharopine YesShort chain fat*-.y acidemia Butyric and caproic acids NoSuccinyl CoA-3-ketoacid CoA 3-hydroxybutyric, acetoacetic acids Notransferase deficiency
Tryptopha malabsorption (blue Kynurenic, xanthurenic and indole-3-acetic acid Nodiaper syndrome)
Tyrosinosis (Modes) 4-hydroxyphenyl pyruvic, 4-hydroxyphenylacetic,
4-hydroxyphonyllnctic acids
Yes
Tyrosinaemia 4-hydroxyphenylpyruvic, 4-hydroxyphenylacetic, 
4-hydroxyphenyllactic acids Yes
Tyrosine amino transferase 
deficiency 4-hydroxyphenylpyruvic, 4-hydroxyphenylacetic, 4-hydroxyphenyllactic acids Yes
Urocanic aciduria Urocanic acid NoXanthurenic aciduria Xanthurenic acid No
TABLE 9
ESTIMATED FREQUENCY OF GENETIC DISORDERS IN THE
NEWBORN POPULATION
Disorders
------ - ----- — — j
Percent
CHROMOSOME DISORDERS
Autosomal disorders, e.g. trisomy 21,
. trisomy 18, etc. 0.2
Sex chromosome disorders, e.g. XO and
X deletions, XXY, XXX, XYY, etc. 0.35
TOTAL CHROMOSOMAL DISORDERS . 0 . 5 5 %
MONOGENIC D I S O R D E R S. MENDELIAN INHERITANCE
Autosomal recessive
Severe mental retardation 0.08
Deafness, blindness 0.07
Cystic fibrosis 0.05Adrenogenital syndrome 0.01Albinism 0.01
Amino, organic acidurias 0.02
Mucopolysaccharidoses 0.0005
Tay Sachs disease 0.001Galactosemia 0.005
0.25%
X-linked, e.g. Duchenne muscular dystrophy,haemophilias, etc. 0.05
Autosomal dominant, e.g. Marfan syndrome,
neurofibromatosis, myotonic dystrophy 0.06
TOTAL MONOGENIC DISORDERS 0 . 3 6 %
MULTIFACTORIAL DISORDERS
Congenital malformations, e.g. spina
bifida, anencephaly, congenital heart, 
pyloric stenosis, etc. 1.65
Common diseases, e.g. diabetes, malignancy,allergies ?
TOTAL MULTIFACTORIAL DISORDERS > 1 . 6 5 %
TOTAL FREQUENCY OF GENETIC DISORDERS > 2 . 5 6 %
^9
abortions.
These birth defects may be divided into three general categories or
389classes (Table 9, after Epstein and Golbus )• The first category 
comprises non lethal chromosome disorders which affect about 0.6 per 
cent of the newborn population. The second is the group of Mendelian 
disorders which result from abnormalities of single genes. It is 
estimated that about 0.4 per cent of the newborn population are affected 
by such conditions and this figure does not include diseases which have a 
high incidence in specific racial or other groups. The organic acidemias 
fall into this group. The third group are less well defined and include 
conditions which are influenced by environmental factors. They include 
congenital malformations which affect about 1 per cent of the population 
and multifactorial diseases such as diabetes and schizophrenia which are 
known to have a genetic component. The first two categories of genetic 
diseases are the ones most amenable to current techniques of prenatal 
diagnosis.
Although techniques of prenatal diagnosis are too expensive at present 
to be used as a general screen for all pregnant women it is possible to 
define groups in which the incidence of disease is expected to be high.
Thus the incidence of Downs syndrome in the general population is about 
1 per 1000 live births, but when maternal age reaches forty the incidence 
is about 1 in 17 and when the mother reaches forty-five years the incid­
ence is about 1 in 12. Similarly the chances of a child with an autosomal 
recessive condition such as methylmalonic aciduria being born is much less 
than 1 in 10,000 but if a couple have already had one affected child the risk 
rises to 1 in 4 for each subsequent pregnancy.
There are a number of advantages in prenatal diagnosis of affected 
foetuses. The opportunity to have non affected children by selective 
abortion of affected foetuses can have a profound affect on the mental 
health of a couple and on their economic and social circumstances. In the 
absence of an abortion decision on moral or ethical grounds, the immediate 
treatment of children at, or even before birth may prevent the mental re­
tardation which accompanies these diseases. The definition and screening 
of high risk groups may also have significant economic advantages for the
50
390-392community despite the moral, legal and ethical problems raised.
■ 393 394Figures collected for Downs Syndrome patients 3 indicate that to
screen all pregnant women over forty for this abnormality would cost
about 20% of the amount required to pay for lifetime institutional care
if the detected affected foetuses were born. To screen all women over
thirty-five the cost is about equal to that of caring for the affected
children and if women over thirty were screened the cost would be about
five times the cost of care. Similar results have been demonstrated
395 396for Tay-Sachs disease 3 when Ashkenazi Jews were screened, using 
mass screening programmes to detect heterozygotes. In this case a 
definite cost benefit could be shown, as the incidence in this population 
was shown to be as high as 1 in 15.
Intrauterine diagnosis during pregnancy was a matter of interest 
even to the ancients and ancient texts from Egypt (about 1350 B.C.) 
and Greece suggest methods for determining the sex of the foetus. In 
this century major advances in prenatal diagnosis have been made by the 
examination of maternal body fluids using the knowledge, techniques and 
technology of the disciplines of chemistry, biology and medicine. In
1930^^ a report of aminiocentesis and amniography in late pregnancy
39 8 . .appeared and in 1950 Bevis suggested the link between amniotic fluid,
bilirubin levels and severity of haemolytic disease of the newborn.
399 .In 1963 Liley published the first treatment of disease in utevo when
he described the technique of interuterine transfusion.
The major impetus to the development of prenatal diagnosis of genetic
disorders derives from three simultaneous technical advances in the late
1950's; the technique for obtaining samples of amniotic fluid early in
gestation and the willingness to use it;^^ the development of methods
. . 401-3for the culture of human cells in vitro; and the development of
better techniques of cytogenetic analysis. In 1966 several
reports^^^3 of karotyping of human amniotic cells appeared, in 1967
. ' J07 . .the diagnosis of a chromosome translocation was reported and in 
1968 Nadler reported the diagnosis and its confirmation after abortion 
of a case of Downs syndrome^^ as well as confirmed diagnoses of
a number of biochemical abnormalities.
TABLE 10
INBORN ERRORS OF METABOLISM THEORETICALLY------------------------------------------ —  428
DIAGNOSABLE BEFORE BIRTH(AFTER MILUNSKY )
LIPIDOSES
Cholesterol-ester storage diseaseFabry disease*
Färber disease
Gaucher disease*
Generalized gangliosidosis (GMj_ ganglio­sidosis Type 1)*
Juvenile GM^ gangliosidosis (GM]_ ganglio­
sidosis Type 2)*
Tay-Sachs disease (GMo gangliosidosis Type 1)*
Sandhoff's disease (GM2 gangliosidosis Type 2)*
Juvenile GM2 gangliosidosis (GM2 ganglio­
sidosis Type 3)
GM2 sphingolipodystrophyKrabbe's disease (globoid-cell leukodystrophy) 
Metachromatic leukodystrophy*
Niemann-Pick disease Type A*
Niemann-Pick disease Type B 
Niemann-Pick disease Type C 
Refsum disease* ■
Holman disease*
MUCOPOLYSACCHARIDOSES
MPS 1-Hurler*
KPS 1-Scheie
KPS - Hurler Scheie
KPS II A - Hunter*
KPS II B - Hunter*
KPS III - Sanfilippo A* 
' Sanfilippo B*
KPS IV - Morquio's syndrome*
KPS VI A - Maroteaux-Lamy syndrome 
KPS VI B - Maroteaux-Lamy syndrome 
MPS Vll-ß-glucuronidase deficiency
AMINO ACID AND RELATED DISORDERS
Argininosuccinic aciduria*
AspartylglucosaminuriaCitrullinemia*
Congenital hyperammonemia Histidinemia*
Hypervalinemia
Iminoglycinuria
Xsoleucine catabolism disorder 
Isovaleric acidemia*
Maple-syrup-urine disease: 
Severe infantile* 
Intermittent 
Methylmalonic aciduria:
Unresponsive to vitamin Bi2* 
Responsive to vitamin Bj.2*
Cystathionine synthase deficiency (homocyst- 
inuria)*
Cystathioninuria*
Cystinuria*
Hartnup disease*
Methylenetetrahydrofolate reductase 
deficiency
Ornithine-a-ketoacid transaminase deficiency
Propionyl CoA carboxylase deficiency (ketotic 
hyperglycinemia) *
Succinyl-CoA: 3 ketoacid CoA-transferase 
deficiency
Vitamin B^2 metabolic defect*
DISORDERS OF CARBOHYDRATE METABOLISM
Fucosidosis
Galactokinase deficiency 
Galactosemia*
Glucose-6-phosphate dehydrogenase 
. deficiency*
Glycogen-storage disease (Type II) 
Glycogen-storage disease (Type III)
Glycogen-storage disease (Type IV) 
Mannosidosis
Phosphohexose isomerase deficiency 
Pyruvate decarboxylase deficiency 
Pyruvate dehydrogenase deficiency
MISCELLANEOUS HEREDITARY DISORDERS
Acatalasemia
Acute intermittent porphyria 
Adenosine deaminase deficiency* 
Chediak-Higashi syndrome 
Congenital erythropoietic porphyria 
Congenital nephrosis*
Lysosomal acid phosphatase deficiency* 
Lysyl-protocollagen hydroxylase deficiency 
Myotonic muscular dystrophy 
Nail-patella syndrome 
Orotic aciduria*
Haemophilia*
Cystinosis*
Familial hypercholesterolemia
Glutathionuria
Hypophosphatasia*
I-coll disease Leigh's encephalopathy 
Lesch-Nyhan syndrome* 
Protoporphyria 
Saccharopinuria 
Sickle cell anemia 
Testicular feminization 
Thalassemia*
Xeroderma pigmentosum*
* Diagnosis made
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During the last decade the scope of possible prenatal diagnosis has been
widened from chromosomal aberation to include about fifty metabolic
:er Milu 
414-420
. 393* 412.413 - - - 413diseases (Table 10, afte nsky ) and a number of multi-
factoral congenital malformations.
The most direct technique of examining the foetus is by visual exam­
ination and instruments have been developed for this purpose. Techniques 
of radiological and radioisotope visualisation of the uterine cavity,
foetus and placenta have been developed but the most useful method of
421 .foetal visualisation is that of ultrasonic scanning. This technique
is not useful for prenatal diagnosis of genetic disease but is essential
in safe sampling of amniotic fluid or foetal tissue. Techniques have
oped fo]
426,427
422 423 424 425been devel r sampling the placenta, 3 foetal blood ~3
and tissue 3 but at present these are not safe and reliable and are 
restricted to studies of diseases such as haemoglobinopathies which cannot 
be studied by other techniques.
For most types of prenatal information we must use indirect sampling 
of the foetus through the analysis of the amniotic fluid and its constit­
uents. The ability to obtain amniotic fluid for analysis referred to as 
amniocentesis is basically the mechanical problem of having an amniotic 
cavity large enough for the safe insertion of a needle to withdraw fluid 
for study. The amount of fluid increases during gestation and at 13-14
weeks it is possible to safely withdraw samples of 15 to 25 ml. with little
422 429risk to the foetus or mother 3 using ultra"sound to locate the
pools of fluid.
. 430The criteria for diagnostic amniocentesis include the possibility 
of diagnosing the disease by the study of the fluid, the cells in the 
fluid or in cells cultured from the fluid; the disease must be severe 
enough to warrant the attempt; the lack of effective treatment of the 
disease of in utero or neonatal treatment; and in general the desire 
to consent to termination if the disease is diagnosed. To balance the 
advantage of prenatal diagnosis there are a number of problems and 
xi^s428*431*432*390-392 including the failure to obtain fluid, or 
contamination of the fluid with maternal blood giving cells that are not 
representative of the foetus, the low risks of damage to the foetus or
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inducing abortions, the sampling of only one of a twin pregnancy, Rh 
isoimmunisation of the mother and moral, legal and ethical consequences« 
There may also be problems with the cell culture as only some cells may 
grow giving cell clones which may not be representative of the population 
of foetal cells, or no viable cells may grow or the cells' characteristics 
may change during subculturing. Appropriate control cell lines may assist 
in delineating these problem areas.
Some diseases such as phenylketonuria are not expressed in the fibro­
blast like cell cultures from amniotic fluid and are not amenable to this
type of study. One problem is the large amounts of cells needed for
. .  ̂ , 418,433 £ _enzymic analysis. This may mean four to eight weeks of culture
before sufficient numbers of cells are available and even using micro
methods ~ ̂  two to four weeks are still required. There is only a
relatively short period between the earliest time an amniocentesis can
be performed and the latest time at which termination should be performed.
Longer culture periods can also lead to psychological and other difficulties
for the patient and doctor. Thus there is need for fast and reliable
tests for metabolic diseases using amniotic fluid or cells from the fluid.
ORIGIN AND COMPOSITION OF AMNIOTIC FLUID 
'Amniotic fluid was considered as a stagnant pool until a few years 
ago, but is now seen^^-*^^ as a dynamic system which continually inter­
changes with the amniotic sac, the maternal and the foetal circulations.
The contents of the uterus during pregnancy are ultimately derived from 
the mother but the metabolism of all cells inside the uterus is under the 
genetic control of the foetus. Current evidence indicates that the 
fluid originates as a transudate from maternal and foetal serum across the 
placenta, foetal membranes, and umbilical cord. The foetus also secretes 
fluid into the amniotic fluid from the renal tract, respiratory tract, skin
and appendages.
There are two basic types of process which are responsible for the 
production and composition of amniotic fluid. These are referred to as 
exchange and net transfer. The first involves bidirectional diffusion 
across membranes in equal or nearly equal amounts in each direction.
It is extensive in terms of the numbers of molecules involved (e.g. water 
exchanges at rates of 4-500 ml. per hour) but results in a neatly 
balanced system. It is operative throughout the whole of pregnancy and
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during early pregnancy appears to be the only functional mechanism. 
Membranes such as the chorioamnion, foetal skin, foetal surface of the 
placenta and umbilical cord are involved.
The seond mechanism, that of net transfer, is of lesser importance in 
terms of the number of molecules involved which are insignificant com­
pared to exchange. In terms of the final composition of the fluid this 
process is the most important. The foetal skin keratonises and becomes 
impermeable at about the eighteenth week and from about the fourteenth 
week the foetal kidneys begin to function. Especially in the later 
stages of pregnancy foetal urination becomes a major source of fluid 
and foetal breathing movements point to a possible excretary function 
of the lungs. Foetal swallowing is the major source of removal of 
fluid and solutes during this transfer process.
The fluid consists of water with a large array of solutes. These 
include electrolytes, uric acid and creatinine, cholesterol, carbo­
hydrates, organic acids, amino acids, hormones, enzymes (Table 11) 
and other proteins and lipids. In the fluid a number of viable intact 
cells as well as cell debris, vermix, non viable cells and organelles 
from disrupted cells are suspended. There are relatively few cells 
(2-3000/ml) before the twelfth week of gestation, but by the fourteenth 
week this has increased to about 30,000 cells/ml and this figure rises 
until the end of pregnancy. These cells are desquamated from the foetal 
skin, amnion, tracheobronchial tree, gut and urogenital tract and about 
50% are viable at fourteen weeks. These viable cells are undergoing 
anaerobic metabolism and this may account for the high levels of lactic 
acid and related acids in the fluid (Table 6)
Although water, electrolytes and other diffusable compounds may 
originate from the mother, the amniotic cavity is a foetal compartment 
surrounded as it is by placenta and membranes all of which result from the 
products of conception. The amniotic fluid constituents therefore re­
flect the foetal condition despite the constant interchange across the 
placenta from the foetal to maternal circulation.
TABLE 11
ENZYMES WHICH HAVE BEEN DETECTED IN AMNIOTIC FLUID,
UNCULTIVATED AMNIOTIC FLUID CELLS AND CULTIVATED
AMNIOTIC FLUID CELLS
Amniotic Fluid Uncultivated Amniotic Fluid Cells
Cultivated Amniotic Fluid 
• Cells
Acid phosphatase Acid phosphatase Acid ceramidase
Aldolase Adenylate pryophosphate Acid lipaseAlkaline phosphatase phosphoribosyl transferase Acid phosphatase
Alanine transaminase* Alkaline phosphatase Adenosine deaminase
a-Arabinosidase a-Arabinosidase Alkaline phosphatase
o-Fucosidase a-Galactosidase a-Arabinosidase
a-Galactosidase a-1,4-Glucosidase a-Fucosidase
o-l,4-Glucosidase a-D-Mannosidase a-Galactosidase
a-Mannosidase Arginase a-1,4-Glucosidase
Aminotripeptidase Arylsulfatase A a-Ketoisocaproate decarboxy-
Amylase B-Galactosidase lase*Arylsulfatase 0-Glucuronidase a-L-Iduronidase
Aspartate transaminase* Galactose-l-phosphate uridyl a-Mannosidase0-Galactosidase transferase a-N-Acetylglucosaminidase
0-Glucosidase Glucose-6-phcsphate dehydrog- Amylo-1, 6-glucosidase
Iduronate sulfatase enase Argininosuccinase*
Kininogen Hexosaminidase Argininosuccinate synthetase
Lactate dehydrogenase* Hypoxanthine-guanine phos- Arylsulfatase A
Leucine aminopeptidase phoribosyl transferase Arylsulfatase B
Lipase Isocitrate dehydrogenase AspartylglucosaminidaseLysozyme Lactate dehydrogenase* B-Galactos idase
Malic dehydrogenase* Methylmalonyl CoA mutase Substrate:p-nitrophenyl-B-
Monoamine oxidase N-Acetyl-B-D-galactosaminidase D-galactopyranosideN-acetyl-8-D-glucos- N-Acetyl-B-D-glucosaminidase Substrate:o-nitrophenyl-B-
aminidase Ornithine transcarbamylase D-galactopyranosideN-acetylglucosaminyl 6-Phosphogluconic dehydrogenase Substrate:GMi0-D-N-acetylglucosaminidasetransferase (fetuin Phosphohexose isomerase
acceptor)
N-acetylgalactosaminyl
Valine transaminase*
0-Glucosidase
transferase (fetuin 
acceptor)
Oxytocinase
p-Phcnylenediamine oxidase 
Pepsinogen
Phosphohexose isomerase 
Renin
Ribose-5-phosphate isomerase 
Sialyltransfcraso (fetuin 
acceptor)
0-Glucuron idase 
Carboxypeptidase 
Cathepsin 
Cholinesterase
a. MEM medium, pH 4.0
b. MEM medium, pH 5.3 
C. F-10 medium
0-Glucuronidasc 
Branched chain kctoacid 
decarboxylase*
a. Leucine
b. Isoleucine
c. Valine
Cobalamin adcnosylating enzyme* 
Cystathionine synthase 
Epimcrase
Galactocerobroside 0-galacto- 
sidase
Dissaccharidases
Lactase
Galactose-l-phosphate uridyl 
transferase
Maltase
Palatinase
Sucrase
Trchalase
Diamine oxidase
Diastase
Galactosyltransférase 
(fetuin acceptor)
Glucose-6-phosphate 
dehydrogenase
Glutamic oxaloacetic trans­
aminase*
Glutamic pyruvic trans­
aminase*
Y-Glutamyl transpeptidase
Glucoccrcbrosidase 
Glucosc-6-phosphate dehydrog­
enase
Glycogen branching enzyme
Hexosaminidase
Histidase
3-Hydroxy-3-methylglutaryl 
CoA reductase*
Hypoxanthine-guanine phospho­
ribosyl transferase 
Isovaleryl-Coa dehydrogenase* 
L-Iduronosulfatc sulfatase 
Lactate dehydrogenase* 
Lysyl-protocollagcn hydroxylase 
Methylene tetrahydrofolateGuanine aminohydrolase 
Hexosaminidase -
reductase
Methylmalonyl CoA carbonylmutase*
Histaminase
• ' '
N-Acetylhexosaminidase 6-SO4 
sulfatase
N-Acetylhexosaminidase 4-SO4 
sulfatase
Ornithine kctoacid transaminase 
Phosphorylase
Phytanic acid a-hydroxylase* 
6-Phosphogluconic dehydro­
genase
Propionyl CoA carboxylase* 
Pyruvate decarboxylase*
Pyruvate dehydrogenase* 
Sphingomyelinase 
Succinyl-CoA: 3 ketoacid CoA 
transferase*
Sulfamidase 
Sulfatide sulfatase 
Valine transaminase*
Enzymes associated with amino acidurias or organic acidurias
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PRENATAL DIAGNOSIS USING AMNIOTIC FLUID
Amniotic fluid obtained by amniocentesis during early pregnancy offers
three possible sources for diagnostic analysis:uncultured cells,
cultured cells and amniotic fluid. The majority of prenatal diagnoses
418have been made using cultured cells. These have been used for
cytogenetic studies, for the detection of chromosome abnormalities and 
for sex determination in the diagnosis of sex linked disorders. Cultured 
amniotic fluid cells have recently been used a great deal in the study 
of biochemical inborn errors known to be characterised by an enzyme 
deficiency or some other specific biochemical abnormality. Prenatal 
diagnosis of biochemical defects depends on the demonstration of the lack 
of the required enzyme or accumulation of the metabolites in the cells. 
The enzymes that have been found in cultivated amniotic fluid cells 
obtained during the mid trimester of pregnancy are outlined in Table 11.
The determination of normal ranges of enzyme activity in amniotic 
fluid cells is often difficult. Results may depend on factors such as 
substrate specificity, low levels of enzyme present, contamination with 
maternal cell lines, assay methods used, stability of the enzyme, cell 
cultivation and medium and length of time of cultivation. The cultured 
cells may also show different enzyme levels in different types of cell 
lines and the use of mixed cell cultures may give false results. Despite 
the delay and technical difficulties involved, cultivated amniotic fluid
cells are the most reliable techniques for prenatal diagnosis of inborn
- . , _ . _ 389,418, 431errors of metabolism at present.
A second source of material for enzyme and metabolite analysis is 
uncultured amniotic fluid cells, but biochemical analysis of such cells 
has not been very successful. The problems of enzyme determination are 
similar to those in cultured cells with the further complication that a 
large but unknown percentage of cells are non viable and have no measur­
able enzyme activity. The other major problem is the low overall activ­
ity thus making microenzyme determination almost obligatory. Disorders
 ̂ 438  ̂ 439,440 , ,such as Pompe's disease and Tay-Sachs disease have been
diagnosed using uncultured cells and some intracellular storage diseases
, 441,442have been diagnosed by electron microscopy of such cells.
Prenatal diagnosis of biochemical metabolic defects using these
TABLE 12
BIOCHEMICAL DISORDERS THAT HAVE BEEN DIAGNOSED PRENATALLY
(AFTER EPSTEIN AND GOLBUS)389 *
DISORDER METABOLIC DEFECT
Acid phosphatase deficiency Lysosomal acid phosphatase deficiency
Adenosine deaminase deficiency Adenosine deaminase deficiency
(combined immunodeficiency)
C-ll or C-21 steroid hydroxylase deficiencyAdrenogenital syndrome
Argininosuccinic aciduriat Argininosuccinase deficiency
Citrullinemiat . Argininosuccinic acid synthetase deficiency
Cystinosist Cystine accumulation
Fabry disease Ceramidetrihexoside a-galactosidase deficiency
Fucosidosis a-Fucosidase deficiency
Galactokinase deficiency Galactokinase deficiency
Galactosemia Galactose-1-phosphate uridyltransferase deficiency
Generalized gangliosidosis (GM^ ganglio- B-Galactosidase deficiency
sidosis, Type I)
Juvenile gangliosidosis (GM^ ganglio- 3-Galactosidase deficiency
sidosis, Type II)
Gaucher disease Glucocerebrosidase deficiency
Glycogen storage disease, Type II o-l,4-Glucosidase deficiency
(Pompe disease)
Hemoglobinopathy (sickle cell) Synthesis of hemoglobin S
Hunter syndrome o-L-iduronic acid-2 sulfatase deficiency
Hurler syndrome a-L-Iduronidase deficiency
Hypophosphatasia (some types) Alkaline phosphatase deficiency
I-cell disease Multiple lysosomal enzyme deficiencies
‘Isovaleric acidemia Isovaleryl CoA dehydrogenase deficiency
Ketotic hyperglycinemia Propionyl CoA carboxylase deficiency
Krabbe disease Galactoccrobroside fl-galactosidaso deficiency
Lesch-Nyhan syndrome Hypoxanthine guanine phosphoribosyltransferase 
deficiency
‘Maple syrup urine diseaset Branched chain ketoacid decarboxylase deficiency
Marotcaux-Lamy syndrome Arylsulfatase B deficiency
Menkes disease Copper accumulation
Metachromatic leukodystrophy Arylsulfatase A deficiency
Methylmalonic aciduria Methylmalonic CoA mutase deficiency
Niemann-Pick disease Sphingomyelinase deficiency
Placental sulfatase deficiency Placental sulfatase deficiency
Porphyria - acute intermittent type Uroporphyrinogen I synthetase deficiency
Pyruvate decarboxylase deficiency Pyruvate decarboxylase deficiency
Sandhoff disease Hexosaminidase A and B deficiency
Sanfilippo syndrome, Type A Heparin sulfatase deficiency
Sanfilippc syndrome, Type B N-acctyl-ci-glucosaminidasc deficiency
Tay-Sachs disease Hexosaminidase A deficiency
o-Thalassemia Decreased synthesis of a chain of hemoglobin
3-Thalassemia Decreased synthesis of 8 chain of hemoglobin
. Kolman disease Acid lipase deficiency
Xeroderma pigmentosum UV endonuclease deficiency
* Organic acidemias 
t Amino acidurias
methods have been practised for the last ten years and some one
thousand cases have been studied 
Epstein and Golbus^^) .
389,418,443 (Table 12 after
Cell free amniotic fluid has also been examined and used for 
prenatal diagnosis. A number of metabolic diseases such as 
Hunters syndrome and Tay-Sachs disease have been diagnosed on the 
basis of enzyme deficiency in the cell free fluid but the origin and 
characteristics of the enzymes present (see Table 11) are largely 
unknown.
The soluble components of amniotic fluid have also been subjected 
to various types of analysis. Amniotic fluid contains one
tenth to one twentieth of the protein content of serum and some attempts 
have been made to study protein disorders. The study of alpha-fetoprotein 
for the diagnosis of neural tube defects is a notable exception
and screening methods are available using maternal serum levels to
. . . . . . 445indicate a high risk group in which amniocentesis should be performed.
The screening for metabolites in amniotic fluid has not proved very 
useful/however, few representative studies are available. The 
increasing foetal contribution to the fluid during pregnancy should 
cause the concentration of the metabolites to increase in the fluid.
This has been demonstrated for the concentration of methylmalonic '
. . a 446acid m Afoetus affected with methylmalonic aciduria and for steroids
. 4 4 7 4 48m  a case of adrenogenital syndrome. * It should be noted that
no abnormality was shown in amniotic fluid branched chain amino acid
. 449levels in one foetus affected with maple syrup urine disease. 450
450Morrow has suggested that the reason for this is that the maternal 
circulation can clear the foetal circulation of the particular 
metabolite, especially if the metabolite can be used by maternal cells. 
In the case of methylmalonic aciduria however the active substrate is 
methylmalonyl coenzyme-A» and this must be hydrolysed before it can 
diffuse into the foetal extracellular space. Thus MMA appears in the 
amniotic fluid and is carried via the maternal circulation to appear in 
the maternal urine. This process should occur for other organic acids 
thus making metabolite measurement suitable for prenatal organic
7 7
acidemia diagnosis. Thus examination of amniotic fluid and maternal 
urine could be a useful adjunct to cell culture in prenatal diagnosis 
of organic acidemias. Up to now experience has been limited to methyl­
malonic aciduria and further developments in this field must await suit­
able techniques and application to other diseases.
AIMS OF THIS WORK
The use of GC-MS profiling of metabolites in amniotic fluid offers 
the possibility of fast accurate prenatal and perinatal diagnosis of 
metabolic disease. The aim of the work reported in this thesis is the 
study of metabolic disease of genetic origin using techniques of GC 
and GC-MS with special emphasis on the prenatal diagnosis of such 
disease in cases where the risk of an affected foetus is known to be 
high. The low levels of acidic metabolites present in amniotic fluid 
reported in the profiling studies (Table 6) and the presence of 
relatively high levels of protein in the fluid suggested the need for 
quantitative recovery studies and methods suitable for accurate precise 
analysis.
R E S U L T S  A N D  D I S C U S S I O N
60
PRENATAL DIAGNOSIS OF INHERITED DISEASE 
BY METABOLIC PROFILING
a. DEVELOPMENT OF METHODS FOR THE ANALYSIS OF 
METABOLITES IN AMNIOTIC FLUID
The diagnosis of organic acidurias and acidemias depends on the
identification and quantitation of organic acids present in biological
fluids. In order to examine the use of metabolite concentrations in
amniotic fluid for the prenatal diagnosis of metabolic diseases accurate
methods of quantitation of these metabolites must be available. This
analytical problem may be divided into two parts, namely the separation of
the acids from the matrix and the derivatisation and analysis of the
organic acids. Very little has been reported on the isolation and
quantitation of organic acids from amniotic fluid. Hagenfeldt and 
139Hagenfeldt quantitated six acids in amniotic fluid and identified
nine other acids by using a perchloric acid protein precipitation
140 257method that they developed for serum. Nichols et al J did not 
pretreat the fluid before extraction but used a preliminary basic extraction 
to remove neutral and basic substances which interfered with the GC
profile. Other early work in the quantitation of specific acids in amniotic 
fluid relied on colounmetnc or enzymatic methods of
analysis using perchloric deproteinised amniotic fluid.
Results for the quantitation of methylmalonic acid (MMA)(I) in amniotic
446 .fluid have been published. Morrow et al used automatic column chromatog­
raphy on silicic acid for separation and quantitation of MMA (I) using
157untreated amniotic fluid. The same group has recently reported 'a 
method in which amniotic fluid is saturated with sodium chloride, acidified 
and extracted in similar fashion to a urine specimen. ; Rosenberg and co-
7 ? 7 7 egworkers 3 have reported the preliminary separation of MMA (I)
using an ion exchange column 
eluate.
162 followed by extraction of the column
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Despite this variation in reported methods Jellum's review states
that due to low protein levels in amniotic fluid acidic metabolites may be
extracted from it using the same methods as those developed for urine.
TABLE 13
RECOVERY OF MMA (I) AND ADIPIC ACID (II) FROM AMNIOTIC FLUID
AND URINE USING SOLVENT EXTRACTION AND ION EXCHANGE METHODS
SPECIMEN TOTAL PROTEIN ACID
RECOVERY►(%)a
Solvent 
Extraction 
Method (157)
Ion Exchange Methods
A (162) B (125)
Amniotic Fluid Pool 1 5.6 g/1 MMA (I) 28 ± 6 22 ± 12 18 ± 9
(14-17 weeks) Adipic (II) 77 ± 5 62 ± 10 66 ± 10
Amniotic Fluid Pool 2 2.9 g/1 MMA (I) 39 ± 7 33 ± 9 26 ± 8
(35 weeks) Adipic (II) 83 ± 6 77 ± 8 79 ± 9
Urine M,MA (I) 79 ± 3 85 ± 2 92 ± 5
Adipic (II) 93 ± 3 94 ± 2 96 ± 3
a Results are expressed as mean % recovery ± 2 x SD and were obtained by analysing at least 
3 samples by GC of the TMS derivatives on Apiezon-N.
6 2
For our initial investigation one solvent extraction and two ion 
. 125,162  ̂ ,exchange methods were selected for detailed examination. The sol­
vent extraction method was modified to use ethyl acetate rather than 
diethyl ether as extracting solvent as the latter caused stable gel 
formation with some samples of amniotic fluid. Initial experiments
were based on extracting acidified amniotic fluid directly but a large
number of extraneous substances were co-extracted which interfered with
the GC analysis of some acids. This problem was overcome by pre-extraction
of the interfering components at pH 7-9. This method gave a recovery of 
aqueous96% when/standard solutions of acids were used.
The two ion exchange methods examined were Giorgio and Ploufs pro­
, 162 .cedure which uses Dowex 3x4 resin for absorbtion of organic acids,
elution with dilute HC1 followed by neutralisation and lyophylisration
125and Thompson and Markey's method which uses barium hydroxide precipit­
ation of sulphate and phosphate followed by absorbtion of the acids on 
DEAE-Sephadex followed by elution with pyridinium acetate and lyophl- 
isation. Both methods gave measured recoveries of greater than 95% when 
standard solutions of acids were used. Both methods were tried on samples 
of pooled amniotic fluid. One pool was derived from fluid obtained at 
14-17 weeks gestation and the other pool was derived from fluid obtained 
after 35 weeks gestation. For comparison the methods were also tried on 
a urine sample. MMA (I) and adipic acid (II) were added to the samples 
and the samples were worked up as described above and the acids were 
quantitated on.the GC as the IMS derivatives.
The results obtained for the 2 amniotic fluids and urine samples are 
shown in Table 13. These results show low recoveries of acids by all 
methods and wide variations in recovery between the two acids.
The lower recoveries of MMA (I) may be due to the ready decarboxylation 
of the acid in strongly basic or acidic solution but this loss was not seen 
when standard solutions or urine were used. This loss then must be due to 
the sample matrix. The major difference between the urine and amniotic 
fluid samples is the presence of protein.
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TABLE 14
RECOVERY OF MMA (I) AND ADIPIC ACID (II) 
FROM DILUTED SERUMa USING SOLVENT EXTRACTION
DILUTION OF 
SERUM3 
(Parts H2O 
added)
APPROXIMATE
PROTEIN
CONCENTRATIONb
% RECOVERY0
MMA ( I) Adipic Acid (II)
g/i
Nil 80 2-14 64-77
2 40 6-19 70-82
3 26 10-24 76-85
10
__________________^
8 72-79 92-98
a Pool obtained from 100 healthy blood donors
b Measured colourimetrically on Technicon 
Autoanalyser.
c Results are range of mean % recovery ± 2 SD 
for 3 samples by GC of the TMS derivatives on 
Apiezon-N.
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The amniotic fluid protein content however varies with the gest­
ation period from 0.7-8.2 g/1 (mean 3.85 g/1) at 13 weeks to a peak of 
4.0-8.0 g/1 (mean 6.28 g/1) at 25-28 weeks and gradually falls to about 
1.5-7-.0 g/1 (mean 2.96 g/1) at term. The recovery of MMA (ij from the 
amniotic fluid samples is less for those samples with a higher protein
content and this suggests that the variable protein content is responsible
162for the low recoveries. When Giorgio and plout's method was used inter­
fering peaks due to phosphate and sulphate TMS derivatives made the quantit­
ation of some organic acids difficult. This result was unexpected as the
452 453reported concentration 3 of phosphate and sulphate in amniotic fluid are
comparable to those in serum which are 10-20 times less than those found
in urine. However much of the phosphate (^ 85%) and sulphate ('V/ 50%) in
serum and amniotic fluid are combined as esters and the free ions may be
released on hydrolysis. The levels of organic acids present however is
much lower than those in urine and the increased sensitivity required for
the analysis increases the effect of the presence of sulphate and phosphate.
125Thompson and Markey suggested a precipitation of sulphate and phosphate 
ions with barium hydroxide to remove this interference but since this step 
may lead to the removal of organic acids as insoluble barium salts, the 
ion exchange approach was abandoned. .
In order to test the suggestion that the increased protein content 
could interfere with the extraction of organic acids, standard amounts 
of MMA (I) and adipic acid (II) were added to diluted pool serum and the 
samples were worked up and quantitated as described above. The protein 
content of the solutions varied from 8-80 g/1. The results obtained in 
these experiments are shown in Table 14. These results show that as the 
protein content of the solution is increased the recovery of both acids 
falls and this effect is more pronounced for MMA (I). The reason for the 
lower recovery of MMA is not clear but similar results were also obtained 
when other substituted malonic acids such as ethyl malonic acid (III) or 
propylmalonic acid (IV) were extracted from serum or amniotic fluid.
The results also highlight the variability in the extraction of the acid 
even when identical matrices were used and that the reproducibility of the 
extraction increases as the protein content falls.
table 15
RECOVERY OF MMA(I) AND ADIPIC ACID (1,1) FROM 
AMNIOTIC FLUID AND SERUM USING GEL FILTRATION
SAMPLE TOTALPROTEIN ACID
RECOVERY3-
2 yg/ml 
added 
acids
5 ug/ml 
added 
acids
Amniotic Fluid MMA (I) 29 ± 7 29 ± 8
Pool 1 5.6 g/1
(14-17 weeks) Adipic 79 ± 6 77 + 7
Amniotic Fluid MMA (I) 39 ± 8 39 ± 9
Pool 2 2.9 g/1
(35 weeks) Adipic (II) 85 ± 7 86 + 9
MMA (I) 3 ± 4 4 ± 7
Serum 80 g/1
Adipic (II) 62 ± 7 66 ± 5
Serum diluted MMA (I) 15 ±. 8 16 ± 4
with 2 parts 26 g/1
h 20 Adipic (II) 64 ± 7 81 ± 5
Standard MMA (I) 94 ± 3 95 ± 4
Solution Adipic (II) 97 ± 2 97 ± 3
a Results are expressed as mean % recovered ± 2 SD 
for 3 samples and were obtained by GC analysis of 
the TMS derivatives on Apiezon-N. .
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' TABLE 16
RECOVERY OF MMA (I) AND ADIPIC ACID (II)
FROM ULTRAFILTRATION OF AMNIOTIC FLUID AND SERUM
SAMPLE
TOTAL
PROTEIN
BEFORE
ULTRA­
FILTRATION
ACID
RECOVERY51
2 yg/ml 5 yg/ml
Amniotic Fluid 5.6 g/1 MMA (I) 26 ± 5 29 ± 6
Pool 1
(14-17 weeks Adipic (II) 74 ± 8 75 ± 6
Amniotic Fluid 2.9 g/1 MMA (I) 37 ± 4 41 ± 7
Pool 2
(35 weeks) Adipic (II) 83 ± 9 88 ± 8
Serum 80 g/1 MMA (I) 6 ± 6 3 ± 3
Adipic (II) 60 ± 5 60 ± 7
Serum Diluted 20 g/1 MMA (I) ’ 13 ± 7 14 ± 5
with 3 parts
H2° Adipic (II) 81 ± 5 83 ± 6
Standard Acids MMA (I) 91 ± 4 90 ± 4
Adipic (II) 94 ± 3 95 ± 4
a Results are expressed as mean % recovery ± 2 SD 
for 3 samples and were obtained by GC analysis of 
the TMS derivatives on Apiezon-N.
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These results suggest that the protein content of the amniotic fluid is 
responsible for the organic acid analysis problems and alternative 
methods of removing protein from the samples should be examined.
In order to determine whether the acids could be retained in the water 
fraction of the fluids an attempt was made to separate the protein and the 
MMA (I) and adipic acids (II) using gel filtration. Molecular sieve 
chromatography using Sephadex G-10 resin was used to separate the high 
and low molecular weight fractions of serum and amniotic fluid which 
contained the added MMA (I) and adipic acids (II). The results of these 
experiments are shown in Table 15. The recovery of a standard solution 
of acids from the low molecular weight fraction is virtually quantitative 
but that from the various protein containing fluids is low and variable.
The possibility of separating the acids from the protein by washing 
was also examined. An ultrafiltrate of fluids was obtained by centrif­
ugation in a size selective semi-permeable membrane cone which retained 
compounds with a molecular weight of greater than 25,000. The sample was 
ultrafiltered and the residue made up to the original volume of the 
sample and further centrifuged. A sample of standard acids gave recovery
of 85% in the first centrifugation. The protein content of the ultra-
454filtrates as measured by trichloracetic acid turbidimetry was less 
than 100 mg/1. The results of these experiments (Table 16) show that 
the acids could not be washed from the protein and again show the lower 
recoveries of added acids from solutions with higher protein concentration, 
These results suggested that the assumption that the protein content of 
amniotic fluid is too low to cause interference is incorrect and that the 
presence of protein was causing the low recoveries of the organic acids.
The usual method of removing such interference in a clinical chemistry 
method is by precipitation of the protein. Precipitation involves the 
changing of protein structure to lower the solubility of the molecules. 
Proteins carry both positive and negative charges and the precipitation 
process depends on factors such as pH of the solution and dielectric 
properties of the solvent. There have been a large number of methods 
developed to achieve this, most of which leave small amounts of protein 
in the solution. However, such techniques must be studied to ensure that
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TABLE 17
RECOVERY OF MMA (I) AND ADIPIC ACIDS (II)
FROM AMNIOTIC FLUID USING PROTEIN PRECIPITATION METHODS
REAGENT
% RECOVERY9,
SAMPLE Amniotic
(14-
Fluid Pool 1 
17 weeks)
Amniotic
(35
Fluid Pool 2 
weeks)
ACID MMA (I) Adipic (II) MMA (I) Adipic (II)
Ethanol (371) 34-47 86-93 37-49 89-93
Methanol (152) 32-46 84-94 38-46 87-93
Heat & Acetic Acid (161) 46-53 92-96 50-61 91-97
Perchloric Acid (235) 10-24 29-47 16-29 33-61
Sulphosalicylic Acid (455) 9-21 31-53 18-27 42-60
Tungstic Acid (142) 11-30 32-50 20-32 45-64
Zinc Sulphate + Sodium Hydroxide (142) 31-46 80-92 34-52 82-94
Zinc Sulphate + Barium Hydroxide 32-45 80-94 30-54 78-94(Somogyi)(142)
«
a Results are expressed as the range of recovery of the acids obtained from 2 samples which 
were analysed by GC of the TMS derivatives on Apiezon-N.
TABLE 18
RECOVERY OF MMA (I) AND ADIPIC ACID (II)
FROM SERUM USING PROTEIN PRECIPITATION METHODS
% RECOVERYa
REAGENT REF. SAMPLE Serum Serum Diluted with 3 parts H2O
ACID MMA (I) Adipic (II) MMA (I) Adipic (II)
Ethanol 371 3-17 62-80 6-22 66-84
Methanol 152 4-20 64-80 6-26 67-81
Heat + Acetic Acid 161 25-46 66-86 28-50 65-90
Perchloric Acid 235 0-12 30-55 2-18 36-61
Sulphosalicylic Acid 455 2-16 49-65 0-14 42-65
Tungstic Acid 142 3-17 37-62 7-24 33-47
Zinc Sulphate + Sodium Hydroxide 142 12-26 82-94 16-29 81-97
Zinc Sulphage + Barium Hydroxide 
(Somogyi) 142 14-32 81-97 16-35 75-93
a Results are expressed as the range of recoveries of the acid obtained from 2 samples 
which were analysed by GC of the TMS derivative on Apiezon-N.
cnvO
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the analyte does not precipitate with the protein, that there is no 
interference from reagents and that there is no decomposition of the 
analyte or any other methodological bias in the result.
Proteins may be precipitated by either physical or chemical means. 
Physical methods include ultrafiltration, microdiffusion and heat dénatur­
ation. Chemical techniques include antigen-antibody reactions, protein 
dehydration by use of organic solvents and insoluble salt formation with 
reagents such as perchloric acid, sulphosalicylic acid or tungstic acid. 
The general nature of these chemical precipitation reactions appears 
fairly certain although some details remain obscure.
A number of reports of the application of these methods to organic
acids in serum have appeared in the literature. The most often reported
method for the measurement of MMA (I) in serum is that developed by 
7 61Oberholzer et al in which serum is diluted thirty times in dilute 
acetic acid and the protein is denatured by heating. Methods using 
organic solvents to dehydrate protein molecules and to lower the 
dielectric content of the solution have been used for the examination 
of organic acids in serum, disrupted cells and other protein containing 
fluids. Acetone, methanol and ethanol have
all been used in proportions varying from one to ten volumes of
solvent for each volume of serum. Precipitation methods using perchloric
23 5 455 .acid and sulphosalicylic acid have also been used to examine
MMA (I) and other organic acids in serum. Unfortunately in all these
reported methods for organic acids no recovery experiments were reported.
We have now carried out recovery studies using Oberholzer et al's
152 371 . ■ • 142,235,455method, alcohol precipitation 3 and a variety of anionic
142 . • •and cationic precipitating agents with both amniotic fluid and serum.
(Tables 17, 18) In each case the use of standard solutions of acids gave 
recoveries of greater than 90%. The highest recoveries in the experiments 
were obtained usinc^ the more gentle physical precipitation method of 
Oberholzer et al. The anionic precipitating agents such as perchloric
and sulphosalicylic acids gave the lowest recoveries suggesting that the 
free acids are precipitated with the protein. The cationic precipitating
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FIGURE 6. Recovery of MMA and adipic acid from amniotic fluid at various
d i l u t i o n s .  5vg/ml aoid added
FIGURE 7. Recovery of MMA and adipic acids from serum at various
d i l u t i o n s .  S\ig/ml acid added
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FIGURE 8 . Recovery of MMA and adipic acids from amniotic fluid after 
samples allowed to stand at pH 10 before acidification and 
extraction of organic acids.
FIGURE 9. Recovery of MMA and adipic acids from serum after samples
allowed to stand at pH 10 before acidification and extraction 
• of organic acids. •
TABLE 19
RECOVERY OF MMA (I) AND ADIPIC ACIDS (II)
FROM AMNIOTIC FLUID AND SERUM USING SODIUM DODECYL SULPHATE
SAMPLE ACID % RECOVERY^
No SDS Present SDSC Present
Amniotic Fluid Pool la MMA„ (I ) ’ . 78 ± 5 84 ± 4(14-17 weeks) Adipic Acid (II) 93 ± 3 95 ± 3
Amniotic Fluid Pool 2a MMA (I) 79 ± 4 84 ± 4(35 weeks) Adipic Acid (II) 93 ± 3 95 ± 4
Serum13 MMA (I) 78 ± 4 83 ± 5
Adipic Acid (II) 95 ± 3 97 ± 4
a Amniotic fluid samples were diluted with water containing SDS (2 ml) and allowed to stand 
at pH9-ll for 20 mins, before extraction.
b Serum was diluted with water (9 ml) containing SDS and allowed to stand at pH9-ll for 20 
mins, before extraction.
c Final concentration in the solution 0.5%.
d Results were reported as mean % recovery ± 2 SD and were obtained by analysing 5 samples 
by GC of the TMS derivatives on Apiezon-N.
agents such as zinc sulphate and the Somogyi procedure give higher but 
variable levels of recoveries as do the alcohol precipitation methods. 
The use of alcohol as precipitating agent gave some problems in the GC 
analysis due to the presence of a number of extra peaks which interfere 
with the organic acid determinations. These were presumably due to the 
presence of lipid materials and other small molecules.
The higher recovery obtainable from the slow precipitation in Ober- 
161holzer's method and in the diluted serum specimens suggested that
the effect of diluting the protein containing fluids as well as the time
required for the dissociation of the acids from the protein be investig-
456ated. Warner and Vahouny have already shown that standing in alkaline 
solutions is important for the dissociation of chemically bound MMA (I)
and succinic acids (IX) in tissue homogenates.
A series of experiments were carried out to find the optimum dilution for 
serum and amniotic fluid to obtain maximum recoveries of the acids.(Figs.
6 and 7) These results were obtained by adding varying amounts of water 
to the fluid before extraction from alkali to remove neutral compounds, 
acidification and extraction of the acids. The results show that the 
addition of 2-3ml water/ml fluid gives maximum recovery of the two acids 
from amniotic fluid and the addition of 8-10ml of water is required 
per ml of serum«
Experiments showed that the time of standing in acid solution before 
extraction of the acids had no measureable effect but that when the sol­
utions were allowed to stand at pH 9-11 the recovery of the acids was 
improved. (Figs. 8 and 9). For both the amniotic fluid and serum the 
optimum time of standing at alkaline pH is 15 to 20 minutes. This time 
presumably represents the time required to dissociate the tightly bound 
acids from the protein.
The addition of sodium dodecylsulphate (SDS) was also investigated 
and was shown to improve the recoveries of the acids, (Table 19). These 
results show that the recovery of the acids was improved by about 5% when 
SDS was used. The use of SDS resulted in a number of additonal peaks on
TABLE 20
ABSOLUTE AND RELATIVE RECOVERY OF ACIDS ADDED TO AMNIOTIC FLUIDS
—
. ACID LEVELADDED
RECOVERIES3,
Amniotic Fluid Pool 1 
(14-17 weeks)
Amniotic Fluid Pool 
(35 weeks)-
2 Serum
Absolute Relative Absolute Relative Absolute Relative
Adipic - 5 yg 95 + 3 95 + 4 97 + 42 yg 96 + 4 95 + 3 96 + 4
Succinic 5 yg 84 + 3 87 + 3 85 + 4 89 + 4 86 + 5 91 + 52 yg 85 + 3 89 + 3 85 + 4 88 ± 4 86 + 5 90 + 5
Glutaric 5 yg 82 + 3 86 + 3 84 + 3 87 ± 3 83 + 3 86 + 32 yg 83 + 4 87 + 4 83 + 3 87 ± 3 83 + 3 87 ± 4
Levulinic 5 yg 71 + 6 74 + 7 74 + 5 77 + 5 74 + 6 77 + 6
2 yg 69 + 4 73 + 4 70 + 4 74 + 4 74 + 4 78 + 4
2-Hydroxyiso- 5 yg 70 + 5 73 + 5 74 + 3 77 + 3 71 ± 5 75 + 5
caproic 2 yg 71 + 5 . 75 + 4 73 4 . 76 + 4 71 ± 3 75 + 3
Phenylacetic 5 yg • 86 + 7 90 + 7 87 + 3 91 + 3 88 ± 5 92 + 5
2 yg 86 + 4 91 4 86 + 4 90 + 4 88 ± 3 92 Hh 3
p -Hydroxyphenyl- 5 yg 93 + 5 97 + 5 . 94 + 3 98 ¿ 3 92 + 5 96 ± 5
acetic 2 yg 89 + 3 94. + 3 94 + 3 99 + 4 92 + 4 97 + 4
Myristic 5 yg 99 + 4 103 + 4 98 + 5 102 + 5 102 + 5 106 + 52 yg 100 + 3 105 + 3 98 + 4 103 + 4 99 Í 5 104 Í 5
a Results are reported as mean %’ recovery ± 2 SD and were obtained by analysing 3 samples by 
GC as the TMS derivatives on Apiezon—N. Pimelic acid was used as external standard and 
Adipic acid (II) used as internal standard.
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FIGURE 10. GC profile from SE-30 packed column of the silylated organic 
acid extract from normal amniotic fluid.
The pcake were identified ao: 1, lactic acid;2,2-hydroxyhutyric acid; 3, 2-hydroxybutyric 
acid;4. urea; 5, glycerol; 6. succiriic acid; 7,phosphoric acid;8.adipic aciddntcrnal standard) 
9,malic acid; 10.citric acid; 11,di-n-butylphthalatc;12.palmitic acid; 12, linoleic acid; 
14totcaric acid.
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TIME (min.)
FIGURE 11. The total ion current profile from the SE-54 capillary column 
of the silylated organic acid extract from normal amniotic 
fluid.
The peaks were identified as :1, 3-hjdroxy butyric acid; 2,2-hydroxy-3-mcthijlbutyric acid; 
3,2-hydroxybutijric acid;1,succinic acid;5,phosphoric acid;G,glutaric acid ;7,adipic 
acid;8,dodccyl-l-ol;9tpimelic acid(internal standard) ; 10tdodccic acid;11tdodccyloulph- 
u ric  acid;12 citric acid. SS=soLvent suppression.
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FIGURE 12. GC profile from the SE-30 packed column of the silylated organic 
acid extract from normal serum.
o
E
T
E
C
T
0
R
R
E
S
P
0
N
S
E
20 . 15 10 5 0
TIME (min.)
FIGURE 13. GC profile from SE-30 packed column of the silylated extract 
from amniotic fluid at alkaline pH.
Temperature programmed at 10°C per minute.
the GC after derivatisation. These were shown to be due to the presence 
of dodecylsulphuric acid-TMS, dodecyl-l-ol-TMS and the related homologous 
compounds. These compounds were present in the reagent, and the alcohol 
and acid components increased when the reagent was kept for some time.
The presence of the acids and alcohol peaks could be minimised by the 
use of a freshly prepared solution of SDS. The presence of these peaks 
in the GC profile did not interfere with the measurement of any of the 
acids studied but where this possibility exists the lower recoveries of 
acids obtainable without SDS must be tolerated.
The increased recoveries in the presence of SDS may be explained by 
its mode of action. This chemical interacts with the water layers 
associated with the surface of protein molecules and alters the tertiary 
structure of the molecules to give globulin like molecules. It is a 
gentle method of denaturing protein which gives molecules which are 
usually insoluble under acid conditions but soluble in base. This ex­
plains the precipitation of the protein when the specimens were acidified 
to pH 1.
The extraction of a series of acids of different types was measured 
using the above method. Known amounts of the acids were added to samples 
of amniotic fluid and serum pools and the recovery of each measured. The 
results of this study are presented in Table 20. These results show that 
the added acids were all extracted with reasonable recoveries but only the 
non polar fatty acid was extracted quantitatively. The reproducibility of 
extraction is high and even when lower recoveries are obtained this allows 
accurate quantitation of the acids in amniotic fluid and serum. The use 
of this solvent extraction method thus allows fast accurate quantitation 
of the metabolite in amniotic fluid or serum samples.
The normal profiles of amniotic fluid and serum obtained using this 
method are shown in Figs. 10 to . 12 and the profile of the alkaline 
extract of serum is shown in Fig. 13. This alkaline extract contains 
a large number of components which were not identified but included 
phenols, alkehydes, ketones and alcohols.
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FIGURE 14. Synthesis of 2 H 3 -MMA.
FIGURE 15. CI-MIS calibration curve for MMA.
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The use of this method allowed the quantitation of organic acids in 
amniotic fluid samples with a lower limit of detection of approximately 
0.3 yg/ml and a precision of 0.1 yg/ml. Variations of MMA (I) concentra­
tion in duplicate samples of less than 4% were obtained using this method.
To overcome the inherent difficulties of measurement of small amounts 
of organic acids in amniotic fluid and serum, an isotope dilution method
was considered to validate the analysis of MMA (I) . Trideuteromethylmal-
• • • 451onic acid diethyl ester (V) was prepared by the malonic ester synthesis
. . . . 458using trideuteromethyl iodide (VI) (Fig. 14). The ester was hydrolised
with potassium hydroxide and the extracted solid recrystallised t o ’constant
melting point. The compound was found to contain about 6% hexadeutero-
dimethylmalonic acid (VII). The trideuteromethylmalonic acid (^H^MMA)(VIII)
had an isotopic purity of greater than 99%. The TMS derivative of 2HjMMA (VIII) had a fractionally shorter retention time than the unlabelled
MMA (I) but the two compounds could not be separated by GC and MIS was
2..used for measurement of the ratio of H^MMA (VIII) to MMA (I). Using 
^ M M A  (VIII) as an internal standard, a calibration curve for MMA (I) 
was then prepared over a range of 0-25.0 yg of MMA (I).
The ion pairs at m/e 218.3, 221.3 and 247.3, 250.3 were chosen for
El-Ml S as the ions at 221.3 and 250.3 retained the deuterium label.
The ratios were measured using EI-MIS as was the ratio of the protonated
molecular ions at m/e 263.3, 266.3 using Cl-MIS. These peak heights
ratios were corrected for forward contribution‘of the MMA (I) to the
internal standard (VIII) and back contribution of the internal standard
(HjMMA) (VIII) to the MMA (I) using a calculator programme (see Appendix
A). The corrected peak height ratios gave straight line calibration curves
with correlation coefficents of greater than 0.99 in each case. The
Cl-MIS calibration curve obtained using uncorrected and corrected peak
height ratios (Fig. 15) shows that use of the correction extends the linearcalibration t
region of the calibration curve and gives a straight line^curve which 
passes through the origin. As expected the Cl-MIS mode gave intensities 
which were much higher than those obtained when the fragment ions pairs 
were used. As we have shown^^ the use of either Cl or El-MIS gives 
comparable results, the use of Cl-MIS was chosen to give greater sensit­
ivity and precision. Injection of aliquots containing 10 ng of MMA (I) 
gave reproducible analysis with variations between duplicate samples of
8 2
TABLE 21
COMPARISON OF LEVELS OF MMA (I) IN AMNIOTIC FLUID 
OBTAINED USING GC PROFILING AND ISOTOPE DILUTION
SAMPLE 
NO.a
CONCENTRATION OF MMA (l)e 
(yg/ml fluid)
-----------------------9
GC Profiling
Isotope
Dilution^FID
Detector0
Total Ion 
Current 
Detection^
1 0.32 0.25 0.30
2 0.30 0.35 0.42
3 1.06 1.12 1.18
4 0.25 0.30 0.35
a Samples are from fluid collected 14-17 weeks and 
organic acids were analysed as TMS derivatives.
b Adipic acid internal standard.
c 3% SE 30 packed column.
d SE54 WCOT capillary column with open coupling to 
Varian MAT 44 MS.
e Results are mean of duplicate determinations.
less than 2% for amniotic fluid samples. Using the capillary coJLumn for 
separation of the MMA (I) the lower limit of detection was approximately 
0.05 ug/ml of fluid and analyses were made to a precision of 0.02 yg/ml.
Table 21 shows the results obtained when four samples were analysed 
for MMA (I) using a packed column GC method with FID, a capillary column 
GC method using the total ion current plot of the mass spectrometer and 
the isotope dilution method. These results show that the isotope dilution 
gives slightly higher values for the amount of methylmalonic acid present 
but the results obtained using the GC method with the packed column and 
FID are sufficiently accurate for clinical diagnosis.
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F a t t y  a c i d -  
(cdd chair.) PROPIO NYL C o A
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Thyr.i
Propionyl CoA 
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Vitamin (Co***) 
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C i t r i c  acid cycle
FIGURE 16. The formation of 5-deoxyadenosyl cobalamin and the metabolism 
of propionate in man.
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b. PRENATAL DIAGNOSIS OF METHYLMALONIC ACIDEMIA
. 460 „ . . . .In 196JL Cox and White demonstrated an increase m  urinary excretion
of MMA (I) in patients with vitamin B 2 deficiency. Inherited methyl­
malonic aciduria was first described in 1967 by two groups of investig- 
152 161ators 3 in retarded infants who suffered from recurrent vomiting, 
life threatening attacks of ketoacidosis and intolerance to high protein 
feedings. Since the original description of the disease a number of 
distinct variants have been described. J The enzyme defect
responsible for the disease variant may be either in the propionate to 
succinate pathway or in the pathway of vitamin B^2 metabolism in which 
5-deoxyadenosylcobalamin, the co-factor for L-methylmalonyl-CoA carbonyl 
rnutase is produced (Fig. 16)
Clinically patients with increased MMA (I) excretion are characterised 
by protein intolerance, bouts of ketoacidosis and inhibited growth and 
development. Patients with deficiencies in the racemase or rnutase activity 
generally die at an early age. In patients with defects of̂  vitamin 2
metabolism treatment with doses of the vitamin often produce clinical and 
biochemical improvement and can lead to a lowering of the excretion of 
MMA (I). The frequency and size of the dose required varies with individ­
ual patients and may vary in periods of metabolic stress such as infection. 
The dose is not related to the measured serum levels of the vitamin or 
metabolic precursors but may be assessed by measurement of the daily 
excretion of MMA (I).
The defects can be demonstrated in cultured fibroblasts and amniotic
. . 156,443,446,467fluid cells and hence prenatal diagnosis is possible.
However several features of this inborn error of metabolism make it possible 
to evaluate the foetus by means other than cultured cells and so avoid the 
time required for cell culture.
Morrow suggested that diagnosis may be made by analysing rnutase 
activity in non cultured cells. In an affected pregnancy both amniotic 
fluid and maternal urine^^* ^6? contain excess MMA (I)/ since
MMA (I) is not readily metabolised and consequently accumulates in both 
foetal and maternal fluids.
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' TABLE 22
ENZYME STUDIES OF CELLS CULTURED FROM AMNIOTIC FLUID 
OBTAINED AT 15 WEEKS GESTATION FROM MRS V.T.(3RD PREGNANCY} 
AND FROM SKIN BIOPSY CELLS OF AFFECTED CHILD
A. STUDIES OF VITAMIN B12 METABOLISM
1;
2.
CO ENZYME SYNTHESIS BY INTACT CELLS
5-Deoxyadenos Ine 
cobalamin 
pg colalamin/ 
mg calls
V.T. Amniotic fluid cells 0.48 
Control amniotic fluid cells 0.54 
Affected child fibroblast cell3 0.23 
Control fibroblast cells 0.16
Methylcobalamin 
pg cobalamin/ 
|tg cells
Total
Cobalamin
Uptake
pg cobalamin/ 
mg cells
0.10 1.2
0.18 2.1
0.92 6.3
0.12 1.1
5-DEOXYADENOSINECOBALAMIN synthesising activity in cell extracts
V.T. Amniotic fluid cells 
Affected child fibroblast cells 
Control fibroblast cells
14.1 pg AdoCbl/mg protein/30 min. 
17.6 pg AdoCbl/mg protein/30 min. 
25.9 pg AdoCbl/mg protein/30 min.
B. STUDIES OF PROPIONATE-SUCCINATE PATHWAY
1
2,
METHYLMALONYL CoA MUTASE ACTIVITY** (HOLOENZYKE IN CELL EXTRACT)
V.T. Amniotic fluid cells 
Control Amniotic fluid cells 
Affected child fibroblast cells 
Control fibroblast cells
173 pmoles succinate/mg prctein/min 
123 pmoles succinato/mg protein/min 
< 1 pmoles succinate/mg protein/min 
224 pmoles succinate/mg protein/min
**C-PROPIONATE FIXATION IN INTACT CELLS DURING 10 HOURS
V.T. Amniotic fluid cells
Control Amniotic fluid cells^ 
Control Amniotic fluid cells2 
Control Amniotic fluid cells3
Affected child fibroblast cells
Affected child fibroblast cells 
1 ng/ml Vit. Bj^
Affected child fibroblast cells 
10 ng/ml Vit. B ^
Affected child fibroblast cells 
100 ng/ml Vit. B 1 2  
Affected child fibroblast cells 
1000 ng/ml Vit. B^2
Control fibroblast cells! 
Control fibroblast cells2
3.77 natons ‘*C/mg protein
4.88 natons ‘"C/mg protein
4.61 natons ‘“C/mg protein
3.65 natons ‘“C/mg protein
0.27 natons 1*C/mg protein
+ 0.32 natons "■C/mg protein
+ 0.52 natons “ C/mg protein
+ 2.26 natons “’C/mg protein
+ 2.69 natons 1*C/mg protein
9.93 natons 1"C/ml protein
7.50 natons 1"C/ml protein
a Performed by Dr. M.J. Mahoney, Department of Human Genetics, Yale University. U.S.A. 
b Measured using a racemic mixture of D and L methylmalonyl CoA. Defect in racemase enzyme 
is indicated by half activity of tested cell and must then be further investigated. Normal 
Cells convert over 30i of substrate to s icciny]-CoA.
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The major reason for developing the present analytical method was to 
accurately measure small amounts of organic acids in amniotic fluid in 
order to distinguish the pregnant heterozygote carrying a foetus affected 
with an organic acidemia from one carrying an unaffected foetus. During 
the course of this work two pregnant heterozygotes at risk for methyl­
malonic aciduria were studied during three pregnancies.
Mrs. V.T. had two children suffering from methylmalonic acidemia but
. . . 466 .one has since died. These children were diagnosed to have a defect m
methylmalonyl-CoA mutase apoenzyme and had normal vitamin metabolism.
<
Amniocentesis was performed at 15 weeks gestation and successful cell 
cultures were begun. Cells were 46 XY karotype indicating a male foetus.
The MMA (I) concentration of the fluid was measured and a value of 0.92 
yg/ml was obtained using GC profiling. The identity of the peak assigned 
to MMA (I) in the profile was confirmed by GC/MS and no extraneous ions 
were present in the MS. When the isotope dilution method became available 
a comparable result was obtained by isotope dilution. When 15 normal amniotic 
fluids of 14-18 weeks gestation were examined using the technique a mean 
value of 0.72 yg/ml with a standard deviation of 0.42 yg/ml (Normal range 
less than 1.56 yg/ml) was obtained for MMA (I).
The value obtained for the MMA (I) concentration for Mrs. V.T. indie-
/
ated that the foetus would be unaffected and so the pregnancy was allowed
4 .
to continue. This prediction was supported by the enzyme studies performed 
by Dr. M.J. Mahoney. (Table 22) '
The studies of vitamin B metabolism show that both the cultured 
amniotic fluid cells and cultured fibroblasts from Mrs. V.T.'s affected sur­
viving child have normal uptake of radioactive vitamin B ^  and normal 
formation of iadeoo^lcobalamin and methylcobalamin in both intact cells 
and cell extracts. The metabolism of propionate to succinate was examined 
in two parts. A mixture of D & L-methylmalonyl-CoA was used as substrate 
by cell extracts to measure methyZmalonyt-CoA mutase haloenzyme and the 
results obtained show a clear distinction between the cultured fibroblasts 
from the affected child and cells grown from the amniotic fluid, which are 
within the normal range. Similarly the fixation of q-propionate shows 
a clear distinction between the amniotic fluid cells and controls, and
TABLE 23
RECOVERY OF STANDARD ACIDS ADDED TO URINE
ACID
ACID ADDED: 5 lag/ml 50 ug/rnl
a% RECOVERY: Absolute Relative to Adipic Acid Absolute
Relative to 
Adipic Acid
Adipic Acid (II) 93 ± 3.8 100% 94 ± 2.7 100%
Methylmalonic Acid (I) 79 ± 3.2 85 ± 3.4 82 + 2.7 87 ± 2.9
y—.Ketovaleric Acid 67 ± 5.7 72 ± 6.0 72 ± 5.9 77 + 6.3
2-Hydroxyisocaproic Acid 65 ±5.9 70 ± 6.3 67 ± 4.2 71 + 6.7
Succinic Acid 83 ± 3.2 89 ± 3.4 84 ± 3.0 89 ± 3.2
Phenylacetic Acid 85 ± 6.2 91 ± 6.7 86 ± 3.7 91 ± 3.9
Glutaric Acid (X) 86 ± 2.5 92 ± 2.7 86 ± 3.0 91 ± 3.2
p - Hydroxyphenylacetic Acid 92 ± 2.3 99 ± 2.5 94 ± 3.1 100 ± 3.3
Laurie Acid 94 ± 3.5 101 ± 3.8 95 ± 3.3 101 ± 3.5
a Each value is the mean % recovery ± 2 SD obtained from at least 3 experiments and were 
obtained by GC of the TMS derivatives on Apiezon-N.
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those of the affected child. This data also illustrates an enhancement 
of activity in the affected child's cells in the presence of a gross 
excess of hydroxycobalamin.
In order to study the urinary excretion of MMA (I) during pregnancy, 
methods were required to accurately measure normal excretion levels of 
MMA in urine. The solvent extraction method used for screening urinary 
metabolites was adapted to this purpose using adipic acid (II) (10 yg) 
as internal standard. A GC calibration curve for MMA (I) was prepared 
using the ratios of the peak height for MMA (I) to the peak height of an 
internal standard over a range of acid concentrations (0-100 pg). The 
curve obtained was a straight line with a correlation coefficient of 0.99.
Initial experiments were done by extracting acidified urine directly 
with ethyl acetate but in some samples extraneous substances such as 
thymol and cresol were present which interfered with the measurement 
of some acids, particularly MMA (I). The interfering substances were 
preservatives and some appeared to be related to diet as they were not 
present in all specimens collected from the same person. The problem 
was overcome by saturating the urines with sodium bicarbonate and 
extracting the basic and neutral compounds at pH 7-8 before acidifying 
the urine to pH 1 and re-extracting the organic acids with ethyl acetate. 
Recoveries of acids from biological fluids however may not be quantitative 
and for accurate quantitation of metabolites recovery studies are also 
necessary. Such studies were carried out for MMA (I) and other represent­
ative biologically important acid^. This was done by adding known amounts 
of the acids and the internal standard to a "normal" urine sample and 
extracting the urine, followed by addition of an external standard to the 
ethyl acetate. The results of these studies are shown in Table 23. The 
#acids were not extracted quantitatively but re-extraction of the urines 
failed to improve the yields significantly. MMA (I) could be measured 
by this method with a lower limit of detection of 0.4 yg/ml and a precision 
of 0.1 vtg/ml.
. 459When the isotope dilution method for MMA (I) became available 
calibration curves were constructed using TMS derivatives both by El“MIS 
using.the ion pairs at m/e 218/221 and 247/250, and by Cl“MIS using the 
protonated molecular ions at m/e 263.3 and 266.3. These calibration
TABLE 24
COMPARISON OF RESULTS OBTAINED FOR URINARY FIMA, ( I ) 
USING GC PROFILING AND ISOTOPE DILUTION METHODS
METHOD
SAMPLE
NO. GC PROFILING CI/MISa EI/MIS
y g MMA/ml lig MMA/ml lig M MA/mlk yg MMA/mlc
1 8.1 * 8.2 8.6 •
00
2 3.6 3.3 3.6 3.8
3 4.7 4.4 5.3 5.2
4 1.7 1.9 1.8 2.0
5 1.1 0.9 1.0 1.3
a Results obtained using protonated molecular ions at 
m/e 263.3, 266.3
b Results obtained using fragment ions at m/e 247,250. 
c Results obtained using fragment ions at m/e 218,221.
TABLE 25
COMPARISON OF MMA (I) EXCRETION5 OF PATIENT V.T. 
DURING AND AFTER 3RD PREGNANCY AND NORMAL CONTROLS
WEEKS
MMA (I) CONCENTRATION0 MMA (I) 
EXCRETION0
GESTATION ug/ml ymol/1 ymol/ymol.
créât.
ug/day
MRS. V.T.
13 3.8 32 3.1
14 3.3 28 5.7
15 10.9 92 5.5
19 weeks 8.1 68 9.4 11.2
33 weeks 
Day 1 11.1 100 12.1 11.8
33 weeks 
Day 2a i
5.3 58 8.4 6.9
6 days P.P. 3.6 30 5.7 8.6
10 weeks 
p.p. * 2.5 22 3.1 3.5
Normal ^ 
Controls 1.8 ± 1.1 1.7 ± 1.1 1.6 ± 1.9
a Values obtained by GC profiling of TMS derivatives on 
SE30. Comparable values were obtained using the 
isotope dilution procedure.
b Values are expressed as mean ± SD of 19 samples obtained 
from 11 pregnant and 8 non-pregnant females.
c All results have been corrected for recovery.
* P.P. = post partum
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curves were linear over the range of 0-250 yg MMA (I)/ml urine and had
correlation coefficients (obtained by the least squares method) of
greater than 0-.-99. The MMA (I) concentration of a number of urine
samples were measured using GC profiling with adipic acid (II) as internal
standard and isotope dilution and the results are shown in Table 24.
These results show good agreement between the two methods and between and EI-MIS
the Cl  - M I  SA methods. The higher ion currents obtained in C l - M I S  gave 
better precision of analysis and this method was used for all further 
isotope dilution studies. The majority of urine results reported in this 
work have been measured by the GC profiling method but some have been 
checked by the isotope dilution method.
A number of urine specimens were obtained from Mrs. V.T. during the 
course of the pregnancy. The first specimens obtained were spot specimens 
and excretion levels were related to urinary creatinine. All other 
specimens were pooled 24 hour collections. Examination of 24 hour urine 
collections from 8 normal subjects and 11 pregnant patients showed no 
significant difference between the excretion of MMA in the two groups.
The excretion obtained in these patients was 1.7 ± 1.1 ymol/ymol creat­
inine (mean ±SD)(normal range <3.9 ymol/ymol creatinine) and all patients 
excreted less than 4 mg/day of MMA (1.6 ± 1.0 mg/day (mean ±SD)). The 
values obtained for Mrs. V.T. are shown in Table 25. The MMA (I) level 
of the random urine specimen collected at 13 weeks is within the normal 
range but after this time the patient excreted increased amounts of 
MMA (I). The two specimens collected during week 33 show the daily 
variation in excretion of MMA (I) but all specimens were above the upper 
limits of the normal range and had not returned to normal by six days 
after parturition. By 10 weeks after parturition however the excretion 
had returned to normal and examination of further random samples has shown 
no other abnormal levels of MMA (I). During the pregnancy normal levels 
of vitamin B £ were demonstrated in this patient and no signs of vitamin 
B12 deficiencY wer© observed.
At delivery a sample of amniotic fluid was obtained and analysed for 
MMA. This sample showed a concentration of 2.46 yg/ml by the GC 
profiling method. The identity of the peak assigned to MMA (I) in the
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profile was confirmed b y  GC-MS and no extraneous ions were present in 
the MS. Examination of 8 specimens of amniotic fluid of greater than 
35 weeks gestation showed a mean value of 1.35 yg/ml with a standard 
deviation of 0.65 yg/ml (normal range < 2.65 yg/ml) . The value obtained 
for the amniotic fluid from Mrs. V.T. was within the normal range.
Urine was obtained from the newborn at 4 days of age when on a normal 
diet and showed MMA (I) concentration of 0.75 yg/ml (6.3 ymol/1), 3.5ymol 
MMA (I)/ymol creatinine. The total excretion of MMA was 0.16 mg/day.
These values are all within the measured normal range. Since that time the 
child has remained healthy except for an episode of haemolytic-uremic syn­
drome . .
Mrs. V.T. undertook a further pregnancy and amniocentesis was again 
performed at 15 weeks. Amniotic fluid MMA (I) was 0.34 yg/ml in this 
specimen and this result was confirmed by isotope dilution. Examination 
of cultured cells showed no abnormality of methylmalonyl-CoA metabolism 
and a normal foetus was predicted. The pregnancy was allowed to continue 
and an unaffected child was born at term. Urine samples from this child 
collected in the first week of life were within the normal range. 
Unfortunately no urine studies were carried out during the fourth 
pregnancy.
Mrs. G.P. was a woman whose second child was affected with methyl­
malonic acidemia caused by a defect in methytmalonyt-CoA mutase enzyme , 
During her third pregnancy amniocentesis was performed at 15 weeks gest­
ation and the amniotic fluid contained0.60yg/ml MMA (I) which was within 
the measured normal range (less than 1.56yg/ml). A normal foetus was 
predicted and this was supported by finding normal levels of methylmalonyZ— 
CoA mutase activity in cultured amniotic fluid cells. The pregnancy was 
allowed to continue and a healthy child was delivered at term. Analysis 
of specimens of urine obtained from the child in the first weeks of life 
contained normal levels of MMA (I) confirming the 'in-utevo prediction.
No urine studies were carried out during this pregnancy.
TABLE 26
AMNIOTIC FLUID MMA (I) CONCENTRATION5
PATIENT WEEKSGESTATION
MMA CONCENTRATION 
yg/ml fluid
GC Profiling IsotopeDilution
V.T. Preg. 1 15 0.92 Ó. 96
38 2.46 2.57
V.T. Preg. 2 15 0.34 0.48
G.P. 15 0.60 0.65
Controls , 14-18 0.72 ± 0.42 0.72+0.37(mean ± SD)D
Controls 35+ 1.35 ±0.65 1.43±0.62(mean ± SD)c
a Values obtained by GC profiling of TMS derivatives 
on SE30 and are corrected for recoveries. The 
identity of the methylmalonic acid was confirmed 
by GC/MS. Comparable values were obtained by 
isotope dilution method.
b Results from 15 AF specimens obtained at 14-18 weeks.
c Results from 8 AF specimens obtained after 35 weeks 
for fetal lung maturity studies.
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The results obtained in this work show that in the pregnancies
monitored, the use of amniotic fluid levels of MMA (I) are as good in the
prediction of the clinical status of the foetus as the enzyme studies.
The metabolite measurements have the added advantage that the results
are available within one working day of receipt of the specimen rather
than the 4-8 weeks required for growth and analysis of cultured amniotic
1 5 7fluid cells. Morrow has also suggested that the absence of MMA (I) in 
amniotic fluid, particularly if confirmed by another amniocentesis is 
very strong evidence that the foetus is unaffected. Thus the use of 
amniotic fluid MMA (!) level is a valuable aid to prenatal diagnosis of this 
condition, particularly if there is only a short time available between 
amniocentesis and the latest time of therapeutic abortion or in cases 
where cell lines are not cultured successfully. The metabolite is also 
stable in the fluid when stored frozen and this alleviates problems of 
sample transport which may occur with cell culture.
Few reports have been published on MMA (I) excretion in heterozygotes
156,157,159,160,446,467 , . .. _ . „ . .and especially during pregnancy. Heterozygotes
usually excrete levels of MMA (I) comparable to the levels obtained in
normal controls. Thus the normal range obtained m
these investigations using pregnant and non pregnant patients is a valid
comparison for heterozygotes MMA (I) excretion.
The exception to this is shown in the report by Netzloff et al in 
which a heterozygote who excreted increased amounts of MMA (I) post partum 
was studied but no levels of acid excretion were given.
A number of studies have been carried out in pregnant heterozygotes.
These studies have suggested that the genotype of the foetus rather than 
that of the mother determines maternal excretion during pregnancy. If the 
foetus is unaffected the maternal excretion of MMA (I) is normal during 
pregnancy. 5 8 , 1 6 0  ^  however the foetus is affected the urinary MMA (I)
excretion rises. The time at which this increased excretion occurs however 
appears to be variable. Morrow et al demonstrated normal MMA (I) levels 
in maternal urine in a heterozygote with an affected foetus at 20 weeks 
gestation but showed a large increase (approximately six times normal) by 
week 31. Gompertz et al^^ did not measure MMA (I) excretion before week
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36 when they found a four times normal increase. Nakamura et al"^
found a rise in MMA (I) excretion comparable to that shown in our patient
by 23 weeks and Bakker et al also reported a similar rise by week 22.
156Mahoney et al however reported levels that were distinctly raised to 2.5 
times normal by week 16 and dropped into the normal range within 2 days 
after the foetus was aborted. This data has given rise to the assumption 
that the maternal urinary MMA (I) excretion remains normal if the foetus 
is not affected and that monitoring of maternal urinary MMA (I) affords 
promise for prenatal diagnosis of affected foetuses, particularly if the 
mother is unwilling to undergo amniocentesis. Our studies of Mrs. V.T. 
show that this assumption is not correct as this heterozygote excreted 
abnormal amounts of MMA (I) when the amniotic fluid and cell cultures 
indicate a normal foetus and this prediction was proven by perinatal 
studies.
The excretion levels in Mrs. V.T. rose to nearly three times normal 
which is nearly as high as those in patients where the foetus was affect­
ed. This abnormal excretion began as early as week 14 and did not return
to normal until more than six days after delivery. This slow decline of
156MMA (I) excretion is not characteristic of other reported pregnancies 9 
258 446 467
9 9 where raised urinary MMA (I) was obtained when the foetus
was affected and normal excretion was found within 48 hours of delivery
or termination. The only other case where raised urinary MMA (I)
excretion has been reported in a pregnant heterozygote with an unaffected
46 8foetus is that of Netzloff et al but in his patient abnormal excretion 
of MMA (I) occurred even when the patient was not pregnant and this 
atypical behaviour of a heterozygote may be due to vitamin deficiency. 
This possible cause was excluded in our patient by serum B^2 and 
haematological studies.
The daily variation in excretion during this time is shown by the 
variation of the two specimens obtained during week 33. Mrs. V.T. 
was not on any controlled diet during the collection but her diet is 
usually low in protein and high in carbohydrates and fats. The variation 
in MMA excretion during these two days may thus reflect protein intake as 
well as variability of metabolism.
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FIGURE 17. Pathways of lysine,5-hydroxylysine and tryptophane degradation 
through glutaryl-CoA.
Glutaconyl CoA has not been detected as a free intermediate. Glutaric acid,glutaconic 
acidand 2-hydroxyglutaric acid are excreted by patients with a block at position 1 but 
are not usually present in normal patients. .
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c .  PRENATAL DIAGNOSIS OF GLUTARIC ACIDEMIA
Large amounts of glutaric acid (X) have been detected in the urine 
of patients with two clearly different syndromes. One syndrome, bio­
chemically dominated by glutaric aciduria and lactic aciduria was
190reported by Przyrembel et al in a neonate who died at 70 hours 
after birth. Besides glutaric (X) and lactic acids (XI), a number of 
mono and dicarboxylic acids, as well as several amino acids were found 
in elevated concentrations in blood and urine. Defective oxidation of 
the branched chain amino and keto acids was demonstrated in fibroblasts 
in this patient. This syndrome has been named glutaric aciduria type 
II.
The other syndrome, glutaric aciduria type I is an autosomal recessive
. . . . 469 470inherited inborn error in the catabolism of lysine (XII) ■* trypto-
• 4 7 2 472 'phane (X3U) and hydroxylysine (XIV) (Fig. 17). The condition
386was first described by Goodman et al in 1975 and seven patients have
. ^ _ 386,387,473-473 ^ ^ ^been reported. The disease is characterised clinically by
an intermittently progressive dyskinetic syndrome of choreoathetosis with
hyperkinesia and dysarthria and may or may not involve mental retardation.
The disease usually runs a progressive course and death in a Reye syndrome-
like state has been observed.476 As well as glutaric acid (X) all patients
are reported to excrete increased amounts of 3-hydroxyglutaric acid (XV)
387and glutaconic acid (XVI)Asome may excrete increased amounts of
2-aminoadipic acid (XVII) and saccharopine (XVIII) together with
• 4762-ketoadipic acid (XIX). The histological changes in the putamen and 
caudate nuclei in this disease resemble those seen in Huntington's Chorea 
and Parkinson's disease. During the course of this work studies were made of 
a pregnant heterozygote for glutaric acidemia Type I where the foetus was 
at risk for the disease.
Mrs. V.M. has a previous child who had been diagnosed as having glutaric 
acidemia when the mother was about 8 weeks pregnant. The affected child 
was eighteen months old and appeared to be normal until 2 weeks before, 
when, following an upper respiratory tract infection she developed an 
acute dyskinetic reaction and lost the ability to stand, sit or crawl. 
Organic acid chromatography showed the presence of glutaric acid (X)
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GLUTARYL CoA DEHYDROGENASE ACTIVITY IN CULTURED FIBROBLASTS 
FROM AFFECTED CHILD, PARENTS AND NORMAL CONTROLS
TABLE 27
Glutaryl CoA Dehydrogenase 
Activitya
Nanomoles C02/hr/mg protein
R.M. (Affected child) 0
V.M. (mother) 1.31
J.M. (father) 1.69
Control 4.23
Normal Controls 2.54 ± 0.26b (N = 6)
Heterozygotes 1.19 ± 0.25c (,N = 13)
a Values obtained by S.I. Goodman, University of 
Colorado.
b Values obtained by D.T. Whelan et al. (473). 
c Values obtained by E. Christensen & N.J. Brandt (477).
TABLE 28
CONCENTRATION OF GLUTARIC ACID FOUND IN AMNIOTIC 
FLUID EXTRACTS OF PATIENT V.M. AND CONTROL SUBJECTS
DATE
COLLECTED
GESTATION
(WEEKS)
GLUTARIC ACID3
ug/mi
V.M. 19/10/78 15.5 4.35
V.M.b 11/12/78 22.5 11.7
Control 1 19/10/78 15 0.38
Control 2 19/10/78 16 0.14
Control 3C 1-10/5/78 14-20 0.22
a All values are corrected for recovery, 
b Specimen obtained at termination.
c This sample was obtained from a pool of 15 amniocentesis 
specimens.
TABLE 29
GLUTARYL-CoA METABOLISM IN CULTURED AMNIOTIC FLUID 
CELLS FROM V.M. , PREGNANT HETEROZYGOTE WITH NORMAL 
FOETUS AND NORMAL CONTROLSa
Glutaryl CoA Metabolised 
Nanomoles C02/hr/mg protein
V.M. Not Detected
Pregnant Heterozygote 2.44
Control I 1.03
Control II 4.94
------------------------------------------ . . . . .
a Results obtained by S.I. Goodman, University of Colorado.
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(19.4 ymol/ymol creatinine ) but 3-hydroxyglutaric acid (XV) and glutaconic 
acid (XVI ) were absent. The glutaryl-CoA dehydrogenase levels obtained
7 Of* dfíttin fibroblast culture from the child and the parents were measured 3 
and no activity of the enzyme could be shown in fibroblasts or leucocytes 
from the child (Table 27). The parents also showed reduced levels of
the enzyme which are comparable to those shown by the heterozygotes
473 477reported by Whelan et al and by Christensen and Brandt.
Amniocentesis was performed at 15 weeks gestation and successful cell 
cultures were begun. The concentration of glutaric acid (X) in the amniotic 
fluid was measured and a value of 4.35 yg/ml obtained using the GC 
method (Table 28)« The GC-MS of the peak assigned to glutaric acid con­
tained no extraneous ions. A careful search was made but no 3-hydroxy­
glutaric acid (XV), glutaconic acid (XVI) or 2-ketoadipic acid (XIX) 
could be found in the fluid. The amino acid levels in this specimen 
were all within the normal range and no a-aminoadipic acid (XVII) or 
saccharopine (xyill) were found.
The recovery of glutaric acid (X) added to pooled amniotic fluid 
showed a recover of 95 t 2% (n-6) ,rélative to the adipic acid (II)
internal standard. The average recovery of the internal standard was
*{■ '9 1 - 6 %  (n=20) relative to pimelic acid (XX).
When twenty four control specimens of amniotic fluid obtained from 
patients with estimated gestational ages of 14-20 weeks were examined 
the mean concentration of glutaric acid (X) was 0.28 yg/ml with a 
standard deviation of 0.11 yg/ml.
The presence of a large increase of glutaric acid (X) in the 
amniotic fluid indicated the foetus was affected and further evidence 
for this was obtained when the enzyme results became available. No 
glutaryl-CoA dehydrogenase activity was detectable in cells cultured 
from the amniotic fluid (Table 29) whereas the cells cultured from 
amniotic fluid from another pregnant heterozygote who was later shown 
to have a normal child, contained normal levels of the enzyme.
These results suggested that the foetus was homozygous for the defect 
and It was decided that the pregnancy should be terminated. A further
TABLE 30
TISSUE GLUTARIC ACID LEVELS AND ENZYME STUDIES ON ABORTUS 
FROM PATIENT V.M. AND NORMAL CONTROLS
. Glutaric Acid (yg/g wet weight) Foetus A Glutaric Acidemia (476) Control Foetuses (n=3)
Glutaric acid (yg/g wet 
weight)
Liver 17,0 330 96 Not detected
Kidney 70.2 1000 1330 Not detected
Brain 112.0 109 88a,165b Not detected
Glutary1-CoA dehydrogenase 
(nmoles C02/hr/mg protein)
Liver 0.15 0C 0 33.8 - 58.0
Kidney 0.03 0C 0 2.6 - 13.8
Glutamate dehydrogenase 
(ymoles NADH oxid/min/mg prot)
Liver 0.38 ■ 1.44° 0.45 0.29 - 0.39
a Frontal cortex 
b Basal ganglion 
c Isolated mitochondria
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FIGURE 18. The total ion current profile from the SE-54 capillary 
column of the silylated organic acid extract of amniotic 
fluid obtained from patient V.M. at 15 weeks gestation (A)
■ and a pool of fluid from 15 normal patients 14-20 weeks 
qestation(B).
' The peaks were identified as:1,lactic acid;2,3-hydroxy butyric acid;3,succinic acid, 4, 
. glutaric acid; S,adipic acid( internal standard) ;6,duodccanol;7tpimelic acvdi external 
standard).
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specimen of amniotic fluid was obtained at termination and the concentra­
tion of glutaric acid (X) in it measured. The level of 11.7 pg/ml 
(Table 28) obtained indicates a large increase in the concentration of 
the metabolite in the intervening seven weeks and is about forty times 
the normal level of glutaric acid. A total ion current profile of the 
15 week specimen is shown in Fig. 18 compared to a specimen from a 
pool, of 15 normal controls *
Studies of glutaric acid (X) content and enzyme activities were 
carried out on tissue homogenates from the abortus (Table 30). These 
results are compared to values obtained on two patients with glutaric 
acidemia at autopsy and on three control human foetuses ranging in 
gestational age from 16 to 24 weeks. The liver, kidney and brain of the 
abortus at risk showed markedly increased amounts of glutaric acid (X) 
and almost no glutajpyl-CoA dehydrogenase activity, a pattern which is ob­
served in tissues from glutaric acidemia patients but not in controls.
The glutamate dehydrogenase activity is normal showing that the tissue 
was still viable at the time of the assay.
The cerebral hemispheres and cerebellum of the foetus were normal to 
both gross and microscopic examination, but there were some slight 
alterations in the size distribution of the nuclei in the striatum, which 
contained many prominent and darkly staining nuclei.
The absence of urinary glutaconic (XVI) and 3-hydroxyglutaric acid
(XV) in the affected child is of interest as it is at variance with all
other reported cases of this disease and would suggest a different
enzyme mutant present in this family. The precise location of the enzyme
defect for glutaric aciduria type 1 has not been determined although a
477 .number of mutants have been demonstrated. Two possible defects have
been suggested to explain the observed urinary products of the reported 
patients.
The accumulation of glutaryl-CoA and the excretion of glutaric acid
, , 481(X) are consistent with a defect in glutaryZ-CoA dehydrogenase. The
appearance of 3-hydroxyglutaric acid (XV) and glutaconic acid (XVI). may
then be explained as being due to an alternative pathway for the oxidation
478 ' .of glutaric acid (X) similar to the one postulated for the conversion
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of propionic acid (XXI) to 3-hydroxypropionic acid (XXII) in patients 
with propionic or methylmalonic acidemia. This defect could also
explain why the leucocytes of patients can metabolise free glutaric
. 479acid. In contrast to this postulated defect Stokke et al have
suggested that the reaction proceeds via two enzymes, glutaryl-CoA
dehydrogenase and glutaconyl-CoA decarboxylase and that the defect is
in glutaconyl-Co A decocrboxylase. The presence of 3-hydroxyglutaric acid
(XV) is then explained by hydration of abnormally high intercellular
~ concentrations of glutaconyl-CoA followed by deacylation. Similar
hydration has been shown to occur normally in the synthesis^^ of
3-hydroxymethylglutaryl-CoA from 3 -methylglutaconyl-CoA and has been
193suggested as the basis for excretion of‘$-hydroxisovaleric acid 
(XXIII) in patients with &-methycrotonyl-CoA carboxylase deficiency.
However, although the main degradative pathway of glutaryl-CoA in
. 481mammalian.cells is well established, it has to date been impossible to
isolate glutaconyl-CoA as an intermediate or to separate glutary1-CoA
dehydrogenase activity from that of decarboxylation. The method of
enzyme analysis of this sequence of reactions is by measurement of 
14CO2 produced and does not differentiate between the two possibilities 
as the production of carbon dioxide from glutaryl-CoA could take place 
by either mechanism. *
Examination of the metabolite excretion pattern of this child how< er
suggests that no alternative pathway exists for the metabolism of gluuaric
acid (X) which produces glutaconic (XVI) and 3-hydroxyglutaric (XV) acids.
479The two enzyme reaction sequence of Stokke appears to be correct and 
the parents of this child are thus heterozygous for a defect in glut- 
aryl-CoA dehydrogenase with the other reported patients having a defect of 
glutaconyl-CoA decarboxylase.
The nature of the movement disorder and its similarity to that found in 
Huntington's Chorea and Parkinson's disease suggests that the biochemical 
cause of the movement disorders may be the toxic effect of the high acid 
levels on enzymes in the basal ganglia. It is thought that proper bal­
ance between acetylchloline, dopamine and Y**aminobutyric acid- containing
J 90 ,4. v vfibres in the basal ganglia is necessary for normal movement. stoKKe 
et al^^ have shown that glutarate (X) glutaconate (XVI) and 3-hydroxyglut- 
::arate (XV) are all potent inhibitors of glutamate decarboxylase (y-amino-  
butyric acid synthetase) which produces y-aminobutyric acid. Since
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the highest concentrations of y— ami no butyric sc id and ŷ ari'i-nohutyriQ 
acid synthetase are found in the basal ganglia the high concentration of 
glutaric acid (X) found in the brain of the affected children and the 
abortus would thus inhibit the synthesis of y-aminobutyric acid in basal 
ganglia and cause the clinical symptoms.
The treatment of glutaric aciduria by dietotherapy, vitamin (ribo­
flavin) supplementation and drugs (Lioresal — a y—aminobutyric acid
"ZQfireplacement and sodium valproate ) has been only variably effective, y 
4 7 3 ,4 7 4 ,4 8 3 ,4 8 4  ^perhaps because irreversible damage has been done to the 
basal ganglia by the time the diagnosis is usually established. The 
observation that glutaric acid (X) is significantly accumulated in the 
brain even during foetal life in this disorder raises the possibility that 
neuronal damage may be done even in utero. The mild striatal changes 
which were noted in the affected foetus may reflect such damage or may 
be due only to terminal anoxia. Careful study of the histology of the 
striatum in normal and affected abortuses will be necessary in the future 
if this issue is to be resolved.
This work describes the first instances in which pregancies at risk 
for glutaric acidemia have been monitored for this disease, and shows 
that affected and unaffected foetuses can be distinguished with comparat­
ive ease by measuring the gZutaryl-CoA dehydrogenase activity in cultured 
amniotic fluid cells or the concentration of glutaric acid (X) in the 
amniotic fluid. The foetus predicted to be affected had the in utero
diagnosis confirmed by determination of glutaric acid (X) and gZutaryZ-
484CoA dehydrogenase in tissues while a foetus predicted to be unaffected 
had normal giutaryZ-CoA dehydrogenase activity in umbilical cord fibro­
blasts and did not show glutaric aciduria on two occasions during the 
first week of life.
Glutaric acid may accumulate in the amniotic fluid of the affected
foetus because, like many other non-amino organic acids it is poorly
reabsorbed from the glomerular filtrate and appears in the foetal urine
485 .and thus in the amniotic fluid« A similar mechanism has been suggest­
ed as the basis of the accumulation of abnormal metabolites in the amniotic
fluid of foetuses with methylmalonic acidemia, ■*
. . . ,  . 4 8 6 ,4 8 7  '  . . . 489succinic acidemia * and propionic acidemia.
1 5 6 ,1 5 9 ,4 4 6 arginino- 
An alternative
mechanism of accumulation may be diffusion through the foetal skin, 
umbilical cord and placenta of the large, amounts of acid stored in the 
foetal cells.
Although it is technically easier to measure the concentration of 
glutaric acid (X) in amniotic fluid than to culture cells to measure 
glutccryl-CoA dehydrogenase, both investigations should be made for 
in utero diagnosis of glutaric acidemia. Further investigations are 
also required to determine the amniotic fluid levels of glutaric 
acid (X) in the case of a foetus heterozygous for the mutant allele.
NOTE ADDED IN PROOF
Mrs. V.M. is undertaking a further monitored pregnancy. Amnio­
centesis was performed at 15 weeks and analysis of the amniotic fluid 
showed a concentration of 0.62 yg/ml of glutaric acid, the presence of 
which was confirmed byGC-MS. The normal range obtained using the above 
method with a packed column has a mean of 0.72 yg/ml with a standard 
deviation of 0.15 yg/ml (normal range 0.5-1.1 yg/ml, 24 specimens).
A 24 hour urine specimen collected at the same time had a glutaric 
acid concentration of 0.86 yg/ml (0.9 ymol/mmol creatinine). The 
specimen had a total volume of 1570 ml (creatinine 7200 ymol/1) and this 
contained 1.35 mg of glutaric acid. The normal values obtained for 16 
specimens of non-pregnant patients has a mean of 1.8 mg/day and a stand­
ard deviation of 1.2 mg/day (normal range < 5 mg/day).
Measurement of glutaryt-CoA dehydrogenase activity in cultured 
amniotic fluid cells shows normal levels and no abnormalities of 
glutaryl-CoA metabolism. -
These results indicate that the foetus is not affected with 
glutaric acidemia and the pregnancy is continuing.
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PERINATAL DIAGNOSIS OF INHERITED DISEASE 
BY METABOLIC PROFILING
a. DICARBOXYLIC ACIDURIA : A SUSPECTED DEFECT 
IN FATTY ACID OXIDATION
Experience has shown that relatively few inborn errors of metabolism
can be diagnosed by clinical criteria alone and that detection generally
depends upon screenincr those patients with suspicious symptoms for a wide
range of metabolites. The application of GC and GC/MS for the profiling
of classes of metabolites has lead to the identification of many new 
. ,  53 .disorders, particularly _ the organic acidemias.
The organic acids which accumulate in organic acidemias are water 
soluble, ninhydrin negative acids most of which originate from the inter­
mediary metabolism of amino acids. However some organic acids, such as 
propionic (XXI) and pyruvic (XXIV) may also be produced from sources such 
as lipids or carbohydrates. Very few genetic diseases have been described 
in which a defect in fatty acid oxidation is the primary biochemical lesion 
responsible for an organic acidemia. These include a defect in green 
acyl-CoA dehydrogenase and glutaric aciduria type II. Refsum's 
disease, in which the defective metabolism of branched chain fatty acids
leads to an accumulation of phytanic acid (XXV); is usually classed as a
492lipid storage disease, since phytanic acid (XXV) is not water soluble 
and only small amounts of free acid are excreted.
The organic acidemias have been discovered and chemically characterised 
primarily by GC and G C / M S .  The metabolites identified and detected in the 
urine in organic acidemias may not be the unutilised substrate of the de­
fective enzyme system but may be the product (s) of the substrate modified 
by alternate pathways. Alternatively the unutilised substrate may or may 
not accumulate in body fluids. For example, alternate pathways found in 
several organic acidemias are glycine conjugation and conversion to the 
hydroxy ¡analogue of aliphatic monocarboxylic acids. These alternate
. .  ^  ^  1 8 8 ,4 9 3 ,4 9 4  . . ,  .pathways produce the major metabolites seen m  isovaleric
acidemia during remission when little free isovaleric acid (XXVI) is
excreted.
I l l
Some biochemical changes not directly related to the primary enzyme 
defect have been observed in several organic acidemias. These may 
include hyperglycinemia, hypoglycemia, hyperammonemia, long chain 
ketonuria, ketosis and lactic acidosis. These accompanying bio­
chemical changes are highly significant because of their importance 
for diagnosis but may be misleading if too much importance is placed 
on them because the primary biochemical defect may be overlooked.
Clinically all of the organic acidemias are accompanied by either 
severe ketoacidosis with lethargy and coma or by some neurological 
manifestations. These acute clinical expressions cf the disease may 
be episodic, reflecting the ability of alternate pathways to detoxify 
unutilised substrate of the defective enzymes except under severe met­
abolic stress. The disease may or may not be accompanied by mental 
deficiency and may demonstrate genetic heterogenicity. These clinical 
variations are not sufficient for diagnosis on clinical grounds alone 
and diagnosis rests on the chemical analysis of metabolites in serum or 
urine and enzymatic assays.
Organic acidurias are not only secondary to genetic enzyme defects 
but may be inducible by nutritional and toxic factors. Examples of
induced organic aciduria are the methylmalonic aciduria of vitamin
■ . 460 „ . . .  192deficiency and Jamaican vomiting sickness.
The major problem in the diagnosis of the organic acidemias is the
n e e d  for rapid identification of the organic acids, enabling early
diagnosis and life saving treatment of the patients. The preliminary
screening for organic acids may be by paper or thin layer chromatography,
chemical tests o r  GC urine screens, but the unequivocal identification
o f  t h e  abnormal acids relies on G C - M S. Our preliminary screening system
213has been described.
There have been a large number of systems described for the isolation
of organic acids from urine. In this work urine samples were saturated .
with sodium bicarbonate and interfering substances extracted at pH 7 8
before acidifying the urine to pH 1 and extraction of the organic acids with
ethyl acetate. When large amounts of acetoacetic acid (XXVII) or other
keto acids were present in the urine these compounds were converted to
i  143the oximes or methoximes by the method of Lancaster et al, be ore
1 1 2
extraction. The oximes and methoximes have characteristic El fragment­
ation patterns and GC retention times.
The preferred acid derivatives for GC and GC-MS are the methyl or 
trimethylsilyl esters. Silyl derivatives were chosen for our studies, 
as the Wollongong laboratory has a lot of experience with these deriv­
atives. A mass spectral library (the Markey library of 1913 compounds 
of biological interest) was.w also available which contained many mass 
spectra of TMS derivatives. Methyl esters were also used at various 
stages of this investigation.
Most of our early work was done with Apiezon N stationary phase.
This phase was chosen initially because of good resolution character­
istics for low molecular weight acids and its high thermal stability.
The use of this phase caused some problems as the TMS derivatives of 
dicarboxylic acids and some keto acids hydrolysed or decomposed during 
chromatography. In view of this, later work was done with an S E - 3 0  
packed column. Some of the later GC work was also done on an SE-5^ 
wall coated capillary column. GC elution temperatures on the three 
columns used and the diagnostic mass spectral ions used for the ident­
ification of metabolites seen in this study have been listed in v 
Appendix B.
To assist in the MS identification of unknown compounds, a series of 
specialist mass spectral libraries were sorted by computer from the NIH 
collection of 20,000 mass spectra. These specialist libraries were 
sorted according to the presence of elements such as silicon, nitrogen, 
halogens or oxygen in the molecule and molecular weights and then 
tables of frequency for the biggest fifteen peaks in each spectrum were 
generated. This work is described in Appendix C.
Fatty acids play an important role as an energy source. Higher plants 
and animals can store large amounts of neutral fat as a fuel reserve in 
a highly concentrated form 9 kcal/g) . The oxidation of fatty acids 
usually provides at least half the oxidative energy in the liver, kidneys, 
heart muscle and resting skeletal muscle. During periods of fasting 
fatty acid oxidation becomes virtually the sole source of energy with 
gluconeogenesis providing the glucose requirements of brain cells.
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FIGURE 19. Activation of fatty acids for 3-oxidation.
- , ATP sadenosine triphosphate, AMP =adenosine monophosph.aspk'**’*
FIGURE 20. 3-Oxidation of fatty acids.
One acetyl Co A io removed during each pass through the sequence .One molecule of 
palm i toy l CoA yields 8 molecules of acetyl Co A. FAD =flavine adcmnc dinuclcotide 
FADH9=reduced FAD,NAD =■nicotinamide adenine dinucleotide, NADH2 -reduced m v  ,
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.115
The major endogenous source of fatty acids for fuel is storage fat 
in the form of fat droplets in the cytoplasm which consists largely of 
triacylgylcerols# since fatty acids must be in the free form before 
they can undergo activation and oxidation, the triacylglycerols must 
first undergo hydrolysis by intracellular lipases to yield free fatty 
acids and glycerol. Another source of fatty acids is the metabolic 
turnover of membrane phospholipids.
Fatty acid oxidation is an intra-mitochondrial process and may be 
divided into two major areas: the activation and transfer of the fatty 
acid to the intramitochondrial space and the oxidative degradation of 
the activated fatty acid (Fig. 19).
Long chain fatty acids are first activated by an energy-requiring 
step in which the fatty acid ester of Coenzyme-A (CoA) is formed 
enzymatically at the expense of adenosine triphosphate(A T P ). There are 
three enzymes responsible for this reaction each of which is specific for 
a given range of fatty acid chain lengths and will activate saturated, 
unsaturated, 2-or 3-hydroxy fatty acids.
Fatty acids have only a limited ability to cross the inner membrane 
as CoA esters and an enzyme fatty acid CoA: carnitine fatty acid, trans­
ferase catalyses transfer of the fatty acyl group from its thioester 
linkage with CoA to an oxygen-ester linkage with the hydroxyl group of 
carnitine (XXVIII). The 0-fatty acyl carnitine so formed readily passes 
through the inner membrance. In the last part of the activation-transfer 
process the fatty acid acyl group is transferred from carnitine (XXVIII) 
to intramitocho.ndrial CoA by the action of intramitochondrial carnitine 
fatty acid transferase. The fatty acyl CoA now is used as substrate by the 
fatty acid oxidation cycle, which occurs in the inner matrix compartment 
(Fig. 20).
The fatty acyl-CoA ester first undergoes enzymatic dehydrogenation at 
the a and 3 carbon atoms to form a A J - unsaturated fatty acyl-CoA as 
product. There are four different enzymes for this reaction, each of 
which is specific for a given range of fatty acid chain lengths.
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FIGURE 21. w-Oxidation of fatty acids.
NADP ̂nicotinamide adenine dinucleotide phosphate, ^reduced NADP
11 7
2 3 2 3The A * bond of the A * —enoyl-CoA ester is reversibly hydrated 
to give an L-3-hydroxyacyl-CoA and this reaction is catalysed by a 
stereospecific enzyme, 3-hydroxyacyl-CoA hydrolyase. In the next 
step of the fatty acid cycle, the L-3-hydroxy-fatty-acyl-CoA is 
dehydrogenated to form 3-ketofatty-acyl-CoA by L-3-hydroocy fatty 
acyl-CoA dehydrogeyiase. This enzyme is relatively nonspecific for 
fatty acid chain length but absolutely stereospecific for the li­
ster eoisomer .
In the last step of the fatty acid oxidation sequence which is 
catalysed by $-ketothiolase, the 3-ketofatty-acyl-CoA undergoes 
cleavage by interaction with a molecule of free CoA to yield a 
carboxylterminal two-carbon fragment as free acetyl-CoA and the 
CoA ester of the fatty acid shortened by two carbon atoms. This 
thiolytic cleavage reaction has a high negative free energy change 
and is energetically favoured.. There¿appear to be two or three forms 
of the enzyme each specific for different chain lengths.
The fatty acyl-CoA, now two carbon atoms shorter^ then re-enters the 
sequence of reactions at the dehydrogenation reaction and this cycle 
continues until the acid is completely oxidised.
This process is known as 3 oxidation and normally accounts for over 
95% of fatty acid oxidation. However an alternative pathway for oxid­
ation of fatty acids exists/known as 0) oxidation (Fig. 21). In this 
process the carbon atom which is furthest from the acid group is
hydroxylated and then oxidised to another acid group. This oxidation
495 . . .probably occurs on the endoplasmic reticulum. The dicarboxylic acid
formed can then be transported into the mitochondria and undergo 3-oxid­
ation to shorten the carbon chaiiv in two unit steps. The appearance of 
dicarboxylic acids in the urine is indicative of increased w-oxidation.
There have been a number of clinical conditions reported where the
urinary excretion of adipic acid (II) and other dicarboxylic acids is
. 495 266increased. These include Glycogen Storage disease, Reyes syndrome,
239 . . 288 . . Congenital Lactic Acidosis and Carnitine deficiency. An increased
excretion of adipic (II) and suberic (XXIX) acids has also been observed
in ketosis where the excretion of these dicarboxylic acids appear to
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FIGURE 22. GC profile from Apiezon-N packed column of the silylated 
organic acid extract from urine obtained from patient M.E. 
at the time of the attack.
The peaka were identified as: 1,3-hy dr oxybutyria acid; 2, urea; glut avia acid;4tadipic acid; 
5,8uberic acid
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parallel the degree of ketosis. However, in all these conditions the 
amount of adipic (II) and other dicarboxylic acids excreted is small and 
is associated with the excretion of large quantities of other organic 
acids such as lactic acid (XI) or 3-hydroxybutyric acid (XXX).
The investigations reported here have been carried out on 3 unrelated 
male children each of non-consanguinous parents and aged 6-14 months, 
who presented in a semi-comatose state. A history of two to four days 
mild gastro-enteritis prior to admission was given and physical exam­
ination showed gross hepatomegaly with mild dehydration. The children 
all showed a mild metabolic acidosis with low serum glucose. Serum 
transaminases were normal or mildly raised to about twice normal and 
plasma ammonia and amino acids were both normal. One patient was 
reported to have fat globules in his urine.
The patients improved on treatment with intravenous fluids and glucose 
and after one to three days were clinically well. The hepatomegaly 
gradually resolved over some weeks and, although the patients have shown 
susceptability to infections, prompt treatment of these have prevented 
further acute attacks.
Our first patient (M.E.) was the seventh child of unrelated Australian 
parents, born at term following a normal pregnancy. Two days prior to 
admission the patient became febrile and began to have diarrhoea. Persis­
tent vomiting continued for the next forty-eight hours and the patient 
became increasingly drowsy. On admission the semi-comatosed?peri­
pherally cyanosed child was mildly hypothermic (axillary temperature 
35.2° C) with normal pulse and blood pressure and 8 cm of firm 
hepatomegaly.
A GC profile of the silylated extract of a urine sample taken from 
the patient close to the time of admission (Fig. 22) was dominated by 
one large peak which was identified by mass spectrometry as the 
disilyl derivative of adipic acid (II). Smaller amounts of suberic (XXIX) 
and sebacic (XXXI) acids were also detected in the urinary extract.
Lactic (XI) and 3^hydroxybutyric (XXX) acids,which elute at the positions 
indicated on the profile ,were present only at low levels. Estimation of 
the amount of adipic acid present in the urine at the time of admission 
showed that up to 4000 mmole of adipic acid were excreted/mole creatinine.
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FIGURE 23. GC profile from the SE-30 packed column of the methylated 
organic acid extract from the urine obtained ftompatient 
M.E. at the time of the attack.
The peaks were identified as follows:!, 3-hydroxy butyric acid; 2, adipic acid; 3, 3-methyladipic 
acid;4,pimelic acid;5,octenedioic acid;6¿suberic acid;? ¿hexanoylglycine + p-hydroxyphenyl- 
acetic acid;8¿azeleic acid;9¿decenedioic acid;!0,sebaoic acid;ll,hippuric acid;12,unknown; 
13,suberylglycine. . _
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FIGURE 24. Synthesis of suberylglycine.
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The methylated extract of a urine sample taken during the attack
was also examined by GC-HS. The GC trace of this sample is shown in
Fig, 23. In addition to the large peaks of adipic (II) and suberic
(XXIX) acids a major peak (peak 13) was observed which eluted at
217° C. This peak was identified as the methylester (XL£fof sub-
erylglycine: (XXXII). The mass spectrum of this compound matched
with that of suberylglycme (XXXII) shown by Gregersen et al
and was identical with that of a sample of suberylglycine (XXXII)
synthesised by a modification of the anhydrous Schotten Baumann pro-
195cedure developed by Sweetman et al for the synthesis of tiglylglycine 
(Fig. 24). This is only the second time that the excretion of this 
compound has been reported. The glycine conjugates (XXXIII-XXXVI) of 
succinic (IX), glutaric (X), adipic (II) and sebacic (XXXI) acid 
were also synthesised but were not detected in the urinary extract of 
this patient. The glycine conjugate (XXXVII) of the monocarboxylic 
acid.,hexanoic acid (XL), was present in significant amounts. The 
presence of this compound was confirmed by GC-MS by comparison with 
a sample synthesised as above. The glycine conjugates (XXXVIII,
XXXIX) of butanoic (XLII) and octanoic (XLIII) acid were also syn­
thesised but were not detected in the urine sample.
Other unusual compounds detected as their methyl ester derivatives were
the monounsaturated dicarboxylic acids ̂ octenedidc acid (XLIV) and
decenedioib acid (XLV) and the unsaturated form of decenedioic acid
(XLVI). These compounds were identified using mass spectrometry by
353reference to library spectra and those published by Tanaka and 
• 239Lindstedt et al. The positions of the double bonds could not be 
determined from the mass spectra and were not determined by other 
methods.
The patient was resuscitated with intravenous glucose and his 
conscious state returned almost to normal within twenty four hours.
Normal feeds were reintroduced at this stage and the child discharged 
ten days after admission with 6 cm firm hepatomegaly below the costal 
margin.
The appearance of the child's metabolic profile changed considerably
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TABLE 31
CONCENTRATIONS OF METABOLITES DETECTED IN THE URINE OF M.E. 
AT THE TIME OF THE ATTACK AND IN A CLINICALLY UNAFFECTED
PERIOD .
COMPOUND
CONCENTRATION (mmole/mole creatinine)
M.E. Attack M.E.Unaffected
Normal Children 
(n=5, mean and 
range)
Adipic Acid 1747 6 - 8 6 (2 - 11)
Suberic Acid 764 7 - 1 0 9 (4 - 20)
Suberylglycine 429 <9 N.D.
Hexanoic Acid* 182 166 N.D.
Octanoic Acid* 216 5 N.D.
* Determined after acid hydrolysis
1974 1974
FIGURE 25. Family pedigree of patient M.E.
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with his clinical condition, so that the recovery from the attack and 
the regression of the hepatomegaly were associated with a drop in the 
level of the urinary adipic acid (II) to the levels seen in normal 
children. The other unusual metabolites detected at the time of the 
attack also either fell to normal levels or disappeared from the urine 
although significant amounts of hexanoylglycine (XXXVII) remained."
The amounts of some of these unusual metabolites detected in a urine 
sample taken at the time of the attack and also in a clinically unaffected 
period are shown in Table 31. It can be seen that although the 
excretion of adipic (II) and suberic (XXIX) acids is within the normal 
range during the clinically unaffected period, there is a very marked 
increase in the excretion of these dicarboxylic acids at the onset of the 
attack. At this time the quantity of suberic acid (XXIX) excreted as 
the glycine conjugate (XXXII) accounted for approximately 35% of the 
total suberic acid (XXIX) present in the urine.
This is considerably lower than that found in the patient described
S47 . .by Gregersen et al, where the percentage of total suberic acid (XXIX)
present as suberylglycine (XXXII) ranged from 65% to 75%.
As well as the marked increase in the dicarboxylic acids, the mono­
carboxylic acids hexanoic (XL) and octanoic (XLIII) were measured after 
acid hydrolysis and these were also found to increase during the attack. 
However, the increase in the excretion of hexanoic acid (XL) was only 
slight.
Since all of the unusual metabolites detected in the urine of the 
patient appeared to be derived from fatty acids and especially from 
increased w—oxidation, we considered that this patient could have a 
defect in $-oxidation of fatty acids. The possibility that this was 
a genetic defect was strongly suggested by consideration of the family 
pedigree (Fig. 25). Two other siblings a boy aged two years and a girl 
aged 10 months had died suddenly during episodes of a gastro-enteritis- 
like illness, when, after two days of diarrhoea and vomiting f they had 
become drowsy for a few hours and abruptly died. To test this hypothesis 
a fasting study was performed to determine whether the excretion of these 
unusual acids could be induced as a result of an increase in endogenous 
fat metabolism. During this study there was no clinical change observed
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FIGURE 26. The excretion of adipic acid,suberic acid and suberylglycine 
in the urine of M.E.(age 8 months) as a function of the time 
of fasting.
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FIGURE 27. The excretion of adipic acid, and suberic acid in the urine of 
M.E.(age 2 years) as a function of the time of fasting.
in the child. The acid excretion during the fasting study (Fig. 26) 
when the child was eight months old shows that there is a marked 
increase in the urinary excretion of adipic (II) and suberic (XXIX) 
acids after 10 hours fasting. After 14 hours of fasting, the urinary 
adipic acid (II) concentration had increased to more than thirty 
times the normal level and the suberic acid (XXIX) to more than twelve 
times the normal level. The level of suberylglycine. (XXXII) at this 
stage was also significantly increased above normal.
Although adipic acid (II), suberic acid (XXIX) and suberylglycine 
(XXXII) were the only metabolites to be monitored quantitatively during 
the fast, all of the unusual metabolites present in the urine at the 
time of the attack were observed in the urine sample obtained at the 
end of the fast.
Five normal children (aged from nine to sixty months) and one child 
diagnosed as having Reyes syndrome (aged two years nine months) were 
fasted under similar conditions and,in each case, no increase in the 
excretion of dicarboxylic acids was observed. Two of these children 
were fasted for more than thirty hours without raising the excretion 
of either adipic (II) or suberic acid (XXIX). In all control studies 
no hexanoic acid (XL) or hexanoylglycine (XXXVII) was observed in any 
urine.
In order to test the effect of an exogenous fat load M.E. was given 
a load of dairy fat (39 g) at the age of ten months. A twenty four 
hour urine collected after the load showed an increase of two to three 
times the levels of adipic (II) and suberic (XXIX) acids with suberyl^ 
glycine (XXXII) and hexanoylglycine (XXXVII) also being detected.
Sixteen months after the initial fasting study, the patient was 
again fasted and once again the urinary levels of dicarboxylic acids  ̂
were markedly raised (Fig. 27). On this occasion however, the increase 
in excretion did not commence until the child had fasted for seventeen 
hours.
These results suggest that the attack which caused the admission of
this child to hospital may have resulted from an inability to fast for 
lengthy periods of time and we have therefore been reluctant to subject 
the patient to fasts of prolonged duration in order to observe clinical 
symptoms.
Our second patient (R.Z.) was the second child of unrelated parents 
born at 35 weeks gestation. His neo-natal course and development were 
satisfactory. At fourteen months he contracted a middle ear and throat 
infection and gastro-enteritis. On day four his condition suddenly 
deteriorated with signs of peripheral shutdown necessitating respiratory 
support. He had a mild metabolic acidosis and a Dextrostick test was 
negative for sugar (serum glucose <20 mg/100 ml). Treatment was 
begun with glucose and general supportive therapy. During day six the 
child began to fit and EEG indicated a severe metabolic encephalopathy.
A GC profile of the silylated extract of a urine specimen obtained on 
day five showed the presence of a large peak which was identified by 
mass spectrometry as the disilyl derivative of adipic acid (II).
Smaller amounts of suberic acid (XXIX) werfalso detected in the urine. 
This specimen also showed only low levels of lactic (XI) and 3-hydroxy- 
butyric (XXX) acids.
A liver biopsy was done on day seven of the illness. This showed 
considerable intracellular lipid accumulation in a non specific macro­
globular pattern which is characteristic of sick children. The char-
496 497 .acteristics 3 of microvesicularity and universal small droplet fat
infiltration without inflammation under light microscopy and enlarge­
ment of mitochondria, decrease in matrix density and loss of mitochond­
rial dense bodies under electron microscopy which indicate Reyes 
syndrome were all absent.
By day eight the child was conscious and eating normally, although 
irritable and improved rapidly until discharged.
At twenty months of age the child was re-admitted for a fat load 
study. The normal total daily intake of milk fat was given at breakfast 
after a fifteen hour fast. The patient became very ill after twenty 
minutes and regurgitated the majority of the fat load. He became 
ketotic over the next few hours and required intravenous glucose for
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FIGURE 28 The excretion of adipic acid and suberic acid in the urine of 
R.Z.(age 2% years) as a function of the time of fasting.
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FIGURE 29. GC profile from the SE-30 packed column of the methylated 
organic acid extract from patient R.Z. at the end of the 
fasting study.(age 2years 3months)
1 The peaks were identified as:l.glutaric acid;2,adipic acid;3-thymol;4,pimelic acid;
5,3-hydroxyadipic acid(?);6.octenedioic acid; 7.suberic acid;8,p-hydroxyphenylace tic acid; 
+ hexanoy Iglycine;9. 3-hyai'oxy suberic acid) ?); 10.decenediozc acid; 11 .hippurtc acid;12, 
unknown M.Wt 204;13 2-hydroxysebacic acid(?); 14,2-hydroxybenzoyIglycine;15,unknowtil 
M.Wt 270;16t2-hydroxydodecanoic acid(?);17,suberyIglycine.
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FIGURE 30. GC profile from the SE-30 packed column of the methylated 
organic acid extract from the urine obtained from patient 
A.M. at the end of the fasting study.(age 16months)
The jpeaks vere identified as:l,adipic acid;2,3-methyladipic acid(?);3,unknown 'i.Wt. 186; 
4,pimelic acid;5,octenedioic acid;6,suberic acid;?}citric acid;6,unknown;0,azelaic acid; 
101heptanoyIglycine(?);11,N-mcihyIsaccharin;12,decencdioic acid;13,schacic acid; 14, 
hippuric acid; 1S,3-hydroxysebacic acidi?);16,palmitic acid;l?, sub erylg lycine.
TABLE 32
PLASMA CARNITINE LEVELS FOR PATIENT R.Z. 
MEASURED DURING FASTING STUDY
Hours of Fasting Carnitine (nmole/ml)
0 3 0 . 0
6 1 8 . 4
1 2 4 4 . 5
1 8 3 7 . 1
Normal controls (̂ 9 8) 1 6 - 1 0 1  ( me a n  4 9 )
✓
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resuscitation. Examination of two subsequent twenty—four hour urine 
collections showed that adipic acid (II) was increased in both 
specimens. The first collection showed six times normal levels and the 
second showed three times normal levels.
At two and a quarter years of age a diagnostic fast of fifteen 
hours duration was performed on R.Z. During this time he became 
drowsy and ketotic and began to vomit after fourteen hours. The 
amounts of adipic acid (II) and suberic acid (XXIX) found during this 
fasting study (Fig. 28) show that the excretion of adipic acid (II) 
is markedly increased after eleven hours of fasting and had risen to more 
than ten times normal. A GC profile of the methylated extract of the 
final urine sample obtained during this fast is shown in Fig. 29. This 
profile reveals that suberylglycine (XXXII) is also present but accounts 
for only about 10% of the total suberic acid. Hexanoylglycine (XXXVII) 
is also present in small amounts as are the unsaturated dicarboxylic 
octenedioic (XLIV) and decenedioii(XLV) acids. The hydroxy acids (XLVII- 
XLIX) corresponding to adipic acid (II) , suberic acid (XXIX), and 
sebacic acid (XXXI) have also been tentatively identified by comparison 
with library spectra. These metabolites were not present in samples 
obtained before the fasting experiment was begun.
In order to test the possibility that carnitine (XXVIII) deficiency 
was the cause of the increased w-oxidation, total acid soluble carn­
itine (XXVIII) was measured in plasma samples obtained during this 
study (Table 32) . These results show some variation during the s-*-”dy
but are all within the normal range of 16-101 nmole/ml (mean 49 nmole/ml)
498reported by Ikeakor and Lake.
A urine sample was also obtained from this child during a mild 
intercurrent infection and the acid profile examined by GC~MS. The 
abnormal metabolites were again detected. The adipic acid (II) level 
was found to be raised to about ten times normal and that of suberic acid 
(XXIX) to twice normal.
Our third patient (A.M.) was the second child of unrelated Australian 
pa^gjits. He was born at term and had some neonatal feeding difficulties 
w i t h  CNS involvment and no acidosis, but these resolved and he had
m
developed normally until eleven months of age. Four days prior to 
admission he developed mild vomiting and diarrhoea and two days before 
admission he became lethargic. He did not respond to treatment with 
intravenous fluids, developed 4 cm of firm hepatomegaly and became 
clinically dehydrated. A low blood sugar and mild metabolic acidosis 
were abnormal laboratory findings. The child responded to intravenous 
glucose immediately and over the next twenty-four hours he became less 
drowsy with a gradual return to normal activity and conscious state with 
the hepatomegaly gradually resolving over two weeks.
Examination of a urine sample obtained during this period showed the 
presence of ketonuria and fat globules. GC-MS of the TMS derivatives of 
an extract of the urine specimen showed the presence of greatly increased 
amounts of adipic acid (II), with raised levels of suberic (XXIX) and 
sebacic (XXXI) acids.
At thirteen months of age the child was re-admitted and after a 
fifteen hour fast received a fat load. He became mildly unwell, began 
vomiting' about two hours after the fat load and became ketonuric. His 
blood glucose fell and he was given intravenous glucose and fluids. A 
urine specimen collected after the fat load showed that the adipic acid 
(II) level had risen to about fifty times normal and that the suberic 
acid (XXIX) level had risen to five times normal.
When a fasting study was performed on A.M. low normal blood glucose 
levels were maintained by the use of intravenous glucose. At the of 
seventeen hours the serum triglycerides and free fatty acids had risen 
above normal and the patient was clinically well. Mild ketonuria 
developed at the end of fifteen hours fasting. After six hours from the 
start of the fast the levels of suberic acid (XXIX) began to rise and 
after eight hours the levels of adipic acid (II) also began to rise. At 
fifteen hours the adipic acid (II) level was twenty five times normal 
and the suberic acid (XXIX) level was twelve times normal. A GC profile 
of the methylated urinary extract of the sample obtained at fifteen 
hours (Fig. 30) showed that the suberylglycine (XXXII) peak accounted 
for about 65% of the suberic acid (XXIX) . Pimelic acid (XX) , sebacic acid 
(XXXI), octenedio'rc (XLIV) and decenedioic (XLV) aaid were confirmed 
by GC-MS to be present in this sample and the hydroxy acid (XLIX) of
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sebacic acid (XXXI) was tentatively identified. Hexanoylglycine 
(XXXVII) was also present in significant amounts.
Although the presence of saturated and unsaturated dicarboxylic 
acids, suberylglycine (XXXII) and hexanoylglycine (XXXVII) character­
ise the metabolic profiles of these children, there was considerable 
variation in the relative amounts of the various compounds detected in 
the urines of the three children as well as in urine samples taken at 
different times from the same child.
The biosynthesis of-dicarboxylic acids via the w-oxidation of fatty
- ' 499-502acids was first studied by Verkade et al and later by several
 ̂ , 503-505 . . .groups of researchers. Their results suggest that co-oxidation
provides an alternative pathway for the oxidation of fatty acids. The
end products of w-oxidation are short chain dicarboxylic acids, since the
long chain dicarboxylic acids initially forcned by w-oxidation on the
microsomes can be further degraded by the mitochondrial 3-oxidation
344 .system. It seems likely that the dicarboxylic acids observed m
these three patients have arisen from a combination of w and 3-oxidation.
The relative importance of the w and 3-oxidation pathways to the over­
all metabolism of fatty acids under a variety of conditions is not known.
506The results obtained by Antony and Landau suggest that in rat liver,
3-oxidation is the predominant pathway under normal conditions. However,
507experiments using branched chain fatty acids or enzyme inhibitors
353 .such as methylene cyclopropylacetyl—CoA have shown that m-oxidation
may assume a major role when the 3-oxidation pathway is hindered. Thus
there are a number of conditions known where an increased excretion of
dicarboxylic acids in the urine is associated with a disturbance in 
133V3473-oxidation.
Recently a number of reports have appeared in the literature concern­
ing children who have been found to excrete large quantities of dicarb— 
oxylic acids as the major urinary organic acids. Przyrembel et al 
have described a child with glutaric aciduria type II whose urine 
contained large amounts of C6, CQ and C1Q dicarboxylic acids as well as 
greatly elevated levels of lactic (XI) (10.3 mole/mole creatinine) and 
glutaric acid (X) (9.6 mole/mole creatinine). The presence of branched-
chain amino acid metabolites in the urine indicated a generalised defect
1 3 6
in the activity of acyt-CoA dehydrogenases. Glutaric acid (X) was often 
observed as a minor component in the urinary GC profile of M.E. and 
the other two children, however the amounts present were well below the 
levels reported for glutaric aciduria type II.
Carnitine (XXVIII) deficiency is known to cause an increased excret­
ion of adipic (IT), pimelic (XX) and suberic (XXIX) acids as well as un­
saturated dicarboxylic acids. In most cases the clinical symptoms des­
cribed have been mainly in relation to muscle dysfunction although often
effects are seen in liver function as well 388 There are three distinct
types of syndromes with respect to carnitine (XXVIII) and lipid metab­
. . 507 508olism. The first is a deficiency or partial deficiency of
carnitine 'pa'imitoy'l transferase in muscle and possibly liver. The second
is where muscle carnitine (XXVIII) levels are low but plasma levels are
normal suggesting some defect in carnitine (XXVIII) transport into
muscle cells. The third is a deficiency of carnitine (XXVIII) in muscle,
388plasma and liver described by Kaparti et al which suggests a defect
in carnitine (XXVIII) biosynthesis which occurs in the liver. In the
last syndrome an increase in dicarboxylic acid excretion was noted due
to increased w-oxidation and this should occur in the other deficiency
syndromes also although it has not been specifically reported. Our
patients had significant differences in dicarboxylic acid excretion
388pattern to that described by Kaparti et al and this fact, together 
with the normal levels of plasma carnitine (XXVIII) found in R.Z. during 
the fasting experiment and the presence of hexanoylglycine; (XXXVII) 
suggests that carnitine (XXVIII) deficiency is not the cause of the 
attacks in our patients.
509
The clinical pictures and the organic acid profiles observed in the
three boys at the time of the attacks closely resemble those reported
in patients suffering from Jamaican Vomiting Sickness, a disease pro—
duced by the ingestion of unripe akee fruit. ■ This fruit contains a
toxic amino acid derivative, hypoglycin A. A metabolite of this amino
acid, methylenecyclopropylacetic acid,inhibits the transport of
fatty acids into mitochondria and also inhibits dehydrogenation of
511 . .several acyl CoA derivatives leading to the disruption of fatty 
acid 3—oxidation and a massive urinary excretion of adipic acid (El) 
and other dicarboxylic acids. Hexanoylglycine (XXXVII) was also
1 3 7
excreted51 a in large amounts in this disease.
A similar clinical case to that of our patients is described by 
513 JChalmers et al in identical twin boys following an adenovirus
infection. One boy died before admission to hospital but the other 
recovered rapidly after treatment with intravenous glucose. Urine sam­
ples taken at the time of the attack showed elevated levels of adipic
and suberic acids, unsaturated dicarboxylic acids and octanoic acid.
The similarities between this disease and Jamaican vomiting sickness 
were noted by the authors who suggested that the attacks may have 
resulted from the ingestion of a toxic analogue of hypoglycin A.
Further investigation by Chalmers and Watts^^^ has shown that unripe sloe 
berries may have been the causitive agent in these cases. In the 
case of the three boys described in this report, the results obtained 
from the fasting experiments indicate that the disease in these children 
is caused by a deficiency in endogenous metabolism rather than the 
ingestion of a toxic compound.
491Tanaka et al have reported a patient suspected of having a defic- 
iencyi of gveeYi aoy L-CoA dehycbpogeyiase, the enzyme responsible for catalysing 
the dehydrogenation of C^-Cg CoA esters. This child excreted large amounts 
of adipic acid (II)rhexanoylglycine (XXXVII) and 2-ethylmalonic acid 
(III). In our patients adipic acid (II) and hexanoylglycine (XXXVII) 
were elevated but 2-ethylmalonic acid (III) was not detectable.
A patient who appears to have most features in common with the three
children presented in this report, is the boy described by Gregersen et 
347al. This child was prone to episodes of lethargy and unconsciousness 
but responded rapidly to intravenous glucose. At the times of these 
attacks, the urine was found to contain large quantities of dicarboxylic 
acids as well as suberylglycine (XXXII), the metabolite present in the 
urine of our patients.
The results of the fasting studies carried out on our patients in­
dicate an inability to adequately cope with the flux of fatty acids 
through the 0-oxidation pathway at times when the body is dependent on fat 
as the source of energy, and it would appear that periods of prolonged 
fasting may have induced the attacks which were responsible for the
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admission of these children to hospital• In support of this view it is 
of interest to note that, the patient described by Gregersen et al^^ 
suddenly following a 39 hour fast for diagnostic purposes.
The reason for the acute clinical state of the patients is unclear.
Although low concentrations of glutaric acid (X) are nephrotoxic over long
periods of time and high concentrations cause permanent neurological 
 ̂ . .  517damage, adipic acid (II) and other dicarboylic acids are relatively 
non-toxic and non-neurotoxic . Thus the relatively high concentration 
of dicarboxylic acids is probably not the cause of the clinical state.
• . 515 519Short chain fatty acids are however, very neurotoxic J and are
known to cause coma when given to experimental animals. This neurotox­
icity explains the observation that in isovaleric acidemia serum acid 
concentration parallels the levels of consciousness during acute
attacks. Short chain fatty acids also cause electro-encéphalographie
, 520,521  ̂ „ . 522 .changes such as slow waves and spindles by causing depression
)of the activating system of the reticular formation in midbrain neocortex
523and by interfering with neuronal membrane function. The symptoms may 
thus be caused by the intracellular build up, of monocarboxylic acids 
affecting the brain cells in combination with -hypoglycemia caused by 
inhibition of gluconeogenesis.
The results from these patients suggest that the patients have a defect 
in one of the enzymes of the $-oxidation pathway. The variability of the 
metabolites excreted may indicate a different defect in 3-oxidation or 
may reflect genetic heterogeneity of a single defect. This question 
cannot be settled until the individual enzymes for 3-oxidation are 
assayed in each patient. The evidence obtained here suggests that the 
defect is in one of the chain length specific enzymes of the 3-oxidation 
pathway and is thus probably in the dehydrogenase or thiolase enzymes. 
This defect then causes the utilisation of the alternate w-oxidation
' • ■ Js*’
pathway to produce energy from the fatty acids.
The appearance of an almost normal GC profile under normal dietary 
conditions may be explained by the 'fat-sparing' effect of carbohydrates 
since, when adequate carbohydrate is available, only minute quantities 
of fatty acids are oxidised to provide energy. Thus a deficiency in
I 3 y
3-oxidation may not become significant until the body becomes reliant
on fat for its energy requirements. The time at which this occurs will
depend mainly on the amount of glycogen stored in the body. Analysis of 
, . . 5 2 4the respiratory quotients suggests that approximately 8-10 hours after 
a meal glycogen stores become depleted and the body becomes dependent on 
fat as the source of energy. This time period coincides with the increased 
urinary excretion of dicarboxylic acids observed in the three children 
during fasting studies.
b. STUDIES OF PATIENTS WITH PROPIONIC ACIDEMIA : 
THE IDENTIFICATION OF 3-KET0-2-METHYLVALERIC 
ACID AND 3-HYDROXY-2-METHYLVALERIC ACID
. 525In 1961, Childs et al described a male infant with episodic 
metabolic ketoacidosis, protein intolerance and remarkably elevated
plasma glycine concentration. Extensive studies of glycine metabol­
ism failed to reveal a definitive abnormality and investigation of the 
protein intolerance showed that five amino acids were ketogenic in the 
patient. These were leucine, (L), isoleucine (LI)', valine (LII),threo­
nine (LIII)and methionine (LIV)* During the next seven years the hyper- 
,glycinemia syndrome was differentiated into non-ketotic and 
ketotic forms and some of the cases of the latter were shown2̂ 161 
to be cases of methylmalonic acidemia. Investigation of the ini­
tial case showed that it was not methylmalonic acidemia and further 
528investigation showed the presence of butanone (kV^^pentanone 
andljhexanone (LVII) as well as acetone (LVIIJ) . The butanone (LV) was 
postulated to arise from the spontaneous decarboxylation of 2-methyl- 
acetoacetic acid(LIX) an intermediate of isoleucine (LI) metabolism.
134In 1968 Hommes et al reported a patient whose neonatal death from 
severe metabolic acidosis was associated with extremely high concen­
trations of propionic acid (XXI) in the blood . (M.00 x normal) together with 
high liver concentration of unusual Cl 5 and Cl 7 ;fatty acids but no 
hyperglycinemia was found. ¡Hsai et al 529 used enzyme studies to 
demonstrate that a sibling of the original patient had an almost
complete inability to metabolise propionate (XXI) and that in another 
530 .patient no activity of propionyl-CoA carboxylase (EC 6,4.1.3) could
be shown. The parents of one patient showed a partial deficiency of
enzyme activity. Since that time a number of other patients have been
described with a defect of this enzyme and prenatal diagnosis has been
531,532 "carried out by enzyme measurements of cultured cells and by
489measurement of secondary metabolites in amniotic fluid. An asympto­
matic patient with a partial enzyme deficiency has recently been
- , 533described.
The propionyl-CoA carboxylase enzyme has been crystallised from pig 
heart and studied e x t e n s i v e l y . I t  is a mitochondrial enzyme with a 
molecular weight of about 700,000 with 4 molecules of biotin as pros­
thetic group for the apoenzyme. The biotin is bound through an amide 
linkage in which the terminal carboxyl group of biotin reacts with
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FIGURE 31. Metabolic pathways leading to the production of propionyl CoA.
1 ^ 2
e-amino group of lysine (XII) . mua ,The structure is probably composed of
four subunits of equal size.
The carboxylation reaction occurs in two stages in which bicarbonate 
is first bound to the biotin-apoenzyme complex through the biotin and 
the complex then reacts with propionyl-CoA to form D-methylmalonyl- 
CoA. The first stage of the reaction requires ATP and magnesium ions. 
The biotin cofactor requirement of the enzyme has been reflected in the 
discovery of some patients with a biotin responsive variant of the 
disease.
This lack of activity of propionyl CoA carboxylase causes a build up
of propionyl-CoA. Propionyl-CoA is a key intermediate in the metabolism
of many percursors (Fig. 31). It is an obligate metabolite of iso­
, . 5 3 5 , . .leucine (LI) which is found in large amounts in food protein.
Threonine (LIII) and methionine (LIV) may be metabolised to propionyl-
5 3 6  53 7CoA through a-ketobutyryl-CoA and Hsai et al have shown that this
is an almost quantitative pathway in methylmalonic acidemia. Valine (LII)
may also be metabolised to propionate though 3-hydroxyisobutyrate (LX),
Odd chain fatty acids with 15 or 17 carbons which are minor constituents 
5 3 8  539of body and dietary lipids, comprise 2-3% of fatty acids and pro­
duce 1 mole of propionate (XXI) per mole of fatty acid oxidised. Large 
dietary intake of fat may make this a major source of propionate (XXI).
A minor but significant source of propionate (XXI) is the side chain
cleavage of cholesterol to bile acids and propionic acid (XXI) A
. . .  . . . . . .  . . 541 .source of propionic acid (XXI) of major importance in ruminants is
bacterial fermentation in the gut but this source has not been evaluated
5 4 2  . . . ,im  man. Studies by Snyderman et al using antibiotics to sterilise the 
alimentary canal suggest that this may be a significant source of propion­
ate (XXI) in man.
The next step in thè metabolism of propionyl-CoA is the carboxylation 
to D-methylmalonyl-CoA and thence to succinyl-CoA for use in the citric 
acid cycle. Many alternative minor pathways for metabolism of propionyl 
-CoA became important when this sequence is blocked and lead to the syn­
thesis of the characteristic metabolites found in propionic acidemia. 
These pathways include conjugation with glycine to give propionylglycine
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FIGURE 32. Metabolic pathways for propionyl CoA
The normal pathway ie through methylmalonyl-CoA and oucciryUCoA to the citric acid cycle 
but if this pathway io blocked urinary excretion of producte from the alternate pathways 
ia observed
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FIGURE 33. The total ion current profile from the SE-54 capillary 
column of the silylated organic acid extract of urine 
obtained from patient Z.K. at the time of admission 
when he was severely ketotic.
The peaks were identified as:l,lactic acid;2y 3-hydrcxy propionic acid;3, 3-hydroxybutyric 
acid;4,3-hydroxy-2-metkyIhutyric acid; 5,acetoacetic acid(isomer 1);633-hydroxyvaleric 
acid; 7,acetoacetic aciddsomer 2) ; 8&9, 3-ketovaleric a.cid;10 , 2-methylacetoacetic acid;
11,3-keto-2-methylvaleric acid;12,3-hydroxy-3-methylglutaric acid;13&143me thy lei trie 
acid;1534-hydroxyphenyllactic acid. SS= solvent suppression
(LXI), w-oxidation to give 3-hydroxypropionic acid (XXII), condensation with 
oxalacetate (LXII) to give methylcitric acid (LXIII) and condensation with 
acetyl-CoA to give 3-keto-n-valerate (LXIV) (Fig. 32).
The most prominent biochemical feature of the defect in proplonyl-  
CoA carboxylase is the accumulation of propionyl-CoA, which is the metab­
olite immediately preceding the enzyme block. This metabolite is hydro­
lysed and excreted as propionic acid (XXI). Compounds occurring earlier 
in the pathway are also excreted as well as secondary metabolites of
propionic acid (XXI). Metabolites such as 2-butanone (LV), 3-pentanone
528 370(LVI), 3-hexanone (LVII) , methyl citric acid (LXIII) , tiglic acid
191 194 197(LXV) , . propionylglycine (LXI) , tiglylglycine (LXVI) , 3-hydroxy-
• 478propionate (XXII ) , 3-keto-2-butyrate (LIX), 3-hydroxy-2-methyl-
butyrate (LXVIII), 3-hydroxy-n-valerate (LXIX) and 3-keto-n-valerate (LXIV)
5"have been identified in these patients. The presence of such secondary 
metabolites may give the initial indication of the diagnosis, as propionic 
acid (XXI) cannot be seen on the usual urinary screen for organic acids 
and specialised methods are required to detect it.
Our patient (ZK) was healthy at birth after a normal pregnancy, labour 
and delivery, but developed a severe metabolic acidosis at 48 hours.
The perinatal deaths of 2 siblings suggested the possibility of an in­
born error of metabolism as the basis for the acidosis. The organic 
acid profile of the child's urine when first admitted with ketosis 
(60U>?) (Fig. 33) was dominated by a large peak of 3-hydroxybutyric acid 
(XXX) and smaller peaks of lactic acid (XI) and acetoacetic acid (XXVII) 
which are characteristic of ketoacidosis. In addition there were a
number of peaks of compounds which have been described as being elevated
544in propionic acidemia. Duran suggests that methylcitric acid (LXIII) 
and 3-hydroxypropionic acid (XXII) were considered to be diagnostic of 
proplonyl-CoA carboocylase deficiency and these compounds were present 
though only as minor components. The five carbon acids 3-keto-n-valeric 
acid (LXIV), 3-hydroxy-n-valeric acid (LXIX) and 3-hydroxy-2-methyl- 
butyric acid (LXVIII) were major constituents of the specimen and Duran 
suggests these may be frequently found in urine from patients with 
propionyl-CoA carboxylase deficiency when they are ketotic. These
i .
compounds were identified by comparison of the mass spectra of the TMS
derivatives with _ . „,205/l those in our library as well as those published by Sweetman et al
and Ando et a l / ^  A urinary keto acids and ketone screen showed the
dsuodssj japjoDay
o
FIGURE 34. The total ion current profile from the SE-54 capillary column 
of the silylated organic acid fxtract of urine obtained 
from patient Z.K. after the ketosis had been controlled.
The peaks were identified as:1,lactic acid; 2,3-hydroxy propionic acid; 3, 3-hydroxy butyric 
acid; 4 , 3-hydroxy-2-methylbuturic acid; 5,3-hydroxyisovaleric acid; 6 , 3-hydroxyvaleric acid; 
7,acetoacetic acid; 869,3-hydroxy-2-methylvaleric acid;10,3-ketovaleric acid;ll, 3-keto- 
2—me thy Ival eric aciddsomer 1); 12, 2-methylacetoacetic acid; 133 3-keto-2-methylvaleric 
acid (isomer 2) ;14 ¡propionylglycine;15 ¡glutaric acid; 16 ¡adipic acid; 17 3furan- 2-hydroxy­
methyl- 5-carboxylic acid; 16, 2-hydroxyglutaric acid;19,3-hydroxy-3-methylglutaric acid;
20,4-hydroxyphenylace tic acid;21622,msthylei trie acid;23,4-hydroxyphenyllactic acid;
24,palmitic acid. SS= solvent suppression
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FIGURE 35. Synthesis of propionylglycine (LXI).
presence of acetone (LVIII), butanone (LV) andBpentanone (LVI) all 
of which have been reported in propionic acidemia. The presence of 
these metabolites- suggested a diagnosis of propionic acidemia and serum 
propionate (XXI) was measured. The result obtained was 3.5 rrJVl/1 ' 
(normal = 1.29- 0.52 yM/1 and serum glycine (LXX) was 356 yM/1 (normal 
range of 92-392 yM/1. The identity of the propionic acid (XXI) was 
confirmed by GC“MS of the butyl ester formed on pyrolysis of the 
tetrabutylammonium salt in the injection port,of the gas chromatographo
The diagnosis of a prop'ionyl-CoA carboxylase defect causing prop­
ionic acidemia was confirmed by the enzyme studies which were not avail­
able until after the patient's death. The activity of prop'ionyl-CoA 
carboxylase in cultured skin fibroblast extracts was 30 pmol/min/mg. * 
protein. A series of normal patients had activities of 860- 200 
pmol/min/mg protein. Thus Z.K. had about 3.5% normal activity of the
enzyme. The fibroblasts complemented into the pcc BC group of 
„ ■  ̂ , 545 , . . .Gravel et al. No other patients in this complementation group have
been biotin responsive suggesting that an initial impression of biotin 
responsiveness may have been due to some other factor in the vigorous 
initial treatment. Management of the patient was based on control of 
the ketoacidosis by fluid therapy, peritoneal dialysis and exchange 
transfusions to remove accumulated organic acids^as well as protein 
restrictions.
The extract of a urine sample obtained the following day when 
ketosis was under control is shown in Fig. 34. At this time the serum 
propionate (XXI) concentration was 2 mM/1 and glycine concentration 
was 382 yM/1. This profile reveals large peaks of 3«-hydroxypropionic 
acid (XXII), 3-hydroxy-2-methylbutyric acid (/ĝ III) and methylcitric 
acid (LXIII). 3-keto-n-valeric acid (LXIV) and 3-hydroxy-n-valeric 
acid (LXIX) which were components of the first sample were barely 
detectable in this sample. Two metabolites, 3 hydroxyisovaleric 
acid (XXIII) and propionylglycine. (LXI) appeared which were not ob­
served in the previous sample. The presence of these metabolites was 
confirmed by GC-MS by comparison with authentic samples. Propionyl­
glycine (LXI) was synthesised (Fig. 35) by a modification of the an-
195hydrous Schotten-Baumann procedure developed by Sweetman et al for 
the synthesis of tiglylg|ycin@; (LXVI). In this method an acid chloride 
is reacted with glycine methyl ester hydrochloride (LXXI) in the
C H , -C H , -C H ,O H  »  C H ,-  CH,- CHO
Nj OH
PROPANOL (LXXlV) PROPANAL(LXXIII)
vKjC03
• C H ,-C H , -C H -  CH-CHO 
r I
OH CH, .
PR0PIÓNALD0L (LXXII)
D*tiUatjorr
from
Adipic acid
Jones
Reagent
CH,
2,4-0IETHYL-5.-METHYL-6- 
HYDROXY-1 ,'3-DIOXANE (LXXV)
CH, -  CH^ -  COO C2H5
ETHYL PROPIONATE 
(LXXVI)
^ ^ ♦ C H , - C H 2-C - C H - C 0 0 C , H 5 — --------- *.H,0 I | 5
0 c h 3
3-KET0-3-METHYLVALERIC 
ACID ETHYL ESTER (LXXVII)
CH3 -C H ,  -C -C H -C O O H  I I
0 c h 3
3-KET0-2-METHYLVALERIC 
ACID (LXVII )
FIGURE 36. The preparation of 3-keto-2-methylvaleric acid (LXVIT*) via oxidation 
of propionaldol and the Claisen condensation of ethyl propionate.
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presence of base under anhydrous conditions at room temperature and 
the resulting acylglycine methyl ester hydrolysed in methanolic sodium 
hydroxide to obtain the free acylglycine.,. This method has a number of 
advantages over the usual methods of synthesis5^ -5^  of acylglycines 
in which the acid chloride or anhydride is reacted with glycine in 
basic aqueous media which gives a product which is often contaminated 
with free acid. The advantages of Sweetman et al's method include 
the production of the methyl ester as intermediate which may be 
purified by distillation. The method gave yields of 85% for the 
condensation and 80% for the hydrolysis. The preparation of the acid 
chloride and glycine methyl ester hydrochloride****^ proceeded in 
quantitative yield.
peaks
Two other prominent were present in the GC trace (peaks 8 and 13,
Fig. 34) which could not be identified. CI-MS of peak 13 indicated the
compound had a molecular weight of 274 as the "IMS derivative and that
peak 11 had an identical molecular weight. Further examination showed # c. to peak 13.peak 11 had an idential El“MSa The peax at m/e 245 corresponding to a loss
of 29 amu from the molecular ion suggested the presence of an ethyl group
within the molecule. Comparison of the mass spectrum with that of 3-keto-
195n-valeric acid (LXIV) showed that the major fragment ions of the un­
known were m/e values 14 amu higher in the unknown than in 3-keto-n- 
valeric acid (tXIV) suggesting the presence of an extra methylene unit.
A possible structure of 3-keto-2-methylvaleric acid (LXV II) was post­
ulated and the synthesis of this compound was undertaken.
Two different syntheses of this compound were carried out. The first
approach (Fig. 36A) was via the oxidation of propionaldol (LXXII) . The
preparation of propionaldolh_XXII) has been described from proponal
e  ̂¿51(LXXHI) by the Aldol reation. The required aldehyde is readily obtained
by the oxidation of propanol (LXXIV) , Propionaldol L̂X-XII) ---c*.
was prepared in low yield using sodium hydroxide catalyst but oxidation 
5F3j554 the product gave no 3-keto-2-methylvaleric acid (LXXVII).
•This may have been due to the acid in the Jones reagent reversing the
Fc C _ -condensation. When Spath et al's modification (Fig. 36B) was 
attempted the intermediate 2,4-diethyl-5-methyl-6-hydroxy-l,3-dioxane 
(LXXVV) was isolated in 51% yield, but distillation from adipic acid(II) 
regenerated proponal. (CX-XIII) and gave no propionaldol (UXII) . This
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FIGURE 37. (a) The El mass spectrum of peak 13 from the GC shown in
Fig.34. (b) The El mass spectrum of the silylated derivative 
authentic 3-keto-2-methylvaleric acid.
c h 3 - o h 2 ■ C - C H - C O O C - H  
il I 
0 CH,
3-KET0-2-METHYLVALERIC 
ACID ETHYL ESTER(LXXVII)
CH3- CH, -  CH- CH- C 0 0 C 3 Hj 
‘ I I v
OH CH3 \
3-HYDR0XY-2-METHYLVALERIC \N a O H
ACID ETHYL ESTER
4* »
C H , -  CH, -  CH - C H - C O O H  
1 1 
OH CH3
3-HYDR0XY-2-METHYLVALERIC 
ACID (LXXIX)
FIGURE 38. Synthesis of 3-hydroxy-2-methylvaleric acid (LXXIX).
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FIGURE 39. (a) The El mass spectrum of peak 8 from the GC profile
showmin Fig. 34. (b) The El mass spectrum of the silylated 
derivative of authentic 3-hydroxy-2-methylvaleric acid.
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approach was abandoned in favour of the Claisen condensation555 
(Fig. 36c). Self condensation^of ethyl propionate (LXXVI) in the 
presence of sodium .ethoxide gave 3-keto-2-methylvaleric acid ethyl 
ester (LXXVII) which may be hydrolysed to the required acid. Conden­
sation was affected in reasonable yield and the product was hydrolysed 
at 4 to minimise a©©afka*ylation. Acidification of the sodium salt was
^y immediate extraction of the acid. This hydrolysis proced—
557ure has b^en used by Kri/eger for the isolation of acetoacetic : acid.
The yield of ketoacid (LXVII) from the ester was over 80%. The dried 
acid was derivatised with BSTFA and GC-MS analysis of the product 
showed it to be identical with that of the unknown urinary component 
(Fig. 37) . Two peaks were obtained in the GC profile of both the 
authentic and urinary 3-keto-2-methylvaleric acid (LXY.II.). These 
silylation products are the ds  and tPans—Qnol. derivatives. By in­
creasing the derivatisation time the majority of the earlier eluting 
peak was converted to the second product which we believe is the 
thermodynamically more stable trans-enol derivative.
The compound present in peak 8 of the silylated urinary acid 
profile (Fig. 34) was shown to have a molecular weight of 276 by Cl-MS* 
Further examination showed that peak 9 in the profile also had a mole­
cular weight of 276. Both compounds had very similar fragmentation 
patterns by El-MS. On the basis of their El-MS the compounds were 
tentatively identified as 3-hydroxy-2-methylvaleric acid (LXXIX). A 
sample of authentic hydroxy acid was synthesised by sodium borohydride 
reduction of the keto acid ethyl ester (LXX'V'H' followed by base 
hydrolysis (Fig. 38). The two silyl derivatives were shown to have the 
same GC retention times and mass spectra as peak 8 and 9 in the profile 
(Fig. 39). The reason for the presence of the two silyl derivatives is 
due to the fact that the hydroxy acid contains two asymetric carbon atoms 
(Fig. 38) and thus can give rise to two diastereoisomers and the 
two peaks correspond to the disilyl derivatives of these two diastereoisomers 
of 3-hydroxy-2-methylvaleric acid (LXXIX). A similar phenomenon was ob­
served for methyleitrie acid (LXIII) where the silyl derivative was resolved 
into two peaks on the capillary column (Fig. 34 - peaks 21 and 22).
Age of patient (hours)
FIGURE 40. (a) The serum concentration of propionic acid(a— «)
compared with (b) the urinary concentrations of 3-hydroxypro 
pionic acid ( o— o ) and 3-keto-2-methy1 vai eric acid ()«— #.) 
in patient Z.K. during the course of his treatment.
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The absolute configuration of the two diastereoisomersof methylcitric acid
(bXIII) excreted by a patient with propionic acidemia have been deter—
. . 558mined previously.
Both 3-keto-2-methylvaleric acid ( LXVII) and 3-hydroxy-2-methyl- 
valeric acid (LXXIX) were found consistently in urine samples taken 
from this patient during his illness. The most likely origin of 3-keto- 
2-methylvaleric acid ( LXVII) appeared to be the thiolase-catalysed self 
condensation of propionyl-CoA and this suggested that the urinary 
excretion of the keto acid (LXVII) may be a useful indicator of intra­
cellular and serum propionic acid levels.
The urinary levels of 3-keto-2-methylvaleric acid (LXVII) and serum 
levels of propionate (XXI) were monitored together to investigate a 
possible correlation and the results obtained show (Fig. 40) a good 
correlation between 3-keto-l-methylvaleric acid (tXVII) and another 
propionate metabolite, 3-hydroxypropionic acid (XXII). There 
seemed to be a reasonable correlation between the urinary excretion of 
these two metabolites and serum propionate (XXI) concentration after 90 
hours but there was a marked deviation from this relationship in the 
sample at the time of admission when the child was severely keto-acid- 
otic« This may be due to the intensive treatment of the child or may be 
due to a lag in the production of metabolites of propionic acid (XXI).
Another possible explanation for the presence of 3-keto-2-methylvaleric 
acid (jlXVII) and 3-hydroxypropionate (XXII) is that they are formed in 
the urine after excretion by the kidney. For example they could be formed 
in the bladder or during storage.
In order to test whether 3-keto-2-methylvaleric acid (LXVII) or 3- 
hydroxy-2-methylvaleric acid (LXXIX) had arisen artificially from the 
self condensation of propionic acid on storage^ propionic acid was 
added to normal urine to give a final concentration of 5 mM and the 
solution was incubated at 37 C for 22 hours. Extraction and derivatis- 
ation of the organic acids failed to show the presence of either 3—keto—
2—methyl valeric acid (jLXVII) or 3—hydroxy—2—methylvaleric acid (LXXIX) .
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The unusual ketone, 3-pentanone (LVI) has been shown to be present 
in the urines of patients with propionic acidemia522 and methylmal- 
o m c  acidemia by means of the  ̂ test although the mechanism of its 
formation has not been discussed. Since 3-keto-2-methylvaleric acid 
( LXVII) is a 3-keto acid, it is possible that it could be responsible
for the formation of 3-pentanone (LVI) by a decarboxylation mechanism. 
The identification of 3-keto-2-methylvaleric acid (LXVII) in the urine 
of our patient prompted us to explore the possibility that 3-pentanone
(LVI) could be derived from this 3-keto acid.
There are two ways in which 3—pentanone (LVI) could be produced from 
3-keto-2-methylvaleric acid ( LXVII): the spontaneous decarboxylation of 
the acid 'in vivo or the artefactual production of the ketone in vitvo 
due to the high concentration of acid in the 2,4-DNP reagent used. 
Support for the latter mechanism as the source of the pentanone is given
conby a study of the decarboxylation reaction of acetoacetic acid. The
first order rate constant for the decomposition of acetoacetic acid is 
-3 -14*2 x 10 sec . in 0.2 M acid (a half life of 5.8 mins) and increases 
with acid concentration whereas that for the anion is 8 x 10"6 sec~* 
(half life 24 hours).
In order to test these possibilities methods of analysis of free
ketones in urine and for ketone-DNP derivatives had to be developed.
The extraction of free ketones from urine without extracting the keto
5 61acids had been reported by Liebich and Huesgen. These authors ex­
tracted heptanones from basic urine with cyclohexane and analysed the
dried organic extract by mass fragmentography. Our approach was to use 
their solvent extraction method with pentane and analyse for the 
presence of ketones by GC using a suitable derivative. The oximes of 
acetone (LXXX), butanone (LXXXI), 3-pentanone (LXXXII) and 3-heptanone 
(LXXXIII) were prepared but attempts to separate them from the solvent on 
the available columns were unsuccessful. Similarly the methoximes of 
acetone (LXXXIV), butanone (LXXXV) 3-pentanone (j^XXVI) and 3-heptanone 
(LXXXVII) were prepared but were found to co-elute with the solvent. 
Derivatisation of the oximes with BSTFA gave some separation from the 
solvent but interference was found from the reagent impurities and by- .
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559 .products. Bachmann et al reported the separation of the dinitrophenyl- 
hydrazones of ketones on lightly loaded silicone columns and the 2 ,4— 
dinitrophenylhydrazones of acetone (LXXXVIII), butanone (LXXXIX),-3- 
pentanone (XC) and 3-heptanone (XC1) were prepared. The Dexil-300 
packing material used by these workers was not available and the use of 
SE30 gave poor resolution of the derivatives. However use of an OV-17 
capillary column gave adequate separation of the free ketones. The 
method gave recoveries of greater than 97% for added 3-pentanone (LVI) 
and the standard curve using 3-heptanone (XCII) as an internal standard 
was a straight line with correlation coefficient, of 0 . 9 9 over the 
range 0-1500 ng 3-pentanone (LVI).
T h e  2 ,4-dinitrophenylhydrazones w e r e  also analysed by T L C  in tw o
562 s e p a r a t e dsolvent systems. One system, that of Seakins et al,
. 2 ,4 -D N P  . . 198acid- a derivatives and the other, that of Daum et al, was used to
2 ,4 -D N Pseparate neutral derivatives. The identity of the ---A derivatives was 
confirmed by solid probe EI and CI mass spectrometry 4
In an initial experiment, several microlitres of 3-keto-2-methyl-
. . , \ 2 ,4 -D N P  5S2 ,valeric acid (L/yiii/were added to the A reagent. An immediate
p r e c i p i t a t e  w a s  f o r m e d  a n d  T L C  a n d  MS a n a l y s i s  s h o w e d  t h a t  t h i s  w a s
2 ,4 -D N Pthe a derivative (XC) of 3-pentanone (LVI). A precipitate of 3-
2 .4 -D N Ppentanone- A (XC) was also obtained when urine containing 5mM 3-keto-
2 - m e t h y l v a l e r i c  a c i d  { L X V I I )  w a s  t r e a t e d  w i t h  t h e  r e a g e n t  u n d e r  t h e
conditions used for urine screening. Since this urine sample had been
thoroughly extracted with pentane to remove 3-pentanone (LVI) prior
to the addition of the dinitrophenylhydraz ir.e reagent, it seemed that 
2 ,4 -D N Pthe 3-pentanone-?A iXC) must have been produced as a result of the
• . 2 ,4 -D N Pdecarboxylation of the keto acid or the ketoacid- ' ̂  in acid solutions. 
When 5mM solutions of 3-keto-2-ethylvaleric acid (XCIII) or 3-keto-2-
methylcaproic acid (XCIV) in urine were similarly treated with 2,4-DI^F
• 2 ,4 -D N P , .reagent a precipitate of 3-hexanone ’ . (XCV) was obtained.
Treatment of 5 mM solution of 2-methylacetoacetic acid (LIX),in urine
with the reagent gave a precipitate which contained about equal amounts
2 - 4 - B N F  2 ,4 -D N Pof butanone ^  (LXXXIX) and 2-methylacetoacetic acid A (xCVI) while
treatment of 3 5mM solution of adetoacetic acid (XXVII) gave less than 10-*
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FIGURE 41. The urinary concentrations of 3-pentanone and 3-keto- 
methylvaleric acid as a function of time.
The lines drawn represent lines of best fit determined by linear regression 
The high initial level of 3-pentanone resulted from the fact that the 3-k.eto- 
valeric acid added to urine contained a significant amount of thts ketone as  ̂
3~Keto-2-methylvaleric acid ( 8 - ----Q  ) j 3-pentanone ( ©  Sproduct.
2-
i analysis.
■ 2-methyl- 
degraaation 
i )
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^ 2,4-DNPof acetone- A (LXXXVIII) the major product being acetoacetic acid—2:*4-DNP
563(XCVII) . Smith has also described the formation of acetone-2 ̂,4-DNP
(LXXXVIII) from solutions of acetoacetic acid (XXVII). When 5 mM
. 2 4-DNPaqueous solutions of keto acids were treated with 9 A reagent similar
. 2.4-DNPresults were obtained. In each case the ketone A must have been
produced as a result of the decarboxylation of the keto-acid or the 
. 2 ,4 -D N Pketo acid ^ in acid solution .
To determine whether 3—pentanone (LVI) could be formed by decarboxyl—
\
ation of urinary 3-keto-2-methylvaleric acid ( LXVII) within the body, 
the keto acid was added *to normal urine at a concentration of approxim­
ately 5 mM and the solution incubated at 37°C. Samples were removed at 
various time intervals for the measurement of 3-pentanone (LVI) and the 
residual keto acid ( LXVII) . These results are summarised in Fig. 41 and 
show an increase in pentanone (LVI) and a decrease in keto acid ̂  LXVII) 
concentrations. This suggests that the keto acid is readily decarboxyl- 
ated at body temperatures.
Using the above technique, urine samples of Z.K. which had been shown 
to contain large amounts of 3-keto-2-methylvaleric acid f LXVII) were shown 
to contain large amounts of 3-pentanone (LVI) (0.35 mole/mole creatinine 
in the 2nd urine sample, Fig. 34). The identity of this ketone as 3- 
pentanone (LVI) was confirmed by G C -M S  of the free ketone and T L C  and
2,4-DNPMS of its A derivative. In urine samples taken after treatment of the 
patient 3-keto-2-methylvaleric acid ( LXVII) concentrations were low, and 
3-pentanone (LVI) could not be detected.
Our second patient (E.B.) was a child who died at age 22 months ' 
after an episodic illness characterised by drowsiness, hypotonia and 
myoclonic jerking. In earlier episodes this was accompanied by peripheral 
circulatory failure and hypothermia. Later the major feature of his 
illness was the presence of severe acidosis. No diagnosis was made while 
he was alive but the amino acid chromatograms showed elevations of urinary 
and serum glycine. He had elevated serum ammonia and neutropenia but 
studies of glycine metabolism in E.B. failed to provide a reason for the 
elevated serum glycine. The child also had sugar intolerance and malabsorb­
tion and his protein restricted diet contained medium chain triglycerides
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FIGURE 42. Total ion current profile from the SE-54 capillary column 
: the silylated organic acid extracts from the urine of E.B.
when medium chain triglycerides were the major calorie 
source.
The peaks were identified ae:l,lactic acid;2,3-hydroxypropionic acid;3,3-hydi'oxybutyric 
acid; 4,2-hydroxy -2-methylbuty via acid;i>, 3-hydrcxyisovaleric acid; 6, 3-hydroxy valeric acid;
Y, 2-hydroxy- '¿-me thy IvaUric acid;8, succinic acid; 9} 3-ke to-2-metkylvalcric acid; 10, pvopionyl- 
glycine;11,glutaric acid; 12,adipic acid; 13tunknown,’-f.Wt. 200; 14,suberic acza;15,10trr,ethyl- 
citric acid;17teebacic acid.
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as the major source of calories. At the age of seven months episodes of 
keto acidosis began. Urinary studies at this time gave equivocal results, 
one group suggesting methylmalonic acid (I ) as the major metabolite 
and another claiming the metabolite was in fact acetoacetic acid (XXVII).
At the age of twelve months he entered a period of relative stability 
and growth when on a restricted protein diet. Episodes of ketoacidosis 
continued and at 22 months the child died following a viral infection. 
Enzyme studies were not available for this patient as attempts to cul­
ture cells were unsuccessful.
A sample of urine from E.B. had been collected when he was 13h months 
old when he in relativelygood health. This sample showed slightly in­
creased glycine concentration and was negative for ketones and ketoacids. 
The metabolic profile of this urine sample is shown in Fig. 42. The 
profile is dominated by large peaks due to adipic (II) and succinic 
acids (ix) .
The presence of the dicarboxylic acid peaks • due to glutaric
acid (X), pimelic acid (XX) suberic acid (XXI) and sebacic acid (XXXI) 
may be explained by the use of the medium chain triglyceride as calorie 
source causing saturation of the 3-oxidation pathway and consequent co­
oxidation of the fatty acids. The presence of lactic (XI) acid and 
3-hydroxybutyric (XXX) acid may be explained by mild acidosis.
The large peak due to 3-hydroxypropionic (XXII) acid suggests the 
diagnosis of propionic acidemia and other metabolites which were identif­
ied to support this diagnosis were 3—hydroxy—2—methylbutyric acid (LXVIII), 
propionylgylcine (LXI) and methylcitric acid (LXIII). 3—Keto—2—methyl— 
valeric acid (LXVII) and 3-hydroxy-2-methylvaleric acid (LXXIX) were also 
present but: in small amounts.
One further prominent peak in the GC trace (peak 13, Fig. 42) could 
not be identified. Cl-MS of the peak indicated the compound had a 
molecular weight of 288 as the silyl derivative. Examination of the 
MS suggested a number of similarities to that of 3-keto-2-methylvaleric 
acid ( uXVII) and two possible structures were proposed: that of 3-keto- 
2-methylcaproic aciu (XCIV) or 3-keto~2-ethylvaleric acid (XCIII) with
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FIGURE 43. Mixed Claisen condensation of ethyl propionate and ethyl butyrate.
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FIGURE 44. Preparation of 3-keto-2-methy1valeric acid (XCIV) and 3-keto-2-ethy1caproic acid(XCIII) via the 
Reformatsky reaction
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the former being the most likely structure. The ethyl esters of these 
compounds were synthesised using the mixed Claisen condensation between 
ethyl propionate (LXXVI) and ethyl butyrate (XCVIII) (Fig.43). These 
compounds could not be separated by fractional distillation but were 
separable on a capillary GC column. A portion of the mixture was 
hydrolysed and the resulting acids silylated to obtain their GC-MS. 
Unfortunately unequivocal identification of the acids could not be made
and it was decided to synthesise the individual keto acids. This was
. 564done according to Fig. 44 by a Reformat$ky reaction. 3-Hydroxy-2-
methylcaproic acid ethyl ester (CIVT) was prepared from 2-bromopropionic
acid ethyl ester (XCIX)f butanal (c) and zinc. In a similar fashion 3-
hydroxy-2-ethylvaleric acid ethyl ester (CITE) was prepared from propanal
(Cl) and 2-bromobutyric acid ethyl ester (CII). The keto acids were
prepared by oxidation and hydrolysis of the hydroxy acids.
Comparison of the GC retention times and MS of the unknown and the
and .synthesised 3-keto-2-methylcaproic acid (XCIV)A 3-keto-2-ethylvaleric 
acid (XCIII) showed that the unknown was not identical to either compound 
and further attempts to identify it were abandoned.
The diagnosis of propionic acidemia is well supported however in this 
patient both on clinical and biochemical grounds although no enzyme studies 
are available. Treatment with high levels of biotin gave no improvement 
in E.B. although in Z.K. a mild response was seen. However neither pat­
ient could be classed as biotin responsive.
The two cases described here show a large number of unusual metabolites 
which have been described as being elevated in patients with propionic 
acidemia. There appears to be considerable variation in the excretion
pattern of these secondary metabolites in these patients and in those des-
544 .cribed in the literature. The origin of many of these metabolites
may be explained by examination of > the precursors and metabolites of
propionylCoA (Figs. 31 and 32) . The reason for the raised levels of ^
glycine shown by our patients and many of those in the literature
remains obscure but is still a valuable indication to the condition.
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The variability of the excretion pattern of metabolites can cause
difficulties with the diagnosis of this disease even in laboratories
which have well established GC screening procedures. Under conditions
such as these, the identification of 3-keto-2-methylvaleric acid (LXVII)
and 3-hydroxy-2-methylvaleric acid (LXXIX) as major urinary components
in our patients may be a valuable aid in the future diagnosis of
propionic acidemia on the basis of secondary metabolites. These two
compounds do not appear to have been reported previously as components
565of human metabolism although Przyrembel et al speculate that 3-keto-
2- methylvaleric acid (UCVII) may be the structure of an unknown compound 
eluting with fumaric acid in their studies of a patient with propionic 
acidemia. The evidence ; these authors present however is not conclu­
sive .
Both 3-keto-2-methylvaleric acid LXVII) and 3-hydroxyvaleric acid 
(LXXIX) have been detected in urine samples from the two patients we 
have encountered with propionic acidemia. In addition, we have also 
detected low levels of these acids in some patients with methylmalonic 
acidemia. However, neither the hydroxy acid nor the keto acid have 
been found in urine samples taken from normal controls.
It seems likely that 3-keto-2-methylvaleric acid(i_XVII) arises 
by an enzyme catalysed self condensation of propionyl CoA in a reaction 
analogous to the formation of acetoacetate from acetyl CoA. Several
3- ketoacyl-CoA thiolases are known which catalyse the general reaction
involving the condensation of two molecules of thioesters to produce a
5663-ketothioester with the release of a thio alcohol. Since 3-keto-
acyl-CoA thiotases have been described in mammalian systems with 
broad substrate spécificités, it is conceivable that, under conditions 
where propionyl CoA is greatly elevated, one or more of these enzymes 
could form 3-keto-2-methylvaleryl CoA by the condensation of two moles 
of propionyl CoA. Enzymic reduction of the 3-keto-2-methylvaleric-CoA, 
catalysed by 3-hydroxy-aeyl-CoA dehydrogenase ( E . C .  L. 1 . 1 . 35) could then 
yield 3-hydroxy-2-methylvaleryl CoA. Hydrolysis of the CoA esters of these 
two compounds would then produce 3-keto-2-methylvaleric acid (LXVII) and 
3-hydroxy-2-methylvaleric acid (LXXIX).
The proposed modes of formation of 3-hydroxy-2-methylvaleric acid 
(pCVII) and 3-keto-2-methylvaleric acid (LXXIX) in this patient could > 
best be tested by administration of stable isotope labelled propionic 
acid (XXI) or isoleucine (LI) , followed by an examination of the 
labelling patterns in the two urinary acids. However these loading 
studies have not been possible due to the death of the patients. The 
increase in the suggested keto acid in Przyrembel et al's patient 
following an isoleucine (LI) load however supports this mode of form­
ation.
The excretion of urinary ketones in a patient with ketotic hyperglyc—
inaemia and patients with ketosis due to starvation, diabetes or a high
528fat intake has been investigated by Menkes. The patient with hyper-
glycinaemia was found to excrete elevated amounts of two unusual ketones
5672-butanone (LV) and 3-pentanone (LVI). Tsao and Pfeiffer proposed 
that 2-butanone (LV) was formed through the spontaneous decarboxylation 
of 2-r-methylacetoacetic acid (LIX) . The origin of the 3-pentanone 
(LVI) excreted in the urine of patients with propionic acidemia and 
methylmalonic acidemia however has remained obscure, although Menkes 
postulated that this ketone could arise via the condensation of pro- 
pionyl CoA and methylmalonyl CoA. In this work we have demonstrated 
that the 3-pentanone (LVI) observed in the urine of patients with 
propionic acidemia and methylmalonic acidemia can arise from the de­
carboxylation of 3-keto-2-methylvaleric acid ^uXVII). This decarboxy­
lation was shown to occur when the keto acid was incubated in normal 
at ou n n e ^ V  C and would presumably be faster in urines of lower pH 
from acidotic patients. It is possible that some 3-pentanone; may be 
produced enzymically from 3-keto-2-methylvaleric acid [ LXVII) in a
reaction analogous to the formatign of acetone (LVIII) from acetoacetic• ' 568acid (XXVII), catalysed by acetoacetate decarboozyla.se (E.C.4.1.1.4.) .
The screening procedure for the presence of unusual ketones usually
involves the addition of 2,4-dinitrophenylhydrazine in 2 M HCl to urine,
2 ,4 -D N P   ̂ .and it was also demonstrated that 3-pentanone i\ (XC) could arise 
directly from the breakdown of urinary 3-keto-2-methylvaleric acid 
(•LXVII) during the course of the reaction. This decarboxylation should 
be taken into account when studying or quantitating urinary ketones as 
2,4-4)NP derivatives.
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An elevated concentration of glycine in plasma and urine has been
195described as being characteristic of propionic acidemia, but in our 
first patient (Z.K.) the serum and urinary levels of glycine at the time 
of admission were within the normal range. At that time the serum prop­
ionic acid (XXI) concentration was 3.5 mM. Analysis of the urinary 
amino acids at that time did however show increased amounts of 
cystine and lysine. These amino acids were also found to be elevated
in the urines of three of eight patients with propionic acidemia in­
. 544vestigated by Duran et al. Qf these three patients did not show
hyperglycinuria. Although neither hyperglycinuria nor hyperglycinaemia was 
present during the acute illness period in our patient, once the serum 
levels of propionic acid were controlled by treatment, both hyper- 
glyceinemia and hyperglycinuria appeared.
From an analysis of the gas chromatography profiles and the results of 
the quantitation of urinary metabolites in Z.K. it would seem that under 
conditions where excess acetyl CoA was available there appeared to be a 
preferential condensation between propionyl CoA and acetyl CoA. Thus, the 
major propionate-derived metabolites appearing in the urine when the child 
was ketotic were 3-ketovaleric acid (LXIV) and 3-hydroxyvaleric acid 
(LXIX). However when the ketosis had been controlled, self-condensation 
to form 3-keto-2-methylvaleric acid ( LXVII), condensation with oxaloacetate 
(LXII) to form methylcitric acid (LXIII) as well as oxidation to produce 
3-hydroxypropionic acid (XXII) and condensation with glycine (LXX), seemed 
to be the major routes of propionyl CoA metabolism.
These observations may have important implications for screening 
laboratories since, under conditions where a child is ketotic, the major 
secondary metabolites to look for in cases of propionic acidemia may be
3-ketovaleric acid (LXIV) and 3-hydroxyvaleric acid (LXIX) whereas
in non-ketotic patients the diagnostic metabolites appear to be 3-
hydroxypropionic acid(XXII) and methylcitric acid (LX3H) . A negative
relationship between the excretion of 3-hydroxybutyric acid (XXX)
544 . .. .and methylcitric acid (LXIII) was noted by Duran et al m  tneir 
study of patients with propionic acidemia.
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It is interesting to speculate on the reason why 3-keto-2-methyl- 
valeric acid ( LXVII) and 3-hydroxy-2-methylvaleric acid (LXXIX) have 
not been observed previously in other patients with propionic acidemia, 
but were major urinary metabolites in patient Z.IC* The reason for 
this may be related to the elevated serum levels of propionic acid 
(XXI) seen in this child, even after control of the ketosis. This 
observation could perhaps indicate that these two metabolites, which 
apparently arise from the condensation of two propionyl CoA molecules, 
may be relatively more prominent in patients who have very high serum 
levels of propionic acid.
NOTE ADDED IN PROOF
The excretion of 2-methyl-3-keto-valeric (1XVII) acid has also 
been reported in a publication by Lennert, W., Schumann, L., Urbanek, R., 
Niederhoff, H., Bohm, N., Eur J. Pediatr.j 128, 197 (1978). These 
authors also suggest that the compound may be formed by self-condensation 
of propionyl-CoA.
E X P E R I M E N T A L
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G EN E R A L
Gas chromatographic . (GC) separations were carried out with a Becker 
Packard model 419 chromatograph (Delft,The Netherlands) fitted with 
flame ionisation detectors. The columns employed were a 1.8mx6mm glass 
column packed with 3% Apiezon-N on acid washed dimethyldichlorosilane 
(DMCS) treated Chromasorb-W (80-100 mesh) and a 1.8mx6mm DMCS treated 
glass column packed with 3% SE-30 on DMCS treated Gas Chrom-Q (80-100 
mesh). Helium was used as carrier gas at a flow rate of 30 ml min
The injection ports and detectors were maintained at 260 C. Programmed 
separations were carried out at 6° C min"1 from 70° or 80°with an 
initial isothermal delay ,using a linear temperature programmer.
The identification of urinary metaboliteswas confirmedby combined 
gas chromatography-mass spectrometry (GC-MS) in which a Varian Aerograph 
GC (model 2700) was interfaced, via a jet separator to a Dupont 491B mass 
spectrometer fitted with a dual electron impact/chemical ionisation 
source. The GC was fitted with a 1.8mx6mm glass column packed with 
either 6% Apiezon-N or 3% SE-30 on DMCS treated Chromasorb-W(80-100 mesh), 
A helium flow rate of 25 ml min ^was used, and during analysis the _ 
temperature was programmed from 80° C to 250° C at a rate of 6° C min 1.
Electron impact (El) mass spectra were recorded at a source temper­
ature of 240° C and an ionising voltage of 70 «V with a block voltage 
and repeller voltage of*1400V. Chemical ionisation (Cl)mass spectra were 
recorded using isobutane at 0.5 to 1 Torr with an electron energy of 
70 eV, and a block voltage and repeller voltage of 1400VDC. The MS 
was interfaced with a Nova 1220 computer (Data General Corporation, 
U.S.A.).
GC-MS and quantitative multiple ion selection (MIS) were carried
out using a Varian MAT44 GC-MS system in which a 25n* SE-54 (Jaeggi)
wall coated capillary column was directly coupled to the ion source of
the mass spectrometer. For GC a helium flow rate of 2 ml min was
oused, and during analyses the temperature v/as programmed from 70 C
. o _ . -1to 220 C at 4 C m m  .
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El mass spectra were obtained using an ionising voltage of 70 eV and an 
emission current of 0.8 mA. The ion source was maintained at 200° c, 
the transfer lines at 250 C and the injection port of the gas chromat­
ograph at 250 . The total ion current was measured from mass 50 to 500 
and was recorded with 320mV full scale.
Cl mass spectra were obtained using isobutane at 45-50Pa with an ion­
ising voltage of 160 eV and an emission current of 0.2 mA.
The concentration of amino acids were determined by ion exchange 
chromatography^^ using a Technicon TSM amino acid analyser.
Infrarecfc’ spectra (IR) were recorded on a Perkin Elmer Model 237 
infra red spectrophotometer and were calibrated using polystyrene film.
All melting points were measured in open capillaries using a therm­
ometer calibrated with standard substances. All boiling points were 
uncorrected.
p-Tolylsulphonylmethylnitrosamide,propionic acid, propionyl chloride, 
butanoic acid, butanoic anhydride, 2-bromobutyric acid ethyl ester, 
2-bromobutyric acid, a-methylacetoacetic acid ethyl ester, trideutero- 
methyl iodide, methylmalonic acid, ethylmalonic acid and succinic acid 
were obtained from Fluka AG chemische Fabrick Buchs, Switzerland. Propanol, 
butanol, acetone, ethanol, methanol, ethyl propionate, ethyl acetoacetate 
pentane and silver oxide were obtained from Ajax Chemical Ltd., Sydney, 
Australia.
Adipic acid, glycine, glutaric acid, diethyl malonate and tetrabutyl- 
ammonium bromide were purchased from Merck Chemical Co., Darmstadt, Ger­
many.
Thionyl chloride,chromic oxide, butanone, pentanone, heptanone, 2,4- 
dinitrophenylhydrazine, sodium borohydride, sodium, molecular sieve( 5A 
and 3A) and zinc wool were supplied by BDH Chemicals Limited, Poole, 
England. Suberic acid, sebacic acid, hexanoic acid and octanoic acid were 
supplied by Sigma Chemical Company, Missouri, U.S.A.. Succinic anhydride 
and adipic acid monomethyl ester m o n ochloride were obtained from
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Chemical
/vProcurement Laboraties Inc., College Point, New York, U.S.A..
Solvents used for extraction of organic acids were analytical 
reagent grade and were obtained from Ajax Chemical Co., Sydney, 
Australia. Each batch was tested for the presence of organic acids 
before use.
Benzene was dried by azeotropic distillation and distilled before
use.
Dry ethanol and dry methanol were prepared by distillation of the 
alcohol from magnesium ethoxide or methoxide.
The BSTFA used for formation of TMS derivatives contained 1% TMCS 
as catalyst and was obtained from Regis Chemical Co., Chicago, U.S.A. 
in 1 ml or 10 ml ampoules stored under nitrogen. Reaction vials 
(1 ml) fitted with rubber caps and tapered reaction vials fitted with 
teflon lined rubber septa were supplied by Regis Chemical Co., and 
were cleaned with CrO^-H^SO^.
Standard solutions of organic acids were made up in ethanol and were 
stored in a deep freeze for periods of up to one month. A range of 
concentrations of the individual organic acids were prepared by pipetting 
standard solutions of an organic acid and internal standard into reaction 
vials and, after derivatisation, calibration curves were determined by 
comparing the GC peak height of the organic acid with the peak height of 
the internal standard.
Quantitation of individual organic acids was achieved by measurement 
of the peak height of each acid relative to the peak height of the internal 
standard and interpolating from a standard curve. The recovery of indiv­
idual acids was determined by the method of standard additions using a 
normal urine, serum or amniotic fluid. All reported results for patient 
samples in this thesis have been corrected for recovery.
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Preparation of Diazomethane
p-Tolylsulphonymethylnitrosamide (2.24g, 10 mmol) was dissolved in 
ether (30 ml) and the solution was cooled in ice. A solution of pot­
assium hydroxide (0.4g) in ethanol (10 ml; 95%) was added and if a 
precipitate formed more ethanol was added to dissolve it. After 5 mins 
the ethereal solution of diazomethane was distilled into an ice/salt 
bath cooled receiver, the outlet of which was connected to a trap con­
taining cold ether (30 ml). The solution from both receivers was com­
bined and stored over potassium hydroxide pellets in a freezer for periods 
of up to five days.
Preparation of Tetrabutylammonium Hydroxide (<v0.4 M) in Methanol
Tetrabutylammonium bromide (3.22g, 10 mmol)/silver oxide (1.75g, 7.5
mmol) and anhydrous methanol (20 ml) were stirred together for two hours.
The solids were removed by filtration and the solution diluted to 25 ml.
Aliquots of the solution were titrated to phenolphthalein end point with
H SO. (0.100 M) to check the concentration and the solution stored over
omolecular sieve below 0 C.
553Preparation of Jones Reagent
Chromic oxide (26.7g, 0.27 mol) was dissolved in water (40 ml),sulphuric 
acid (21.3 ml) was added and the solution was diluted to 100 ml. This 
solution is 8N in chromic acid and contains the calculated amount of 
sulphuric acid.
Preparation of 2 ,4—Dinitrophenylhydrazine Reagent
--- ---------------------- -------- ; i 562 , aThis reagent was prepared according to Seakms et al ana was a
saturated solution of 2 ,4-dinitrophenylhydrazine (^0.5%) in hydrochloric 
acid (2 M).
Screening Procedure for Organic Acids in Urine
Urine (1 ml) was saturated with sodium bicarbonate and then extracted 
with ethyl acetate (3 x 2 ml). This extract was discarded. The aqueous 
layer was then adjusted to pH 1 with hydrochloric acid, saturated with 
sodium chloride and extracted with ethyl acetate (3 x 3 ml) . The organic
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layers were dried (MgSO^ ) , filtered and evaporated to dryness under a 
stream of nitrogen at room temperature. The dried extract was silylated 
with BSTFA (50yl; 60° C; 30 min) and an aliquot injected into the gas 
chroma t ¿¡graph.
Extraction and Quantitation of Organic Acids in Amniotic Fluid
Internal standard (5yg; usually adipic acid (II)),water (2 ml) and sodium 
dodecylsulphate (0.3 ml of 5% solution) were added to amniotic fluid 
(1 ml) . The solution was saturated with salt and adjusted to pH 9-11 with 
sodium hydroxide (1 M) . The solution was left to stand at room temper­
ature for 20 mins and extracted with ethyl acetate ( 3 x 3  ml) and these 
extracts were discarded. The solution was acidified to pH 1 with hydro­
chloric acid (5 M) and extracted with ethyl acetate ( 3 x 3  ml). External 
standard (5yg; usually pimelic acid (XX)) was added to the combined ex­
tracts which were dried (IMgSO^) and evaporated under a stream of nitrogen. 
The residue was dissolved in a few drops of ethyl acetate and transferred 
to a tapered reaction vial. The dried residue was derivatised for GC 
analysis with BSTFA (30yl; 65 C; 1 h). An aliquot (0.5-lyl) of the 
solution was injected into the chromatograph. Quantitation of acids 
was achieved by measurement of the peak heights of the unknown, relative 
to the peak height of the internal standard and interpolating from a 
standard calibration curve. The external standard was used to check the 
recovery of internal standard. For the preparation of methyl esters the 
dried residues were derivatised by treatment with diazomethane.
Extraction and Quantitation of Organic Acids in Serum or Plasma
Internal standard (5yg; usually adipic acid (II)), water (8 ml) , 
sodium dodecylsulphate (1 ml; 5% solution) were added to serum (1 ml). 
The solution was saturated with salt and adjusted to pH 9-11 with sodium 
hydroxide (1 M) . The solution was left to stand at room temperature for 
20 mins and extracted with ethyl acetate (3 x 10ml) and these extracts 
were discarded. The solution was acidified to pH 1 with hydrochloric 
acid (5 M) and extracted with ethyl acetate (3 x 30 ml) . External 
standard (5yg; usually pimelic acid (XX)) was added to the combined 
extracts which were dried(Mg S04) and evaporated under a stream of
m
nitrogen. The residue was dissolved in a few drops of ethyl acetate and 
transferred to a tapered reaction vial. The dried residue was derivat- 
ised for GC analyses with BSTFA (30yl, 65° C, lh) and an aliquot injected 
into the chromatograph. For the preparation of methyl esters the dried 
residue was treated with diazomethane and evaporated to about 30yl and 
an aliquot injected into the chromatograph.
Quantitation of Urinary Organic Acids
To urine (1 ml) or diluted urine (1 ml) was added an internal 
standard (usually adipic acid (II);5pyl of lmg/ml solution in ethanol) and 
sufficient sodium bicarbonate to obtain a saturated solution. The 
solution was extracted with ethyl acetate ( 3 x 3  ml) and these extracts 
were discarded. The urine was acidified to pH 1 with hydrochloric acid 
and then extracted with ethyl acetate ( 3 x 3  ml). The organic extracts 
were dried (MgSO^ ) and the solvent removed under a stream of nitrogen 
at room temperature. The residue was transferred to a small vial using 
ethyl acetate and again evaporated to dryness. The dried residue was 
derivatised for GC analysis with BSTFA (50yl; 65 C; 30 min) and an 
aliquot (usually lyl) was taken for injection.
Preparation of Oxime-TMS Derivatives of Urinary Keto Acids
Internal standard (50yg; usually adipic acid (II)) was added to urine
(1 ml) and the solution adjusted to pHlO with sodium hydroxide. Freshly
prepared hydroxylamine hydrochloride solution (200yl; 100 mg in 1 ml) waŝ
added and the solution incubated at 65 for 30 mins. The cooled solutionpH 10
was saturated with salt, the pH adjusted back to a  if necessary and then 
extracted with ethyl acetate (3 x 2 ml). These extracts were discarded. 
The aqueous layer was acidified to pH-2 with hydrochloric acid (1 M) and 
extracted with ethyl acetate (3 x 2 ml). The ethyl acetate was dried 
(MgSO. ) and evaporated under a stream of nitrogen. The residue was 
dissolved in a few drops of ethyl acetate and transferred to a reaction 
vial and again dried under nitrogen. The residue waa derivatised for 
GC analysis with BSTFA (50yl; 65° C; 30 mins) and an aliquot injected 
into the chromatograph.
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Hydrolysis and Quantitation of Urinary Acylglycines
To a volume of urine containing 1 mmol creatinine, was added hydro­
chloric acid (3 ml; 6 M) and the solution heated at 110° for 3 hours.
The internal^^¡^-^adipic acid(ll)) was added to the cooled solution and 
the acids extracted with ether ( 3 x 3  ml). The ether extracts were 
dried (MgSQ^ ) and evaporated at room temperature under a stream of 
nitrogen to final volume of about lOOyl. BSTFA (50yl) was added and the 
extract heated (60°; 3 min). GC analyses were performed on 3% SE30 
using an initial temperature of 55° C.
Measurement of Propionic Acid (XXI) in Urine
Propionic acid was measured by a modification of the sample pre-
204treatment method of Chalmers et al combined with the GC method of
569 .Otterstein and Bartley . Urine (200yl) and internal standard {isobutyric
acid (CV)(5mg/ml; lOOyg)} were mixed with a portion of damp neutral
+ ,Dowex 50W x 12 resin; (H Form; Biorad Ltd.,) . The tube was mixed by
inversion and allowed to stand for ten minutes and centrifuged. An
aliquot (5yl) was injected into the GC.
The separation was carried out on a 1.8 M x 2 mm column packed with 
100% SP 1200/1% H^PO^ at a column temperature of 125° in a Hewlett 
Packard model 402 chromatograph with flame ionisation detector and using 
nitrogen as carrier gas. The injector temperature was 140 and the 
detector temperature 150°. The column was flushed with injections of 
phosphoric acid or water between samples.
Measurement of Propionic (XXI) Acid in Serum
- 213•Propionic acid was measured by a modification of the sample treatment
208method of Remesçy and Ilemigne combined with the GC method of 
Otterstein and Bartley5^ .  Serum (200yl) , internal standard (isobutyric 
acid; 5 mg/ml ; 20yl) and ethanol (1 ml) were mixed together in a glass 
stoppered centrifuge tube, allowed to stand for 15 minutes and centrif 
uged. The supernatant was decanted, neutralised with sodium hydroxide
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(20yl; 0.2 M) and evaporated to dryness under a stream of nitrogen. The 
residue was reconstructed with distilled water (15yl) and acidified with 
phosphoric acid (5yl) just prior to injection. An aliquot (0.2-2yl) 
was injected into the GC.
Test for Production of 3-Keto-2-methylvaleric: Acid(t-XVII) and 3-Hydroxy- 
Propionic Acid (XXII) in Urine
To freshly voided urine (100 ml; pH 5.5) from a healthy male subject 
was added propionic acid (XXI) (37 mg, 0.5 mmol) and the urine warmed at 
37° C for 24 hours. An acidified aliquot (3 ml) was saturated with sodium 
chloride, adipic acid (II) (50yg) was added and the solution extracted, with 
ether (3 x 10 ml) . The extracts were dried ( MgSO^.) , the solvent removed 
and the silylated (BSTFA; 50yl; 65°; 30 mins) residue examined by GC.
No trace of 3-keto-2-methylvaleric acid^WXVII) or 3-hydroxypropionic 
acid (XXII) were found.
Measurement of Urinary 3-Pentanone (LVI)
To urine ( 4 ml) were added internal standard (lOOyl of 1 mg/ml of 
3-heptanone (XCII) in water) and saturated sodium carbonate solution 
(lOOyl) . The pH was checked and if it was below 9 more sodium carbonate 
was added. The solution was immediately extracted with pentane (0.5 ml) , 
the organic phase separated and an aliquot of this solution was injected 
onto a 60 m OV-17 SCOT coluim (Scientific Glass Engineering). After 
injection, the GC oven temperature was maintained at 50 C for four 
minutes and then increased at 3° C min-1. Quantitation of 3-pentanone 
was achieved by measurement of the peak height of 3-pentanone (LVI) rel 
ative to the peak height of 3-heptanone (XCII) and interpolating from a
standard curve.
Reaction of Urinary Acetoacetic Acid (XXVII) with 2,4- Dinitrophenyl_
hydrazine Reagent
Freshly voided urine (100 ml) was spiked with freshly prepared 
acetoacetic acid (XXVII) (51 mg; 0.5 mmol). A portion of the solution 
was basified (NaOH; 1M) and then extracted with ether. The ether extracts 
showed no acetone (LVII)) by GC or 2 ,4-dinitrophenylhydrazine reagent.
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Spiked urine (8 ml) and 2,4-dinitrophenylhydrazine reagent (8 ml) 
were left to stand at room temperature (3 hours). A slight cloudiness 
developed in the solution and when this was recovered by filtration, 
washed and dried weighed < 1 mg. The precipitate was examined by solid 
probe CI MS and TLC (silica gel, chloroform:acetic acid (100 : 7); 
hexane:chloroform (1:1) and was shown to be the 2,4-dinitrophenylhydra- 
zone of acetoacetic acid (XCVII) with a trace of the 2,4-dinitrophenyl- 
hydrazone of acetone (LXXXVIII). On standing for a further 48 hours a 
further amount of precipitate formed which had the same composition.
Reaction of Urinary 2-MethylacetoaceticAcid with 2,4-Dinitrophenyl- 
hydrazine Reagent
Freshly voided urine (100 ml) was spiked with freshly prepared 2- 
methylacetoacetic acid (LIX) (58mg; 0.5 mmol). A portion of the urine 
was basified (NaOH; 1M) and extracted with ether. The ether extracts 
showed no butanone (LV) by GC or 2,4-dinitrophenylhydrazine reagent.
Spiked urine (8 ml) and 2,4-dinitrophenylhydrazine reagent were left to 
stand at room temperature. Cloudiness developed after 10 minutes and a 
large amount of precipitate had developed after 3 hours. The precipitate 
was recovered by filtration, washed and dried ^yield 9 mg). The precipitate 
was examined by solid probe Cl MS and TLC (silica gel, chloroform:acetic 
acid {100: 7} and hexane:chloroform {1:1} and was shown to be a mixture 
of the 2,4- dinitrophenylhydrazones of 2-methylacetoacetic acid (XCVI) and 
butanone (LXXXIX) in the ratio of 3:2.
Reaction of Urinary 2-Methyl-3-oxovaleric Acid (LXVII) with 2,4-Dini-
trophenylhydrazine Reagent
Freshly voided urine (100 ml) was spiked with freshly prepared 3-Keto-12- 
methylvaleric acid (LXVII) (65 mg, 0.5 mmol) . A portion of the solution was 
basified (NaOH; 1M) and extracted with ether ( 3 x 2  ml) . The dried (Mg SO^) 
ether extracts showed no pentanone (LVI) by GC or 2 ,4-dinitrophenylhydrazine 
reagent.
Spiked urine (8 ml) and 2 ,4-dinitrophenylhydrazine reagent were 
mixed together at room temperature. A small amount of gas was produced and
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a precipitate began to form immediately. After ten minutes the solution 
was filtered and the precipitate was washed and dried. No further 
precipitate formed in the urine on standing. The precipitate (11 mg.) was 
examined by solid probe Cl MS and TLC (silica gel, chloroform:acetic acid 
{100:7} and hexane :chloroform {1:1} and was shown to be the 2,4-dinitrophen- 
ylhydrazone of pentanone (XC). No trace of the acid derivative was 
found.
Reaction of Urinary 3-Keto-2-methylcaproic Acid (XCIV) with 2,-4-
Dinitrophenylhydrazine Reagent •
When urine (100 ml) spiked with freshly prepared 3-keto-2-methyl- 
caproic acid (XCIV) (72 mg; 0.5 mmol) was treated with 2,4-dinitro- 
phenylhydrazine reagent as described above a quantitative yield of the
2,4-dinitrophenylhydrazone of 3-hexanone (CVI) was obtained in 10 
minutes.
Reaction of Urinary 3-Keto-2-ethylvaleric Acid (XCIII) with 2,4- 
Dinitrophenylhydrazine reagent
When urine (100 ml) spiked with freshly prepared 3-keto-2-ethyl 
valeric acid (XCIII) (72 mg; 0.5 mmol) was treated with 2,4-dinitrophenyl— 
hydrazine reagent as described above a quantative yield of 3—heptanone—2,4— 
dinitrophenylhydrazone (CVI) was obtained in 10 minutes.
Preparation of Diethyl Trideuteromethylmalonic Acid (V)
Sodium (1.6g, 0.07 mol) was dissolved in dry absolute ethanol (30 ml) 
in a 100 ml flask equipped with a reflux condenser and drying tube (CaCl2). 
Redistilled diethyl malonate 11.lg,0.07 mol) was added to the stirred 
solution. After 5 mins trideuteromethyl iodide (VI) (10g, 0.07 mol) was 
added slowly during one hour while the flask was gently heated. When all 
the trideuteromethyl iodide (VI) had been added the mixture was heated 
under reflux for a further half hour and then neutralised with acetic 
acid (^5 ml). The majority of the alcohol was removed by distillation 
and dilute hydrochloric acid (10 ml; 0.3M) was added. The aqueous lower 
layer was separated from the ester and extracted with ether (3 x 20 ml). 
The combined organic layers were dried by shaking quickly with calcium
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chloride , filtered . and the solvent removed. The crude ester was
shaken for exactly one min with a cold solution of sodium hydroxide
( 1 ml.; 30%) and then with dilute hydrochloric acid and dried (MgSO ) .. . i 4The crude ester was distilled to give pure trideuteromethylmalonic acid
diethyl ester (V) bp 88-90 /16 mm (lit.^^ for unlabelled ester 82-3°/12
ram), yield 5.6g (46%),Cl-MS {MH}+ 177.
Preparation of Trideuteromethylmalonic Acid (VIII)
Trideuteromethylmalonic acid diethyl ester (V)(3.5g, 20 mmol), was 
added dropwise to a stirred solution of potassium hydroxide (7 ml; 50%) 
under reflux during lh. The solution was heated under reflux for a fur­
ther 2h and then distilled until the vapour temperature reached 100°.
The cooled alkaline solution was washed with ether (2 x 10 ml) and acidified 
with cold hydrochloric acid (50%) to pH Z. The crude acid was extracted 
with ethyl acetate (5 x 20 ml) , the extracts dried ( MgSO^ ) and the sol­
vent removed. The residue was reçrystaïlised from benzene-ether then 
three times from ethyl acetate-light petroleum to give pure trideutero­
methylmalonic acid (VIII) m p 125-6° (lit^^ for unlabelled acid 126-7°) 
yield 2.0g (83%).
Preparation of Glycine Methyl Ester Hydrochloride (LXXI)
To anhydrous methanol (35 ml) cooled in dry ice acetone was added 
freshly distilled thionyl chloride (3.5 ml) drop wise. Glycine (LXX)
(5g, 66 mmol) was then added and the mixture refluxed for 45 min. After 
removal of the solvent the crystalline residue was dissolved in methanol 
and the solution evaporated to dryness. The residue was finally re­
crystallised from methanol-ether to give pure glycine methylester hydro­
chloride (LXXI), long needles, m.p. 176° (lit.5^  mp 177°) yield 7.9g 
(94%) .
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Preparation of Propionylglycine (LXI)
Propionyl chloride (2.3g, 25 mmol) and glycine methyl ester hydro­
chloride (LXXI) (3.8g, 30 mmol) were stirred together in dichloromethane 
(30 ml)* Triethylamine (6.1g, 60 mmol) in dichloromethane (15.ml) was 
added dropwise and the solution stirred at room temperature for 16
®• Dilute hydrochloric acid (20 ml; 20% was added and the layers
separated. The dichloromethane layer was washed (Ho0),.dried CMgSO )2 4
and the solvent removed. The residue was distilled under reduced 
pressure to give pure propionylglycine methyl ester bp 130/2.5 mm, yield 
3.1g, (85%), CI—MS {MH} 146. The compound had a retention time of 
7.5 min (elution temperature 125 ) on 3% SE30 and the El mass spectrum
, X  . » i
contained ions at m/e 146 {MH} ,145 {M}*, 113 {M- CĤ OI}}, 86 {M-C00CH,} * 
and 67 {M-NHCH^OOCHj}'!'  ̂ ‘
A portion of the methyl ester (725 mg, 5mmol) was refluxed in sodium 
hydroxide (15 ml; 1.25 M in 50% ethanol) for 1 hour. Water (10 ml) was 
added and the solution was extracted with ether (3 x 20 ml) . These 
extracts were discarded and the solution acidified (6 M HCl) and extracted 
with ether (3 x 20 ml) . The ether extracts were dried (MgSO^ ) and the 
solvent removed. The residue was recrystalised from acetone to give 
pure propionylglycine (LXI), mp 126° (lit^^ mp 126-7°), yield 520 mg (80%). 
Treatment of a sample of this compound with BSTFA gave the disilyl 
derivative which had an elution time of 11.3 mins (elution temperature 
148°) on 3% SE 30, Cl-MS {MH}+ 276, and the El spectrum contained ions at 
m/e 275 {M}t 260 {M-CH^t 232 {M-<CH3 + CO) }+, 158 {M-C02‘fMS}+ and 102 
{TMS-(NH=CH2) A  small amount of monosilyl derivative was also formed 
which had an elution time of 11.2 min (elution temperature 147°) on 3% 
SE30, Cl-MS (MH}+ and the El spectrum contained ions at m/e 203 CM}*
188 {M-CH3>t 159 {M-C02}t 144 (M-(C02 + C H ^ a n d  131 {M-(TM$ + H)}+ .
Preparation of Butyrylglycine (XXXVIII)
Butanoic acid (2.2g, 25 mmol) was refluxed with thionyl chloride 
(15 ml) for 4 hours. The excess thionyl chloride was removed under vacuum 
and benzene (2 x 10 ml) added and removed under vacuum. The acid chloride 
was treated as above to give butanoylglycine methyl ester bp 126 /2 mm 
(lit 574 118/0.9 mm), yield 2.8 g (72%) Cl-MS (MH}+ 160. The compound had
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a rentention time of 9.2 min (elution temperature 135°) on 3 % SE 30 
and the El mass spectrum contained ions at m / e 160 {MH>t 159 {M }* , 131 
{^ 2  -  C(0H)NHCH2C00CH3: (McLafferty rearrangement), 127 {M-CH^OH}*
1 0 0  {M-COOCH^} and 71 {M- (NH-CH^COOCH^}* . Hydrolysis of a portion of 
the ester (800 mg, 5 mmol) and recrystallisation of the residue from
* 1 0 7
ether gave pure foutyrylglycine (XXXVIII) mp 69 (lit mp 68-70°) 
yield 410 mg (56%). Treatment of a sample of this compound with BSTFA 
gave the disilyl derivative which had a rention time of 1 2 . 7  mins (el­
ution temperature 156°) on 3% SE 30, Cl-MS {MH}+ 290 and the El mass 
spectrum contained ions at*m / e 289 {M }* , 274 {M -C H ^ t 246 {M^CO+CH^) }| 
218 (M-(TMS+2H)}; 200 {M-0TMS}* 172 {M-C02TMS}T 1 0 2 (TMSNHCH2)T
Preparation of Hexanoylglycine(XXXVII)
Hexanoic acid (XL) (3.2g, 25 mmol) was treated as above to give 
hexanoylglycine methyl ester, bp 133-5°/3mm (lit^^ bp 127-30°/2.5mm) , 
yield 2.6g (56%), CI-MS {MH} 188. The compound had a retention time 
of 13.2 min (elution temperature 159°) on 3% SE-30 and the El mass 
spectrum contained ions at m / e 188 {MH}, 187 {Ml*, 158 {M-^H^}, 156 
{M-CH-0}f 144 {M-C,H7}t 131 {CH2=C(0H)-NH-CH2-C00CH3>t (McLafferty 
rearrangement) t 128 {M'-C00CH 99 {M- (NHCl^COOCHj) }, 98{M- (NH^HCOOCH^) }*
and 71 {C^H^}+ . Hydrolysis of the ester (930mg, 5 mmol) and recrystal- 
isation of the residue from ethyl acetate/hexane gave pure hexanolygly- 
cine (XXXVII) mp 94° (lit 1 7 4 mp 93-4°) yield 420 mg (48%). Treatment 
of a sample of this compound with BSTFA gave the disilyl derivative which 
had a retention time of 16.5 minutes (elution temperature 179°) on 3%
SE 30, Cl“ MS {MH}+ 318 and the El mass spectrum contained ions at m / e  
317 {M}f , 230 {M- (TMS + C H j } + , 2 0 1 {M-C02 TMS + H>t 1 0 2 (TMSNH = 
CH2}+ , 99 {C5Hn  C = 0>+ .
Preparation of Octanoylglycine
Octanoic acid (3.6g, 25 mmol) was treated as above to give 
octanoylglycine methyl ester bp 143^2.5Ayield 3.9 g (72%), CI-MS {MH}
216. The compound had a retention time of 17.5 min (elution temperature 
185° C) on 3% SE 30 and the El mass spectrum contained ions at 216 {MH} ,
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215 {M}», 184 {M-CH,0}+ , 156 {M-COOCH,}+ ' 144 , 131 {CH2
 ̂ . \ 4-C (OH)NHCH^COOCH^}• (McLafferty rearrangement), 127 (M - (NH^CH^COOCH^)} 
and 99 {C^H^c}+ . Hydrolysis of the ester (l.lg, 5 mmol) and recrystall­
isation of the product from ethyl acetate/hexane gave pure octadrapyi“;
o - «glycine mp 101.5-2,5 C, yield 5lo0 mg (56%) . Treatment of a sample ox
this compound with BSTFA gave the disilyl derivative which had a retent­
ion time of 2 0 .2 mins (elution temperature 2 0 1°) on 3% SE 30 Cl-MS {MH} 
345 and the El mass spectrum contained ions at m/e 345 {M}*, 248 {M-(TM$
+ CH,)}+ , 127 {C7H 1 5 CO}+, 1 0 2 {TMSNH = CH2}+ .
Preparation of Adipylglycine (XXXV)
Adipic acid monomethyl ester monochloride (4.5 g, 25 mmol) was 
treated as above to give adipylglycine dimethyl ester bp 198-202°/
2.5 mm, yield 2.3 g (40%), CI—MS {MH}+ 232. The compound had a 
retention time of 19.7 mins, (elution temperature 198°) on 3% SE 30 
and the El mass spectrum contained ions at m/e 232 {MH} , 231 {M}*,
200 {M-CH30}+,172 {M-C00CH3>+, 158 {M-(NHCH^OOCH^ }+, 131 (CH2=C(0H) 
NHCH2C00CH3}+ (McLafferty rearrangement), 115 {(CH2)^C00CH3 } , 111 
{M-(CH30H + (NHCH2C00CH3))}+, 89 {NH2CH2C00CH3}+ and 73 {CH2C00CH3>+ . 
Hydrolysis of the ester (1.15g; 5 mmol) and recrystallisation of the 
residue from ethylacetate/hexane gave pure adipylglycine (XXXV) mp 
143° (lit575 mp 139-46°) yield 0.67g (60%).
Preparation of Suberylglycine (XXXII)
Suberic acid (XXIX) (4.3g, 25 mmol) was refluxed with freshly dis­
tilled thionyl chloride (15 ml) for 4 hours. The excess thionyl chloride 
was removed under vacuum and the last traces of reagent removed by treat­
ing the residue with dry benzene (2x10ml) and removing the solvent under 
vacuum. The acid chloride was dissolved in benzene (20 ml) and methanol 
(0.8 g, 25 mmol) in benzenef5 ml) added dropwise to the cooled stirred 
solution during 10 min. The mixture was stirred for 1 hour and the 
solvent removed under vacuum. The crude suberic acid monomethyl ester 
monochloride was treated as above to give suberylglycine dimethyl ester 
bp 214°/0.3mm,yield 1.9 g (30%) Cl-MS {MH}+ 260. The compound had a 
retention time of 22.8 mins, (elution temperature 217 C) on 3% SE 30 
and the El mass spectrum contained ions at m/e 260 {MH} , 259 {M}*,
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228 {M-CH30}+ , 200 {M-COOCH3}+ , 186’ {M-(CH^OOCH ) }+ 171 {M-NHCH^OOCHj }+, 
139 {M-iCHjOH + (NHCH2COOCH3)}+ 131 {CH2=C(0H)NHCH2 C00CH3} (McLafferty 
rearrangement). Hydrolysis of the ester (1.3 g, 5 mmol) and recrystallis­
ation of the residue from the ethyl acetate/hexane gave pure suberyl-
o 575glycine (XXXII) mp 126 (lit 125-6°) yield 0.52g (45%)
Preparation of Sebacylglycine (XXXVI)
Sebacic acid (XXXI) (2.0g, lOmmol) was treated as above to give sebacyl­
glycine dimethyl ester bp 235°/0.2mm, yield 1.73g (60%), CI—MS {MH}+ 288.
The compound had a retention time of 26.6 min (elution temperature 241°) 
on 3% SE 30 and the El mass spectrum contained ions at r#/e 288 {MH}+,
287 {M}* , 256 {M-CH^0}+, 228 {M-C00CH3}+, 199 {M-NHCf-^COOCH^*, 131 
{Ch^^OHNHCh^COOCH^}^ (McLafferty rearrangement) . Hydrolysis of the
ester (0.85g, 3 mmol) and recrystallisation of the residue from ethyl acetate
o ' 575 ohexane gave pure sebacyclglycine (XXXVI) mp 120 (lit mp 123-126 ) 
yield 0.28g (37%).
Preparation of Glutarylglycine (XXXIV)
Glutaric acid (1.6g, 12.5 mmol) was treated as above. Only a small 
amount of glutarylglycine dimethyl ester was formed and most of the 
glutaric acid was recovered as mono methyl glutarate. GC of the diazo— 
methane treated product on 3% SE 30 gave 2 peaks with retention times 
5.7 mins, (elution temperature 114°) and 16.3 mins (elution temperature 
178°). GC-MS showed the first peak to be dimethyl glutarate by comparison 
with an authentic sample. The El mass spectrum of the second peak con­
tained ions at Tn/e 218 {MH} , 217 {M}#, 185 {M-CH^OH} , 158 {M-COOCH^} ,
129 (M-(NHCH2C00CH3)}+ and 101{M-(CONHCI^COOCH^} and was identified as
glutarylglycine dimethyl ester by comparison with the published mass 
575spectrum.
Preparation of Succinylglycine (XXXIII)
Succinic anhydride (3g, 30 mmol) was heated under reflux with meth­
anol (8 ml) for 1.5 hours. The solvent was removed and the residue 
treated with benzene (2 x 10 ml) and evaporated to dryness. The residue 
was treated at room temperature with thionyl chloride (5 ml) for 3 hours
m
removed under vacuum and the residue treated with benzene (2 x 1 0  ml)
, . acidwhich was removed under vacuum. The crudeAchloride was treated as
above to give succinylglycine dimethyl ester bp 184°/3 mm, yield 2 .3g
(34%) Cl-MS {MH} 204. The compound had a retention time of 13.8 mins.
(elution temperature 163°) on 3% SE 30 and the El mass spectrum contained
ions at m/e 204 {MH}+ , 203 {M}-,172 {M-CH,0}+ , 171 {M-CHj0H}+, 144
{M-C00CH3)+ , 115 {M-(NHCH2C00CH3)}+ , 1 1 2  {M-(CH,0H + COOCH^)}*, 87
{Cl^CI^COOCH^}*. Hydrolysis of the ester (l.Og ; 5 mmol) and recrystallisation
of the residue from ethyl acetatate/hexane gave pure succinylglycine mp
145° (lit5 7 5 mp 145.5-146° C) yield .46g (53%). *
576Preparation of Propanal (LXIII)
and then heated at 70 for 1 hour. The excess thionyl chloride was
A solution of potassium dichromate (108g, 0.36 mol) and sulphuric 
acid (80 ml) in water (660 ml) was added dropwise with stirring to boiling 
propanol (66g, 1.1 mol) in a two litre flask fitted with a fractionating 
column. The addition was made at such a rate that the temperature at the 
top of the column did not rise above 75° and this took 20-30 minutes.
The mixture was then heated for a further 15 minutes until the temperature 
at the top of the column rose above 75°. The crude product (32g) was 
collected in an ice-cooled flask and dried with magnesium sulphate. Slow 
distillation through a short fractionating column gave pure propanal
r n n
(LXIII), bp 48° (lit f 47-50 ), yield 21g (33%).
Preparation of Butanal (c)
Butanal (C) was prepared using the above method and substituting
obutanol (Cl)(82g, 1.1 mol) for propanol. The product had bp 73-2 
(lit577 74.5°), yield 30g (38%).
Attempted Preparation of 3-Keto-2-methylvaleric Acid via Aldol Conden­
sation using a Sodium Hydroxide Catalyst
Sodium hydroxide (0.11 ml, 2.5M) was added to cooled (4 ) stirred 
propanal (LXIII) (5.8g, 0.1 mol) during thirty minutes. The reaction 
mixture was stirred for a further 90 minutes and tartaric acid (421mg, 0.1 
mol) was added. The acid solution was filtered and the filtrate distilled
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(water bath, 70 ) until no more passed over. The residue weighed 0.68g 
(12% yield).
A portion of the residue (0.116g) was dissolved in acetone and 
cooled in an ice bath. Jones*reagent was added dropwise to the stirred 
solution until a permanent orange colour was obtained. This required 
0.27ml, instead of the theoretical usage of 0.25 ml.
The solution was stirred for a further 10 minutes, water (20 ml) was 
added and the solution was saturated with salt and extracted with ether 
(3 x 25 ml) . The combined ether extracts were washed (,satd. NaCl ) dried 
(Na^SO^) and the ether removed. The residue (0.85g) was examined by 
GC-MS but no evidence of the desired product was found.
The reaction was repeated at room temperature and the intermediate 
condensation product distilled (bp 84°/ll mm; lit^^ bp of propionaldol 
(LXII) 84~6°/llmm), yield 1.6g (14%). MS examination of this product 
indicated a Cl molecular weight of 116. The intermediate (400mg) in 
acetone (40 ml) was oxidised with Jonesr reagent until no further decolon­
isation of the reagent occurred (0.9 ml). The solution was saturated with 
NaCl and extracted with ether (3 x 50 ml) and the ether extracts were 
back extracted with sodium hydroxide (2 x 10 ml; 1 M) . The neutralised 
(91 HC] ) aqueous layer was again extracted with ether (3 x 20 ml) and the 
dried 1̂ gSO^) extract examined by GC-MS. No 3-keto-2-methylvaleric acid 
((.KXVII ) was found in this extract.
Attempted Preparation of Proponaldol (LXII) using a Potassium Hydroxide
Catalyst
Propanal (26g, 0.45 mol) and ethanol (5g, 0.11 mol) were stirred at 
room temperature and potassium hydroxide (1.2ml; 0.7 M) was added dropwise 
so that the temperature did not exceed 35 . Stirring was continued 
for two hours and acetic acid(0.66 ml) was added. The excess propanal 
was removed on a Rotovap at room temperature but no propanaldol (LXII) was 
obtained.
Attempted Preparation of Propanaldol (LXIII) using a Potassium
Carbonate Catalyst
Saturated potassium carbonate (20 ml) was added dropwise to propanal 
(16.4g, 0.28 mol) and the mixture stirred at 8°C for 4 hours. The solution 
was filtered and 2,4-diethyl-5-methyl-?6-hydroxy-l,3-dioxane (8.4g) was 
obtained by vacuum distillation of the filtrate bp 84°/l mm, (yield 51%). 
Distillation of the compound from adipic acid in Vaocuo gave no 
propanaldol (LXII) but regenerated propanal (LXIII).
Preparation of 3-Keto-2-methylvaleric Acid Ethyl Ester (tXXVII)
Finely divided sodium (4.6g, 0.2 mol) was prepared by melting sodium 
beneath xylene and then cooling the mixture with vigorous magnetic stir­
ring, in a three necked flask equipped with a reflux condenser and a 
thermometer. The powdered sodium was washed with ether (2 x 50 ml) by
decantation and suspended in ether (50 ml). Absolute ethanol (11.7 ml,
and0.2 mol) was added,¿the mixture stirred until the sodium had dissolved and 
the solvent was removed by distillation. Ethyl propionate (LXVI) (122g, 
1.2 mol) was added and the mixture heated and stirred under reflux for 
sixty hours keeping the pot temperature at 95°. At intervals of about 
12 hours the ethanol formed was removed by fractional distillation. The 
reaction mixture was cooled, and acetic acid (36g, £M) was added to the 
stirred mixture at such a rate that the temperature did not rise above 
20° C. The layers were separated and the aqueous layer washed with 
ether (4 x -50 ml). The combined organic layers were dried (Na2S0^)and 
the solvent removed. The crude product was fractionally distilled under 
reduced pressure to give pure 3-keto-2-methylvaleric acid ethyl ester 
(LX*VII) bp 108-10/22mm (lit55  ̂88-90°/12mm), yield 10.lg (32%); pyra-
zalone mp 108—10° (lit ^108—10 ). IR (CHC1~) 1741 cm (ester stretch);
l —1 ^1717 cm (keto group); 1191 cm (conjugated ester stretch); Cl-MS
<MH}+ 159.
The TM S derivative of the ester showed two peaks on G C with elution
°time of 7.7 and 8.4 minutes (elution temperature 100.4, 103.4 ) on 
SE54. Both had CI-MSiMH? 231 and both El mass spectra contain ions 
at m/e 230 {M it 215 {M-CH,}*, 2 0 1 { M 187 185 -
C„Hr0 }+.184 fli-C,H1:0H}+ 157 113, 112, 111, 83 ^-(TMS +2 5 2 5
187
C00C2H5 + H)}+ ,75 {CH )2S;OH}+ , 73 {TM S}+ .
Preparation of 3-Keto-2-Methylvaleric Acid(i.XVII)
The ethyl ester (LXXVII) (100 mg, 0.6 mmol) was hydrolised with 
potassium hydroxide (2.5ml; 1 . 8  M in 50% ETOH) at 4°C for 24 hours.
The unreacted ester was extracted from the basic solution with ether 
(3 x 10 ml) . The solution was cooled in an ice bath and the pH care­
fully adjusted to 1 with hydrochloric acid (2 M). The acid was 
immediately extracted with ether and the extracts were washed and 
dried \J*\ gSO^) . Pure 3-keto-2-methylvaleric acid (LXVII) was obtained by 
removal of the solvent under a stream of nitrogen as an oil (68mg, 83%) ,
Cl-MS {*1H}+ 130. The oil could be stored in a freezer (-20° C) for 
periods of up to two weeks without significant decomposition.
G C of a sample of the acid derivatized with BSTFA gave three peaks with
retention times 4.0 mins, 8.5 mins and 9.6 mins, (elution temperatures
85.8, 104,1 and 108.4% on SE 5^* On further heating with the reagent the
first peak disappeared and this was shown to be the mono-silyl derivative
of the keto acid Cl-MS (MH}+ 203 with ions in the El spectrum at m/e 20 2
{M}*, 187 {M-CH_}+ , 173 {M-C-Hc}+ , 146 {(CH,), SiO C(0H)=CH-CH,}+
-> L 11 + 1 +(McLafferty rearrangement), 143 {M — (C H ̂ ^  SiH} t 130 {M-TMS + H) } , 129
{M- 1MS}+ , 115 , 86 {C0Hr-C(OH) = CH-ChL}+ (McLafferty rearrangement of m/e_ j
130), 75 {(CH3)2SiOH}+ , 73 (IMS) and 57 {(^H C0}+ .
The other two peaks (retention time 8.5 and 9.6 minutes) had CI-MS)
W H } + 275 and identical El mass spectra which contained ions at m/e 274 
{M}t, 259 (M-CH }+ , 245 {M-C2H5) + , 185{M-0WS}+ 184 {M-HOTMS}* 169 {M-(CH3 + 
H0TM S) }+ , 157 {M-C00TMS}+ ,147 {(CH3)2Si=0TMS}+, 75 {(CHj^iOH }+ and
73 {IMS} and were assigned to the cis/trans isomers of the disilyl 
derivative of the enol CH^CH2 C(OH)=CH(CH^)COOH.
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3-Keto-2-methylvaleric acid ethyl ester (LXXVII) (200mg, 1.26 mmol) 
and the sodium borohydride reagent (2.5 ml; 6mg dissolved in 1 ml of 0.25M 
. ethanolic' NaOH)were warmed together in a screw-capped tube at 65°C 
for three hours. Acetic acid (200 yl) and water (2 ml) were added and 
the solution was extracted with ether (3 x 10 ml) . The ether layers were 
dried (MgSO^) and distilled to give pure 3-hydroxy-2-methylvaleric■ acid 
ethyl ester (192mg, yield 95%). Free 3-hydroxy-2-methylvaleric acid 
(LXXIX) was obtained by hydrolysing the ester (lOOmg, 0.6 mmol) with pot- » 
assium hydroxide (2.5 ml, 10% KOH in 50% EtOH) at 65° for two hours.
After extracting the unreacted ester from the basic solution with ether and 
acidification to pHl with hydrochloric acid the solution was extracted 
with ether ( 3 x 5  ml), the ether extracts were dried (HgSO ) and the. ksolvent removed. Pure 3-hydroxy-2-methylvaleric acid (LXXIX) was obtained 
as an oil, yield 68mg (83%) Cl-MS {MH}+ 133.
Preparation of 3-hydroxy-2-methylvaleric acid (LXXIX)
G C of a sample of the acid derivatissd with BST FA gave the disilyl
derivative .which gave two peaks due to the 2 di a stereoisomers of ret­
oention times 7.3 minutes and 7.6 minutes (elution temperature 99.1 and 
100° C) on SE 5^. Both had a molecular weight of 276, Cl-MS {MH} 277 
and .an El mass spectra which contained ions at m / e 261 {M-CH^} , 247 
{M-C2H5>+, 218 {M-(C02 + CH3) + H} + , 203 (H-TMS} + , 147 {(CH3)2Si=07MS}+ 
131 {CH3CH2 CH01MS}+ , 117 {COOTM S }+, 75 { ( C H ^ S  i 0H}+ and 73' {TMS}+
G C of a sample of the acid treated with diazomethane followed by 
BSTFA derivatisation gave the methyl ester silyl derivative which also 
gave two peaks with retention times 5.9 and 6.2 minutes on SE 5̂  
(elution temperatures 93.5 C and 94.4 C). Both had molecular weights 
of 218, Cl-MS {M H}+ 219 and El mass spectra which contained ions at m /e  
218 {M}*, 203 {M-CH3>+, 189 {M-CH^O}*, 174 {M- ( C ^ + C H ^ } +, 159 (M-CH3 
C00}+, 143 {M-(C00CH- + CH^)}+, 133 {M-(TMS + CH^)} , {CH2=0TM S}+, 75
4- ■ +{(CH,)2SiOH} , 73 {IMS} .
Preparation of Acetone Oxime5 7 7 ( L X X X )
Acetone (0.5 nil) was added to a solution of hydroxylamine hydro­
chloride (lg) and sodium acetate trihydrate (2g) in water(10 ml) and the
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mixture shaken. A few drops of methanol were added to obtain a clear 
solution and the flask was heated on a water bath for 10 mins. The 
solution was cooled and the precipitate recovered by filtration. The 
product was recrystallised from methanol/water to give pure acetone
f C 9 7  '
o x i m e  (LXXX) mp 5 9  ( l i t  mp 5 9 ° ) ,  C l - M S  ( M H } +  7 4 .
Preparation of Butanone Oxime (LXXXI)
Butanone was treated as above to give pure butanone oxime (LXXXI) bp 152°C 
( l i t  580 b p  1 5 2 °  C ) ,  C I - M S  ( M H } +  8 8 .
Preparation of 3-Pentanone Oxime (LXXXII)
3-Pentanone was treated as above to give 3-pentanone oxime (LXXXII) bp 
1 6 5 °  ( l i t  580 b p  1 6 5 ° ) ,  C l - M S  ( M H } +  1 0 2 .
Preparation of 3-Heptanone Oxime (LXXXIII)
3-Heptano*ne was treated as above to give 3-heptanone oxime (LXXXIII) 
bp 193° (lit **^bp 193° C)/CI-MS IMH}+ 130.
Preparation of Acetone Methoxime (LXXXIV)
This compound was prepared by a modification of the above method. 
Acetone (1.0 ml) was added to a solution of methoxylamine hydrochloride 
(2g) and sodium acetate trihydrate (g) in water (20 ml) and the mixture 
shaken. A few drops of methanol were added to obtain a clear solution 
and the flask was heated on a water bath for 10 mins. The cooled mixture 
was extracted with ether ( 3 x 1 0  ml), and the extracts were dried and the 
solvent removed.
Distillation of the residue gave pure acetone methoxime (LXXXIV) bp 
7 2°  (lit581 bp 72-72.5),. C I - M  S 1 M H } +  88.
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Preparation of Butanone Methoxime (LXXXV)
Butanone was treated as above to give pure butanone methoxime 
(LXXXV) bp 91° (lit552 bp 91.5°), CI-MS (MH}+ 102.
Preparation of 3-Pentanone Methoxime (LXXXVI)
3-Pentanone was treated as above to give pure 3-pentanone methoxime
r n  <7
(LXXXVI) bp 116 (lit bp 116-117 ) CI-MS {MH} 116.
Preparation of 3-Heptanone Methoxime (LXXXVII)
3-Heptanone was treated as above to give pure 3-heptanone methoxime 
(LXXXVII) bp 142°,CI-MS (HH}+ 143.
Preparation of Acetone 2,4-Dinitrophenylhydrazone (LXXXVIII)
2,4-Dinitrophenylhydrazine was suspended in methanol (5 ml) and 
sulphuric acid (0.5 ml) was added. To the filtered solution was added 
acetone (o.2 ml) and the mixture was shaken and then left to stand for 
10 mins. The crude product was recovered by filtration and recrystalised 
from ethanol to give pure acetone 2,4-dinitrophenylhydrazone (LXXXVIII) 
mp 128° (lit577 mp 128°), CI-MS {MH}+ 239.
Preparation of Butanone 2,4-Dinitrophenylhydrazone (LXXXIX)
Butanone was treated as above to give butanone 2 ,4-dinitrophenylhydrazone 
mp 115° (lit5 7 7 mp 115°), CI-MS {MH}+ 253.
Preparation of 3-Pentanone 2,4-Dinitrophenylhydrazone (XC)
3-Pentanone was treated as above to give 3-pentanone 2,4-dinitrophenyl­
hydrazone mp 156° (lit^^mp 156°) CI-MS {MH} 267.
Preparation of 3-Heptanone 2,4 Dinitrophenylhydrazone (XCI)
3-Heptanone was treated as above to give 3-heptanone 2,4-dinitrophenyl-
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hydrazone mp 75° (lit5 ? 7  mp 75°), CI-MS {MH}+ 295.
Preparation of Ethyl Butyrate (XCVIII)
Butyric anhydride (79g, 0.5 mol) , ethanol (138g, 3 mol) and sul­
phuric acid ( ml) were heated under reflux for four hours. Most of the 
alcohol (^90 ml) was removed by distillation. The residue was washed 
with water (50 ml) , potassium carbonate (50 ml; saturated solution) and 
sodium chloride (50 ml; saturated solution) and dried (MgS04 ). On
distillation the residue gave pure ethyl butyrate (XCVIII) bp 121-2°
5 70(lit bp 121.6 ), yield 92.lg (79%), CI-MS (MH}+ 117.
Preparation of Mixed Condensation of Ethyl Propionate (LXXVI) and
Ethyl Butyrate (XCVIII)
Dry sodium ethoxide (0.2 mol) was prepared in a three necked flask 
equipped with a reflux condenser, a thermometer and a magnetic stirrer by 
dissolving sodium (4.6g, 0.2 mml) in excess ethanol (50 ml) and 
the solvent by distillation. Ethyl propionate (LXXVI) (51g, 0.5 mol) 
and ethyl butyrate (XCVIII) (58g, 0.5 mol) were added and the mixture 
stirred and heated under reflux for forty hours with a pot temperature of 
95°. The ethanol and some ethyl propionate (total volume 60 ml) was 
removed by fractional distillation every twelve hours. The reaction
, -4mixture was cooled and acetic acid (36g, 6M) was added to the stirred
. omixture at such a rate that the temperature did not rise above 20 .
The layers were separated and the aqueous layer was washed with ether 
(4 x 50 ml). The combined organic layers were dried (Na2$0^) and the 
solvent removed. The residue was fractionally distilled under vacuum and 
two fractions with bp range of 102-120°and 124-144 were collected. The 
esters could be easily separated by capillary G C but further fractional 
distillation did not improve the separation.
The first fraction bp 102-120° (mainly 110 C)/25 mm weighed 2.6g and
contained 3—keto—2—methyl valeric scid ethyl ester (LXXVII) (12.5-s) , 3— 
keto-2-ethylvaleric acid ethyl ester (44.7%) 3-keto-2-methylcaproic acid 
ethyl ester (31.3%) and 3-keto-2-ethylcaproic acid ethyl ester (11.6%).
The second fraction bp 122-144° (mainly 139-141 C)/25 mm weighed 3.4g
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and contained 3-keto—2—methylvaleric acid (4.4%) , 3-keto-2-ethylvaleric acid- * j •—
ethyl ester (16%), 3-keto-2-methylcaproic acid ethyl ester (47.9%) and 
3-keto-2-ethylcaproic acid ethyl ester (31.6%). A small portion of each 
fraction (lOOmg) was hydrolysed as described for 3-keto-2-methylvaleric 
acid ethyl ester and the residue obtained (70mg) was silylated and the 
G C-M S was run on S E 5^.
The G C of the silylated residue of•fraction A showed the presence
of 6 peaks. Peak 1 had retention time of 8.7 minutes, (elution temper­
o -j- 3f>ature 104.6 C), CI-MS {MH} 274, with^ identical mass spectrum to that
obtained for the IMS derivative of 3-keto-2-methylvaleric acid. Peak 2
had a retention time of 10.0 mins (elution temperature 110.2°C) CI-MS 
+ an +
{MH} 289 and hadAEI mass spectrum which contained ions at 288 (H } * ,
273 tl-CH3}+ ,259 {M-C2H }+ , 245 {M-C02 + H}+ , 199 {M - 0TMS}+ , 198
{M-(H + 0TM S) }+185, 184, 171 {M-C00TMS}+ , 147 {(CH )2 Si=0=1MS}+ and
this spectrum was in agreement with 2-ethyl-3-ketovaleric acid (XCIII)
diTMS.
Peak 3 had a retention time of 10.8 mins (elution temperature 112.9°C) 
CI-MS {MH}+ 289. The El mass spectrum contained ions which suggested the 
presence of a mixture of 2-ethyl-3-ketovaleric acid (XCIII) diTMS and 
3-keto-2-methylcaproic acid (XCIV) diTMS.
Peak 4 had a retention time of 11.7 minutes (elution temperature 
116.7° C), CI-MS {MH}+ 289, and had an El mass spectrum which contained 
ions at m/e 288 {M}*, 273 -15>+ , 245 {M-C02 + H}+ , 218 {M-(C«H_ + CO)
-H} , 199 {M-0TMS} , 198 {M-TMS0H}, 183* {M-(CH + 7MS0H) } , 170, 147 
{(CH^)2 Si=0=lMS}+ and 131 and this was assigned to 3-keto-2-methylcaproic 
acid (XCIV) diTMS. •
Peaks 5 and 6 had retention times of 11.9 and 12.5 (elution temperature 
117.2° C and 119.4° C), CI-MS {MH}+ 303 and had identical mass spectrum 
containing ions at 302 {M}?*, 287 {M-CH^}+ , 231, 217, 213 (M-TMS0>), 2 1 2  
{M-TMSOH}* 197 + TMS0H)}+ , 185 {M-COOTMS}^ i84 {M-HC00TMS}+ 171, 147
{(CH^ ) 2 Si=0=TMS} and these were assigned to 3-keto-2-ethylvaleric acid.
1 9 3
^ ̂  th© silylated rosidus from fraction 0 showed th© presence 
of the same 6 peaks with identical retention times, elution temperatures 
and mass spectra.
Preparation of 2-Bromopropionic Acid Ethyl Ester (CII)
2-Bromopropionic acid (30.6 g, 0.2 mol) and thionyl chloride (30g,
0.25 mol) were heated under refiux for 1 hour. The excess thionyl chloride 
was distilled off and the residue added dropwise with stirring to cold 
ethanol (10g, 0.22 mol). After stirring at room temperature for 1 hour 
the solution was distilled to give pure 2-bromopropionic acid ethyl 
ester (CII) bp 76°/25mm { l i t 5 7 0 bp 63°/14 mm) yield 30.5 g (85%),CI-MS 
{MH}+ 181, 183.
Preparation of 3-Hydroxy-2-methylcaproic Acid Ethyl Ester (CIV)
To zinc (9.6g, 0,15 mol) was added a small portion of a mixture of 
2-bromopropionic acid ethyl ester (20g 0.11 mol) and butanal (9g,
0.125 mol) in benzene (60 ml). A crystal of iodine was added, the 
mixture warmed to initiate the reaction and the remainder of the 
mixture added. The mixture was heated under reflux for three hours 
and sulphuric acid(3.5M; 120 ml) was then added to the cooled mixture.
The organic layer was separated and the aqueous layer extracted with 
ether (3 x 30 ml). The combined organic layers were dried ( MgSO^ 7 
and the solvents removed. The residue was distilled in vacuo to give 
pure 3-hydroxy-2-methylcaproic acid ethyl ester bp 107-10 /25 mm 
(lit*W  bp 115-21°/38 mm), yield 3.5g (19%) Cl-MS (MH) 175.
G C of the silyl derivative of the ester gave 2 peaks with elution 
times 7 . 8  minutes and 8 . 1  minutes on$E 5^ (elution temperature 1 0 0 . 6  
and 1 0 2 .2°) with identical molecular weights,CI -M S {MH} 247 and El 
mass spectra which contained ions at m / e 231 {M-CH^} , 203 ,
174 f1-(C H + C2H5)}+,157 {M-0-MS}+ , 145 {CHjCH^CHOTM S}+, 130,
117 {C00TMS}+ , 103 {CH =0=TH S}+ , 75 {(CH^) 2S iOH}*73 {TMSyf
Preparation of 2-Ethyl-3-Hydroxyvaleric Acid Ethyl Ester (Cll )
A portion of a mixture of 2-bromobutyric acid ethyl ester (CII)
(25g, 0.13) mol), propanal (9.7 g, 0.17 mol) and benzene (66 ml) was 
added slowly to zinc (13.7g, 0.21 mol) containing a crystal of iodine 
and the mixture was gently warmed until the reaction began. The 
remainder of the reaction mixture was then added and the solution heated 
under reflux for 3 hours. Dilute sulphuric acid (3«5M; 120 ml) was added 
to the cooled solution and after vigorous stirring the mixture was 
separated and the organic layer was dried fMgSO ,.) and the solvent re­
moved. The residue was distilled to give pure 2-ethyl-3-hydroxyvaleric 
acid ethyl ester bp 123-4/25 mm (lit^^ bo 95-7°/12mm) , yield 5.4 g (25%) 
CI-MS W H } + 175.
G C of the silyl derivative of the ester gave 2 peaks with elution
o o .times 7.3 and 7.6 minutes (elution temperatures 98.2 and 99.6 with 
identical molecular weights^CI -M S {MH}+ 247. The El mass spectra con­
tained ions at 231 217 173 {H-COOC^H^}, 157 {M-OTMS}
131 fl-CH(C2H5|C00TMS}, 117 {C00TMS}+ , 75 {(CH?) 2S i 0H}+ 73 {TMS}+ .
Oxidation of 2-Ethyl-3-HydroxyvalerlC Acid Ethyl Ester (CIII)
2—Ethyl—3-hydroxyvaleric acid ethyl ester (CIII) (350mg, 2 mmol) was 
dissolved in acetone (35 ml) and the solution was cooled to 5 . The acid 
was titrated with Jones* reagent until a permanent orange colour persisted 
(0.6 ml) . The stirring was continued for 30 minutes and water (30 ml) 
was then added and the solution was extracted with ether (4 x 50 ml) .
The ether extracts were washed with saturated sodium chloride (2 x 25 ml) 
and dried ( MgS04 ) . The ether was evaporated to give 2-ethyl-3-ketovaleric 
acid ethyl ester in quantitative yield. This ester was shown to be pure by 
GC and TtC (silica gel, benzene/chloroform; 95:5). A small portion was 
hydrolysed with NaOH and the resulting 2-ethyl-3-ketovaleric acid (XCIII) 
was silylated. The retention times and mass spectrum of the trimethyl- 
silyl derivative was identical to that obtained for 2—ethyl 3 ketovaleric 
acid (XCIV) made via the mixed Claisen condensation.
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Oxidation of 3-Hydroxy-2-Methylcaproic Acid Ethyl Ester (CIV)
3-Hy droxy-2-methy1caproic acid ethyl ester (CIV) (350mg, 2 mmol) 
was dissolved in acetone and cooled in ice to 5 with stirring. The 
solution was titrated with Jones' reagent until a permanent orange 
colour was obtained (0.7 ml). The stirring was continued for 30 
minutes and water (30 ml) was then added and the solution saturated 
with salt before extraction with ether (3 x 50 ml) . The ether extracts 
were washed (satd NaCI  ? 2 x 20 ml) , dried <jMgS0"4 ) and the solvent 
removed.3-keto-2-methylcaproic acid ethyl ester was obtained in quantit­
ative yield and its purity demonstrated by G C and T L C  (silica gel; 
benzene chloroform (95:5)). A small portion was hydrolysed with NaOH 
and the resulting 3-keto-2-methylcaproic acid (XCIV) was silylated.
v
The retention times and mass spectra of the two diastereoisomers wgre 
identical to those obtained for 3-keto-2-methylcaproic acid made via 
the mixed Claisen condensation.
(
A P P E N D I X  A
CORRECTION FORMULA FOR INTENSITY 
MEASUREMENTS
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During the course of this work it was found that the use of 
isotopically labelled internal standards which were only moderately 
enriched isotopically gave calibration curves which were not linear 
over extended regions. To overcome this problem a formula was developed 
which when applied to the uncorrected peak height ratio gives the 
absolute ratio between internal standard and unknown.
For a pure material A with an ion at m/e M let the ratio of the 
intensity of the M + n peak to the M peak be R. For another pure
’k  k  'material B with an ion of m/e M let the ration of the M - n peak to*the M peak be S .
Diagramatically this may be represented as follows:
FOR PURE MATERIAL A FOR PURE MATERIAL B
X Y
X y
m/e M M + n M* -i n M*
X ym  <
Ix M* Y
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When we examine a mixture of the two materials A and B where the M +
*n peak due to compound A is coincident with the M peak of compound B we
have the case where the measured intensity of M is due to a contribution
*X from compound A and Y from compound B and the intensity at M is similarly 
due to a contribution x from coumpound A and Y from compound B and this may 
be represented as follows: •
T
X
)kA y
*
m/e
x
Y
M M*
Where I.M
T * IM
X
Y
x
y
= observed intensity of peak at Mass M
*
= observed intensity of peak at mass M 
= contribution of compound A to i.M 
= contribution of compound B to Im *
= contribution of compound A to IM 
= contribution of compound B to I M
We can see that x
y
= RX ' 
= SY
Let 1M
I  M*
J is the observed ratio between the intensities at masses M and M
We can write I m = X+y
Im *= y+x
X + SY -(1)
-(2)Y + RX
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On multiplying Eqn. (1) by R we obtain 
R.lM = R.X + R.S.Y -(3)
Subtracting Eqn (2) from Eqn (3)
t *Xm  - R-Im  = Y - R.S.Y. -(4)
This may be rearranged to give: 
y = Im * - r .Im
1 - R.S
Similarly we see that 
X = Im - s .Im *
1 - R.S
The actual ratio of compound A to B is given by - 
X I m -  s . I m*
y I m*- r .I.m
= I m . ( l  -  s. I;m* / I m )
----- x ------------------■----- — —
Im  ( i - r . Im/Im * )
by substituting J for lid
I M*
= J (1 - S/J) .
1 - RJ
= J - S
1 - RJ *
Thus by measuring S and R in separate experiments we may correct 
the observed ratio to give the true ratio of the amounts of A and B present.
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RATIO
jjg  L e c i t h i n
FIGURE A-l.
13''
CI-MS calibration curve for Lecithin using l-( C-palmitoyl)- 
2-palmitoyllecithin internal standard and measuring the ■: 
intensity/ of the protonated molecular ions of the palmitic 
acid obtained by hydrolysis.
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The use of this correction may be illustrated by the analysis of
lecithin by hydrolysis and measurement as palmitic acid. The lecithin
13internal standard available contained 50% of C labelled palmitic 
acid and the samples after hydrolysis were analysed by measurement of 
the 257/258 peaks of the protonated molecular ions of palmitic acid 
in the Cl isobutane mass spectrum. The contribution from natural 
isotopic labelling in the unknown to the intensity of the 258 peak 
was 18.5% of the intensity of the 257 peak, (R) and in the pure . 
internal standard the ratio of the 257 peak to the 258 was 93.8% (S).
The curves obtained using lOyg of internal standard are shown in Fig.
A-l. These curves show that use of the correction substantially improves 
the range of linearity of the curve.
The formula was used for correction of the experimental mass spectral 
intensity ratios in all isotope dilution results, reported in this thesis 
and a programme was written for use with a portable calculator to obtain 
corrected intensities.
A P P E N D I X  B
ELUTION TEMPERATURES 
AND
CHARACTERISTIC MASS SPECTRAL IONS
APPENDIX B 
TABLE B-l
ELUTION TEMPERATURES AND CHARACTERISTIC MASS SPECTRUM IONS 
FOR TMS DERIVATIVES OF SOME METABOLITES SEEN IN THIS STUDY
COMPOUND ELUTION TEMPERATURE (°C) CHARACTERISTIC IONS IK MASS SPECTRUM
APIEZON SE30 SE54
Glyoxylic acid methoxime 102 189, 174, 158, 147, 130, 116, 100,86.
Propylene glycol 101 104 220, 219, 205, 147, 147, 117.
Phenol 114 106 166, 151, 135, 91.
Pyruvic acid methoxime 108-9, 189, 174, 158, 117, 115, 100, 99,113 89.
Lactic acid 106 109 234, 219, 191=190, 117.
Hexanoic acid 111 188, 173, 132-131, 117.
Glycolic acid 111 112 220, 205, 177, 161, 149, 147.
2-Ketoisovaleric methoxime 113, 119 217, 202, 186, 170, 147, 116, 100,
(27) 89.
2-Ketobutyric acid meth- 114 203, 188, 172, -147, -129, 89.
oxime
Pyruvic acid Di TMS 113 232, 217, 147, 133, 131, 117, 115,105, 103, 101, 99, 87, 79.
a-Hydroxy-2-methylbutyric 119 115 262, 247, 233, 219, 147<145.
acid
Glyoxylic acid oxime 115 243, 218, 190, 147, 144, 133, 131,116.
2-Hydroxybutyric acid 116 116 248, 233, 205, 191, 190, 131.
201
p-Cresol 134 117
Oxalic acid 113 117y-Ketovaleric acid oxime 117
Ketoma Ionic acid methoxime 117 f
2-Hydroxy-3-methylbutyric 121 118
acid
Pyruvic acid oxime 118
Acetoacetic acid methoxime 1193-Hydroxybutyric acid 122 120Levulinic acid 120
3-Hydroxypropionic acid 116 121
3-Hydroxyisobutyric acid 118 122a-Ketobutyric acid oxime 122
2-Keto-3-methylvaleric 123,acid methoxime
Methylmalonic acid 128 126Benzoic acid 144 1262-Methyl-3-hydroxybutyric 125 127acid
2-Hydroxyisocaproic acid 128di TMS
2-Hydroxy- 3-methylvaleric 134 128acid
180, 165, 149, 137=135, 109, 107, 
105, 91.234, 219=190, 147.
275, 260, 186, 170, 158, 147, 133, 
129, 103.
262, 247, 219, 190, 147<145.
247, 232, 204, 158, 147, 130, 114, 
100, 89.
203, 188, 147, 144, 116, 00 VO •
248, 233, 191, 143, 130.188, 173, 155, 145, 131, 129, 99,98, 75, 73.234, 219=177, 133, 131, 129, 116,103, 101.
248, 233, 218, 177, 147, 143, 103261, 246, 218, 172, 163, 147, 144133, 131, 128.
2 31, 216, 203, 200, 189, 172, 156147, 114, 113, 89.262, 24 7-218.194, 179, 135, 105.262, 247, 218, 191, •0000
276, 261, 245, 233, 219, 203, 190177, 171, 159, 147, 143, 133, 131,129, 117, 103.
276, 261, 233, 219, 217, 190, 159,147, 143, 133, 117, 103, 69.
TABLE
3-Hydroxy- 3-methy lbutyr ic 131 129acidUrea 134 1292-Ketoisocaproic acid 130methoxime
Acetoacetic acid 137 131
Phosphoric acid tri TMS 135 1323-Hydroxyvaleric acid 132
O-Cresol 133
Octanoic acid 143 134
2-Methyl-3-hydroxyvaleric
acid
Phenylacetic acid 145 134
2-Keto-3-methyl-n-valeric 134
acid oxime
Maleic acid 140 135
Di-ethylene glycol di TMS 135
2-Ketoisovaleric acid 135
oxime
Levulinic acid methoxime 135
3-Ketovaleric acid 137
Thymol 157 138
Succinic acid 141 138
2-Ketoisocaproic acid 138
oxime
B-2 (cont. ) 
92.8
92.14;
97.93
96.0
98.9
99.7
99.7,
101.8
262, 247, 205, 131, 115, 95.
204<189, 171, 147, 114, 100.
231, 216=200=189, 157, 110, 99 , 89
246, 231, 232=157.
314, 299, 283, 211.
247, 233, 205, 189, 147, 144, 133,
131.
180-165, 149, 135, 91.
216, 201, 132, 117.
261, 247, 218, 207, 205, 203, 191,
171, 157, 147, 145, 143, 132, 131,
115.
208, 193, =̂ 164 •
289, 274, 261, 24 7, 200, 172, 147.
260, 245, 215, 171, 170, 147, 143,133, 126, 115, 83.
250, 235, 207, 205, 191, 161, 147,
145, 117, 103, 101 *
275, 260, 232, 186, 158, 147.
217, 202, 186, 127, 119, 100, 89.260, 245, 231, 171, 170, 163, 155.
222, 207, 165, 149, 105.
262, 247, 218, 173, 172, 116.
289, 274, 247, 200, 172, 147, 133,
129, 110, 89, 82.
3-Keto-2-methylvaleric 139acid oxime
Acetoacetic acid oxime 142
2-Methylacetoascetic acid 142Fumaric acid 151 14 3
Glyceric acid tri TIMS 145
3-Ketovaleric acid oxime 146
2-Methyl-3-ketovaleric 146acid
Glycerol tri TIMS 139 147
N~Propionyl glycine mono 147
TMS
N-Acetylglycine di TMS 147
Glutaric acid 157 149
3-Methylglutaric acid 160 153
3-Methylglutaconic acid 164f 171 155, 16
Butanoyl glycine di TMS 156
Butanoylglycine mono TMS 157
Ketomalonic acid oxime 157
289, 274, 259,
261, 247, 201.
260, 245, 217,
143, 133.322, 307, 292,
130, 117, 103.
275, 260, 232,
147, 129.
259, 247, 218,
133, 131.
308, 293, 218,
117, 103.
203, 188, 159,102, 88, 86.
261, 246, 218,
171, 147, 145=
102.
276, 261, 233,147, 117, 116.
290, 275, 247,147.
288, 273, 244,
109, 82.
289, 218, 202,
145, 132, 131,
100.
217, 202, 189,
116, 104, 102,
349, 334, 262,
131, 99, 84.
, 184.
157, 155, 147
189, 14 7, 133
185, 170, 158
163, 157, 147
147, 133, 129
132, 131, 104
176,
132,
174,
130,
172
104,
187>186, 158,
201, 172, 159
198, 183, 170
189,116,
173,
104,
15 8 
102
158, 145, 132
155, 147, 133,
200
171
205
186
174
205
144
190
144,
204
204
229
200
130
173
100
172
TABLE I
Adipic acid 171 163Furan-2-hydroxymethyl- 5-carboxylic acid
2-Hydroxyphenylacetic 186 172acid
Pimelic acid 185 173
2-Hydroxyglutaric acid
3-Hydroxy-3-methyl- 185 174glutaric acidPhenyllactic acid 186 1762-Ketoglutaric acid tri 184 177
TMS
3-Hydroxyphenylacetic 189 177
acid
Hexanoylglycine mono TMS 178
Glutaconic acid 189 178
2-Ketoglutaric acid 178
methoxime
Hexanoylglycine di TMS 179
Salicylic acid 179 179
4-Hydroxyphenylacetic acid 193 180
2-Ketoglutaric acid oxime 184
Tartaric acid 184
3-Hydroxy-3-methyl tartaric 185
acid4-Hydroxy-cyclohexylacetic 188, 193
acid
3-2 (cont.) 
128.6 
136.8
146.4
151.5
157.1
290, 275, 145, 111.271, 197, 169, 147, 123.
296, 281, 252, 164, 149, 147.
304, 289, 217, 204, 199, 186, 173
155, 147, 125, 117.247, 203, 157, 147, 129, 85.378, 363, 273, 247, 231, 199, 115109.310, 267, 220, 193.362, 347, 318, 291.
296, 281, 252, 164, 149.
245, 230, 189, 172, 158, 148, 145132, 130, 104, 99.274, 259, 95.
319, 304, 288, 244, 229, 202, 198186, 156, 147, 89.317, 279, 230, 202, 201, 189, 172
158, 145, 132, 130, 104, 102.
282, 267, 209, 195, 193, 147,135.
296, 281, 252, 179, 164.377, 362, 260, 244, 170, 156, 147438, 423, 292, 219.378, 363, 273, 231, 247, 199.
287, 212, 204, 197, 171, 170, 147
Suberic acid 200 186Phenylpyruvic acid di TMS 207 189
Homovanillic acid 194 191Phenylpyruvic acid methoxime 1912-Ketoadipic acid methoxime 191Phenylpyruvic acid oxime 192
2-Ketoadipic acid oxime 197Hippuric acid 224 199Octanoylglycine mono TMS 200
Octanoylglycine di TMS 201
Citric acid 205 2034-Hydroxy-3-methoxy 
mandelic acid
208 204
Methyl citrate 208
Sebacic acid 225 208
p-Hydroxyphenyllactic acid 224 211
4-Hydroxyphenylacetic acid 210
Di-n-butylphthalate 228
Palmitic acid 249
p-Hydroxyphenylpyruvic oxime: 230
p-Hydroxyphenylpyruvic
methoxime
227
172.2
177.3 
191.1
318, 303, 187=169, 129, 217, 204.
308,
90.
293, 265, 237, 190, 147, 118
326, 311, 267, 209, 179.
265=250=189, 147, 116.
333, 318, 302, 258, 170, 147, 89.
323, 308, 280, 206, 189, 147, 118
117, 91, 90, 89.391, 376, 302, 258, 184, 170, 147
251, 236, 206=105.
273, 258, 202, 200, 189, 172, 158
148, 145, 130, 127, 99.
345, 279, 258, 189, 172, 158, 145132, 130, 127, 99.
480, 375, 363, 347, 274, 272.
414, 399, 371, 297.
479, 389, 377, 361, 287, 271, 231
225, 221.
346, 331, 217-215, 204, 166, 149,
147, 129, 117.398, 308, 179.
326, 311, 267.278, 223, 205, 149.
328, 313, 145, 132.
411, 396, 277, 206, 205, 190, 179
147, 116, 105.353,
105.
338, 278, 277, 205, 190, 116
APPENDIX B
TABLE B-2
ELUTION TEMPERATURE AND CHARACTERISTIC MASS SPECTRAL IONS
FOR ESTER DERIVATIVES OF SOME METABOLITES SEEN IN THIS STUDY
COMPOUND
ELUTION TEMPERATURE (°C) CHARACTERISTIC IONS 
• IN MASS SPECTRUM
Apiezon SE 30 SE54
Glutaric acid 114 160, 129, 128, 112, 100, 101
3-Hydroxybutyric 115
Propionylglycine 125 . 145, 113, 90, 88, 86, 84, 74, 70,69.
Adipic acid 127 174, 143, 114, 111, 101, 73, 74.
Butanoylglycine 135 159, 144, 142, 131, 128, 127, 103,100, 90, 88, 71.
Thymol-underivatised 135 150, 135, 115, 107, 105, 91.
3-Ketoadipic 139 158, 157, 156, 129, 125, 115, 101,97, 88, 87, 69.
Pimelic acid 140 188, 157, 128, 125, 115, 101, 97,96, 87, 83, 74, 73, 69.
Octenedioc acid 151 118.2 200, 169, 168, 140, 136, 137, 126,127, 108, 109, 85, 81, 74, 67, 59,
55.
Suberic acid 154
Citric acid 155Hexanoylglycine 159
p-Hydroxyhenylacetic
acid
159
Decenedioc acid 175
Glutarylglycine 178
Hippuric acid 183
Octanoyl glycine 185
Adip ylglycine- 198
Palmitic acid 211
Suberylglycine 217
141.1
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The large amount of data generated in a typical G C-M S profiling 
experiment leads to the problem of identification of the peaks obtained 
on the GC from their recorded mass spectra. Manual interpretation of 
the relevant mass spectra is often difficult and time consuming and 
identification may be greatly assisted by reference to mass spectral 
libraries. The simplest method of identification of the unknown com­
pounds is to match the mass spectrum of the unknown with that of a - '#
known compound. The problem of identification is then changed to that of 
searching a library to find an identical mass spectrum to that of the 
unknown or a structurally similar compound.
The National Institute of Health Library of 20,000 mass spectra was 
available in our laboratory. The library was in the form of three 
computer files, one of which contained information about each compound 
such as the formula, molecular weight, identification number as well as 
information about the mass spectra recording conditions (CHEM10)
The other two files contained identification numbers and mass intensity 
data of the ions present in the mass spectrum for each compound
(CHEMll and CHEM12). These files were not in readily accessible form 
and contained a number of errors. The aim of this work was to facilitate 
ready access to the library to help in the identification of unknowns.
The initial section of the work was the development of a computer 
programme to print out the complete spectra. The file of information 
was processed to form a new file (NIHNAMES) which contained a single 
line of information about each compound. This line contained the id­
entification number, the molecular weight, the formula, the name and the 
original library in which the mass spectrum was recorded for each com­
pound. A programme was developed, written in Fortran, to read the 
name file (NIHNAMES) and the MS data file (CHEMll and CHEM12) for the 
name, information and MS of each compound. This information and the 
complete mass spectrum of each compound was printed out in a standard 
format with 12 mass intensity pairs per line (Programme PRINT, Fig;
Ol, c-2)* The first section of the programme (start to 2 Fig. C-l, lines 
1-62, 74, 76, Fig. C-2) reads a line from the compound information,
* See pages 215 ff for all Figures relating to this work.
2 1 0
( NIHNAMES ) searches the MS data file (CHEM 11) to find the data for 
the relevant compound, checks for and corrects errors in the data and 
reads the mass and intensity of the ions into arrays. The second part 
of the programme (2 to end Fig. C-l lines 63-73 Fig. C-2) calculates 
the number of lines of output, prints the identification number, mole­
cular weight, formula, name and library source of the compound and 
then prints out the mass and intensity information (Fig. C-3).
The process of searching such a large library for matching spectra 
is still time consuming and there have been many approaches to simplify­
ing the search task (see Ref. 73, Chapter 5).
Since the organic acid samples used in this work were all IMS der­
ivatives, the compounds with matching spectra must all contain silicon. 
The creation of a sublibrary of silicon containing compounds thus elim­
inates a large number of compounds from consideration. The use of
cn Qfi ^R7 7R7specialised libraries has been reported by other authors 3 3 3 some
_ . . , , . . . 588-90of whom have used only spectra generated m  their laboratories.
The generation of a sublibrary of all silicon containing compounds was
carried out using the conversational time sharing processor(CTS) text
editor available on the Univac 1106 computer to search the molecular
formula in each line of NIHNAMES for the presences of silicon. If
silicon ŵ jr present the line of information about the compound was
moved and a new file (TMSCOMPS) (Fig. G-4) created containing only
those compounds which contained silicon in the molecular formula. This
file was used as input for the encoding programme.
One of the problems in constructing a successful library matching 
system is the selection of a suitable coding scheme which will compress 
data sufficiently to allow a large data base but still retain as much 
information as possible. The compression of data bases has a number of 
advantages since the retaining of the full spectrum presents an inord­
inate amount of data for storage and searching except for small 
specialised libraries. Abbreviation of the spectra also improves the
performance of the search by minimising the variability of recorded 
spectra. For example the use of a minimum intensity threshold ensures 
that low intensity peaks of doubtful reproducability are not used in the
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mactching procedure. Fortunately the majority of spectra contain much
more information that is required for a unique identification of the
592compounds. Thus Mathews and Morrison showed that the matching of 
six to eight major peaks in terpene spectra gave results comparable to 
use of the full spectra. .
The choice of an encoding system can be made in terms of three 
basic systems;
(a) Recording of the intensity of a limited number of peaks where
the number is usually between five and ten. This method is simple and 
direct both in encoding and subsequent matching and allows a surprisingly 
unique description of each component. ■* The method is most
applicable to compounds of lower molecular weights and especially where 
libraries of limited size are employed. A natural development of this
approach is the encoding of N peaks every M mass units which improves
. . . 592the discrimination between higher mass compounds. Mathews and Morrison
have shown that encoding the 6 or S most intense peaks in each spectrum 
gave the best matching of the very similar mass spectra of terpenes.
(b) The transformation of the spectrum into features such as the 
presence of ion series, low medium and high mass characteristic ions, small 
and large neutral losses, secondary neutral losses and fingerprint ions.
(c) Encoding as a mathematical function in which a single valued 
representation of the spectrum is calculated to be stored in the data 
bank.
The problems with the latter two included the large volume of calcu­
lation needed for treatment of the library and the difficulties of finding 
suitable functions or features.
The use of intensity information in encoding spectra necessitates
an increase in the storage space required. However, the addition of
. 592,598-600some intensity data enables better matching results.
The encoding scheme chosen was the use of the mass and intensity
m ,values of the 15 most intense peaks in the spectrum above /e 30 
(Big 15). Although Mathews and Morrison showed that 6-8 peaks gave
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maximum discrimination for terpenes experience with a library system
using the 10 most intense peaks showed that, since IMS compounds have . mass spectrum 'a number of intense ions in their A which are related to the 7MS group,
use of more than 10 peaks was required to obtain a unique representation 
o f  the MS of structurally similar TMS compounds. The intensity values 
were normalised on the most intense peak (range 0-99),(Fig. C-5, C-6)
A FORTRAN programme was developed (BIG15, Fig. C-5, C-6) to read the name 
file (TMSCOMPS) and the MS data file (CHEM11 and CHEM12) for the required 
information and compute and output the 15 most intense peaks with normal­
ised intensities. The input of data to this programme was the same as
for PRINT with the added step of clearing the intensity array before
the data input for each compound (lines 1—62, 67—69). A subroutine
(BIG, Fig. C7, C8) was called to find the 15 most intense peaks and write
them into new arrays (A-B Fig. C-7, Lines 1-13 Fig. C-8). These arrays
flfilwere resorted into order of decreasing mass using a ripple sort 
(B-C Fig. C-7 lines 14-34 Fig. C-8) and an array combining the mass and 
intensity data passed back to the main programme (C-END Fig. c-7 and 1 
lines 35-40, Fig C-8). The main programme then prints out the compound 
identification and the 15 most intense peaks in order of decreasing mass 
(Fig. C-9) (File BIG15) .
To facilitate the matching of spectra of unknown compounds whose
molecular weights were known by CI-MS it was considered desirable to sort the
^output of programme BIG 15 into order of ascending molecular weights.
In the FORTRAN programme written to do this (FILESORT, Fig. C-10, C-ll) 
the file to be sorted was copied into a direct access file (also called 
a random access file)and the number of compounds calculated. The line 
numbers of the lines containing the identification number and molecular 
weight were calculated, and these values were read from the direct access 
file into arrays (A to B Fig. C-10 Fig. C-ll lines 1-28). The mass array 
was then sorted using a monkey-puzzle sort ’ (called a list processing 
sort or tree sort) (B-C Fig. C-10, lines 31-57 Fig. C-ll).
This efficient sorting .algorithm uses two associated vectors to point 
to the items that are to the left and right of any item. It suffers 
from the fact that a large amount of workspace is needed but was chosen 
because the items to be sorted do not need to be moved. The latter 
section of the programme (C to D, Fig. C-10 lines 52-74 Fig. C-ll) is 
used to read the data for each compound from the direct access file and
213
write it on the output file (S0RTBIG15) in order of increasing molecu­
lar weight.
In order to further facilitate searching the library and to prepare 
it for computer searching a programme was written to generate tables of 
frequency of molecular weight, frequency of occurrence of ions of a 
given m/e in the BIG15 and to list all spectra which contained an ion 
of a given m/e ( MFTABLE / Fig. C-13, C-14) . The amount of space re­
quired for the information to generate the spectra list table (400fc- 
words) was greater than the available user core in the Univac 1106 
(64K words) and an unformatted direct access file was used for this 
table. The maximum number of spectra whose individual identification 
numbers will be recorded if a peak of given m/e is present is specified 
as 130. The direct access file is structured as an array of 3000 
lines of 132 words. The first two words in any line contain the m/e 
value for the ion and the frequency of occurrence of the ion and the 
remainder of the line is an array of numbers to identify the compounds 
containing that ion among the 15 most intense ions. Lines 1-1000 contain 
arrays using the NIH identification numbers, lines 1001-2000 contain 
arrays using identification numbers based on the molecular weight and 
lines 2001-3000 have arrays containing the line number of the name, 
identification data and BIG15 MS in a second direct access file. These 
files have been retained for adaption to an already available MS 
library search on the Univac 1106 (QUADNOVA*RCHEM),
The data input section of the programme (A-I Fig. C-13, lines 1-65) 
reads in the compound information and the 15 most intense peaks in the 
mass spectrum (the output of FILESORT) . A new identification number is 
calculated containing the molecular weight and the molecular weight 
frequency array and the number of spectra are updated. For each mass ̂i.n 
a BIG15 MS) the relevant lines are read from the direct access file into 
core, the identification arrays are updated and then rewritten to the 
direct access file (I-BFig. C-13, lines 68-111 Fig. C-14). The identif­
ication number, name, formula, molecular weight and BIG15 MS are written 
to the other direct access file and to the output file. The programme 
then returns for further data input (B-C Fig. C-13 lines 111-125 Fig. C-14).
When all data has been processed the programe sorts out the number of
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spectra, the molecular weight frequency table, and the frequency of 
occurrence of each m/e value from 31 to 1000 (C- DFig. C-13,lines 126­
160 Fig. C-14). The programme next prints out the lists of identific­
ation numbers of the mass spectra containing ions of each m/e value.
Both the NIH identification number and the identification number based 
on the molecular weight are printed out (D-E Fig. C-13, lines 161-216 
Fig. C-14). The molecular weight frequency array and the ion occurrence 
frequency array were then written to the first 20 lines of the direct 
access file.
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YES
Write out heading 7 
for compound-identi fi 
ication no.,formula, 
molecular wt.»name 
librarv source
Define no of lines for 
mass»intensity printout
—
Write out mas: 
intensity 
>airs
FIGURE C-l.Flowchart for programme PRINT.
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1 C P R O G R A M  P R I N T  "
2 C THIS P R O G R A M  IS TO P R I N T  OUT C O M P L E T E  S P E C T R A  F R O M  C H E ^ l l .
3 c A Flit- (tlNTT 14 ) W H T f H  C O N T A I N S  THF I D E N T I F I C A T I O N  N U M F t P . T H F  M O L E C U L A A  .
4 c W E I G H T . T H E  F O R M ULA A N D  THE N A v f  OF T h e  C O M P O U N D  EG O U A D N C V A *  NIH N A  M £  5 •
5 c
6 r 2 6 FT1 K D M T  I n ) W H I C H  C O N T A I N S  T U F I C F N T I F I C A T I C N N U M B E R . T H F  NlJMfF
7 c M t c S x M  l!f c .T h F m a r s  AfT T m F TT f N S T T v OF THE 'MASS S P E C T R A L  PF A K  EG M  ___
8 C S P E C D A L FILE O ijA C N C V A * C H E m i i
9 c T r E I N T E N S I T Y  V A 1 U F S  APE R E A P  TN T O  2 A R R A Y S  OF MA S S  AND TNT 5lT L O N G
in c t h e  t * p a r r a y s  c o n t a t n m a s s  i n t e n s i t y  p a i r s
l i c
i ? c V A P I A 3 l F S  U S E D
1 7. c A JUNK r RuBf-.TSH TN F T R S T  u L T N T S  CHE.M11
14 c o I N u O  : T D F N T I F I C A T I O N  NO R E A D  F P Q M  UN I T  14 I E . N l H N A M E S .  •
1 5 c C M 0 L W T - M O L E C U L A R  W E I G H T  R E A D  F R O M  UNT 14
16 c ' !) F O R M  r F O R M U L A  R t « D  F R O M  UN I T  14
17 r E n a m e  r N A m t OF C O M P O U N D  R E A D  r RPM UN'IT 14
18 c F S O u P C F r  R F F F P F N C F  TO FI No FULL S P E C T R U M
1 9 c G ID = T U F N T T F I C A T I O N  NO P E A D  FPO M  U N I T  16
20 c H N M V - N j M F E R  CF M A S S  V A L U E S  R E A D  FPO*' U N I T  16
2 1 c T m a s s  : M ASS V Al 11: OF W A S S - I N T  P M R - P F A D  F R O M  U N I T  16 .
22 c - J I N T F N - I N T E N S I T Y  U S E D  k H t N C H r C k I N G I D N O  - R E A ?  FROM, U N I T  16
23 c THE APR AYS APE T H E N  P P T N T E D  IN A C O M P R F S S F D  FORM,
2 4 c
28 c
26 D I M F N S I P N  M A S S ( 5 C D ) .  I n T ( 5 l PI. J U M K ( 1 ? C )  ' .. --
27 D I M E N S I O N  F O R m (S). N A M F  ( P r ) . S 0 U P C L (2 ) - . ....  . ..
28 C O M M O N  M A S S .  INT. F O R « . f i a M f .S O U R C E  -.....
29 c THE F I R S T  6 L I N F S  OF C H r Mlll ARF F I L L r D W I T H  J U N K  AND ARE R E A D  IN AND D I S C A R D E D
3D DO 1 I : l . n ' ............ ..
3 1 lr RF A D (16.1 6D ) JUN *  ........... . ... .
32 c READ  P R O M  L I S T  OF O O M P C U N D S  ID W 0 , M C L W T , F OR M . N A M £ , SO UR C E . .... .
33 21' RF A D ( 14. 1 9 r . F R P r l 2 n .F,ND3l5f') I D N 0 , M OL w T , F 0 9 M , N A M E , S O U R C  E ..........
34 c
35 c PF A C D O W N  ( H f - i l  TO F I N D  THE S T A R T  OF THE I N F O R M A T I O N  FOR THF R E Q U I R E D  C O M P D L / ^ D
36 3‘ RF A C ( 1 6 . 2 L r , E R R r l 4 C . F N D = 1 5 P )  ID . *'MV , MA S S  ( 1 ) , I NT ( 1 ) . ____
• 37 IF ( I D . F O . I O N O )  GO TO 4r' _. . _ .. .....  ...
38 GO TO 3 C - - • ... -
39 c THIS S E C T I O N  S O P T S  O U T  T h E E R R O R S  IN C h E M U
40 4 l IF ( I D N Q . r o .  297) GO TO 9U___________  • ’' 4 1 IF ( I D N C . E C . 473) Go TO 9 l
42 IF ( I D N C . E O .  39 3 3  ) M 0 L W T  = 11 5 647 IF ( I D N P . E 0 . b 7 5 1 )  H O L W T - 1 6 7 4 ____________________________
44 IF ( I D N C . E O .  111,4 ) GO TO 9L * ......................
4 5 IF ( IDN''-. FO. 1113 ) GO TO 9? _ _.. .......
46 50 IDUMM iY-N MV - .........
47 IF (I D N O . E C . 354) I u U M M Y r33
48 IF ( I D N C . E O . 351) I D U m m Y = 46
49 • IF ( I D N O . F G . 353) I u U M M Y = 6 7
50 IF (I D N O . E G . 697) I D U M M Y = 1 5 1  .............
51 IF ( I D N O . r u . 698) I D U M M Y - 127
5? IF (IDNC.E0.tj99) IDUKHY=73
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53 IF (I O N O . F O . 701) I D U M M Y = 1 8 9
5«» DO 6 G J-2 t I D U M M  Y
55 R E A D  (1 6 , 2 u 0 , E R R = 1 3 0 , F N D = 1 5 D )  IP , N H V ,m A S S (J ) , I N T (J )
_ 56 JJ-J
. 57 rF < T D . V E . T D N n )  g o  T o i l
. 58 IF (M A S S <J ) .GT . 40) S I G X - S T G X + T N T  (J)
59 IF (M A S S (J ) . E G . M O L w T ) GO TO 70
6 P r F ( M & S 5 ( J ) . NF . MCI V, T ) GO TO 60
61 S T 0 °
62 6C c o n t i n u e
....... 6 3 7G L I N E S : < J J / L ? )+1
64 « R ITE (15. 21..J T r ‘;c .MOl y T . F P R V . M A V F  . SCDOCF
65 L-J
66 DO 8 .; T:l .1 T;,FS
67 I S - L + 1
68 L- 1*12
69 IF (JJ.L T . L )  L rJj
7 C W R I T E  <15.16^) ( M A S S ( K ) . I N T ( K ) . M z T S . L )
71 G
72 80 C O N T I N U E
73 GO TO 20
74 9 C DO 1 v.0 LL- 1 , iOG
75 120 R E A D  (16.2.0) I D N . N V M . M S S . I T N
76 GO TO 5 0
77 C E R R 0 R M E S S A G E S
78 11 J «RI T E  (6.?20)
79 ..RITE (6,210) l O N O . ^ O L W T , F O R M , N A M E  .SOURCE
80 «■RITE (6,230) jo
e l GO TO 2°
82 • 120 « R I T E  (6.740)
8 3 « R I T E  (6,210) 1 0 N O , M 0 L « T , F O R M , N A M F , S O U R C E  '
84 GC TO Z-’
' 85 130 « R I T E  (6,250)
86 « R ITE (6.20,0) ID . *JKV . '-'ASS ( I ) , INT ( T )
. 87 . GO TO 20 ____________
88 14 U W R I T E  (6.250)
89 W R I T E  (6,2^0) ID , N M V ,M A S S ( i ) ,I N T ( 1 )
90 GO TO 7 o
91 15C W R I T E  (6,170)
92 STOP
93 C
94 16 C F 0 R M 4 T  ( 1 2 ( 1 4 . 1 H . . I U . 1 H , I X )  )
95 17.) F O R M A T  ( ’ P R O G R A M  R F A C E D  F\0 OF Fl L F  •)
96 1 3 G F O R M A T  ( A 4 )
97 _L 9Q  F O R M A T  (16 11.4 , j X t 4 , 2 w A 4 ̂ jX , 2 A jjj______________________________
98 21.0 F O R M A T  ( ) \
99 210 F O R M A T  ( / / . T E . l X , T i , l X . 5 A 4 , ? S A 4 , l X . ? A 4 . / )
ICG 22G F O R M A T  ( ’ ID NO P R O M  C ^ E ^ l l  IS NOT E Q U A L  TO THAT FR O M  T M S C O M P S * )
... lfil____ ^30 FORmaT (« IDf.Q FR O M  C H E “ 11 = * . I 5 )
. U-.2 --Z-4G. F O R M A T  (* ¿ P ROP IN RI L l L O G I C A L  U»'I T 14 » )______________
________ 103 250 F O R M A T  (//.• F R R C R  IN C H E M i l . M
1C4 c
1L5 — END____________________________ riiaUKt L - c . Listing^! programme rKirU .■■■■-
i n c i t i  ì c , ;  c u  . M f c  . 0 F ! P C r - I  T C . \ E
?9 • 7k.' , 39. ti „ , 9 1 '* t 9 ? . 1 7 „ , “ 3. ’ 8-, 5 3. 3 1 U*
77. 19. , 7 9. 2 ! w , q 1. M T ,  b 2 . c 899, HZ. 7 ? r , 91 . 2 1L *
1 " 8. 21 U  , n - . n ' . M i n . 6 60, 121. U ' c 123. l b ' , 129. 5 6 o  1
1 P 8 5 5  H 2 C 1Î. • I* 1 6 • 0 P - ü E M H N  1(7) , iP-DIPN-i:. -PL
28 • 29i , 2 9. 9 f_, t 31. 17T, 39 . 2 5 6, 9 i. • Pc'", 9 1.2 L P v.57.117.- t fP. lrc t l • 2 9 r , 6 6 . 6 2 c 6 7.3 7 3 f' , 6 5.125c-
79. V99C f bP. 2 5 81. lier, c ? • Z3w, 93. 62'" , fe9.183199.22 2'" , 85.15' Li 9b. 927 , 97. 1 b 2 , ir3. ?';r. 1 L 9 . 2 2 c-
111. 12' , 
191,. 1 r.r ,
117. 2 c-.., 
112. I'1,,
Ilf. 13 7, 119. 5 6 6 1 , 1 2 c  8 3 c 1 2 1 . ic:«
1 0 9 5 6  1 L 2 C U U  HI 6 . 0 CAKPH02.
39. 7 1 ' , 9 ? .  2 6 7 , 9 3. 9 7 •' t 5 5. l97 o , 56. 117, 57. 11 L
8 1 . 7 6 3 c 8 2 . 1 9 7 u. 8 3.289-', L 9 . 2 6 1, 91. 1 3 r f 93. 11 8 L
I P 9 . 3 1 6 1 , 1 1 7 . 1 9 2 , , 111. 21 ° ,  119. 1 lo, 123. 16' , 129. 1 6 u
1 C 9 5 7  152 C 1 L . H 1 6 . 0 FENCKOf.r
29. 5 8 ' ,  
66. 16 r , 
8 2 . 9  C 9 2 , 
1 5 2 . 1 6 9 T,
39. 38',, 
6 7 . 2 5 5 „ ,  
81 . 19 o ,
9- . 171" ,
6 8.2! 9 ! <, 
o v or*7 w • £. s/ '• f
9 1 , 6 3 b c  
6 9 . 9 9 8 9 ,  
8 5. 9 7 L ,
92. 9 1 r , 
7u. 191T-, 
96. 150,
9 3.127c! 
7 2 . 1 0 9 G  
97. 13c
1 "9 5 6 1 5 2 Cli . H 16 • 0 K Y R T t N O l
29. 16 ', 31. 9 3u * 3 2. 7 6 !J, 91 . 9 1 c “ 2. 19'*, 55• 9 90
69. 9 3;*, 7''. lfl,, 79. 1 9 P » 77. 9 1 , 7b. 35", 7 9 . 9 9 9 9
9 2 . 1 2  v**, 5 3 . 1 9 “ .., 99. 3 5 7 , 95. 9 7 o , 96. 77H, 97. 1 0 0
111 . 196 , 1 1 7 .  1 ? o , 1 1 9 . 1 5 9 P , 127. 2 r.! «j, 121 . 8 8 r , 122. 1 9 6
111 . 1 2 r ,
FIGURE C-3. Output from programme PRINT.
K.SC 6 9 9  R
S4. 22i T, 55. 69 0 , 67. 7 8 1 , C* CO • l l ü , 69. 4 4 0 , 7 0 .  1 1 0 ,
93. 21 f>, 94. ICC, 9 5 . 3 3 6 0 , 96. 2 8 ü  , 1P7. 130, 1 0 6 .  16 0 1
137 . 2 6 L Ü , 1 3 8 .  21 c, 1 5 2 . 1 ? 4 L ,
K S C 7 L 0 R
U 2 • 25 0 , 4 3 . 1 7 5 0 , 53. 6 7 0 , 54. 3 5 ü , 55. 2 1 7 0 , 5 6 .  6 2 0 ,
69. 5 9 C , 70. 3 U 0, 71. 18 0 , 75. 1 9 U , 77. 1 6 7 0 , 7 8 . 1 2 5 L ,
St. 17H, 89. 230, 9r. 4 6 0  , 91 . 6 2 5 0  , 92. 7 2 5 0 , 9 3 . 9 9 9 9 ,
IPS. 4 3 30 , 1 C 6 . 6 2 5 U , 107. 9 2 0 , 118. 4 2 0 , 1P 9 • uro, H O .  17 C ,
122. 17C, 12 3 .  390, 133 .  340, 134. 1 8 3 0 , 135. 2 30, 1 3 7 .  1 2 0 ,
M S C 7 C 1 R
67. 1 0 3 0 , 6 8 . 1 5 3 C , 6 9 . 3 6 8 0 , 70. 32 o , 79. 180, 8 0 . 1 8 2 0 ,
9 U • 18P, 9 5 . 9 9 9 9 , 9 6 . i r e r , 97. 740, 107. 160, 1 0 8 . 6 0 5 0 ,
13 7 . 55 0, 1 3 8 .  11C, 1 5 2 . 3 6 6 C ,
M SC 7 0 3 R
53. 1T9ÏÏ, 54. 24 0, 5 5 . 1 U 5 G , 56. 2 5 Ü , 57. ?L0, 6 5 .  2 1 0 ,
76. 3 U 0, 77. 36 C, 76. 17C, 79. 1 3 6 0 , 8 0. 6 09 0 , 8 1 . 9 9 9 9 ,
1 P 7 * 160, 1 c8 . lfc, 1 C 9 . 2 3 6 P , n e . 2 8 0 , 123. 180, 1 3 7 .  6 8 0 ,
K S C 7 T 4 P
56. 2cn, 57 . 120, 5 9 .  4 3 0 , 66 . 180, 67. 7 8 0 , 68. 29f ,
8 L • 92 0 , 61 . 69 0, 82. 310, 83. 2 6 G , 85. 26 0 , 9 1 . 3 5 3 0 ,
* 8 . 1 GO , 1 U 5 .  690, 106. 5 1 0 , 117. 1 1 6 0 , 1C 8 •3 7 2 C , 1 0 9  . lcCl ,
12 3. 180, 1 3 3 .  120, 1 3 4 .  24 0 , 135. 2 0 0 , 137. 1 20, 1 5 2 .  2 4 L ,
6£ 228 C 1 2 . H i e . 0 7 . S I 3 - K r T H O X Y P H r N ' Y L *  C E T I C  A C I P - M O N O T M S O A M 68
69 958 C 1 9 . H 3 S . 0 5 . S I 9 3 , 9 , b - T P I H Y 0 0 X Y n C N 2 0 I C  A C I D - T E T R A T K S O A M 69
71 2 66 C12 . H 2 2 . G 9 .$12 T , T - 8 ' J C C M C  A C I D - D I T M 5 O A M 70
71 3 11 C 1 5 . H 2 b . 0 3 . S I 2 3 - H Y n R O X Y P H E ^ Y L P h O P I O M C  A C I G - D I T M S O A M 71
72 37i C 1 6 . H 3  . . U 9 . S I 3 2 , 9 - D l H Y D P 0 X Y B E K ,2 0IC A C I D - T P I T M S O A M 72
73 3 9 v. C l f c . H 2 6 . 0 9 . S I 2 V A M L L Y L P » O P I O t . I C  A C I P - D I T y S O A M 73
79 21 L C 8 . H 1 2 . C 2 . S . S 1 2 - T H E K O T C  A C I 0 - M C N 0 T M 5 O A M 79
75 2 ? i. C 1 2 . H 1 6 . 0 2 . S I ci?;NAMir A C l D - f P N O T M s OAM 75
76 326 C15.K2fc . 0 9 . S l 2 ¿ - m F T H O Y Y K A N G E l TC A C i r - D I T K S  . OAM 76
77 3 1 ( CIS. H 2 6 . 0 2 . S12 M-h V f  P u X Y P H r M Y L P H O P I O M C  h i d - o i t m s OAM 77
7ft 3 36 Clfc. h 2 6 . 0 9 . S I 2 F E R U L I C  A C I D - O I T K S OAM 78
79 166 C 9 . H 1 9.0 . S I P H E N O L - ^ O N O T h s 0 A * 79
Si 276 Cl 1 . H 2 9 . 0 9 . S I 2 E T H Y L f A L C M C  A C I D “ D I T M S O A M 60
61 2' 6 C12.r-.32.02.S13 b L Y C F P I N - T R I T K S O A M 81
s: 229 Cll . K 1 6 . 0 Z . S I v A N I L L  I*:-MO\OThS O A M 82
23 972 cr, ,H9:. . o r ,si9 3 , 9 - D I H Y D R O X Y m a n o EL I C  A C I C - T E  TRA TMS OA * 83
39 2 19 C19 . H U 2 . 0 . S I i - h e x a l i f c a n c l - m o ?«o t k s . O A M b 9
35 276 Cl 1 . H 2 9 . 0 9  .S12 O I M . E T H Y L M A L O U I C  A C I D - O I T M S  - 0 A M 85
£6 199 C 1 C . K 1 9 . 0 2 . S I 9 - H Y C R 0 X Y 3 L N Z A L n L H Y D E - M 0 N 0 T K S O A M 86
67 3 36 Cl 2. h2 6 . 0 5 . S I 3 H Y D P C X Y ,,A L O N I C  A C I D - T p ITHS O A M 87
86 9 r 8 C l S . H3fc.05.Sl9 H Y C R O X W A L O N I C  A C I D - T r T P A T K S 0 A v 86
89 286 C 1 2 . H 2 2 . 0 9 . S I 2 K O J I C  A C I O - D I T h S 0 A * £9
9 L 3! 8 CIS. H 2 9 . 0 3 . SI 2 2 - C O D Y A D I C  A C I O - U l T  M S O A M 90
91 389 C 2 3 . H 9 8 . 0 2 . S I A R A C H I O T C  A C I D - h O N O T H S OA M 91
92 266 C 1 3 . H 1 8 . 0 9 . S I P H T H A L I C  AC I D  M P N O T M S - M O N O E T H Y L  E S T E R C A M 92
93 32 6 C15.Hicfc.09.SIi.’ 5 - M E T H O X Y M A N D E L I C  A C I P - D I T M S OA M 93
99 28 1 C13.H23....0: .SI? S A L I C Y L  a m i o f - P I T k S OA M 99
95 298 C 1 3 . h l 6 . 0 3 . S I hi" 3 C Y L A C R  YLIC i C I D - M P N O T M S O A M 95
9 6 2 ‘' 9 Cl'-.. HI 5. .',.02.51 A C T H P i M L l C  AC I D - M 0 K 0 7 MS C A M 96
97 2? 1 C 1 3 . H 2 3 . U . 0 2 . S I ? ANTHPA:-, TLIC A C I P - D I T M S 0 A M 97
9 c 262 C l l . H 2 6 . 0 3 . SI 2 2 - M E T H Y L - 3 - H Y 0 P C X Y D U T Y f t I C  A C I D - D I T M S OA M 98
99 276 Cli. • r- 2 c . 6 * .Sli. i , 2 - L l H F T H Y L - 3 - u Y D R O X Y B u T Y R I C  A C I P - D I T M S OAM 99
111 285 c i 9 . H i 5 . ' ; . o ? . s i ? 9 - A C E T Y L A ^ I ’,’0Phr.\0L-DITMS OAH U C
FIGURE C-4. A part of TMSCOMPS generated by the CTS text editor on the Univac 1106 for preparation 
of the sublibrary of silicon containing compounds. .
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FIGURE C-5. Flowchart for programme BIG15.
1 C P R O G R A M  b I G 1 5  ' " ' - -----------------
2 C THIS P R 0 3 P A U 1^ D C S I G N l P TU USL TOW INPUT F I L E S ? -
_3________ C___  A PILL' (UNIT l « O W H I C H  C O N T A I N S t h e  I D E N T I F I C A T I O N  N U M g £ P t T H F HOLECUA-fl< .
H C w E I o N i ,  THt F O R M  uL A ANu THE NAME OF THE C O M P O U N D  EG Q U A D NO V A * T MS C 0 MPS
5 ______C _ J _______________ '
6 ______C 2 A F I L e C U M T  1 o ) W H I C H  C O N T A I N S  THE I D E N T I F I C A T I O N  N U M B E R , T H E  N U M E E R  Q  F
7 C M A S S  V A L U E S , T H E  MA S S  AND THE I T E N S I T Y  OF THE M A S S  S P E C T R A L  PEAK EG M H  /*1rfSS
8 C S P F C P A L  F I L E  O u A D N C V A * C H L v ll '
9 C THF I N T E N S I T Y  V A L U E S  APE READ I N T O  AN A R R A Y  OF I N T E N S I T 1ES IOC T  L O N G
10 C W H I C H  THE P O S I T I O N  IN T h e  A R RAY I N D I C A T E S  THE M A S S  OF THAT PEAK C A PizA^ O F
11 C MASS 2 H 5 AND I N T E N S I T Y  999 W O U L D  BE IN P O S I T I O N  I N T 1 2 R 5 )
12 c V A R I A B L E S  U S E D
13 c 6 J U N K  t RUP.BISH IN F I R S T  u L I N E S  C H E M 1 1
1H c B I D N C  r I D E N T I F I C A T I O N  NO P E A D  F P O v U N I T  1H I E . T M S C O M P O U N D S
15 c C M 0 L w T : M O L E C U L A R  W E I G H T  R E A D  F R O M  UNT -1H •
16 c O F O r x M  = F O R M U L A  REA D  FROM U N I T  1H ' —
17 c E NA M E  r n a m e  OF C O M P O U N D  RF A D  F R O M  U N I T  1H
IS c F S O U R C E -  R E F E R E N C E  TO F I N u  FU L L  S P E C T R U M  . ,
19 c G ID — I D E N T I F I C A T I O N  NO P E A D  F p 0 * U N I T  16
2D c H N M y r N U M B E R  CF »AS S  VALL'clS R E A D  F R O M  UN I T  16
21 c I M A S S  r M A S S  VALUE OF M A S S - i N T  P A I R - R E A D  F R O M  U N I T  16
22 c J I N T E N r  I N T E N S I T Y  U S E D  WH E N  C H E C K I N G  IDNC1 - R E A D  F R O M  UN I T  It
23 c K D R O M r  D R O M E Y  IND E X  C A L C U L A T E D  If S U B R O U T I N E  . . •
2H c -K 1 ""
25 c
26 D I M E N S I O N  IN T (2 0 L C ) , M B I G 1 5 < 3 U ) ,  J U N K ( 1 2 C ) ,  F 0 R m (5) .
27 D I M E N S I O N  N A M E (2D), S 0 U R C E ( 2 )  i
28 c THE F I R S T  6 L I N E S  OF C H E M 1 1 1  ARE F I L L E D  W I T H  J U N k AND ARt R E A D  IN AND
29 DC U  I t 1,6
3C ID R E A D  ( 1 6 , 1 6 0 )  JUNK - .
31 c C L E A R  THE I N T E N S I T Y  ARR A Y
32 2C DO 3o I = 1 , 2 0 U U
33 3 0 IN T (1 ) T j
3H c R E A D  F R O M  L I S T  OF C O M P O U N D S  I D N O ,M O L W T  , F O R M ,N A M t .S O U R C E
35 R E A D  ( 1 H , 19P , E R R = 1 2 r »E N 0 = 1 S O ) I D N O  , M O L w T  , F O R M ,NA M E ,S O U R C E
. . 36 c RE A D  D O W N  C H E M 11 TO FI N D  THE S T A R T  OF THE I N F O R M A T I O N  FOP THE R E O U I P
37_____________ HP R E A P  < 1 6 ,2uC ,EKR: 1 H O , END = l 3 r ) I D , N M V , M A S S , I N T E N
38 IF ( I D . E G . I D N O )  GO TO 50
39 GO TO Hi-
HC C TH IS S E C T I O N  S O R T S  OUT T h E E R R O R S  IN C H E M 1 I
HI 50 IF ( I D N 0 . E 3 . ¿97> GO TO 9u
H 2 IF ( I O N C . E O . i l G H )  GO Tu 90
H 3 IF ( I D N 0 . c C . i l l 3 )  GC TO 93
HH IF (I D N O . E O . H 7 3  ) Gu TO 90
H 5 IF (I D N O . E O .  3933 ) M 0 L w T = 1 1 5 6
H 6 IF (I D N O . E O .  6751) M 0 L W T - 1 6 7 H
H7 60 I D U M M Y - N M V
H 8 I N T ( M A S S ) - I N T E N
H 9 IF (I D N O . E Q . 351) I D U M M Y = H 6
5C IF ( I D N 0 . E 3 . i 5 H )  I D U M M Y - 3 3
51 T Ë  ( IDNO.EQ» 353 ) Iü UMm.Y = 67 ' — — — -52 IF ( IDNO. EQ . b97 ) I D U M K Y r 1 51 ' ...... ' .... '53 IF (IDNO.Ea.696) 10 UMmY = 127 .
5** IF ( IûNC.Eü. 699 ) Iü UMMY-73 ' .. .
55 Ir ( 1 DfsO . E 0 • 70L ) lDUKMY-189 '
56
57 ____
DC 7^ J-2 ,ID U M M Y
k EAD ( 16,2_-),tPR = l 3'0,END = 15G) 10 , NM V , M A SS , IN T ( M A S S ) ' '58 IF (IO.Nt.IDNO) GO TO llu . " '' ‘
59 IF ( MASS .Ew.MOL.vT ) GO TO 80 ........... .....
60 IF ( MASS .NE.MOLWT ) GO TO 7u ' ' ----6 1 S T 0 ° ...- ■
62 7 G CONTINUE —  - -----— — -------------------------------------
6 3 30 CALL 3 IG (MOLWT,I\T,M3IG15) " " "" ........
6** wRITt ( 1 7 » 21 u. ) I L N ü , M 0 L'W T , F 0 R M , N A M E , S 0 U R C E ' '
6 5 WRITE (17,16.. ) -5 IG 15 .... ""
66 GO TO 2° ' ' " '
6 7 90 DO 1 -j u L-ljluU
6 8 100 RE AD ( 16,2uG) I DG,NVMrMS S,ITN ...
69 GO TO 6C ........  -
7 ü C ERROR MESSAGES •
7 1 11 G «RITE (6,220)
72 " R I T c. (6,21'’) IDNO,MOLWT,FOPM,NAMF,SOURCE ....... .
7 3 W R I T E  (6,230) 10 .. ........
74 3 0 TO 2 0 . . . .  ..
75 12C w P ITE ( 6,240 ) ' — ' — - -------- - --------------
7 6 «RITE (6,210) IDNO , MOLwT,FûPM,NAMF,SOURCE "
77 GO To 2r’ " ..
78 13C w P I T E ( 6 ,2 5 0 ) —
7 9 « P I T t ( 6,1 9 C ) I D , N M V , M A S S , IN T ( « A S S ) --
8Q GO TO 2 < ' ' "" - ---
81 1 4 U wPITE (6,250)
82 «RITE (6,190) ID , NMV , MASS , IN TEN " . ~
8 3 JÜ 1 Ü 4 Îj
84 150 «RITE (6,170) "
8 5 STOP .. "
8 6 C
a i  16U r O R M A I  (/,15(ZX , I3 , IH. , 12 ) ) — ------------------------------ — ---------------------------
68 1 7Q F Or?« A T T1 PROGRAM RFACED END OF FILE ~ ) “ --------------------------------------- --------- - -- — —
BV 180 F O R M A T  ( 2 ü A  4 )
90 1 9 G r C R M A T ( 16, IX,13, 1X,5A4,2 0A4,1X , 2 A 4 )
9 1 ' ¿ C w F C R M A T ( ) _
92 Z 1G FORMAT (///,I6,1X,:3,1X,5A4,20A4,1X,2A4)
9 3 c 2 u FORMAT (’ i 0 NO FROM C H EM11 IS NOT E 0 U A L TO THAT FROM TMSCOMPSM
94 Z 3 o FORMAT (’ IDNO FROM CHEM11 = ’,15) '
. 95 Z 4 G FORMAT (’ E R B O R I H FILE LOGICAL UNIT 1 4 » )  ... ... ' ,
96 25Ü FORMAT (//,’ E R R O P T N C H E M i l . ’) "  .......... '
9 7 C
98 END
FIGURE C-6 Listing of programme BIG15
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FIGURE C-7,Flowchart for subroutine BIG
1 S U B R O U T I N E  B I G (M O L W T ,I N T ,M 6 I G 15)
2 D I M E N S I O N  I N T ( 2 0 0 0 ) , M 3 I G 1 5 ( 3 U ) , M I N ' T ( 1 5 ) , M A X M A S ( 1 S )
3 DO 20 1 = 1 , 1 5
4 M I N T ( I )  = I N T (31)
5 M A X M A S ( I )  =31
6 DO 1U J = 3 2 , M O L W T
7 IF ( I N T ( J ) . L E . M I N T ( I ) ) G 0  TO 10
8 M I N T ( I )  = IN T ( J )
9 M A X M A S C )  = J
10 10 C O N T I N U E
11 N'JM= M A X M A S ( I )
12 IN T ( N U M ) = G
13 20 C O N T I N U E
1«» 00 53 L = 1,15
15 C SET A L I M I T  ON T H E  p A S S  T H R O U G H  THE O A T A
16 J J - 1 d -L
17 C SET A F L A G  TO I N D I C A T E  NO E X C H A N G E S  H A V E  O C C U R R E D
18 M A R K E D
19 00 99 K = 1 , J J
20 K P 1 3 K + 1
21 IF {M A X M A S ( K ) . G E . M A X M A S t K P l ) )G0 TO 99
22 c E X C H A N G E  t h e  T w o  M A S S  a n d  i n t e n s i t y  a r r a y s  a n o  s e t  f l a g
23 J E X C H - M A X M A S ( K P 1 ) *
24 J E X C H 1 = M I N T (KP1 ) -
25 M A X M A S ( K P 1 ) = M A X * A S ( K >
26 M I N T (K P 1 ) = M I N T ( K )
27 M A X M A S (K ) = J E X C H
28 M I N T (K )r j E X C H l
29 MARK z 1
30 99 C O N T I N U E
31 C T E S T  TO SEE IF A N Y  E X C H A N G E S  H A V E  T A K E N  P L A C E
32 I F (M A R K , E 0 .0 ) GO TO 30
33 50 C O N T I N U E
34 30 C O N T I N U E
35 DO 4 u M = l, 15
36 N = 2 * M - 1
37 N N = 2 * M  ’
38 M 9 I G  15 (N ) =M-AXMAS <M ) .
39 40 M 8 I G 1 5 < N N » = M I M T ( M ) / 1 0 0
40 R E T U R N
41 E N D
FIGURE C-8. Listing of subroutine BIG.
7 273 C11.H23.N.03.SI2 PYROGLUTAMIC ACID-DITMS
258* 6 230. 6 221. 3 158. 4 157.13 156.99 147.15 75.10
8 201 C9.H19.N.02.SI PIPECOLIC ACIO-MONOTMS
186. 3 156. 2 103. 3 85. 6 84.99 82. 2 75. 9 73. 6
9 311 C15.H29.N.02.SI2 3-METHQXYTYRAMINE-OITMS 
296. 3 210. 3 2Q9• 2 180. 2 179. 3 104. 4 103.10 102.99
10 319 C12.H25.N.05.SI2 METHYLMALONYLGLYCINE-DITMS 
304.12 260. 7 158.31 147.13 102.10 86. 6 75.36 74. 9
11 132 C5.H12.02.SI ACETIC ACIO-MONOTMS
119. 1 118. 4 117.42 77. 4 76. 7 75.99 74. 3 73.13
12 303 C13.H29.N.03.SI2 N-VALERYLGLYCINE-OITMS 
288.16 261.16 186.28 176.17 171.13 147.16 102.73 100.10
13 313 C13.H23 .N.04.SI2 N-FUROYLGLYCINE-DITMS 
298. 8 296.10 270. 7 226. b 197.12 196.60 169. 6 147.22
FIGURE C-9. Output from programme BIG15
OAM 7
7*1 • 7 73.82 59. 5 58. 3 95.17 99. 9 *»3. 7
0AM 8
56. 9 55. 5 97. 2 95. 9 99. 3 93. 2 91. 2
0AM 9
75. 3 79. 9 73.96 59. 5 58. 1 95. 6 93. 2
0AM IQ
73.99 59. 6 56.10 55. 6 97. 6 95.19 93. 6
0AM 11
61. 5 59. 3 97. 5 95.16 99. 1 93.13 92. 2
0AM 12
85.11 75.25 79. 9 73.99 57.19 95.20 91.13
0AM 13
95.98 81.10 75.20 79. 9 73.99 95.19 39.10
228
229
A
2
2
OO
FIGURE C-10. Flowchart for programme FILESORT.
1 C O M P I L E 1? ( X * z 2 )
2 C PPC'GRAM F I L E S O P T
3 C THI S P R O G R A M  TREATS F I L E S  C R E A T E D  BY P R O G R A M  S O R T  AND S O P T S  THE
4 C C O M P O U N D S  INTO A S C E N D I N G  M O L E C U L A R  W E I G H T
5 C THE P R O G R A M  TH E N  R E W R I T E S  THE F I L E S  IN O R D E R  OF I N C R E A S I N G  M O L E C U L A R
6 C WEI GHT
7 C t h e F I L L  10 BE SORT E D  IS A S S I G N E D  TO FI L E  14 AND IS D E C L A R E D  A
8 C R A N D O M  A C C E S S  FILE
9 c THE ID N 0 AND M O L E C U L A R  W E I G H T  ARE R E A P  IN T O  2 A R R A Y S  AND T h E
1C c MOLE C U L A R  W E I G H T  S O R T E D  BY A M O N K E Y  SORT - SEE U A Y , A.C., F C'P TR A N
11 c T C C H N l O U t S  - C A M B R I D G E  UNIV P R E S S  1 9 7 2  - 0 0 1 . 6 4 2 4 / 3 2  P o 0
12 c THE D E F I N E  FILE S T A T E m ENT C O N T A I N S  4 F I E L D S
13 c A r THE N U M B E R  OF P E C O R D S  IN THE F I L F  - I N  THIS CASE THE N U M B E R  OF LIN
1«* c B = N U M B E R  OF C H A R A C T E R S  PER R E C O R D
15 c C = A L E T T E R  D E F I N I N G  THE TYPE OF R E C O R D  -F M E A N S  F O R M A T T E D  C H A R A C T E R S  ■
16 c D = AN I N T E G E R  V A R I A B L E  W H I C H  D E F I N F S  A LINE AFT E R  IT IS R E A D
17 c IL P A N D  IRE ARE V E C T O R S  W H I C H  D E F I N F  THE S O R T E D  ARRAY.
18 D E F I N E  FI L E  1 4 { 1 5 D u d  , 1 3 2 , F ,IPT )
19 D I M E N S I O N  LIN E (3 3)» F O R U M S ) ,  N A “ E ( 2 0 ) ,  S 0 U R C E ( 2 ) ,  C 0 P Y ( 3 3 )
2 0 C O M M O N  M A S S  ( ¿Ou.'C ), IDNO ( 2ou.rL, ), ILF (2 0 CuD ), I R5 ( 20000)
21 DO 10 M : 1 L 0 L G E u .
22 R E A D  ( 1 3 , 2 u L , E N D  = 2liJ CO P Y
23 2 G W R I T E  < 1 4 * M . 2 U L )  COPY
24 2 U N C C O M P - ^ / G
25 w P I T E  ( 3 4 ' M , 2 i* c ) COPY
26 UO 3c N:l, N O C O m P
27 IX - 4 + ( N - i )*6
28 3 C R E A D  ( 1 4 ' I X , 2 6 0 , E P R - i 8 D , E N D - 4 C )  I D N C ( N ) , M A S S ( N )
29 4L N C O M P r N
30 W P I T E  ( 6 ,210) N
31 c SET THE P O I N T E R S  TO ZERO
32 . I L B ( 1 ) - D
33 I P B (I )-0 .
34 CTPiE F O L L O W I N G  L O O P  MUST BE DO N E  FOR E A C H  R E C O R D .
• 35 DO 9 a I = 2 , N C 0 M P  ~~
36 I L b ( I ) - 0
37 ■ I R d ( I ) - G ■ .
38 J = i
39 5U IF ( M A S S ( I  ) . G T . M A S S < J )  ) GO TO 70
4 0 IF ( ILb(J) . E 0.0) GO TO 60
<il J - I L B ( J )
«♦2 GO TO 50
43 6Ü I R d < I )=-J
44 I L B ( J ) - I
45 GO TO 9c
*♦6 70 IF ( I R 6 ( J ) .LE.C) GO TO 8u ---- --------------
47 J- I R E (J )
^8____________  G O T O  5L. ______________• ~ -...................................89 80 IRB( I ) = I R B (  J )  ........ .......
SO 1Pq (J) = I .....
5Ì 9Ü CONTINUE — — —
52' c THE f ó l l g m ng s t a t e m e n t s  r e a d the i t e m s AK'D w r i t e Them i n T'cT'a n E'w FILE!5 3 j r  1
54 ______________GO TO 1 lu '
55 ___  iüC J- ILB ( J )
56__ H U  IF ( I L a ( J ) .GT.o) GO TO 1LC
57 120 JP T - 4 ■* ( J-l ) *6
58 H E A D  ( 1 4 * J P T , 2 3 0 )  I D N ,M O L W T ,F O R M ,N A M E ,S O U R C E
5 9 IF ( I D N . n E • I 0 N 0 ( J ) ) GO TO 19 <j
6H 130 ¿ R I T E  ( 1 6 » 2 4 o ) I C N , * C L - J T , F O R M , N A M E , S O U R C E
61 K l - J P T  *1
5 ? ' K I J - J P  T + 4
63 DO 14 0 L-K 1 i K 11,
64 R E A D  ( 14 • L » 2 5 u ) LINE
65 14 0 « R I T E  ( 1 6 , 1 5 G ) LINE
6 6 IF ( I D 3 ( 0 ) ) 1 6 0 , 1 7 G , 1 5 O
67 I5D J - I R d (J )
68 GO TO 110
69 16 C J = - I R 8 ( J )
70 GO TO 1 2 U •
71 1 7 U ST O P
72 18 C ¿ R I T E  (6,27(1)
73 ' * R I T E (6,22 0) N ,I X
74 STOP
. 75 190 « R I T E  (6,230)
76 GO TO 130 ■
77 C
78 2 DO F O R M A T  ( 3 3 A 4)
79 ¿10 F O R M A T  ( ’ NO OF C O M P O U N D S  IN FI L E  = *,112)
80 ¿20 F O R M A T  (* C O M P O U N D  NO = *, 1 1 0 , *  LIN E  N U M B E R  =* , 1 1 2 )
81 23 0 F O R M A T  ( 16 , 14, 5A4 , ¿f*A4 , IX , ZA4 ) •
32 ¿40 F O R M A T  (//, I 0 , I 4,5 A 4 , 2 uA 4 , 1 X ,2 A 4)
83 250 F O R M A T  (33A4)
84 ¿6 0 F O R M A T  (16, I 4)
85 ¿70 F O R M A T  (* c P R O R  IN P E A D I N G  IN M A S S  A\D IONO ’ )
86 2 8 U F O R M A T  (* E R R O R -  1ÙN0 NOT t O O A L  TO ION*) '
87 C
88 END
FIGURE C-ll. Listing of programme FiLESORT
379 268 C13.H20.0A.SI *-METHOXY- 3-HYDROXYPHENYLACETIC ACID-MET HYL ESI ER—M ONOTMS MGH 531
26 8» 83 25*1. 7 253.38 2*0. 6 239.18 238.99 210.13 209. 76 153. 6 180.1* 179.9* 1*9.16 73.36 59.11 *5.10
353 268 C13.H2G.0 *.SI HOMOV ANILLIC ACID-METHYL ESTER-MONOTMS ETHER MCH 505
268.*6 253.35 239.1«T 238.92 210.10 209.73 193. G 180.13 179.99 1*9.21 89. 9 77. 6 75. 7 7*. 6 73.83
**5 269 C8.H2A.N.03.SI2.P 1-AMINOETHYLPHOSPHONIC ACID-OITMS ESTER ....  -- MGH 597
269. 5 226.19 213. * 212. 9 211.5* 195.15 1*9. * 1*7. 9 135.15 133. 9 75.11 73.27 *5.13 **.99 *2. *
360
270.
27C C17.H3A.02 
6 1*3. 6 83. 3
PALMITIC ACID-METHYL ESTER 
87.35 83. 3 75.13 7*.99 71. 3 69. 6 59. 3 58. 6 57. 8 55.12
MGH 512 
*3.16 *1.12
213 272 C15.H32.02.SI 
258.10 257.51 1*5.16
L AURIC ACID- MO NOT MS 
132.39 129.25 117.51 1C*.13 75.82 7*.11 73.99 5 7. 9 55.2* *5.12
8FS 363 
43.*2 *1.35
166
258.
273 C11.H23.N.03. 
6 230. 8 158. <t
SI2 PYROGLUTAMIC ACID-DITMS 
157.1* 156.99 1*8. 2 1*7.19 75. 9 7*. 7 73.78 59. 3 58. 2 *5.12.
3FS 316 
**• 3 *3. 3
153
230.
273 C12.H27.N.02. 
* 168. 3 158. *
SI2 CYCLOLEUCINE-DITMS
157.15 156.99 1*7. 8 8*. 5 75. 7 74. 6 73.58 59. 5 *5.11 **• 2
BFS 308 
*3. 2 41. 2
FIGURE C-12. Output fom programme FIIESORÏ
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FIGURE C-13. Flowchart for programme MFTABLE.
„1________ C P R O G R A M  MF T A B L t __________________________________________________________
_2________£______P--RT.GR A m TO S C - T  P I G  15 S P E C T R A  OF M A S S  S P E C T R A  AND 
.3________C______EJ1ÜÜU CL A T A B L E  OF M A S S E S . T h F F R E Q U E N C Y  CF E A C H  PASS.
_«J_________C A NO A I IST GP S P E C T R A  W H I C H  C O N T A I N  THT PE A K ____________
_5_________C THF P R O D U C E S  Two D I R E C T  t Ç r Ç S S  F I L E S  -_________
J6________ C_______ I A F l L F  A T T A C H E D  TP L O G I C A L  UNIT 1« W H I C H  C O N T A INS
7 C THE. m a S S . T h p FRFOI'FNTY OF THAT M A S S . A N D  T U E I D U M B E R
8 c OF THE S P E C T R A  C O N T A I N I N G  THE P^ A* AS »FLL AS THE P O S I T I O N
9 r O r THE S P E C T R U M  IN A N O T H F R  D I R E C T  A C C E S S  F I L R  __ '
10 c
11 c 2 A F I L E  A T T A C H E D  TO L O G I C A L  U N T T  15 W H I C H  C O N T A I N S
12 c THE I O N O t F R O m C H  E M11 « a n d . O N r B A S E D  ON M O L E C U L A R  » E I G H T  )___________________
13 c THt- MO! FCll! AR W E I G H T . T h F F ü P m U I A . T h F N A ^ E . T H E  S O U R C E  OF
19 c THE S P E C T P U “ AND TUF B I G F S T  15 P E A K S  T O C E T H E R  W I T H  T H E I R
15 c I N T E N S I T Y
3 6 c
17 c
18 c THE P R O G R A M AL S O  P R O D U C E S  A  P R I N T O U T  OF THE e i G 1 5  S P E C T R A
19 c w h i c h  a r f  IN THE SAMT O R D E R  AS T h e  I N P U T  S P E C T R A  BUT » M I C H  ‘
2C c HA VE THE IDNIIMRER C H A N G E D  TO THAT C A L C U L A T E D  F R 0 M M O L E C U L A R
21 c W E I G H T  T I M E S 1 n p, *A N U M B E R  TO U N I O E L Y  I D E N T I F Y  E A C H  S P E C T P U M
22 c
23 c
29 c V A R I A B L E S  U S E u *"
25 c
26 c
27 c 1 I D N C  = I D E N T I F I C A T I O N  N U M B E R  F R O M  NTH F I L E _________________________________________________________
28 c 2 M O L w T  r M O L E C U L A R  W E I G H T
29 c 3 F O R M  = F O R M U L A
3D c 9 N A M E  = N A M E
31 c 5 S O U R C E  r S O U R C E  CF S P E C T R U M  IM 0 P I G O N A 1__COLLECTION_______________ :___
32 c 6 M A S S  = M A S S  OF PEA K
33 c 7 I NT - I N T E N S I T Y  OF PEAK
39 c 8 M w T F P  = M O L E C U L A R  W E I G H T  F P E O U E N C Y  - N O  OF C O M P O U N D S
35 c W I T H  M O L F C U L A R  » E I G H T  M
36 c 9 I P K F P  = F R E C U E N C Y  OF A G I V E N  P E A K  M A S S  M
37 c in ICOUN'T = P O S I T I O N  OF I D E N T I F I C A T I O N  N U M P F R S  IN A R R A Y
38 c
39 c
90 D I M E N S I O N  MW TF R ( 1 Uu n ) « M A S S C 1 5 ) ,  T N T (15 ) . I P F R ( l ü O o )
91 D I M E N S I O N  N A M E (2 E ) . S C U R C E < 2 ) ,  F 0 P M ( 5 )
92_________________ D E F I N E  F I L E  i5(lfrr.^r,78«VtlJK), l«4(3Lrc.,132tVtIJKL)
.4.3_________________ D I M E N S I O N  L I S T I 1 3 2 ) .  L I S T 1 U 3 2 ) .  I S P T R ( 1 3 2 ) »  M F ( 2 H )
99 D A T A  IP F R  /lGul:*E/ ,m w TFR /l^C u*C/
95 C
96 I C O U N T = R9JL
98
Vi
Z
N S P E C - 1 2 G
_ 5 C _____________10 RE AD C 1?, 1 6 n . E N D  = 5'J.ERR=5D) I D N O .^ O L k T ,F O R M .N A * E .SOUR C E
...51________________ REAP ( 1 2 . 1 7 P . C N D  = 5J) (MfiS S ( I 3 ) , I N T ( I 3 ) .13= 1 . 1 5 )___________
52 ______________ I F ' ( t t O L W T . G T . l C P L ) M 0 L w T - 9 9 9 ______________________________________
53 ________________ IF ( M O L W T . L T . 3c) * 0 L WT = 3C'_______________________________________
SM________ C _________________________________ _̂______ ;_________________________________________
55 ~  C TO CALCULATE: TH£ INDEX N U m BLP
56 ______C ____________________________________________________________ ___________________
57 ________________ MN Q-ttQLWT» iiIl c  + M W T F P  ( M O L W T  )
_J\S_______ C _______________________________________________________
59 ______C apO 1 TO M O L E C U L A R  ¿ F I G H T  F R E Q U E N C Y  TA^LE_____________________
60 _______C______________________ _ _____________________________________ _____________________
6 1________________ t t W T F R ( M O L W T ) = M W T F R ( M G L * T ) + l ____________________________________
62_________ C_______________________________ __________________________________________________
__6J_________ C SET THE C O U N T E R ____________ _____________________________________________
6 *♦_________ C________________________________ ___
_  6 5_______  I C Q U N T - I C O U N T + 1
_  66_________ £___________________________________________________________________________________
__6 7 _________C________ __________________________________________________________________________
68 ______________ u 0 « u 1 = 1,15_______________________________________________ .____________
69 ______ _£___________________________________________________________________________________
__L0_________ £____ StT THE C O U N T E R S  TO THE p £ L L V A N T  MOSS___________________________
71 _________________ IF (ttASS(I ) , S E .999) M A S S ( I ) = 9 9 9 _______________________________
72 _________________ IF ( SS ( T ) . LE . 3 1 ) GO TO u ̂ ___________________________________
73 ___________________ K C N = tt a S S ( I )___________________________________________________________
7 U___________________ K 0 N 1 r v Q n * I u ; • C________________________________________________________
_ 7 5 ___________________ KO N 2  = K o r n * l Q ’jQ_______________________________________________________
76____________________N U m -I P F R ( K U N ) ___________________________________________
7 7_________ £__________________________________________________________________________
__L3.________C P£3D FffOw THE D I R E C T  A C C E S S  FILE__________________________________
79_________ C___________________________________________________________________________________
e o____________________IF 1 M)M «GF- .N SP E C ) GO TO ¿V_____________________________________
_6_1____________________ IF (NUM.LE.iJ) GO TO 20___________________________________________
82 _________________ READ ( m ’KQfl) X C N 2 .TFP . ( L I S T (TJ) , I J = 1 , N U M )________________
83 _________________ READ ( m  *K ON 1 ) K Q N H . I F R . ( L I S T T ( T J J ) . I J J = l . N U M ) __________
____________________R-EA.Q _i m  ' K 0N 2 ) K ON' 5 , IFR . ( I SP TP ( IJL ) . IJL r 1 , NUH )__________
85_____________23 I P F P (K O N ) = IPFR (KQN ) » 1____________________________________________
__6 6_____________________________________________________________________________________________
87 _________________ ,\IUM = MJM+ 1______________ ~_____________________________________________
88 ______ C___________________________________________________________________________________
89 ______ £___________________________________________________________________________________
90 ________C THIS S T A T E M E N T  SETS THE » A X I M u m  NUMB E R  OF D I A G N O S T I C S
__9 J._________ C___________________________________________________________________________________
92 _________________ IF ( MUM ,GT .NSPEC ) GO TO .a0_____________________________________
93 _________________ LIST ( N U M ) = IQ N 0_____________________________________________________ _
9H___________________ l I S T 1 ( M J M ) - M N Q _______________________________________ ;______________
__9 5 ___________________ I SPTP(NUM) - I COUNT__________________________________________________
6 r
_JV9
Z
+
iZ
5JL______ Q____ WRITE RESULTS TO DA FILE
98 C
2 W  V_l_^ _ T V 3J x u u  • . -------  ------- ---------  : ....... - -  ............  ■ ------  ■ ■ ■ ---- — ------------------------- -
99 wP I TF ( It* * K O N  ) « A S S  { r > .NUM. ( I. 1ST ( IJ1 ) . I Jl = 1 . N U M  )
ICC C
101 « R I T E ( 1 4 ' K O N l )  M A S S  ( I ) .NUM. ( L T S T I (T J 2 ) .IJ2 = l . N U M ) - -
1 C 2 c
1 U 3 - R I T E (14 * K O N Z  > M A S S ( I ) tiiUMi ( I S P T R ( l J 3 )  » I J 3 - 1 iNUW)
_ . 1C** c
. 1C5
o>—osO 4 P
1Ç6_____________ 3 0 w P I T E (l*»,KON> ^ A S S  1 I ) i N u M
1 C 7____________________„ R I T E  I H ' K O M )  * A S S  ( I ) »r.Utt
IÜ8____________________w R I T E  ( W K 0 N 2 )  MflSS(I),\UM
1 0 ?_  0_________________ I______________________
1 1 0________C____________________________________________
' _ _ 1 11___________U Q CONTINUE
'___ U?______ ç______________
113 C W R I T E  THE S H E C I P U V  TC T h E O T H E R  PA FILE
i n C
1 is f
116 " R I T E  ( 1 5 ’I C G U N T  ) I P N O . V O L w T . M N P . F O R K , N A M E . S O U R C E , (M AS S (I > ,I NT < I ) ,
1 1 7 1 1 - 1 . 1 5  1 . . ...
1 1 P c
119 c W R I T E  T H l B I G 1 5  S P E C T R A  TO FILE 16
12P h P I T L  ( I t . 18^1 M K O . F O R K . N A M E  .S O U R C E . I P N O  . .
121 W R I T E  (16.19s.) ( V A S S ( I ) , I M ( I ) , I  = 1,15) . .
122 Ç
123 C _____P E A.ij IN' ME XT S P F C T P U ”____________________________________________________________________________________  .
12** .. C
125 60 TO ln
126 Ç.
127 c W R I T E  OUT THE N U M 9 £ P  OF S P E C T R A . ______________________________________________________________________________________________________________________________
128 ' c
129 5U W R I T E  ( 1 8 . 1 5 c )  I C O U N T _____________________________________________________________________________________________________________________________________________
. 130 c
131 c W R I T E  C U T  THE F R E Q U E N C Y  OF E A C H  ^ Ü L L C U l A R  WT.
CMroH c.
133 W R I T E  ( 1 6 , 2 1 0 ) _______________________________________________________ !_____________________  _
134 DO 7 si N I - 1 .49 .
1 35 c
136 Ç _______ C A L C U L A T E  H A S S E S . _________________________________________________________________________________________________________ ____ ___________________________________
137 ç
1 38 _________DO 6 L J T l  , 2 D _______________________________________________________________________________________________________________________________________________________
1 39 63_______ M F f . l ) = M » 2 Q * J ____________________________ !_____________________________________________________________________________________________________________________
1 4 C c
1 4 1 r S E T  COt.lMERS _ ____________________________________________________________________________________________________________ _
142 c
143 _________K 1 = N I » 2 I ’+1 ______________________________________________________________________________________________________________ _____________________________________
U*u K ? - K  1 ♦ JLS.
JL*L5______ L
1<*6 <L_ W R I T E ■OUT A R R A Y  OF M A S S  F R E Q U E N C I E S ________________ ___ _____________________________________________________
____£_
1»8 — 7.P.. W R I T E  ( 1 8 . 2 0 0 )  ( M F ( J ) . j r i . 2 0 ) . ( ^ W T F P ( H )  . M T K 1 . K 2 )
1*49 c
_______ 150 c W R I T F O U T  T A B L E  OF K A S S / F R E O U F N C T F S  *
. 151 .WRITE ( 1 6 . 2 2 : )
15? JlO 9. K I H , *49
_ 1 5 i  . HQ..BC J = 1. 2 n
1 5*4 __a c . MF ( J ) r MI *?fi* J
______1.51 K l r ^ J * 2 n +l
.... 156 K 2 - K 1 ^ 1 9
. 157 ____£L_
15 B C -J4.RI.IE OUT THE M AS S F R E Q U E N C Y  A R R A Y
_15S_ _ ____£L_
itn c r  y u W R I T E  ( 1 8 , 2 0 0  (MC ( K J ) . K J - 1 . 20). ( I P F R ( K ) . K r K l , K 2 )
_______ 111 ____C_
162 c W R T T F OUT THE H A S S  S P E C T R U M  NO T A B L E
163 w P I T E  (JÇ.23-,)
16*4 N P A G E - c
165 N L I N E = r  .
‘ 166 DO 15 U 1-31, ID UP
167 IF ( I P F R (I ) .LE.r ) GO TO
168 IF < IPFR (I ) .LT . N S P E C  ) GO To 110
169 I I N E N  = NLINE**4
170 IF ( L I N E N . G E . 5 6 )  N P A G E = N P A G E + 1
171 ..IF ( L I N E N .  GC. 56) W R I T E  (13,2*40) NP A G E ...- ---
172 W R I T E  ( 1 8 . 251) ) I . T P F R ( I )
17 3 N L I N E = L I N E N
1 7 *4 _IfL 1 L I N  F N • G E . 5 6 ) M L T N F  = 5
175 JLQ T.O . 1 3 'J
176 inu L l N E N r N L l N E + U
177 IF ( L I N E N . G E . 56) N P A G E - N P A G E  + 1
________ L I 3 .. . -IF (LIN E JL*. j  E • 5 6 ) W P I T F  (13.2*4^) N P A G E
JL19____ W R I T E  (13,25'i) I . I P F R ( I )
160 . NL I N F - L I N F N
131 IF ( L I N E N . G E . 56) v L I N E - 5 '
182 J K L - N .......
______ 1 3 .2________ c_
18*4 w P I I E  J L 4  ’ I ) I.JKL
185 Il = I»luLi.
186 « R I T E  (1<4’ I1) I . JKL "
________ Lil____ JL2JLI ♦ ? u u u " '
188 W R I T E  ( 1 W * 12) I.JKL ' ------------------------
________ LS9 GO TO 13-J ..
19 0 c
________ LLl________ £L THIS S E C T I O N  W R I T E S  OUT THE I Q N O ’S OF THE 5 P F C T R A  W H I C H  C O N T A I N
.19 2 _ ____ £L THE P E A K S  .
193 .. ____ £L
*7*
7?
n u _________ u n  j = i P F R m
JLS5_________C______________________________________________________________________
JL2J&____________________ R E A D  ( 1 4 * 1 )  H . I F R .  ( L I S T ( I I )  .11 = 1 . J)__________
JL9I____________________ ___________________________________________________________
.L2J5____________________RE.4Q..ILlL’I l ) M . I F P . (L I S T I t I J I  .nLJr-Li-JJ_______
199___________________ LJLl,_________________________________________________________
2SlQ___________________ L l N E S - ( I F P / l S - » l ) ______________________________________
Z Z I _________C R E S E T  L I N E  C O U N T E R S  C T A * E  NEW PAG E  IF N E C £ S S A R.Y__«_
Z Z I ____________________ L I N E N  RNL I N E M L l N E ç *3) + 4___________________________
Z Z Z ____________________ IF ( L I N E N . GE.5fc) N P A G E ^ N P A G E + l _________________
2 04____________________ IF (Ll.NfN.CE-.56) W R I T E  ( 1 9 . 2 4 H )  N P A G E _______
2 C 5____________________ IF ( L I N E N . G E . 5 6  ) N L IN F - L I N E N — 5 6________________
2 F 6____________________ IF ( L I N F N . L T . 56) N'LINE-LIN£N____________________
¿Cl____________________ w P I T L  ( 1 8 , 2 5 0  I . I P F R ( I ) __________________________
2C8___________________ LJLv_________________________________________________________
2 1 9 ___________________ DO 12F K-l »LINES______________________________________
2 1 C I S - L ♦ 1
211 L-K * 15
2 1 2 IF ( I F R . L T .  L) L - I F R
2 1 3 « R I T E  ( t o . 2 5 C 1 ( L I S T ( M ) . M : I S . L )
214 « R I T E  ( 1 1 , 2 7 0 )  ( L I S T I ( M ) . m z IS.L)
215 120 C O N T I N U E  .
_2JJ>____________1 3 0 C O N T I N U E _______
2 1 7________________ M W T F R  ( 1 ) - I CO UN T
219 DC 14 U JJ= 1 . 10 -- ....
21 9 J1 = ( JJ - l  > * 1 0 O 1  _.......-------- ---  -
2 2 0 J 2 - ( J J)*lOt, .........  . . . .
221 JK - J J + 1 J ........  -- -
222 C
22 3 W R I T E  ( 1 4 ' J J ) ( M „ T F R (I ) , Irj 1 ,J 2 » ---  ---
224 14 0 « R I T E  ( 1 4 * JK ) ( I P F R ( 1 ) , I = J 1 ,J 7 >
22 5 STOP ------  -----------
226 C
2 2 7 150 F O R M A T  (•!** ’N U M B E R  CF S P E C T R A  : *,I7)
Z Z A . 1 FC FORMAT ( / / . I 6 « 14.5 A 4.2 Q A 4 . ¿.A 4.t / J„
22 9
2 3 0
170 F O R M A T  ( 1 5 ( ? X . I 3 . 1 X . I 2 ) / / 1
180 F O R M A T  ( l X . I f e . l X . 5 A 4 , 2 L A 4 , / , T l l rt» ? A 4 , 2 X . I 6 )
2.3JL
232,
233
2 342 35-
JLS-j. IÜ
F O R M A T  ( 1 5 ( 2 X « I 3 . 1 H « . I 2 1 .  t . Z - L
F O R M A T  1 »  MA S S  * . 2uT6. / . » F 0 EQ .?,.2016 .//_/ )_
210 F O R M A T  I T . n ; , ’ TABLE OF O C C U P P F N C E  OF M O L E C U L A R  W E I G H T  *.///)
22(1 F O R M A T  ( * 1 * . T 1 9 . *  T A 3 L L  OF O C C U R R E N C E  OF *AS S  S P E C T R A L  P E A K S *  t///.)
230 F O R M A T  f  1 * . T 1 9 . »  TAB L E  OF P E A K S / F P E C TfiUM N_LLH_££RS ' , U /.?_
F O R M A T  f * 1 ' . T 1 9 . 1 TAB L E  OF PE AK S / g P E C T RUM N U M B E R S ’ » T 11 J .* P A G E  NO
? \ 7 1 Z * . T 5 )
2 38 250 F O R M A T ( / / . T i n . *  m A 5 s r * . 1 5 . T 2 9 t * FPEOUEN'CY = ^ 1 5 . / ) _____________
23 9 260 F O R M A T ( ’ N I H  ID. N UM •.15131
2 u n 2 7(1 F O R M A T (* I D E N T  NO____ • .151 s ./j ___:.................. ..... ...............................................................................................
2 4 1 C . ______________________ _______________________________ _— -------- ---------------------------------------------------------------------------------------
242 E N D
FIGURE“C-14. Listing of programme MFTABLE
SPECTRA OF TRIMETHYLSILYL DERIVATIVES PAGE NO = 3*»
27200«* C15.H32.02.SI LAURIC acid-monotms BFS 36 213
258.10 257.51 l«»5.i6 132.39 129.25 117.51 10«*.13 75.82 74.11 73.99 57. 9 55.24 45.12 43.42 41.35
273000 C12.H27.N.02.SI2 BISTRIMETHYLSILYL PIPECOLIC ACID SER 02 6375
230. 3 158. «* 157.m 156.99 1 «* 7 • «* 8«*. 5 75. 5 74. 4 73.49 59. 5 58. 1 55. 2 45.11 4 4 .  2 43. 3
273001 C11.H23.N.03.SI2 BISTRIMETHYLSILYL PYPOGLUTAMIC ACID SEP 02 6372
258. 6 230. 6 221. 3 158. «* 157.13 156.99 147.15 75.10 74. 7 73.82 59. 5 58. 3 45.17 4 4 .  4 43. 6
27 3002 Cl 1.H23.N.03.SI2 TMS N-TMS-2-PYRROLIDONE-5-CARBOXYLATE MSC 19 1978
273. 5 258.10 157.20 156.99 93. 5 75.40 73.70 47. 5 45.20 44. 5 43. 5 31. 0 31. 0 31. 0 31. a
273003 C11.H23.N.03.SI2 P YROGLU T AM IC ACIO-OITMS
BFS 31 166
258. 6 230. 8 158. 4 157.14 156.99 148* 2 147.19 75. 9 74. 7 73.78 59. 3 58. 2 45.12 44. 3 43. 3
27300«* C12.H27.N.02.SI2 CYCLOLEUCINE-DITMS BFS 30 158
230. «* 168. 3 158. «* 157.15 156.99 147. 8 84. 5 75. 7 74. 6 73.58 59. 5 45.11 44. 2 43. 2 41. 2
273005 C11.H23.N.03.SI2 PYROGLUTAMIC ACIO-OITMS OAM 7
258. 6 230. 6 221. 3 158. 4 157.13 156.99 147.15 75.10 74. 7 73.82 59. 5 58. 3 45.17 4 4 .  4 43. 7
27«*000 C12.H26.03.SI2 BISTRIMETHYLSILYL 2-KETOI SOCAPRO IC ACID
1 SEP 05 6409
27«*. 6 259.19 215. 8 157. 6 156.10 149.11 148.18 147.99 141. 7 133. 7 75.16 74. 7 73.83 69.15 45.23
27«*00 1 C11.H22.0«*.SI2 BISTRIMETHYLSILYL ITACONIC ACID SER 04 6398
259.13 230. 6 215. 7 149.10 148.16 147.99 133. 5 75.17 74. 8 73.90 67. 5 47. 5 45.17 43. 4 40. 6
27«»C02 Cil .H23.O5.0.SI A-FUCOPYPANOSIDE-1-METHYL-3 , 4-METHYLB0R0NATE -2-TMS CBM 42 1179
157.«* 3 1 «*6 • 29 14 3. 15 131.33 130.96 115.40 89.32 75.65 74.20 73.99 59.24 45.32 44.36 43.26 41.16
27«* 00 3 C11.H22.04.SI2 ITACONIC ACIO-OITMS BFS 37 224
259.15 230. 7 201. 6 149. 8 148.14 147.93 83.12 75.25 74. 9 73.99 67. 5 47. 5 45.19 43. 6 40. 7
FIGURE C-15.Bigl5 mass spectra produced by programme MFTABLE
TABLE CF OCCURRENCE OF MOLECULAR WEIGHT
MASS 21 22 23 2*4 25 26 27 28 29 30 31 32 33 3*4 35 36 37 38 39 *40
FREQ n n 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 P 0 0
MASS <♦1 *42 *43 *4*4 *45 *46 *47 *48 *49 50 51 52 53 5*4 55 56 57 58 59 60
FREQ o rj 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 a 0 0
MASS bi 6 2 63 6*4 65 66 67 68 69 70 71 72 73 7*4 75 76 77 78 79 80
FREQ a n 0 0 C 0 0 0 0 0 0 0 0 1 0 0 1 0 0 1
MASS 81 82 83 8*4 85 86 87 88 89 90 91 92 93 9*4 95 96 97 9e 99 100
FREQ a P 0 0 0 1 0 1 G 0 0 2 0 0 0 a 0 0 0 3
MASS 101 102 103 1 U*4 105 1U6 107 108 109 110 111 112 113 11*4 115 116 117 118 119 120
FREQ 0 C 0 0 0 2 0 2 0 0 0 0 0 0 0 1 0 2 a 1
MASS 121 122 123 12*4 125 126 127 128 129 130 131 132 133 13*4 135 136 137 138 139 1*40
FREQ 0 0 1 1 0 a 0 1 a 0 0 2 0 1 2 0 0 1 0 11
M A S S 1*41 1*42 1*43 1*4*4 1*45 1*46 1*47 1*4 8 1*49 150 151 152 153 15*4 155 156 157 158 159 160
FREQ 0 1 a 3 0 6 0 1 0 2 0 1 0 3 0 2 0 P 0 9
MASS • 161 162 163 16*4 165 166 167 168 169 170 171 172 173 17*4 175 176 177 178 179 183
FREQ 1 *4 1 1 1 *4 0 1 n l 0 11 0 8 5 1 0 l 2 7
FIGURE C-16. Table of frequency of occurrence of molecular weights produced by programme MFTABLE.
TABLE OF OCCURRENCE OF MASS SPECTRAL PEAKS
MA S S 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40
F R E Q 0 0 0 0 0 0 0 0 0 0 0 12 0 1 0 10 3 4 61 57
MA S S 41 2 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
FREQ 36«* 35 . 7G6 243 1026 12 172 7 8 23 50 36 35 23 366 70 153 99 461 18
MA SS 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80
FR E Q 61 5 35 10 67 41 102 35 205 58 82 88 1985 994 17 76 99 26 4 35 165 14
MAS S 81 82 83 84 85 86 37 88 89 90 91 92 93 94 95 96 97 98 99 1UQ
FR EQ 253 72 120 70 80 63 36 36 2 1 7 33 285 44 249 22 1 4 3 30 59 39 59 167
M A S S 101 102 1 u 3 104 105 106 107 108 109 110 111 112 113 114 115 116 117 118 119 120
FRE Q 79 87 445 83 2 9 0 53 208 24 36 17 34 19 49 32 79 150 411 77 106 45
MA S S 121 122 123 124 125 126 127 128 129 130 131 132 133 134 135 136 137 138 139 140
F R E Q 110 8 20 7 41 35 27 48 572 175 2 7 9 103 468 24 197 30 33 16 33 39
M A SS m i 14 2 143 144 145 146 147 148 149 150 151 152 153 154 155 156 157 158 159 160
F R E Q 39 4 8 211 58 175 102 1193 258 285 27 46 30 29 29 53 71 113 86 106 56
M A S S 161 162 163 164 165 166 167 168 169 170 171 172 173 174 175 176 177 178 179 180
F R E Q 6 0 28 50 34 49 36 22 22 97 90 75 82 155 106 89 62 51 32 162 81
FIGURE C-17. Table of frequency of occurrence of mass spectral ions prdduced by programme MFTABLE.
TABLE OF PEAKS/SPl CTRUM NUMBERS
M A S S = 51 F R E Q U E N C Y r 50
N I H  IO# NU M 4344 3 6 9 0 6 4 0 3 5 8 6 4 8 8 7° 2 4 3 9
I D E N T  NO 1 2 3 0 u P 1 6 2 0 U 1 1 6 6 0 t Ü 1 6 6 0 0 1 1 6 6 0 0 3 1 7 9 0 0 1
N I H  ID. NUM 6*4 78 75 7429 169 6 5 2 0 54
I D E N T  NO 2 2 0 0 0 3 2 2 0 0 0 8 2 2 2 C G 4 2 2 2 0 0 7 2 2 3 0 0 1 2 2 3 0 0 4
N I H  ID. NUM 95 6 5 0 8 2bl 4 0 9 4 0 8 4 0 3 8 1
I D E N T  NO 2*48015 2 5 1 0 0 3 2 5 1 0 0 5 2 6 3 0 U 4 2 6 8 0 0 5 2 7 U 0 C 0
N I H  ID. NUM 3 5 8 4 9 1658 1 6 5 9 9 3 5 8 7 8 8 8
I D E N T  NO 4 1 8 0 0 2 4 4 3 0 0 0 4 4 5 0 0 1 5 5 3 0 0 4 5 5 3 0 0 5
M A S S : 52 FREOUF.NCY = 36
N I H  ID. NU M 434 4 3 8 1 0 7 3 6 9 0 6 169 183 241
I D E N T  NO 1 2 3 0 U C 1 6 2 0 0 0 1 6 2 0 0 1 1 7 2 0 0 7 1 9 5 0 0 0 1 9 8 0 0 2
N I H  ID. N U M 1291 4 3 4 8 7 1 3 2 4 6 5 4 0 6 4 7 1 163
I D E N T  NO 2 4 2 0 0 3 2 5 6 0 0 C 2 8 2 0 0 4 2 8 6 OC 1 2 8 6 0 0 3 2 8 6 0 1 0
N I H  ID. .NUM 16 59 4 3 2 4 5 9 3 5 8 7 8 8 8 9359, 7887
I D E N T  NO 4 4 5 0 U 1 4 5 0 D 0 2 5 5 3 0 0 4 5 5 3 0 0 5 6 1 5 0 0 0 6 1 5 0 0 1
M A S S . = 53 F R E O U E N C Y = 35
N I H  ID. N U M 2 3 9 2 4 7 3 9 4 7 5 5 5 9 8 7 5 8 1 2 2 3 8 9
I D E N T  NO 7 4 Ö U P 8 6 0 0 0 8 8 0 0 0 1 0 0 0 0 2 10 8 0 0 0 - 1 0 8 0 0 1
N I H  ID. NUM 59 9 5 24 3 7 6 5 3 2 169 53 2 0 5 7
I D E N T  NO 164 CO O 16 5 0 0 Ü 1 7 2 0 0 2 1 7 2 0 0 7 1 7 2 0 0 8 1 8 0 0 0 1
N I H  ID. NUM 2 5 7 0 4 3 4 8 7 244 188 3 5 8 4 9
I D E N T  NO 2 4 8 0 0 9 2 5 6 0 0 0 28 8 OC 1 3 0 1 0 0 1 4 1 8 0 0 2
FIGURE C-18. Listing of identification numbers
PAGf NO 3
6*4 95 
19*4000
6 3 9 0
19*4001
86
19*«007
183
1 9 5 0 0 0
3
1 9 5 0 0 1
2*462
1 9 8 0 0 1
2*41
1 9 8 0 0 2
12 9 3
2 0 6 0 0 5
*43205
2 1 1 0 0 0
1*471
22*4003
2*461
2 3 2 0 C 2
6*462
2 3 8 0 0 1
6*457
2 3 8 0 0 2
66
2 3 8 0 0 8
63
2 3 e 0 0 9
5 9 8 5
2*4*4001
6*407
2*48007
2 5 7 0
2*48009
2 6 5
27900*4
*43666
2 8 0 0 0 0
*403
2 8 2 0 0 8
2 6 2
2 9 3 0 0 6
2 6 6
3 3 5 0 0 8
«43*437
3 3 8 0 0 0
*4 3*4 38 
3*47000
3 8 9 7 7
3 5 8 0 0 1
3 8 9 7 6
3 7 2 0 0 0
2*458
20000*4
*«3215
2 0 6 0 0 0
1 2 9 3
2 0 6 0 0 5
*43205
2 1 1 0 0 0
1 8 0 8
2 1 9 0 0 1
1*4*4
2 1 9 0 U 2
7*429
22200*4
1 3 2 8
2 3 3 0 0 2
6 3 7 9
23*4006
70
2 8 6 0 1 2
13 2 5
2 9 6 0 0 3
*4 3*457 
3 0 0 0 0 0
1 3 2 6
3*42006
3 8 9 7 7
3 5 8 0 0 1
3 8 9 7 6
3 7 2 0 0 0
*4387
3 7 6 0 1 0
13 8 7
3 9 8 0 0 1
1658 
*4*4 30 0 0
2 3 9 6
1 1 6 0 0 0
3 9 9 6 5
1*40002
5 0 6 6
1*40005
«4*405
1*40008
599*4
1 5 0 0 0 0
5 9 8 8
1 5 0 0 0 1
506*4
15*4000
26 6 1
15*4001
2*451
15*4002
5 0 6 7
1 8 8 0 0 1
5 6 5 6
1 9 2 0 0 0
2*462
1 9 8 0 0 1
2*41
1 9 8 0 0 2
5 0 6 5
2 0 2 0 0 2
2*40
2 1 2 0 0 7
7 0 3 5
2 2 6 0 0 3
187
2 2 9 0 0 0
2*461
2 3 2 0 0 2
of Big 15 MS which contain an ion of stated m/e
A P P E N D I X  D
CLINICAL SUMMARIES OF PATIENTS 
STUDIED IN THIS WORK
PRENATAL DIAGNOSIS - V.T. - METHYLMALONIC ACIDEMIA
Amniocentesis was performed at 15 weeks gestation on a woman whose 
two previous children were affected with methylmalonic acidemia which was 
not diagnosed till they were over two years of age. A report on these 
children has appeared. One child died at the age of 3 years 2 months.
The other is still living and excretes up to 3g MMA(I) per day. The 
enzyme defect was shown to be at the methylmatonyl CoA mutase apoenzyme 
with normal cobalamin metabolism. The children were not responsive 
although a mild response was shown to very large amounts of added 
hydroxycobalamin in cultured cells. The surviving child is well and 
developing on a self selected low protein diet and has slightly below 
average mental development (IQ is in the low normal range.)
Enzyme studies and amniotic fluid MMA(I) levels predicted that the 
foetus was not affected and the pregnancy was allowed to proceed to delivery 
which occurred at term. Urine samples from the baby collected during 
the first week showed no increase in MMA(I) and thus confirmed the diagnosis. 
The baby is well and normal but did suffer from an episode of haemalytic- 
uremic syndrome at 1 year of age.
A further pregnancy undertaken by this couple has been monitored using 
amniotic fluid MMA(I) levels and enzyme assays. These both predicted 
an unaffected foetus and the pregnancy was allowed to proceed to delivery. 
MMA(I) was present in normal amounts in samples collected during the neo­
natal period confirming the in utero diagnosis. The baby has been healthy 
and well since birth.
PRENATAL DIAGNOSIS - G.P. - METHYLMALONIC ACIDEMIA
Amniocentesis was performed at 15 weeks gestation on a woman whose second 
child was affected with methylmalonic acidemia. This was diagnosed at 7 
months of age as a defect in the methytmatonyt CoA mutase enzyme following 
investigations of the child for failure to thrive.
Analysis of the amniotic fluid showed a normal level of methylmalonic 
acid present. Examination of the cultured amniotic fluid cells showed that 
they also had normal levels of methylmalonyl CoA mutase activity. The 
foetus was predicted to be unaffected and pregnancy was allowed to proceed
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to delivery which occurred at term. Urine samples from the baby collected 
during the first weeks of life showed no increase in methylmalonic acid 
and thus confirmed the in v.tevo prediction.
PRENATAL DIAGNOSIS - V.M. - GLUTARIC ACIDURIA
Amniocentesis was performed at 15 weeks gestation on a woman whose only 
other child had been diagnosed as having glutaric aciduria seven weeks 
previously at the age of 18 months. The child had appeared to be normal 
until two weeks before when, following an upper respiratory tract infection 
and some vomiting, she developed an acute dyskinetic reaction with 
dystonia and tremor and lost the ability to stand, sit and crawl. Recovery 
from the encelphalopathy was slow and incomplete, leaving residual dystonia 
and athetosis. Organic acid chromatography of the urine showed glutaric 
aciduria (22mg/mg creatinine) without 3-hydroxyglutaric aciduria or glut- 
aconic aciduria and glutaryl-CoA dehydrogenose activity was deficient in 
both peripheral leucocytes and cultured fibroblasts.
The diagnosis of an affected foetus was predicted seven weeks after
amniocentesis and the pregnancy was terminated at 22^ weeks by intra-
amniotic injection of prostaglandins with the foetus being born dead 20
hours after induction. Autopsy was performed 4 hours after delivery;
half the brain was fixed in buffered formalin for histological examination
oand the liver, kidney and remainder of the.brain were frozen at -80 and 
maintained at that temperature until enzyme analysis was performed.
PERINATAL DIAGNOSIS -M.E. - DICARBOXYLIC ACIDURIA
M.E. is the seventh child of unrelated Australian parents. Of his 
six siblings, two had died suddenly during episodes of gastroenteritis, 
when following two days of diarrhoea and vomiting with apparently little 
systemic effect, they had become very drowsy for a few hours and abruptly
died.
M.E. is the second of non-identical twins born at term following a
normal pregnancy. There were no neonatal problems and he had developed
thnormally» His weight at six months was at the 75 percentile and his
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thheight was at the 97 percentile. Two days prior to admission the 
patient became febrile and began to have mild diarrhoea. Persistent 
vomiting continued for the next forty-eight hours and a few hours before 
admission the child had become increasingly drowsy. On admission the 
patient was hypothermic (axillary temperature 35.2° C) and was noted 
to have 8 cm of firm hepatomegaly below the costal margin. He had 
normal blood pressure and pulse but was semi-conscious and peripherally 
cyanosed but was not clinically dehydrated. He was slightly hypertonic 
but no other CNS or general clinical abnormality was noted. On admission 
the following laboratory results were obtained: blood glucose 1.4 mMl”1, 
blood pH 7.386; pO 108.4 mm Hg; pCO 25.4 mm Hg; base excess - 8.6
-1 . z -1 2 -l _ i, bicarbonate 17.3 mMl ; sodium 129 mMl , potassium 4.4 mMl , 
urea 17 mMl , serum aspartate aminotransferase 68 U/l (Normal < 20 U/l); 
serum alanine aminotransferase 31 U/l (normal < 20 U/l). Haematological 
studies were normal and blood, urine and CSF cultures were negative.
Urinalysis showed mild ketonuria but was otherwise negative. Urinary 
amino acids were within the normal range at the time of the attack.
The child was resuscitated with intravenous glucose and his conscious 
state returned almost to normal within twenty-four hours. Mild irritability 
continued for the next few days. Normal feeds were reintroduced after 
twenty-four hours and the child was discharged after ten days with 6 cm of 
firm hepatomegaly persisting below the costal margin and no changes in the 
serum transaminases. The hepatomegaly and raised transaminases resolved 
during the next six weeks and the child has developed normally since that 
time.
At eight months of age a fasting study showed early development of 
dicarboxylic aciduria with no clinical effects and at ten months a fat 
load study also had no clinical effects. The fasting study was repeated 
at two years of age and despite the absence of clinical effects gross 
dicarboxylic aciduria recurred.
PERINATAL DIAGNOSIS - R.Z. - DICARBOXYLIC ACIDURIA
R.Z. is the second child of unrelated parents. He was born at 35
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weeks to a mother with a previous bad obstetric history. The breech 
birth was rapid and the child showed no respiratory distress but developed 
mild neonatal jaundice (74 yMl which resolved without treatment. He 
developed normally and at eight months his milestones were satisfactory 
and his weight was on the 75 percentile.
At fourteen months he contracted a bilateral otitis media and in­
fected throat and began to vomit. He was treated with antibiotics but . 
was unable to retain fluids and continued vomiting for two days when 
treatment with Stemitil failed to control the vomiting. He continued to 
vomit and his condition deteriorated and he was admitted on the fourth 
day. Examination of the child showed that he was mildly dehydrated, with 
no diarrhoea or raised temperature, normal heart, blood pressure and 
urinalysis but having an enlarged liver (5cm below right costal margin). 
Chest x-ray revealed a coin wedged in the oesophagus which had been present 
for a number of days and was later removed.
The child’s condition suddenly deteriorated very rapidly. He lapsed 
into semi-consciousness, had obvious signs of peripheral shutdown and 
dextrosticks test was negative for sugar. Blood gas analysis showed a 
pH of 7.25, pC^ of 105 mm Hg and /̂ CÔ  of 11 mm Hg. After the onset of 
coma the pH was 7.15, pO^ 60 mm Hg, and pCC>2 15 mm Hg with a base excess 
of -18. Treatment was begun with intravenous dextrose but because of 
rapidly deepening coma and marked restlessness, paralysis of the respir­
atory muscles with curare and intubation with assisted ventilation was 
begun.
The patient's condition remained comatosed and acidotic for 5 days 
with the pH varying between 7.24 and 7.27 despite treatment with base. An 
electroencephalogram taken at that time showed a deep sleep record. 
Treatment was supplemented with lasix, antacid and dexamethasone but the 
serum calcium dropped dramatically during day five. On day six despite 
pethidine given to control restlessness the child began to fit in short 
generalised convulsions. The electroencephalogram showed mixed variable 
patterns and indicated severe metabolic encephalopathy. The metabolic 
acidosis was over-corrected and the pH rose to 7.48 and pC02 to 35 mm Hg 
with a base excess of + 10. The blood calcium was still low but towards 
the end of the day a few purposeful movements occurred and the pH began to 
return to normal despite intermittent fits.
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Fitting had ceased by day seven and normal consciousness began to 
return. A liver biopsy done at this time showed considerable lipid 
accumulation in a non-specific macroglobular pattern commonly seen in
sick children but failed to show the microvesicularity, mitochondrial and
. . 496 497other histological changes seen in Reye's syndrome. ■* By day eight
the child was able to breathe by himself and began to open his eyes and
from that time the improvement was rapid until discharge on day sixteen.
Since that time the child has remained well except for some minor 
illnesses. At 20 months of age the child was admitted for a fat load 
study. The normal daily intake of milk fat was given at the end of a 
fifteen hour fast. The patient became ill and vomited after twenty 
minutes. He became very ketotic over the next few hours. Intravenous 
glucose was required for resuscitation. At twenty-seven months of age 
the child was fasted for fifteen hours. During this time he became 
drowsy and ketotic and began to vomit after 14 hours.
PERINATAL DIAGNOSIS - AM - DICARBOXYLIC ACIDURIA
A.M. was born at term following a normal pregnancy with a birth weight 
of 3.70 Kg. Lethargy was noted from twenty-four hours of age following 
attempts at breast feeding, and the child was tube fed with expressed 
breast milk. Persistently poor feeding, repeated hypertonic posturing 
and vomiting led to transfer to a pediatric hospital for further invest­
igation. On admission he had lost weight (weight was 3.25 Kg) and was noted 
to be lethargic, with poor Moro reflex and no other CNS findings. There 
were no other clinical findings. Blood gases, serum calcium, and serum 
magnesium were normal and blood sugar was 2.7 mMl ,CSF, urine and blood 
culture proved sterile and haematological investigations were normal. The 
problems continued during the next week but when normal feeding began the 
child was discharged apparently normal. A.M. subsequently thrived with 
normal developmental milestones on a normal diet until eleven months of 
age.
Four days prior to admission A.M. developed mild vomiting and diarrhoea. 
Two days before admission he became lethargic and was admitted to a peri­
pheral hospital. The child initially improved with intravenous fluids but 
over the next forty-eight hours became increasingly unresponsive, and
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developed 4 cm of hepatomegaly. On transfer to Royal Alexandra Hospital 
for Children he was unresponsive to most stimuli and hypotonic. He had no 
other CNS abnormalities but the firm liver edge was 4 cm below the costal 
margin and clinically he was markedly dehydrated.
Biochemical investigation showed a blood sugar of 1.1 mMl Blood
gases were pH 7.396, base excess -9.2 mMl \  standard bicarbonate 16.5
mMl and pCO 25.1mm Hg. Plasma sodium was 143 mMl plasma potassium 
-1 z _14.2 mMl , plasma urea 14.0 mMl and haemoglobin 10.8 g/100 ml. The 
child responded immediately to intravenous glucose given on arrival, be­
coming more alert and active. However he remained drowsy during the next 
twenty-four hours with a gradual return to normal activity and normal 
conscious state. During this time he was maintained on intravenous 
glucose and other fluids for rehydration. Serum transaminases were initially 
raised but ammonia and lactate were both normal. The electrolytes remained 
normal and urea gradually returned to normal on rehydration. Blood, C FS 
and urine culture proved sterile. Urinary investigations showed fat glob­
ules, ketonuria and high levels of adipic acid on admission but these re­
solved during the first twenty-four hours. Following the initial recovery 
the child remained clinically well but hepatomegaly (4 to 6 cms) and 
mildly raised serum transaminases persisted, but slowly resolved during the 
next two weeks. Serum cholesterol was normal with mildly raised serum tri­
glycerides (1.3 mMl”1). Serum alpha-l-antitrypsin, copper and cerrulo- 
plasmin were normal and the child was discharged after two weeks.
At thirteen months of age the child was readmitted for investigation, 
thHe was at the 75 percentile for height and weight and was clinically well. 
After a fifteen hour fast the child received a fat load and became mildly 
unwell and drowsy with repeated vomiting. His blood glucose fell to 2.7 
mMl”1 and he revived after a few hours of intravenous glucose and fluids.
The child continued to thrive physically on a normal diet and he has 
remained developmentally normal. At sixteen months of age he was re­
assessed and subjected to a twenty—four hour fast during which normal 
glycemia was maintained and he was clinically well. Mild ketonuria 
developed at fifteen hours of fasting and adipic and other dicarboxylic 
acids were grossly raised.
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Since that time he has continued to thrive and his development
. thremains at about the 75 percentile.
PERINATAL DIAGNOSIS - Z.K. - PROPIONIC ACIDEMIA
The patient (Z.K.) was a newborn boy of half first cousin Turkish 
parents. Two sisters had died aged 2 days and 2 months in Turkey.
A 7 year old sister and a 4 year old brother are normal.
Z.K. was born at term after a normal pregnancy, labour and delivery. 
Birth weight was 2.820kg. The infant was initially fed a milk formula 
containing 2.8g protein per 100 ml, but he was noted to be unwell at 48 
hours with depressed conscious state and acidotic breathing, and was 
said to smell ketotic. Mild jaundice was present. Laboratory investig­
ation revealed a marked metabolic acidosis (pH 7.06, bicarbonate 4 mMl  ̂
pC02- 14 mm Hg and base excess -25) and the nitroprusside test for urine 
for ketones was strongly positive. Intravenous sodium bicarbonate was given. 
The infant was transferred to Royal Children!* Hospital, Melbourne, at 60 
hours of life.
Initial investigations confirmed the metabolic acidosis and demonstrated 
a plasma ammonia of 569yM ml  ̂ (Reference range < lOOyM ml ). High 
voltage electrophoresis showed elevated lysine and cystine in urine and 
elevated lysine and decreased alanine in serum. Thin layer chromatography 
of urinary keto acids, as the DNP derivatives showed increased acetone, 
butanone and pentanone. Other serum results were as follows: sodium 152 
mMl potassium 4.4 mMl *̂, chloride 110 mMl , calcium 1.65 mMl , mag­
nesium 1.0 mMl \  urea 11.4 mMl \  glucose 4.3 mMl \  p09 74 mm Hg, and
-1total bilirubin 140 yMl . The initial haematology was normal but later
3 - 3  3 - 3leucopenia (3.2 x 10 mm ) and thrombocytopenia (15 x 10 mm ) appeared.
A urine screen for short chain fatty acids was positive for propionic
acid and screening for urinary organic acids showed elevated lactic,
3-hydroxybutyric,acetoacetic and 4-hydroxyphenyllactic acids plus
many other elevated unidentified acids.
Management of Z.K. consisted of intravenous 10% dextrose, peritoneal
257
dialysis from 65 hours of life, exchange transfusions at 90 and 100 
hours of life and megavitamin therapy including biotin (100 mg) 
orally immediately after the second exchange transfusion. Rapid improve­
ment in the infant's clinical condition followed. Dietary protein was 
introduced and increased to 1.5 gm/Kg/day on the eleventh day of life. 
Biotin was continued at a dose of 10 mg/day orally. The impression of 
biotin responsiveness gained during the initial illness was to have been 
formally tested later, however, a further metabolic crisis developed after 
two months of relatively good progress on biotin and protein restriction. 
Hyperammonemia (1700 yMl and propionic acidemia proved uncontrollable 
and he died at the age of three months.
PERINATAL DIAGNOSIS - E.B. - PROPIONIC ACIDEMIA
E.B. was born at term to a healthy 18 year old unmarried mother and
there was no family history available. Labour and delivery were uneventful
and birth weight was 4.280 kg. He made very satisfactory progress in the*first week of life and was discharged to a children's home.
He was admitted to Royal Children's Hospital, Melbourne, at the age of 
fourteen days because of drowsiness and hypotonia. These features were 
accompanied by myclonic jerking and some vomiting and diarrhoea. Examin­
ation showed no apparent physical abnormalities with some minor liver en­
largement (2 cm below RCM). During the next month there were several 
episodes of gram negative septicemia with peripheral circulatory failure and 
deterioration of conscious state. Vomiting and diarrheoa were fairly 
constant problems. During this phase electrolyte estimations never showed 
more than a mild acidosis and the pH did not drop below 7.26 with a base 
excess of -6. Myclonic twitches occurred whenever the child was ill. The 
episodes of septicemia were treated with antibiotics. Biochemical, invest­
igations showed massive amounts of urinary glycine and raised serum 
glycine (4.lmg/100ml, 40 x normal) with raised blood ammonia (262yg/100 ml, 
2.5 x normal). Neutropenia was a striking feature and a diagnosis of 
primary hyperglycinaemia was made but the absence of significant acidosis 
suggested significant differences to the type described by Nyhan and
c p i r* Childs. A number of studies of glycine metabolism were performed but no
further information was found.
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Maintenance of the child based on this diagnosis consisted of very low 
protein feeding with maximum calories from other sources. The patient 
showed severe sugar intolerance and malabsorbtion and medium chain tri­
glycerides were used as the major calorie source with a gradual increase 
in glucose content. Initial protein levels were restricted to 0.5mg/Kg/ 
day but after some time this was increased to lg/kg/day.
Over the next several weeks there were wide variations in the clinical 
state and the declines had no apparent reason. Serum and urine glycine 
levels had returned to the normal range when low protein feeding was instit­
uted and did not ever rise above the normal range again. During this 
period the blood ammonia was continually rising.
At the age of seven months an episode leading to a severe decline 
occurred, precipitated by a viral infection. During this episode the 
blood ammonia failed to rise but the child became severely acidotic.
This pattern of severe episodes of acidosis with massive ketonuria marked 
each decline in conditioncf the child for the rest of his life. Identif­
ication of the urinary acids gave equivocal results. Chemical tests 
suggested that methylmalonic acid was present but gas chromatography 
suggested the major compound present was acetoacetic acid and not methyl­
malonic acid. This conflict of results remain unresolved.
At the age of eight months a particularly severe illness occurred which 
was only controlled with IV fluids and massive amounts of bicarbonate. After 
this time he entered a fairly even period of good health and developed 
to about 60% of normal.
At sixteen months of age an attempt was made to feed him a normal diet. 
This produced initially only a very slight metabolic acidosis which was 
compensated. For three weeks he remained in good health but then became 
acutely acidotic and after restabilisation the normal diet was withdrawn.
His final illness began with a viral infection which led to massive 
acidosis which was difficult to control. He never regained physical 
strength and remained floppy and lethargic till his death. Aspiration of 
milk led to a persistent chest infection which was never satisfactorily
259
cleared. Massive amounts of vitamins and trace elements were given but 
no improvement in clinical condition occurred. He died at age twenty 
two months.
During this prolonged illness it was clear that protein over load 
either by exogenous protein or indogenous protein released during acute 
infections resulted in acute intoxication. During the first 6-7 months 
this state of cerebral intoxication was not accompanied by any acidosis 
but hyperglycinaemia and hyperammonemia were constant features. From 7 
months until death each of the many episodes of deterioration were accom­
panied by severe ketoacidosis and the absence of significant hyperammonemia 
or hyperglycinaemia. All episodes of ketoacidosis could be explained by 
protein overload, endogenous or ^exogenous. The most probable diagnosis 
is a defect in the pathway of some organic acid.
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Antenatal_Diagnosis_of Glutaric Acidemia 
Introduction
Glutaric acidemia is an inborn error of amino acid metabolism which is 
characterized clinically by an intermittently progressive dyskinetic syndrome 
in childhood, chemically by the excretion of large amounts of glutaric and 
(usually) 3-hydroxyglutaric acids in urine, and pathologically by chronic 
neuronal loss in the putamen and caudate nuclei (1-8). The disorder is due
m
to deficiency of glutaryl-CoA dehydrogenase, an enzyme in the pathway of lysine, 
hydroxylysine and tryptophan oxidation, and is inherited as an autosomal 
recessive trait (5,9).
The purpose of this communication is to document in-utero diagnosis of 
this disorder, which can be established by demonstrating deficiency of 
glutary1-CoA dehydrogenase in cultured amniotic cells and (probably) accumu­
lation of glutaric acid in amniotic fluid. .
2
Case Reports 
Pregnancy A
Amniocentesis was performed at 15 weeks gestation on a woman whose only 
previous child had been diagnosed as having glutaric acidemia some seven weeks 
earlier at the age of 18 months. The child had appeared to be normal until 
two weeks before when, following an upper respiratory tract infection and some 
vomiting, she developed an acute dyskinetic reaction with dystonia and tremor 
and lost the ability to stand, sit and crawl. Recovery from the encephalopathy 
was slow and incomplete, leaving residual dystonia and athetosis. Organic acid 
chromatography of urine showed glutaric aciduria (22.6 mg/mg creatinine) without 
3-hydroxyglutaric and glutaconic aciduria, and glutaryl-CoA dehydrogenase activity 
was deficient in both peripheral leukocytes and cultured fibroblasts.
The diagnosis of an affected fetus was predicted seven weeks after amnio­
centesis and the pregnancy was terminated at 22-1/2 weeks by intra-amniotic in­
jection of prostaglandins, with the fetus being born dead 20 hours after induction. 
Autopsy was performed 4 hours after delivery; half of the brain was fixed in buf­
fered formalin for histological examination and the liver, kidney and remainder 
of the brain were frozen at -80°C and maintained at that temperature until enzyme 
analysis was performed about 5 weeks later.
Pregnancy B
Amniocentesis was performed at 15 weeks gestation on the mother of a child 
with glutaric acidemia who has already been reported (5); the fetus was predicted 
to be unaffected and pregnancy was allowed to proceed to delivery, which occurred 
at 41 weeks. Glutaric acid was not detected in either of two urine samples col­
lected during the first week of life, and the activity of glutaryl-CoA dehydro­
genase in fibroblasts cultured from the umbilical cord was 0.76 nmoles C02/hr/mg 
protein (Hamilton laboratory normal =* 0.54 * 0.04), confirming the in-utero
prediction. The baby, a male, did however have congenital heart disease (trans­
position of the great vessels, coarctation of the aorta, and patent ductus 
arteriosus) which required surgical correction.
Methods
The activities of glutaryl-CoA dehydrogenase in cultured amniotic cells and 
in tissue sonicates, and of glutamate dehydrogenase in tissue sonicates, were 
measured as previously described (1,10). The method used to measure tissue 
content of glutaric acid has also been described (7).
In the Denver and Hamilton laboratories, amniotic fluid content of glutaric 
acid was measured by gas chromatography using the technique of internal standard­
ization (11); internal standards used were phenylacetic acid (Denver) and 
eicosane (Hamilton). Organic acids in 1 ml amniotic fluid were extracted and 
silylated as previously described (12) using 10 mcl BSTFA and 2 mcl TMCS, and 2 
mcl of the derivatized extract was chromatographed on a 10 foot column of OV-22 
on 90/100 mesh Supelcoport (Supelco Inc., Bellefonte, Pa.). The carrier gas was 
nitrogen (30 ml/min) and the column was kept at 90° for 4 minutes before the oven 
temperature was raised to 280° at the rate of 8°/minute. The identity of organic 
acids in the extract was established by combined gas chromatography-mass spectro­
metry using an AEI MS-12 medium resolution mass spectrometer.
In the Wollongong (Australia) laboratory, amniotic fluid content of glutaric 
acid was measured as follows. Adipic acid (5 meg) , water (2 ml) and 5% sodium 
dodecylsulfate (0.3 ml) were added to 1 ml amniotic fluid and the solution was 
saturated with NaCl and adjusted to pH 9-11 with 1M NaOH. After standing at room 
temperature for 20 minutes the solution was extracted three times with 3 ml ethyl 
acetate, and the extracts were discarded. The solution was then acidified to
pH 1 with 5 M HCi and the organic acids were extracted into ethyl acetate.
Pimelic acid (5 meg) was added as an external standard and the extract was 
dried with MgS04 an<̂  evaporated under nitrogen. The dried residue was derivatized 
using 30 mcl BSTFA (1 hour at 65°) and approximately 0.5 mcl of the silylated 
extract was injected onto a 20m x 0.2mm (i.d.) capillary column which was wall- 
coated with SE-54. The inlet split was 10:1. Carrier gas was helium (2 ral/min) 
and temperature was programmed to rise fro 80° to 250° at 6°/minute. All peaks 
were identified by feeding the gc effluent through an open coupling into a 
Varian-MAT44 quadrupole mass spectrometer, and the concentration of glutaric 
acid was measured by the technique of internal standardization (internal standard =» 
adipic acid).
Results
The’results of the studies performed on the two fluids obtained by amnio­
centesis are shown in Table I. Both glutaric acid concentration in the fluid 
and activity of glutaryl-CoA dehydrogenase in cultured amniotic cells were 
abnormal in pregnancy A and it was decided that the pregnancy should be terminated. 
The concentration of glutaric acid in amniotic fluid at termination of pregnancy, 
also shown in Table I, had increased considerably in the intervening 7 weeks.
Table II shows the results of studies performed on the abortus and compares 
them to values obtained on two patients with glutaric acidemia at autopsy and 
on three control human fetuses ranging in gestational age from 16 to 24 weeks.
The liver, kidney and brain of the abortus at-risk contained markedly increased 
amounts of glutaric acid and almost no glutaryl-CoA dehydrogenase activity, a 
pattern which is observed in tissues in glutaric acidemia but not in controls.
The cerebral hemispheres and cerebellum of the fetus were normal to both 
gross and microscopic examination, but there were some slight alteration in the 
size distribution of nuclei in the striatum,.which contained many prominent and 
small darkly-staining nuclei.
5
Discussion
This report describes the first instances in which pregnancies at risk for 
glutaric acidemia have been monitored for this disease, and shows that affected 
and unaffected fetuses can be distinguished with comparative ease by measuring 
glutaryl-CoA dehydrogenase activity in cultured amniotic cells and the concentration 
of glutaric acid in the amniotic fluid. Two pregnancies were monitored; the fetus 
predicted to be affected had the in-utero diagnosis confirmed by determinations of 
glutaric acid and glutaryl-CoA dehydrogenase in tissues, while the fetus predicted 
to be unaffected had normal glutaryl-CoA dehydrogenase activity in umbilical cord 
fibroblasts and did not have glutaric aciduria on two occasions during the first 
week of life.
Glutaric acid may accumulate in the amniotic fluid of the affected fetus be­
cause , like many other non-amino organic acids, it is poorly reabsorbed from the 
glomerular filtrate and appears in fetal urine and thus in the amniotic fluid (13); 
a similar mechanism has been suggested as the basis of the accumulation of abnormal 
metabolites in the amniotic fluid of fetuses with methylmalonic acidemia (14-16), 
arginosuccinic acidemia (17,18) and propionic acidemia (19). Although it is 
technically easier to measure the concentration of glutaric acid in amniotic fluid 
than it is the activity of glutaryl-CoA dehydrogenase in cultured amniotic cells, 
in-utero diagnosis of glutaric acidemia should probably rest on the latter deter­
mination until it can be shown that glutaric acid does not accumulate in the 
amniotic fluid of the fetus heterozygous for the mutant allele.
The treatment of glutaric acidemia by dietotherapy, vitamin (riboflavin) 
supplementation, and drugs (Lioresal^* and valproic acid) has been only variably 
effective (1,3,5,8,20,21), perhaps because irreversible damage has been done to
6
the basal ganglia by the time the diagnosis is usually established. The obser­
vation that glutaric acid is significantly accumulated in the brain even during 
fetal life in this disorder raises the possibility that neuronal damage may be 
done even in-utero. The mild striatal changes which were noted in the affected 
fetus may reflect such damage or may be due only to terminal anoxia, and careful 
histopathological examination of the striatum in normal and affected abortuses 
will be necessary in the future if this issue is to be resolved.
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Table I
Pregnancy A
Amniocentesis (15 wk) 
Termination (22 wk) 
Pregnancy B
Amniocentesis (15 wk)
Amniotic fluid 
Glutaric acid 
- mcg/ml -
4.351
11.71,13.32
not detected2'3
Controls 0.2810.11(m±sd)1 
not detected2'3
Amniotic cell
Glutaryl-CoA dehydrogenase 
nanamoles C0 2/hr/mg protein
not detected2
2.442
1.03, 4.942
JWollongong laboratory 
2Denver laboratory 
3 Hamilton laboratory
Fetus A
Glutaric acid 
(mcg/g wet weight)
Liver
Kidney
Brain
Glutaryl-CoA dehydrogenase 
(nmoles CC^/hr/mg prot)
Liver
17.0
70.2
112.0
0.15
Kidney 0.03
Glutamate dehydrogenase 
(mcmoles NADH oxid/min/mg prot)
Liver 0.38
Frontal cortex
2Basal ganglion 
^Isolated mitochondria
Table II
Glutaric acidemia (7,8) Control Fetuses (n- 3)
330 96 not detected
1000 1330 not detected
109 881, 1652 not detected
O3 0 33.8 - 58.0
03 0 2.6 - 13.8
1.443 0.45 0.29 - 0.39
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fectivity. 1 he converse is often true for patients with acute Type B 
hepatitis. Similarly, fibrinogen and prothrombin complex arc 
highly infectious and yet generally HBsAg-negaiive. The occur­
rence of overt hepatitis B in human beings after receipt of only 
HBsAg-negative blood is not uncommon. Lastly, plasma was still 
infectious when diluted far beyond the range of any current radio­
immunoassay and far beyond the dilutio/i achieved by freezing and 
deglycerolization.2 Thus, the fact that our starting inoculum was 
HBsAg-positive by radioimmunoassay is not the relevant point. Of 
note was the initial infectivity titer. The initial !-ml inoculum con­
taining 10* infectious units per milliliter was diluted in 500 ml of 
whole blooti before freezing and deglycerolization. This procedure 
reduced the concentration of virus to approximately 2 X 103 infec­
tious units per milliliter, a level well below that previously observed 
in chronic carriers of hepatitis B virus and one that should have sub­
jected the freeze-wash process to a fair test. >
Because of the disparity between hepatitis B antigenicity and in- 
fectivity and because a low dose of virus is not necessarily equated 
with,development of mild disease,3 we did not consider it justifiable 
to commit an additional large number of this scarce and expensive 
animal resource to establish the concentration of hepatitis B virus 
that might be rendered noninfectious by freezing and deglyccroli- 
zgtion. The question raised by Dr. Goldfinger can only be answered 
by a large-scale, controlled, prospective study in human beings. In 
the interim, we believe that our chimpanzee studies subjected freez­
ing and deglycerolization to a valid test and that these studies do 
not currently support the use of frozen erythrocytes to reduce the in­
cidence of Type B post-transfusion hepatitis.
We omitted the controls suggested by Dr. Smith because the 
inoculum had previously been “pedigreed” in other chimpanzees so 
that its infectivity titer and clinical sequelae were known. One can 
only use the chimpanzee as a model for infectivity, not for clinical 
illness, since oven discasd'almcst never occurs in them regardless of 
the infectivity titer of the inoculum, in terms of chronicity, one 
would anticipate the opposite of what Dr. ismith suggests. In both 
human and chimpanzee studies* the tendency toward chronicity 
has been highest in subjects receiving the most dilute inoculum. 
Thus, in theory at least, frozen red cells that did not prevent infec­
tion, but reduced the titer of virus, would be more, rather than less, 
likely to result in a chronic carrier state.
* H arvey  J. A lter, M.D.
P a u l  V. H o l l a n d , M.D.
- R obert J. G erety, M.D.
Bethesda, M I) 20014 National Institutes of Health
1. Gerin JL, Ford EC, Purcell RH: Biochemical characterization o f 
Australia antigen: evidence for defective particles o f  hepatitis B virus. 
Am J Pathol 81:651-663. 1975
2. Barker LF, Murray R: Relationship o f  virus dose to incubation time o f 
appearance o f hepatitis-associated antigen. Am J Med Sci 263:27-33. 
19723. Barker LF. Maynard JE, Purcell RH, et al: Hepatitis B virus infection in 
chimpanzees: titration o f  subtypes. J Infect Dis 132.451-458, 1975
4. Alter HJ. Holland PV, Schmidt PJ. et al: Gamma-globulin for hepatitis­
virus B; prevention or extension? Lancet 1:1110-1111, 1972
SUSPECTED DEFECT IN FATTY ACID OXIDATION
To the Editor: Wc wish to report on a child with a possible abnor­
mality of fatty acid metabolism, who presented with an illness 
resembling Reyc’s syndrome. He was the seventh child of unrelated 
Australian parents. Two of his six siblings had died suddenly, after 
two or three »lays of repeated vomiting, at 10 months and two years 
of age. This child was well until six months of age, w hen diarrhea 
and frequent vomiting developed. After 48 hours he became in­
creasingly drowsy anti was admitted to the Royal Alexandra 
Hospital for Children, Sydney. On admission he was semiconscious 
and slightly dehydrated and hail hepatomegaly (6 cm). Hypogly­
cemia (bl«*>«I glucose of 1.4 mmol per liter) with a mild metabolic 
acidosis (pH 7.38 and plasma bit arbonatr of 17.3 mmol per liter) 
was shown on admission. Further investigation indit ated an aspar­
tate aminotransferase of 68 units per liter (normal <20) and an al­
anine aminotransferase of 31 units per liter (normal <20). The sub­
sequent clinical course was uneventful, and with intravenous fluids 
for 36 hours, he improved rapidly.
On admission the urine show ed a normal pattern of amino acids, 
but analysis ct organic acids by gas chromatography/mass spec­
trometry demonstrated a very high concentration of adipic acid 
(4500 mmol per mole of creatinine), with increased amounts of su­
beric and sebacic acids. This excretion of dicarboxylic acids exceeds 
10-fold the increased secretion reported in carnitine deficiency and 
in ketosis.
Later investigation of this child has shown that adipic acid excre­
tion could be increased by fasting for more than 10 hours. In con­
trast, no increase in adipic acid excretion was found on fasting in 
five normal controls.
YVe have since seen two further, unrelated children with a similar 
history and clinical picture, whose urines contained large amounts 
of adipic acid on admission and who excreted increased amounts of 
adipic acid on fasting. The clinical picture and organic acid profilg 
in their acute illness resemble those reported in patients with 
Jamaican vomiting sickness,* in which a toxic metabolite inhibits 
fatty acid beta-oxidation. YVe suggest it is possible that these three 
children share a defect in the activity of short-chain CoA dehydro­
genase, which leads to an accumulation of dicarboxylic acids from 
omega-oxidation, and that this defect becomes clinic t̂ly important 
in periods of prolonged fasting.
R. T ruscott 
C. Pullin 
B. H alpern 
YVoIIongong University
B. YVilcken
Sydney, New South YVales Oliver Latham Laboratory
M. Stt.lNK 
H. G RIFKITltS 
H. KtLHAM 
Royal Alexandra Hospital
F. G runseit
Sydney, New South YVales Prince of YVales
Australia Children’s Hospital
Sydney, New South YVales
YVoIIongong, New South YVales
‘ Tanaka K, Kean EA. Johnson B: Jamaican vomiting sickness: biochem­
ical invesigation o f  two cases. N Engl J Med 295:461-467, 1976
ZOLLINGER-ELLISON SYNDROME YVITH MULTIPLE 
ENDOCRINE ADENOMATOSIS TYPE II
To the Editor: YVe report here an unusual association of Zol- 
linger-Ellison syndrome with multiple endocrine adenomatosis 
Type II in a young man. '
This 28-year-old man was admitted to the Yale-New Haven 
Hospital because of epigastric pain. There was no recent history of 
vomiting, melena or salicylate abuse. He was a member of a local 
kindred with multiple endocrine adenomatosis Type II (Sipple’s 
syndrome).* Five years before, medullary carcinoma of the thyroid 
was treated by total thyroidec tomy; follow-up serum calcitonin lev­
els and a liver biopsy revealed metastatic disrasc. One year 
previously, he had entered the Beth Israel Clinical Research Center 
for evaluation of diarrhea and weight loss; steatorrhea (excretion of 
16.9 g of stool fat per day) ^ml an elevated serum calcitonin were 
noted, and a barimn-meal examination showed only a non­
specifically abnormal small bowel. Small-bowel biopsy ant! tests lor 
urtnarv 5-hydroxy indoleacetir acid ami phoov hrotnoi ytomo were 
negative. The snout gastrin was |M) pg per milliliter (normal, less 
than 200). The diarrhea was thought to be a result of the high 
serum calcitonin level or of some other tumor produtt and was 
bronchi under i o m i i o I with diphcnoxvf.itr hvdro* lilonde with atio- 
pinr (Lomotil) and psyllium hydrophilic colloid (Mclaur.it i!)
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Summary
The urine o f a child who presented with an episode o f a disease resembling 
Reye’s syndrome was found to contain large quantities o f the dicarboxylic 
acids adipic and suberic acids, as well as the glycine conjugate o f suberic acid, 
suberyl glycine. A variety o f other dicarboxylic acids, both saturated and un­
saturated, were also found in the urine at the time o f  the attack. It was found 
that the excretion o f these unusual metabolites could be markedly increased by 
fasting for periods o f greater than 10 h.
These results indicate that the patient may have a defect in fatty acid oxida­
tion which becomes clinically significant during periods o f prolonged fasting.
Introduction
There have been a number o f clinical conditions reported where the excre­
tion o f adipic acid in urine is increased. These include glycogen storage disease 
[1], Reye’s syndrome [2] and congenital lactic acidosis [3 ]. An increased 
excretion o f adipic and suberic acid has also been observed in ketosis [4 ], 
where the excretion o f  these dicarboxylic acids appears to parallel the degree o f 
ketosis. However in all these conditions the amount o f adipic acid excreted is 
small, and the increased excretion o f  this dicarboxylic acid is associated with 
the excretion o f large quantities o f  other organic acids such as lactic acid or 
3-hydroxybutyric acid.
We now describe a patient who was found to excrete considerable quantities 
of adipic acid and other dicarboxylic acids without having significantly elevated 
urinary levels o f  either lactic or 3-hydroxybutyric acid. A preliminary report on 
this work has been presented [5 ].
* To whom correspondence should be addressed.
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Materials and methods
Case report .
The male patient (M.E.) was the seventh child o f  unrelated Australian 
parents, bom  at term following a normal pregnancy. Tw o o f his six siblings, a 
boy aged 2 years and a girl aged 10 months, died suddenly during episodes o f  a 
gastroenteritis-like illness, when, after two days o f  diarrhoea and vomiting, they 
had become very drowsy for a few hours, upon which they abruptly died.
Two days prior to admission the patient became febrile and began to have 
mild diarrhoea. Persistent vomiting continued for the next 48 h and a few 
hours before admission the child became increasingly drowsy.
On admission the patient was hypothermic (axillary temperature 35.2 C), 
semi-conscious and was noted to have 8 cm o f  firm hepatomegaly below the 
costal margin. At the time o f the attack the following laboratory results were 
obtained: blood glucose, 1.4 mmol/1; blood pH 7.38; blood bicarbonate, 17.3 
mmol/1; serum aspartate aminotransferase, 68 U/l; serum alanine aminotrans­
ferase 31 U/l. Urinary amino acids at the time o f  admission were within the 
normal range.
The patient was resuscitated with intravenous glucose and his state o f  con ­
sciousness returned almost to normal within 24 h. Normal feeds were reintro­
duced at this stage and the child was discharged ten days after admission with 
6 cm firm hepatomegaly below the costal margin.
Materials
Chemicals were obtained as follows: Succinic acid (1,4-butanedioic acid) 
from May and Baker Ltd., Dagenham, U.K.; hexanoic acid, octanoic acid, 
adipic acid (1,6-hexanedioic acid) and suberic acid (1,8-octanedioic acid) from 
Sigma Chemical Co., St. Louis, MO, U.S.A.; and iV,0-bis(trimethylsilyl)tri- 
fluoroacetamide (BSTFA) from Regis Chemical Co. Morton Grove, IL, U.S.A.
Identification o f  compounds
The identification o f  urinary metabolites was confirmed by com bined gas 
chromatography-mass spectrometry (GC/MS) in which a Varian Aerograph 
(2700)GC was interfaced, via a jet separator, to a Dupont 491B mass spec­
trometer fitted with a dual electron impact/chemical ionisation source. The GC 
was fitted with a 6 ft X | inch glass column packed with either 6% Apiezon N or 
3% SE-30 on 8 0 -1 0 0  mesh dimethyldichlorosilane-treated Chromosorb W. A 
helium flow  rate o f  25 ml/min was used, and during the analyses the tempera­
ture was programmed from 80°C to 250° C at a rate o f  6°C/m in.
Extraction and quantitation o f  urinary acids
Succinic acid (10 jug) was added as an internal standard to 1 ml o f  urine and 
the solution was acidified to pH 1 with HC1 (0.1 ml, 6 mol/1). Saturated 
aqueous NaCl (1 ml) was then added and the mixture extracted with ethyl ace­
tate ( 3 X 2  ml). The organic extracts were pooled, evaporated to dryness with a 
stream o f  dry nitrogen, and the dried residue derivatised for GC analysis with 
BSTFA (50 jliI ,  60°C, 30 min). Quantitation o f  individual acids was achieved by 
measurement o f  the peak heights o f  each acid relative to the peak height o f  the
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m rnal standard and interpolating from a standard calibration curve. The 
recoveries o f  adipic acid and suberic acid using the above method were deter­
mined by extracting 1-ml samples o f  water spiked with 20 jug o f  each o f  the 
com pounds. The efficiency o f  extraction was calculated to be 94% for adipic 
acid and 96% for suberic acid.
For the examination o f  organic acids and acyl glycines as the methyl ester 
derivatives, urine samples were extracted with diethyl ether/ethyl acetate and 
the extract methylated at room  temperature with an ethereal solution o f  diazo­
methane.
Hydrolysis o f  acylglycines
Urine samples containing 1 mmol creatinine were hydrolysed in 3 ml o f  6 M 
HC1 (110 C, 3 h). The internal standard was added to the hydrolysate and the 
organic acids were extracted with diethyl ether ( 3 X 3  ml). The pooled ether 
extract was dried over M gS04 and evaporated at room  temperature to a final 
volume o f  approximately 100 ¡jl\. BSTFA (50 pi) was then added and the 
extract silylated (60°C, 30 min). GC analyses were performed on 3% SE-30 as 
described previously, using an initial temperature o f  55°C.
Results
A GC profile o f  the silylated extract o f  a urine sample taken from the 
patient close to the time o f  admission is shown in Fig. 1. The profile was 
dominated by one large peak which was identified by mass spectrometry as the 
disilyl derivative o f  adipic acid. Smaller amounts o f  suberic and sebacic acids 
were also detected in the urinary extract. Lactic acid and 3-hydroxybutyric 
acid which elute at the positions indicated on the profile were present only at 
low levels. Estimation o f  the amount o f  adipic acid present in the urine at the 
time o f  admission showed up to 4 mol adipic acid per mol creatinine.
The methylated extract o f  a urine sample taken during the attack was also 
examined by GC/MS. The result is shown in Fig. 2. In addition to the large 
peaks o f  adipic and suberic acids a major peak (peak 13) was observed which 
eluted at 217°C. This peak was identified as the methyl ester o f  suberyl glycine. 
The mass spectrum o f  this com pound matched that o f  suberyl glycine shown 
by Gregersen et al. [6 ] and was identical with that o f  a sample o f  the reference 
compound synthesized in our laboratory. This is only the second time that the 
excretion o f  this com pound has been reported. The glycine conjugates o f  adipic 
and sebacic acid were not detected in the urinary extract o f  this patient 
although the glycine conjugate o f  the m onocarboxylic acid, hexanoic acid, was 
present in significant amounts.
Other unusual com pounds detected as their methyl ester derivatives were the 
mono-unsaturated dicarboxylic acids, octenedioic and decenedioic, and the di­
unsaturated form  o f  decenedioic acid. These com pounds were identified using 
mass spectrometry by reference to the spectra published by Tanaka [7] and 
Lindstedt et al. [3 ]. The positions o f  the double bonds could not be deter­
mined from the mass spectra and were not determined by other methods. The 
appearance o f  the child ’s metabolic profile changed considerably with his 
clinical condition, so that the recovery from the attack and the regression o f
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Fig. 1. Gas chromatogram of the silylated urinary organic acids from M.E. at the time of the attack. Peaks 
were identified as follows: 1, 3-hydroxybutyric acid; 2, urea; 3, glutaric acid; 4, adipic acid; 5, suberic 
acid.
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Fig. 2. Gas chromatogram of the methylated urinary organic acids from M.E. at the time of the attack. 
Peaks were identified as follows: 1, 3-hydroxybutyric acid; 2, adipic acid; 3, 3-methyladipic acid; 
4, pimelic acid; 5, octenedioic acid; 6, suberic acid; 7, hexanoyl glycine + p-hydroxyphenylacetic acid; 
8, azeleic acid; 9, decenedioic acid; 10, sebacic acid; 11, hippuric acid; 12, unknown; 13, suberyl glycine.
the hepatogemaly were associated with a drop in the level o f  urinary adipic acid 
to the levels seen in normal children o f approximately 10 mmol/mol creatinine. 
The other unusual metabolites detected at the time o f the attack also either fell 
to normal levels or disappeared from the urine although significant amounts o f 
hexanoyl glycine remained.
The amounts o f  some o f these unusual metabolites detected in a urine 
sample taken at the time o f the attack and also in a clinically unaffected period 
are shown in Table I. It can be seen that, although the excretion o f adipic and 
suberic acids is within the normal range during the clinically unaffected period, 
there is a very marked increase in the excretion o f  these dicarboxylic acids with 
the onset o f  the attack. At this time, the quantity o f suberic acid excreted as 
the glycine conjugate accounted for approximately 35% o f the total suberic 
acid present in the urine. This is considerably lower than that found in the 
patient described by Gregersen et al. [6] where the percentage o f total suberic 
acid present as suberyl glycine ranged from 65 to 75%.
As well as the marked increase in the excretion o f the dicarboxylic acids, the 
monocarboxylic acids hexanoic and octanoic, when measured after acid hydro­
lysis, were also found to increase during the attack. However, the increase in 
the excretion o f  hexanoic acid was only slight.
Since all o f the unusual metabolites detected in the urine o f this patient 
appeared to be derived from fatty acids, we considered that this patient could 
have a defect in fatty acid metabolism. To test this hypothesis, a fasting study 
was performed to determine whether the excretion o f these unusual acids could 
be induced as a result o f  an increase in endogenous fat metabolism. The results 
of this fasting study are shown in Fig. 3. At the time o f  this fast the child was 8 
months o f  age. The graphs show that there is a marked increase in the urinary 
excretion o f adipic and suberic acids after approx. 10 h fasting. After approx. 
14 h o f fasting, the urinary adipic acid concentration had increased to more 
than 30 times the normal level and the suberic acid concentration to 12 times 
the normal level. The excretion o f suberyl glycine at this stage was also sig­
nificantly increased above normal.
Although adipic acid, suberic acid and suberyl glycine were the only metab-
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TABLEi
CONCENTRATIONS OF METABOLITES DETECTED IN THE URINE OF M.E. AT THE TIME OF 
THE ATTACK AND IN A CLINICALLY UNAFFECTED PERIOD
Compound Concentration (mmol/mol creatinine)
M.E. Normal children (n = 5)
Attack Unaffected Mean Range
Adipic acid 1747 6—8 6 2—11
Suberic acid 764 7—10 9 4—20
Suberyl glycine 429 <9 N.D.
Hexanoic acid * 182 166 N.D.
Octanoic acid * 216 5 N.D.
* Determined after acid hydrolysis.
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Fig. 3. The excretion of adipic acid, suberic acid and suberyl glycine in the urine of M.E. as a function of 
the time of fasting.
olites to be monitored quantitatively during the fast, all o f  the unusual metab­
olites present in the urine at the time o f  the attack were observed in the urine 
sample taken at the end o f the fast.
Five normal children (aged from 9 to 60 months) and one child diagnosed as 
having R eye’s syndrome (aged 45 months) were fasted under similar conditions 
and in each case, no increase in the excretion o f  dicarboxylic acids was 
observed. Two o f  these children (aged 9 and 36 months) were fasted for more 
than 30 h without raising the excretion o f either adipic or suberic acid above 
the normal level.
Sixteen months after the initial fasting study, the patient was again fasted 
and once again the urinary levels o f  dicarboxylic acids were markedly raised. 
On this occasion however, the increase in excretion did not commence until he 
had fasted for 17 h. This delay may reflect a decreased rate o f  lipolysis with 
age. These results suggest that the attack which caused the admission o f  this 
child to hospital may have resulted from an inability to fast for lengthy periods 
o f time, and we have therefore been reluctant to subject the patient to fasts o f 
prolonged duration.
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Since the discovery o f  the first patient with dicarboxylic aciduria, we have 
examined tw o other unrelated children with similar clinical histories whose 
urines at the time o f  admission were found to contain large amounts o f  adipic 
acid as well as the other unusual dicarboxylic acids found in the urine o f  the 
first child. Both o f  these children (aged 17 and 27 months) were found to 
excrete greatly increased amounts o f  adipic acid, and suberic acid on fasting.
Although the presence o f  saturated and unsaturated dicarboxylic acids and 
suberyl glycine characterise the metabolic profiles o f  these children, there was 
considerable variation in the relative amounts o f  the various com pounds 
detected in the urines o f  the three children as well as in urine samples taken at 
different times from  the same child.
Discussion
The biosynthesis o f  dicarboxylic acids via the co-oxidation o f fatty acids was 
first studied by Verkade et al. [8 ] and later by several groups o f  researchers 
[9 11]* Their results suggest that co-oxidation provides an alternative pathway 
for the oxidation o f  fatty acids. The end products o f  co-oxidation are short 
chain dicarboxylic acids, since the long chain dicarboxylic acids form ed by 
co-oxidation on the microsomes can be further degraded by the mitochondrial 
/3-oxidation system [1 2 ]. It seems likely therefore that the dicarboxylic acids 
observed in the urine o f  M.E. and the other two boys have arisen from fatty 
acids by a com bination o f  co- and /3-oxidation.
The relative importance o f  the co- and /3-oxidation pathways to the overall 
metabolism o f  fatty acids under a variety o f  conditions is not known. The 
results obtained by Antony et al. [13] suggest that in rat liver, /3-oxidation is 
the predominant pathway under normal conditions, however, experiments 
using branched-chain fatty acids [14] or enzyme inhibitors such as methylene 
cyclopropylacetyl-CoA , [7 ] have shown that co-oxidation may assume a major 
role when the /3-oxidation pathway is hindered. Thus there are a number o f 
conditions known where an increased excretion o f  dicarboxylic acids in the 
urine is associated with a disturbance in /3-oxidation [15 ,16 ].
Recently a number o f  reports have appeared in the literature concerning 
children who have been found to excrete large quantities o f  dicarboxylic acids 
as the major urinary organic acids. Przyrembel et al. [17] have described a child 
with glutaric aciduria type II whose urine contained large amounts o f  C6, C8 
and Cio dicarboxylic acids as well as greatly elevated levels o f  lactic (10.3 m ol/ 
mol creatinine) and glutaric acid (9.6 m ol/m ol creatinine). The presence o f  
branched-chain amino acid metabolites in the urine indicated a generalised 
defect in the activity o f  acyl-CoA dehydrogenases. Glutaric acid was often ob ­
served as a minor com ponent in the urinary GC profile o f  M.E. and the other 
two children, however the amounts present were well below the levels reported 
for glutaric aciduria type II.
Carnitine deficiency is known to  cause an increased excretion o f  adipic, 
pimelic and suberic acids as well as unsaturated dicarboxylic acids. Although 
there were significant differences between the metabolic profiles observed 
under normal dietary conditions for the three children and the patient with 
systemic carnitine deficiency described by Karpati et al. [1 5 ], carnitine
38
deficiency cannot be excluded as the cause o f the disease seen in these children.
The clinical pictures and the organic acid profiles observed in the three boys 
at the time o f  the attacks closely resemble those reported in patients suffering 
from Jamaican vomiting sickness, a disease produced by the ingestion o f  unripe 
akee fruit [16 ]. This fruit contains a toxic amino acid derivative, hypoglycin A. 
A metabolite o f  this amino acid, methylene cyclopropyl acetic acid inhibits the 
transport o f  fatty acids into mitochondria [18] and also inhibits the dehydro­
genation o f several acyl-CoA derivatives [19] leading to the disruption o f  fatty 
acid 0-oxidation and a massive urinary excretion o f adipic acid and other dicar- 
boxy lie acids.
A similar clinical case to that o f  M.E. has been described by Chalmers et al. 
[20] in identical twin boys following an sldenovirus infection. One boy died 
before admission to hospital but the other recovered rapidly after treatment 
; with intravenous glucose. Urine samples taken at the time o f the attack showed 
elevated levels o f  adipic and suberic acids, unsaturated dicar boxy lie acids and 
octanoic acid. The similarities between this disease and Jamaican vomiting sick­
ness were noted by the authors who suggested that the attacks may have 
resulted from the ingestion o f a toxic analogue o f hypoglycin A. In the case o f 
the three boys described in this report, the results obtained from the fasting 
experiments indicate that the disease in these children is caused by a deficiency 
in endogenous metabolism rather than the ingestion o f  a toxic compound.
Tanaka et al. [21] have reported a patient suspected o f having a deficiency 
o f green acyl-CoA dehydrogenase, the enzyme responsible for catalysing the 
dehydrogenation o f C4—Cs-CoA esters. This child excreted large amounts o f 
adipic acid, hexanoyl glycine and 2-ethylmalonic acid. In our patients adipic 
acid and hexanoyl glycine were elevated but 2-ethylmalonic was not detectable.
A patient who appears to have most features in com m on with the three chil­
dren presented in this report, is the boy described by Gregersen et al. [6 ]. This 
child was prone to episodes o f  lethargy and unconsciousness but responded 
rapidly to intravenous glucose. At the times o f these attacks, the urine was 
found to contain large quantities o f  dicarboxylic acids as well as suberyl gly­
cine, the metabolite present in the urine o f M.E.
The results o f  the fasting studies carried out on our patients indicate an 
inability to cope adequately with the flux o f fatty acids through the 0-oxida­
tion pathway at times when the body is dependent on fat as the source o f 
energy, and it would appear that periods o f prolonged fasting may have 
induced the attacks which were responsible for the admission o f these children 
to hospital. In support o f this view it is o f interest to note that the patient 
described by Gregersen et al. died suddenly following a 39-h fast for diagnostic 
purposes.
If these children do have a defect at the level o f  fatty acid oxidation, the 
appearance o f an almost normal GC profile under normal dietary conditions 
may be explained by the ‘fat-sparing’ effect o f  carbohydrates since, when ade­
quate carbohydrate is available, only minute quantities o f  fatty acids are 
oxidised to provide energy. Thus a deficiency in 0-oxidation may not become 
significant until the body becomes relient on fat for its energy requirements. 
Analysis o f the respiratory quotients [22] suggests that approx. 8—10 h after a 
meal, the body becomes dependent on fat as the source o f energy. This time
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period coincides with the increased urinary excretion o f dicarboxylic acids 
observed in the three children during fasting studies.
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The Identification of 3-Keto-2-methylvaleric 
Acid and 3-Hydroxy-2-methylvaleric Acid in a 
Patient with Propionic Acidemiaf
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Department of Chemistry, The University of Wollongong, Wollongong, NSW 2500, Australia
Judy H am m ond, Eric Haan and David M. Danks
Departments of Biochemistry and Pediatrics, Royal Children’s Hospital, Parkville, Victoria 3052, Australia
Two abnormal metabolites, 3-keto-2-methyIvaleric acid and 3-hydroxy-2-methylvaleric acid, have been 
identified and quantitated in the urine of a child with propionic acidemia. These metabolites may be produced as a 
result of the self-condensation of propionyl-CoA. Data are presented to show that the unusual ketone, 
3-pentanone, which has been observed previously in the urine of patients with propionic acidemia, is produced as 
a result of the decarboxylation of 3-keto-2-methylvaIeric acid.
IN T R O D U C T IO N
The investigation of children suspected of having an 
inborn error of metabolism, often involves a screening 
procedure for urinary organic acids, since the 
identification of abnormal organic acids can often pro­
vide valuable information about the site of an enzyme 
defect.1
Propionic acidemia is an inborn error of metabolism 
in which there is a defect in the activity of propionyl- 
CoA carboxylase (E.C.6.4.1.3).2 This defect in activity 
may result from a mutant propionyl-CoA carboxylase 
holoenzyme or from a deficiency in the utilization of 
biotin, the coenzyme involved in carboxylation. This 
disease is difficult to detect by the usual urinary screen­
ing procedures since the pattern of metabolites excreted 
by patients with propionic acidemia varies considerably. 
It appears, however, that a diagnosis can be made on the 
basis of the secondary metabolites, 3-hydroxypropionic 
acid and methylcitric acid, which appear in the urine 
even at times when the excretion of propionic acid is not 
greatly elevated.3
We now describe the identification of two previously 
unreported metabolites, 3-keto-2-methylvaleric acid 
and 3-hydroxy-2-methylvaleric acid, in the urine of a 
child with propionic acidemia. These two metabolites, 
both of which appear to result from the condensation of 
two propionyl-CoA molecules, may provide an addi­
tional means for the identification of propionic acidemia 
on the basis of secondary metabolites.
E X P E R IM E N T A L
Case history
The patient (Z.K.) was a newborn boy of half first cousin 
Turkish parents. Two sisters had died of unknown
t Abbreviation: DNP = dinitrophenyl hydrazone.
$ Author to whom correspondence should be addressed.
causes aged two days and two months in Turkey. A  
seven year old sister and four year old brother are 
normal.
Z.K. was born at term after a normal pregnancy, 
labour and delivery. Birth weight was 2.820 kg. The 
infant was initially fed a milk formula containing 2.8 g 
protein per 100 ml but he was noted to be unwell at 48 h, 
with depressed conscious state and acidotic breathing, 
and was said to smell ketotic. Mild jaundice was present. 
Laboratory investigation revealed a marked metabolic 
acidosis (pH 7.06, bicarbonate 4 mM L 1, pC 02 
14 mmHg and base excess —25) and the nitroprusside 
test of urine for ketones was strongly positive. 
Intravenous sodium bicarbonate was given.
The infant was transferred to the Royal Children’s 
Hospital at 60 h of life. Initial investigation confirmed 
the metabolic acidosis and demonstrated a plasma 
ammonia of 569/xMl \ High voltage electrophoresis 
showed elevated lysine and cystine in urine and elevated 
lysine and decreased alanine in serum. Thin layer 
chromatography (TLC) of urinary ketones, as the DNP 
derivatives, showed increased acetone, butanone and 
pentanone. The initial full blood count was normal, but 
later leucopenia (3.2 x 103 mm-3) and thrombocyto­
penia (1 5 x l0 3mm-3) appeared. Fibroblastic cell 
cultures are being established for assay of propionyl- 
CoA carboxylase acitivity.
Management consisted of intravenous 10% dextrose, 
peritoneal dialysis from 65 h of life, exchange trans­
fusions at 90 and l lOh of life, and megavitamin 
therapy including biotin 100 mg orally immediately 
after the second exchange transfusion. Rapid 
improvement in the infant’s clinical condition began 
around this time. Dietary protein was introduced and 
increased to 1.5 g kg-1 day-1 on the eleventh day of life. 
Biotin was continued at a dose of 10 mg daily. The 
impression of biotin responsiveness gained during the 
initial illness was to have been formally tested later, 
however a further metabolic crisis developed after two 
months of relatively good progress on biotin and protein 
restriction. Hyperammonemia (1700/xMl-1) and pro­
pionic acidemia proved uncontrollable and he died.
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3-KETO- AND 3-HYDROXY-2-METHYLVALERIC ACID
Methods
The concentrations of amino acids in serum were 
determined by ion-exchange chromatography4 using a 
Technicon TSM amino acid analyser. Serum propionic 
acid was measured by gas chromatography (GC) 
according to the method of Remesy and Demigne.5
In the routine screening procedure for urinary organic 
acids, NaCl (0.5 g) was added to 1 ml of urine, the pH 
adjusted to 10 with NaOH and the solution extracted 
with ethyl acetate ( 3x2  ml). This extract was discarded. 
The aqueous layer was then adjusted to pH 1 with HC1, 
and extracted twice with ethyl acetate (2x2  ml) and 
once with diethyl ether (1 x 2  ml). The pooled organic 
phases were evaporated to dryness with nitrogen at 
room temperature. The dried urinary extract was silyl- 
ated with 125 ¡i 1 of BSTFA containing 1% TMCS 
(60 °C, 30 min) and an aliquot corresponding to 40 nmol 
creatinine injected onto the GC column.
The separation and identification of urinary metabol­
ites was performed by gas chromatography mass spec­
trometry (GCMS) using a Varian MAT44 GCMS 
system in which a 25 m SE-54 (Jaeggi) wall-coated 
capillary column was directly coupled to the ion source 
of the mass spectrometer. For GC, a helium flow rate of 
2 ml min-1 was used, and during the analyses the 
temperature was programmed from 70-220 °C at 
4 °C min-1.
Electron impact (El) mass spectra were obtained 
using an ionizing voltage of 70 eV and an emission 
current of 0.8 mA. The ion source was maintained at 
200 °C, the transfer lines at 250 °C and the injection port 
of the gas chromatograph at 250 °C. The total ion cur­
rent was measured from mass 50 to 500 and was recor­
ded with 320 mV full scale.
Chemical ionization (Cl) mass spectra were 
obtained using isobutane at 45-50 Pa with an ionizing 
voltage of 160 eV and an emission current of 0.2 mA.
For the quantitation of urinary metabolites, adipic 
acid (50 ¿¿g) was added to a urine sample containing 
approximately 1 ¿¿mol creatinine and the solution made 
up to 1 ml with H20 . This solution was acidified to pH 1 
with 6 M HC1, saturated NaCl solution (1 ml) added, and 
the mixture extracted with diethyl ether (3x3  ml). The 
pooled ether extract was dried over M gS04, filtered, 
then evaporated at room temperature to a final volume 
of approximately 100 ¿¿1. N,0-bis-(trimethylsilyl)- 
trifluoracetamide (BSTFA) (50 ¿¿1) was then added and 
the extract silylated (60 °C, 30 min). The derivatives 
were analysed by GC on a 6 ft x gin column of 3% 
SE-30 on 80/100 mesh Gas Chrom Q (Applied Science 
Labs). Quantifipation of individual acids was achieved 
by measurement of the peak heights of each acid relative 
to the peak height of adipic acid and interpolating from a 
calibration curve. For compounds which ran as two 
peaks on the gas chromatograph, the combined peak 
heights were used for the calculations. When urine 
samples contained appreciable amounts of endogenous 
adipic acid, the results were corrected for this contribu­
tion.
For the measurement of urinary 3-pentanone, 100 ¿¿1 
of 4-heptanone solution (1 mg ml-1 in water) and 0.1 ml 
of saturated Na2C 0 3 solution were added to 4 ml of 
urine. This solution was extracted with pentane (0.5 ml) 
and an aliquot of the organic phase injected onto a 60 m
OV-17 SCOT column (Scientific Glass Engineering). 
After injection, the gas chromatograph oven tempera­
ture was maintained at 50 °C for 4 min then increased at 
3 °C min-  . Quantitation of 3-pentanone was achieved 
by measurement of the peak height of this ketone rela­
tive to the peak height of 4-heptanone and interpolating 
from a calibration curve.
Synthesis of 3-keto-2-methylvaleric acid and 
3-hydroxy-2-methylvaleric acid
The ethyl ester of 3-keto-2-methylvaleric acid was pre­
pared in 33% yield by the Claisen condensation6 of ethyl 
propionate (Fluka, Buchs, Switzerland). The distilled 
ester had a b.p. 110 °C at 27 mm (lit.6 88-90 °C at 
12 mm). The infrared spectrum of the purified ester 
showed two carbonyl bands at 1741 cm-1 (ester group) 
and 1717 cm-1 (keto group) and a band at 1191 cm-1 
(conjugated ester stretch). GCMS analysis of the 
product confirmed its identity.
3-Keto-2-methylvaleric acid was obtained from the 
ethyl ester by hydrolysis with 10% ethanolic potassium 
hydroxide at 4 °C. After the addition of water, the 
solution was extracted with ether and the extract dis­
carded. The aqueous layer was acidified and the free acid 
extracted into ether. GCMS analysis of the silyl deriva­
tive showed the presence of two peaks with almost 
identical El mass spectra ([M]+‘ = 274) having retention 
times on the SE-54 column of 8.4 and 9.7 min.
3-Hydroxy-2-methylvaleric acid was prepared by 
sodium borohydride reduction7 of 3-keto-2-methyl- 
valeric acid ethyl ester, followed by base hydrolysis. 
GCMS of the silyl derivative of the acid showed the 
presence of two peaks with m /z values of 276 (CIMS) 
and with almost identical El mass spectra having reten­
tion times of 7.2 min, and 7.5 min.
RESULTS
The organic acid profile of the child when first admitted 
with ketosis is shown in Fig. 1. At the time of admission 
the concentration of propionic acid in the serum was 
3.5 mM (normal = 1.29±0.52 /¿M)8 and the serum gly­
cine level was 356 /¿M which is within the normal range 
of 92-392 ¿¿M.8 The urinary organic acid profile was 
obtained by chromatographing the silylated acids on an 
SE-54 capillary column which we have previously shown 
to give excellent separation of these derivatives.9
The organic acid profile was dominated by a large 
peak of 3-hydroxybutyric acid and smaller peaks of 
lactic acid and acetoacetic acid. In addition to these 
metabolites, which are characteristic of ketosis, there 
were a number of other compounds present in the 
urinary extract which have been described as being 
elevated in propionic acidemia. Methylcitric acid and 
3-hydroxypropionic acid, metabolites which have been 
considered to be diagnostic of propionyl-CoA carboxy­
lase deficiency,3 were present as only minor components 
in this first urine sample, but the five-carbon acids 
3-ketovaleric, 3-hydroxyvaleric and 3-hydroxy-2- 
methylbutyric acid were major constituents of the 
chromatogram. These compounds were identified on the
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Figure 1. T h e  total ion current  profi le  from  t h e  SE -54  capil lary  c o lu m n  of  th e  s i ly la ted  urinary extract  f r o m  p a tie n t  Z.K. 
This u rine s a m p l e  w a s  taken  at th e  t im e  of  a d m is s io n ,  w h e n  th e  child  w a s  s e v e r e ly  ketotic.  T h e  n u m b e r e d  GC p e a k s  w e r e  
identif ied  by M S a s  fo l lo w s :  1, lactic acid; 2, 3 -h y d r o x y p r o p io n ic  acid; 3, 3 -h y d r o x y b u ty r ic  acid; 4, 3 -h y d r o x y -2 -  
m eth y lb u ty r ic  acid; 5, a c e to a c e t ic  acid  ( i s o m e r  1); 6, 3 -h y d r o x y v a le r ic  acid; 7, a c e t o a c e t i c  ac id  ( i s o m e r  2); 8 an d  9, 
3 -ke tova ler ic  acid; 10, 2 - m e t h y la c e t o a c e t ic  acid; 1 1 , 3 -k e to -2 -m e th y lv a le r ic  ac id; 1 2 , 3 -h y d r o x y -3 -m e th y lg lu ta r ic  acid; 13  
and  14, m ethylc itr ic  acid; 15, 4 -h y d r o x y p h e n y l la c t ic  acid. S S  =  s o l v e n t  s u p p r e s s io n .
basis of their mass spectra by reference to those shown 
by Sweetman et a l8 and Ando et al.
The extract of a urine sample taken on the following 
day when the ketosis had been controlled produced a 
very different GC trace (Fig. 2). At this time, the serum 
propionic acid concentration was 2 mM and the serum 
glycine 382 ^M.
The urinary profile on this occasion revealed large 
peaks of 3-hydroxypropionic acid, 3-hydroxy-2- 
methylbutyric and methylcitric acid. 3-Ketovaleric and 
3-hydroxyvaleric which were major components of the 
first urinary extract were barely detectable in the second 
urine. In contrast, two metabolites, 3-hydroxyisovaleric 
acid and propionyl glycine appeared which were not 
observed in the previous urinary extract. The glycine 
conjugate of propionic acid, which has been described 
previously in a patient with propionic acidemia by 
Rasmussen et al.,11 was identical on the basis of reten­
tion time and mass spectrum with a sample of the 
authentic compound synthesized in our laboratory.
In addition to these metabolites, two prominent peaks 
were present in the GC trace (peaks 8 and 13, Fig. 2) 
which could not be identified. A  Cl mass spectrum
showed that the compound in peak 13 had a molec­
ular weight of 274 as the silyl derivative, and the 
El mass spectrum displayed a prominent ion at m /z 245 
corresponding to a loss of 29 amu from the molecular 
ion, suggesting the presence of an ethyl group within the 
molecule. Comparison of the El mass spectrum with that 
of 3-ketovaleric acid showed that there was an increase 
of 14 amu in all of the major high mass fragments. This 
information allowed us to postulate that the unknown 
compound was 3-keto-2-methylvaleric acid.
The authentic compound was synthesized via a 
Claisen condensation reaction using ethyl propionate, 
and the silyl derivative was shown to be identical with 
that of the unknown urinary component on the basis of 
GC retention time and mass spectrum (Fig. 3). As 
expected, two peaks were obtained in the GC profile of 
the silyl derivatives of both the authentic and urinary 
3-keto-2-methylvaleric acid (peaks 11 and 13). 
Presumably these peaks are the disilyl cis- and trans- 
enol derivatives. With an increased time of derivatiza- 
tion, the earlier eluting peak was converted to the later 
peak which may correspond to the thermodynamically 
more stable trans-enol derivative.
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Figure 2. T he total ion current profile  from  th e  SE-54 capillary c o lu m n  of  the  si ly lated urinary extract from  patient  Z.K. 
This urine s a m p l e  w a s  taken  after th e  k e to s is  had b e e n  contro l led .  The n u m b e r e d  GC p eaks w e r e  identif ied by M S as  
fo l lo w s :  1, lactic acid; 2, 3 -h y d ro x y p ro p io n ic  acid; 3, 3-hydroxybutyr ic  acid; 4, 3 -hydroxy-2 -m ethy lbutyr ic  acid; 5, 
3 -h y d r o x y is o v a le r ic  acid; 6, 3 -hyd roxyva le r ic  acid; 7, a c e to a c e t ic  acid; 8 and 9, 3 -h y d roxy-2 -m eth y lva ler ic  acid; 10, 
3 -ke tova ler ic  acid; 11, 3 -k e to -2 -m eth y lva ler ic  acid ( i so m er  1); 12, 2 -m e th y la c e to a c e t ic  acid; 13, 3 -ke to-2-m ethylva ler ic  
acid  ( i s o m e r  2); 14, pro p io n y lg ly c in e ;  15, glutaric  acid; 16, adipic acid; 17, furan-2 -h ydroxym eth y l-5 -carb oxy l ic  acid; 18, 
2-hy d ro x y g lu ta r ic  acid; 19, 3 -hyd roxy-3 -m eth y lg lu tar ic  acid; 20, 4 -h y d r o x y p h e n y la c e t ic  acid; 21 and 22, methylcitric  
acid; 23, 4 -h y d r o x y p h e n y l la c t ic  acid; 24, palmit ic  acid.
The compound present in peak 8 of the urinary profile 
(Fig. 2) was shown to be 3-hydroxy-2-methylvaleric 
acid, the corresponding hydroxy acid of 3-keto-2- 
methylvaleric acid. This compound was synthesized by 
borohydride reduction of the authentic 3-keto-2- 
methylvaleric acid, and the silyl derivative was shown to 
have the same GC retention time and mass spectrum as 
the urinary component (Fig. 4). Once again, two GC 
peaks having almost identical mass spectra were 
obtained for both the authentic and the urinary 3- 
hydroxy-2-methylvaleric acid (peaks 8 and 9, Fig. 2). 
These two peaks presumably correspond to the disilyl 
derivatives of the two diastereoisomers of 3-hydroxy-2- 
methylvaleric acid. A  similar phenomenon was observed 
for methylcitrate where the silyl derivative was resolved 
into two peaks on the capillary column (peaks 21 and 
22). The absolute configurations of the two diaster­
eoisomers of methylcitrate excreted in a patient with 
propionic acidemia have been determined previously.
3-Keto-2-methylvaleric acid was found consistently 
in urine samples taken from the patient during his
illness. Since the most likely origin of 3-keto-2-methyl- 
valeric acid appeared to be a thiolase catalysed self­
condensation of propionyl-CoA, the urinary levels of 
3-keto-2-methylvaleric acid were monitored together 
with the serum levels of propionic acid to determine if 
the urinary excretion of this organic acid could be used 
as a useful indicator of the serum propionic acid concen­
tration.
The results of this study are shown in Fig. 5. It can be 
seen that the urinary excretion of 3-keto-2-methyl- 
valeric acid correlates well with the excretion of another 
propionate-derived metabolite, 3-hydroxypropionic 
acid. There seemed also to be a reasonable correlation 
between the excretion of these two urinary metabolites 
and the serum concentration of propionic acid from 90 h 
onwards; however, there was a marked deviation from 
this relationship in the samples taken at the time of 
admission. At this time, the child was severely ketotic.
In order to test whether 3-keto-2-methylvaleric acid 
or 3-hydroxy-2-methylvaleric acid had arisen artefac- 
tually from the self-condensation of propionic acid in
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Figure 4. (a) T h e  El m a s s  s p e c tr u m  o f  peak  8  f rom  t h e  GC profi le  
s h o w n  in Fig. 2. (b) T h e  El m a s s  s p e c tr u m  o f  t h e  s i ly la ted  
d e r iv a t iv e  o f  a u th e n t ic  3 -h y d r o x y -2 -m e th y lv a le r ic  acid .
Figure 5. (a) T h e  s e r u m  c o n c e n tr a t io n  o f  p r o p io n ic  ac id  ( ■ — ■ )  
c o m p a r e d  w ith  (b) th e  urinary c o n c e n t r a t io n s  o f  3 -h y d r o x y -  
p ro p io n ic  acid  (O— O) an d  3 -k e to -2 -m e th y lv a le r ic  ac id  ( • — • )  in 
p atien t  Z.K. during  th e  c o u r s e  o f  h is  t r e a tm e n t .
urine, propionic acid was added to normal urine to give a 
final concentration of 5 mM and the solution incubated 
at 37 °C for 22 h. Extraction and derivatization of the 
organic acids as described in the Experimental section 
failed to show the presence of either 3-keto-2-methyl- 
valeric acid or 3-hydroxy-2-methylvaleric acid.
The unusual ketone, 3-pentanone, has been identified 
as the DNP derivative in the urines of patients with 
propionic acidemia13 and methylmalonic acidemia,14 
although the mechanism of its formation has been 
unknown. The identification of 3-keto-2-methylvaleric 
acid in the urines of patients with these diseases promp­
ted us to explore the possibility that 3-pentanone could 
be derived from this /3-keto acid by decarboxylation.
In an initial experiment, several microlitres of 3-keto- 
2-methylvaleric acid was added to 2 ml of a saturated 
solution of 2,4-dinitrophenylhydrazine in 2 M HC1. The 
precipitate which formed was analysed by TLC, and was 
shown to be composed predominantly of a compound 
which co-chromatographed with the DNP derivative of 
authentic 3-pentanone. The structure of this compound, 
as 3-pentanone-DNP, was confirmed by direct insertion 
mass spectrometry. A  precipitate of 3-pentanone-DNP 
was also obtained when 1 ml of a saturated solution of 
dinitrophenylhydrazine in 2 M HC1 was added to an 
equal volume of urine containing 5 mM 3-keto-2- 
methylvaleric acid. Since this urine sample had been 
thoroughly extracted with pentane to remove 3- 
pentanone prior to the addition of the dinitrophenyl­
hydrazine, it seemed that the 3-pentanone-DNP must 
have been produced as a result of the decarboxylation of 
the keto acid or the keto acid-DNP derivative in acid
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solution. A  similar phenomenon was observed for 
urinary 2-methylacetoacetic acid, where a precipitate of 
2-butanone-DNP was obtained. The formation of 
acetone-DNP from solutions of acetoacetic acid has 
been described by Smith.15
To determine whether 3-pentanone could be formed 
by decarboxylation of urinary 3-keto-2-methylvaleric 
acid within the body, the keto acid was added to normal 
urine at a concentration of approximately 5 mM and the 
solution incubated at 37 °C. Samples were removed at 
various time intervals for the measurement of 3- 
pentanone and residual keto acid. The results are shown 
in Fig. 6 and demonstrate that 3-keto-2-methylvaleric 
acid is readily decarboxylated by standing in urine at 
37 °C.
Using solvent extraction with pentane, urine samples 
of Z.K. which had been shown to contain large amounts 
of 3-keto-2-methylvaleric acid were also found to 
contain corresponding large amounts of 3-pentanone 
(0.35 mol mol creatinine in the second urine sample, 
Fig. 5). The identity of this ketone as 3-pentanone and 
not 2-pentanone, a ketone which has also been 
described as being elevated in this disease,13 was 
confirmed by GCMS. In urine samples taken after 
treatment, when the concentrations of 3-keto-2- 
methylvaleric acid were low, 3-pentanone could not be 
detected by our method.
DISCUSSION
Although a large number of unusual metabolites have 
been described as being elevated in patients with pro­
pionic acidemia, there appears to be considerable vari-
Figure 6. T h e  urinary c o n c e n t r a t io n s  o f  3 - p e n t a n o n e  an d  3 -keto-  
2 -m e th y lv a le r ic  ac id  a s  a fu n c t io n  o f  t im e .  3 -K e to -2 -m e th y lv a le r ic  
acid w a s  a d d e d  to  a no rm a l  urine s a m p l e  to  g iv e  a r o u g h ly  5 m M  
so lu t io n  (pH 5.1) a n d  th e  s o lu t io n  in c u b a te d  at 37  °C. S e p a r a te  
a l iq u o ts  w e r e  r e m o v e d  at  v a r io u s  t i m e s  for  th e  d e te r m in a t io n  of  
k e to n e  an d  keto  acid  l e v e l s .  T h e  l in e s  d r a w n  r e p r e s e n t  t h e  l in es  of  
b e s t  fit d e t e r m in e d  b y  linear  r e g r e s s io n  a n a ly s i s .  T h e  h igh  initial 
level  o f  3 - p e n t a n o n e  re s u l te d  fr o m  th e  fact  that  th e  3 -keto-2-  
m e th y lv a le r ic  ac id  a d d e d  to  t h e  urine c o n t a in e d  a s ig n i f ica n t  
a m o u n t  o f  th is  k e t o n e  a s  a d e g r a d a t io n  p rod u ct .  3-K eto-2-  
m e th y iv a le r ic  ac id  (H— W ,  3 - p e n t a n o n e  ( #  ♦ ) .
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ability in the excretion pattern of these secondary 
metabolites. This factor can cause difficulties with the 
diagnosis of this disease even in those laboratories which 
have well established gas chromatographic screening 
procedures. Under conditions such as these, the 
identification of 3-keto-2-methylvaleric acid and 3- 
hydroxy-2-methylvaleric acid as major urinary 
components in our patient, may be a valuable aid in the 
future diagnosis of propionic acidemia on the basis of 
secondary metabolites. These two compounds do not 
appear to have been reported previously as components 
of human metabolism.
Both 3-keto-2-methylvaleric acid and 3-hydroxy-
2- methylvaleric acid have been detected in urine 
samples from the two patients with propionic acidemia 
which we have encountered. In addition, we have also 
detected low levels of these acids in patients with 
methylmalonic acidemia; however, neither the hydroxy 
acid nor the keto acid could be found in urine samples 
taken from normal controls.
It seems likely that 3-keto-2-methylvaleric acid arises 
by an enzyme catalysed self-condensation of propionyl- 
CoA in a reaction analogous to the formation of 
acetoacetate from acetyl-CoA. Several 3-ketoacyl-CoA 
thiolases are known which catalyse the general reaction 
involving the condensation of two molecules of thio­
esters to produce a 3-ketothioester with the release of a 
thioalcohol.16 Since 3-ketoacyl-CoA thiolases have 
been described in mammalian systems with broad sub­
strate specificities,17 it is conceivable that, under condi­
tions where propionyl-CoA is greatly elevated, one or 
more of these enzymes could form 3-keto-2-methyl- 
valeryl-CoA by the condensation of two molecules of 
propionyl-CoA. Enzymic reduction of the 3-keto-2- 
methylvaleryl-CoA, catalysed by 3-hydroxyacyl-CoA 
dehydrogenase (E.C.1.1.1.35) could then yield
3- hydroxy-2-methylvaleryl-CoA. Hydrolysis of the 
CoA esters of these two compounds would then produce 
3-keto-2-methylvaleric acid and 3-hydroxy-2-methyl- 
valeric acid.
The proposed modes of formation of 3-hydroxy-2- 
methylvaleric acid and 3-keto-2-methylvaleric acid in 
this patient could best be tested by administration of 
stable isotope labelled propionic acid or isoleucine 
followed by an examination of the labelling patterns in 
the two urinary acids. However, these loading studies 
were not achieved before the child died.
The excretion of urinary ketones in a patient with 
ketotic hyperglycinaemia and patients with ketosis due 
to starvation, diabetes or a high fat intake has been 
investigated by Menkes.13 The patient with hypergly­
cinaemia was found to excrete elevated amounts of two 
unusual ketones, 2-butanone and 3-pentanone. Tsao 
and Pfeiffer18 proposed that 2-butanone was formed 
through the spontaneous decarboxylation of 2-methyl­
acetoacetic acid. The origin of the 3-pentanone excreted 
in the urine of patients with propionic acidemia and 
methylmalonic acidemia has remained obscure, 
however, although Menkes postulated that this ketone 
could arise via the condensation of propionyl-CoA and 
methylmalonyl-CoA.13 In this paper we have demon­
strated that the 3-pentanone observed in the urine of 
patients with propionic acidemia and methylmalonic 
acidemia can arise from the decarboxylation of 3-keto- 
2-methylvaleric acid. This decarboxylation was shown
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to occur when the keto acid was incubated in normal 
urine at 37 °C and would presumably be faster in urines 
of lower pH. It is possible that some 3-pentanone may be 
produced enzymically from 3-keto-2-methylvaleric acid 
in a reaction analagous to the formation of acetone from 
acetoacetic acid, catalysed by acetoacetate decarboxy­
lase (E.C.4.1.1.4).19
The screening procedure for the presence of unusual 
ketones usually involves the addition of 2,4-dinitro- 
phenylhydrazine in 2 M HC1 to urine, and it was also 
demonstrated that 3-pentanone-DNP could arise 
directly from the breakdown of urinary 3-keto-2- 
methylvaleric acid during the course of the reaction. 
This decarboxylation should be taken into account when 
studying or quantitating urinary ketones as DNP 
derivatives.
An elevated concentration of glycine in plasma and 
urine has been described as being characteristic of pro­
pionic acidemia,8 but in our patient the serum and 
urinary levels of glycine at the time of admission were 
within the normal range. At this time the serum pro­
pionic acid concentration was 3.5 mM. Analysis of the 
urinary amino acids at this time did show increased 
amounts of cystine and lysine, however. These amino 
acids were also found to be elevated in the urines of 
three of the eight patients with propionic acidemia 
investigated by Duran etal.3 Two of these three patients 
did not show hyperglycinuria. Although neither hyper- 
glycinuria nor hyperglycinemia was present during the 
acute illness period in our patient, once the serum levels 
of propionic acid were controlled by treatment, both 
hyperglycinemia and hyperglycinuria appeared.
From an analysis of the GC profiles and the results of 
the quantitation of urinary metabolites in this patient, it 
would seem that under conditions where excess acetyl- 
CoA was available, there appeared to be a preferential 
condensation between propionyl-CoA and acetyl-CoA.
Thus, the major propionate-derived metabolites 
appearing in the urine when the child was ketotic were 
3-ketovaleric acid and 3-hydroxyvaleric acid. However, 
when the ketosis had been controlled, self-condensation 
to form 3-keto-2-methylvaleric acid, condensation with 
oxaloacetate to form methylcitric acid as well as oxida­
tion to produce 3-hydroxypropionic acid and conden­
sation with glycine, seemed to be the major routes of 
propionyl-CoA metabolism.
These observations may have important implications 
for screening laboratories since, under conditions where 
a child is ketotic, the major secondary metabolites 
to look for in cases of propionic acidemia may be 
3-ketovaleric acid and 3-hydroxyvaleric acid, where­
as in non-ketotic patients the diagnostic metabolites 
appear to be 3-hydroxypropionic acid and methylcitric 
acid. A  negative relationship between the excretion of 
3-hydroxybutyric acid and methylcitric acid was 
noted by Duran et al.3 in their study of patients with 
propionic acidemia.
It is interesting to speculate on the reasons why 3- 
keto-2-methylvaleric acid and 3-hydroxy-2-methyl- 
valeric acid have not been observed previously in other 
patients with propionic acidemia, but were major 
urinary metabolites in this patient. The reason for this 
may be related to the elevated serum levels of propionic 
acid seen in this child, even after control of the ketosis. 
This observation could perhaps indicate that these two 
metabolites, which apparently arise from the conden­
sation of two propionyl-CoA molecules, may be rela­
tively more prominent in patients who have very high 
serum levels of propionic acid.
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Methylmalonic acid (MMA) is a metabolite in the 
catabolic pathway of branched chain amino acids 
and of fatty acids with an odd number of carbon 
atoms (Fig. 1). Normal adults excrete less than 
5 mg/day of this acid in the urine. Excessive ex­
cretion of M M A  in urine (levels of up to 5000 mg/ 
day) can arise as a result of either vitamin B12  
deficiency (Pernicious Anaemia) or a defect in one 
of the enzymes involved in the degradative path­
way of MMA. Four inborn errors of metabolism 
leading to increased excretion of M M A  are known: 
a deficiency of the enzymes racemase or isomerase 
and two abnormalities of vitamin B12 meta­
bolism. Clinically, patients with increased M M A  
excretion present with protein intolerance, inter­
mittent keto acidosis and show inhibited growth 
and development. Patients with deficiencies in the 
racemase or isomerase enzyme activity generally 
die at an early age, but patients with defects of 
vitamin B 12 metabolism may respond to vitamin 
B 12 therapy. The frequency and size of the dose 
required for treatment varies with individual 
patients and may need adjustment in periods of 
metabolic stress. Since the therapeutic dose is not 
related to the measured serum concentration,2) 
the effectiveness of the treatment is best assessed 
by measurement of the daily urinary excretion of 
MMA.
Published methods for the quantitative deter­
mination of urinary M M A  rely on the use of thin 
layer3) or gas chromatography.4) However, the 
presence of other urine constituents with similar 
retention behaviour makes the analysis of small 
amounts of M M A  both difficult and unreliable.
To overcome these inherent difficulties we now 
describe an isotope dilution method using GC/MS 
with [2H]3-M M A as an internal standard. Quanti­
tative multiple-ion selection (M IS: Q U A N T IT A ­
T IVE ) was selected since this mode of operation 
allows precise intensity measurements of the 
specific ions involved and thus provides a sensitive 
method for determining the levels of excreted 
M M A  within the range of interest. Since the 
method is applicable to a large number of com­
pounds, we describe it in some detail, by way of 
example.
Isoleucine 
Methionine 
Threonine 
Fatty acids 
(odd chain)
X
PROPION Y L CoA
Valine
Thymine
Biotin Propionyl CoA 
aarboxyLase
d - M E T H Y L M A L O N Y L  C o A
d-Me thy Imalonyl 
CoA racemose
I - M E T H Y L M A L O N Y L  CoA
VITAMIN B12
5-Deoxyadenosyl
cobalamin
l-Me thyImalonyl 
CoA isomerase
S UCCI NYL  CoA
Citric acid cycle
Fig. 1 Major pathway of production and 
catabolism of methylmalonic acid
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In general, quantitative M IS  requires the prepara­
tion of a suitable derivative of the compound of 
interest as well as that of an appropriate internal 
standard. The validity of the method in a specific 
case is established by constructing a calibration 
curve using the intensities of relevant ions in­
volved. For monitoring complex mixtures quanti­
tative M IS  requires accurate and' reproducible 
retention times. To meet these requirements iso­
thermal oven conditions are desirable as this 
eliminates the need for time consuming column 
stabilization prior to each injection (Fig. 2).
For the T M S  — derivatives of M M A  we found an 
oven temperature of 95 °C to be satisfactory, 
since this gave good separation from the solvent 
and a relatively short retention time (Fig. 3). A s  
part of the process of establishing these parame­
ters, we obtained El spectra of both [2H]3 — 
M M A  and M M A  which determined those frag­
ments that retain the deuterium label (Fig. 4 and 
Fig. 4a).
P C  I B = b 84- M b T G C I  = 24-3 °C
P S O U  = 11 n b T  G C O  = 9 5 . 3 °c
C E L E  = 7 1  . 5 K> T  G C S  = 24-9 °c
C E M I  = 0 . 0 0 mA T G C L  = 2 5 6 °c
C S E M  = 2 0 . 1 V T  S O U  = 1 9 9 °c
n t i l  = 5 0 . 0 •u
M T  I H = 2 9 9 -u
T E f I L  = 9 5 . 0 °c
T  I ML = 0 . 0 0 rn
T  GR A = 0 . 0 0 9̂ rn
TEf1H = 9 5 . 0 °c
T  I MH = W . 0 0 m
T G C  I = 2 4-9
T  G U -b = 2 4-9 °c
T G C L  = 2 4-9
T  S O U  = 1 9 9 °c
m I m :j  = 1 . 0
Fig. 2 GC parameters entered in the M IS: 
Q U A N T IT A T IV E  programme to 
obtain isothermal conditions 
(95 °C) for a total period of 4 
minutes
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PSOU= 13 
C E L E = 7 0  
C E M 1=0. 
C SEM =17
ip . 8 M b TGO I == 2 5 6 . 2  °C
:. 3  9 n b T G C Ü == 9 5  . 3  9 °C
i . 1 P C T G C S  == 2  P 9 . 8 °C
5 6 7 mPl T G C L  == 2 5 5 . 8 °G
8 3  . V T S O U  == 2 0 8 . 3  °C
* T I 6 P
* S P 6 P
I T 2  Pr
# 1 5 1
GO 1 , 1 51
-m— —rh—I—i—y
250
Lf ir iA P L
C H , M , l.  , ••- :i ?
Fig. 4 El spectrum of the TMS-deriva- 
tive of [2 H]3 — MMA. Compari­
son with Fig. 4a shows retention 
of the deuterium label in frag­
ments m/e = 250 and 221
PC  IB  = 6 8 Lf . ¡2» .•u b T G C I = 2 5 0 . 2  °C
P S O U = 13 . 3 9 n b T GCO = 9 5 . 3 9  °C
C E L E  = 7 0 . 1 P C T G C S = 2 P 9 .8  °C
C E N  1 = 0 . 5 0 7 mA T G C L  = 2 5 5 . 8  °C
C S E M  = 17 8 3  . C T S O U  = 2 0 8 . 3  °C
* T  I *SP 
I T
6P  
6P  
2  Pi 
1 5 1
r-r-r' -H- t *r -3.6
Fig. 4a El spectrum of the TM S — deriva­
tive of unlabelled MMA.
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After determining the retention time, the meas­
uring time window defining parameters ST A R T  
and D U R A T IO N  (DUR) were entered to just 
cover the on-column time of MMA. The short 
duration time and the high resolving power of the 
W COT column ensured that no other interfering 
peaks were encountered within the measurement 
window. The same ions were also monitored prior 
to the elution of M M A  to allow adjustments for 
background noise contributions where necessary.
After entering the accurate mass values and GC  
parameters shown in Fig. 5, the programme was 
started by pressing " / "  on the keyboard and 
waiting till the message" R E A D Y  FOR S T A R T "  
appeared on the visual display unit. A  calibration 
sample was then injected and the space bar depres­
sed on the keyboard. The solvent was diverted for 
2 minutes, after which all of the eluent was taken 
into the mass spectrometer by activating the 
appropriate switch. Several El runs were also car­
ried out for both labelled and unlabelled M M A  in­
jected separately, to establish percentage cross 
contribution due to natural isotope abundances, 
and to calculate the purity of the synthesized in­
ternal standard. Results of a typical run are shown 
in Fig. 6.
PC I B= 684- m b TGC I = 250 °C
PSOU = 11 n b TGCO = 95.5 °C
VELE = 71 . 5 V TGCS = 24-9 °c
CEfl I = 0. 00 mA TGCL = 256 °c
VSEN = 21 . 5 V TSOU = 198 °c
QUANTITATIVE NULTI ION SELECTION
# NASS TINE START DUR REF
1 221.3 1.0 3.1 0.1 100.0
221.3 'T75-----373 0.6 100.0
2 218.3 1 . 0 3.1 0.1218.3 3.2 3.3 0.6
3 24-7.3 1 . 0 3.1 0.1
24-7.3 3.2 3.3 0.6
4- 250.3 1 . 0 3.1 0.1
250.3 3.2 3.3 0.6
- - - -
GC
Fig. 5 Parameters entered for El quanti­
tative M IS
PC I B= 684- 
PSOU= 1 3 . 3  
V EL E=  7 0 . 1  
C E N I = 0 . 6 0 9  
USEN= 1 7 8 0  
# N A S S
JJ b 
n b
V 
mA
V
T I N E
TGC I = 24-9 °C 
TGCO= 9 5 . 2  °C 
T GCS = 24-9 °C 
T GCL = 2 5 5  °C 
T SOU = 2 0 7  °C 
IN T E N S I  TV
1 2 1 8 . 3 3 . 6 1 . 5  1 0 0 . 0
2 2 2 1 . 3 3 . 6 1 8 7 . 9  224-4-. 8
3 24-7 .3 3 . 6 1 . 5  1 0 0 . 0
4- 2 5 0 . 3 3 . 6 2 3 2 . 9  4-94-. 4-
Fig. 6 Results for El quantitative M IS
of [2 H]3 — MMA. By averaging the 
results of five consecutive injec­
tions the following results for 
[2 H]s — M M A  were obtained.
(i) percentage peak height ratio 
218/221 = 0 .7 %
(ii) percentage peak height ratio 
247/250 = 0.6 %
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Optimum Cl conditions (i. e. PCIB = 468 jub) were 
then obtained for M M A  and [2H]3 -  M M A  using 
iso-butane as reagent gas (Fig. 7). Typical results 
are shown in Fig. 8. The values found were used in 
making appropriate adjustments in establishing a 
calibration curve for Cl conditions (Fig. 9).
Patient samples were run under the same condi­
tions as those used for calibration purposes, with 
the exception that, following the elution of MMA, 
other higher boiling components were removed 
from the column by a suitable setting of the oven 
temperature. Prior to the next run the programme 
was re-initialized automatically by typing " R N "  
and pressing the "R E T U R N "  key on the keyboard. 
A typical set of results for two patients' samples 
are shown in Fig. 10 to Fig. 13. The results show 
the close correspondence between values obtained 
by either Cl or El quantitative M IS  and allows 
double checking of values if the question of inter­
fering ions arises.
P C  I B = 4-68 * b T G C  I = 2 5 0 °c
P S O U =  0 . 0  nb T G C O  = 9 5 . 3 © |~*
V E L E  = 1 5 8  V T G C S  = 24-9 °c
C E N I =  0 . 0 0 m A T G C L  = 2 5 6 °c
V S E M  = 2 . 8 7  U T S O U  = 1 9 9 °c
Q U A N T I  T A T  I V E N U L T I  I O N S E L E C T I O N
#  N A S S T I N E S T A R T DUR R E F
1 2 6 6 . 3 1 0 3 . 1 0 . 1 1 0 0 . 0
2 6 6 . 3 — T 7 2
y - y
0 . 6 1 0 0 . 0
2  2 6 3 . 3 1 . 0 3 . 1 0 . 1
2 6 3 . 3 3 . 2 3 . 3 0 . 6
3  - - - -
4- - - - -
_ - - -
—
“
u c
Fig. 7 Table of values entered for Cl 
(isobutane) quantitative M IS
P C  I B = 6 6 M b T  G C I = 2 5 0  °C
P S O U  = 0 . 0 n b T  G C O  = 9 5 . 3  °C
V E L E  = 1 5 8 0 T  G C S  = 2 5 0  °C
C E N I  = 0 . 2  0 rn A T  G C L  = 2 5 5  °C
U S E N  = 1 7 8 0 0 T S O U  = 2 0 1  °C
#  MA c*o o T  I ME I N T E N S I  T V
1 2 6 3 . 3 3 . 1 0 . 3  1 0 0 . 0
2 6 3 . 3 3 . 6 1 3 3 9 . 7  1 0 0 . 0
2  2 6 6 . 3 3 . 1 0 . 1  3 3 . 3
2 6  6 yr, 3 . 6 1 7 . 6  1 . 3
Fig. 8 Data obtained for unlabelled
M M A  run in the Cl quantitative 
M IS  mode. The result shows that 
the contribution to m/e = 266 
from unlabelled M M A  must be 
taken into account particularly 
when monitoring high levels of 
M M A
5 -
PEAK
HEIGHT
RA TIO S
3­
2 ­
1-
Fig. 9
50 100 150 200 250 Mg MMA
Calibration curve for methyl-
malonic acid. Plot of peak height
ratios of M M A  against constant
amount of internal standard
(50 jug [2 H]3 -  MMA)
Key:
□ = m/e 218 versus 221
o = m/e 247 versus 250
a  = m/e 263 versus 266
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P C  I B = 4-77 A) b T G C I  = 2 5 0  °C
P S O U  = 0 . 0 0 n b T G C O  = 9 5 . 5  °C
<JELE = 1 5 3 Y T G C S  = 24-9 °C
C E N I  = 0 . 1 0 1 mA T G C L  = 2  5 6  °C
U S E M  = 1 7  9 0 Y T S O U  = 1 9 6  °C3.9
2 6 3 . 3
■*
2 6 6 . 3
G L-
Fig. 10 Real time visual display (in the 
Cl quantitative M IS  mode), of 
the ion-currents corresponding 
to indicated mass values
P C  I B = 6 8 4- ai b TG C  I = 2 5 0  °C
P S O U  = 1 3 n b T G C 0  = 9 5 . 3  °C
Y E L E  = 7 0 . 1 Y T G C S  = 2 4-9 °C
C E N I  = 0 . 6 0 m A T G C L 2 5 5  °C
Y S E N  = 1 7  9 0 Y T S O U  = 1 9 7  °C
3 . 8
2 5 0 . 3
i
2 4-7
.  1
2 1  8
JÊL
. 75
1
.  1
2 2 1 . 3
1 GC
Fig. 12 Real-time visual display record in 
the El quantitative M IS  mode 
of the silylated urine extract 2
URINE EXTRACT 1.
P C  I B =  4-71 A) b T G C I = 2 5 0 °c
P S O U =  0 . 0 0 n b T G C O  = 9 5 . 5 °C
Y É L E  = 1 5 8 y T G C S  = 24-9 OQ
C E N 1 = 0 . 1 0 1 m A T G C L =  2 5 6 ° c
Y S E N  = 1 7 8 0 y T S O U =  1 9 8 ° c
#  N A S S T I N E I N T E N S I T Y
1 2 6 6 . 3 3 . 1 0 . 0 0 . 0
2 6 6 . 3 3 . 6 4 - 2 3 . 0  1 0 0 . 0
2  2 6 3 . 3 3 . 1 0 . 0 0 . 0
2 6 3 . 3 3 . 6 51  . 9 1 2 . 2
URINE EXTRACT 2.
P C  I B =  4-77 A) b T G C  I = .2 50 °C
P S O U =  0 . 0 0 n b T GCO  = 9 5 . 3 °C
y E L E =  1 5 8 y T G C S  = 24-9 00
C E N I = 0 . 1 0 1 mA T G C L  = 2 5 5 °C
Y S E N  = 1 7 8 0 y T S O U  = 1 9 6 00
#  N A S S T I N E I N T E N S I T Y
1 2 6 6 . 3 3 . 1 0 . 0 0 . 0
2 6 6 . 3 3 . 6 2 3 5 . 2  1 0 0 . 0
2  2 6 3 . 3 3 . 1 0 . 1 0 . 0
2 6 3 . 3 3 . 6 2 7 7 . 2  1 1 7 . 8
Fig. 11 A  typical set of Cl results ob­
tained for different urine ex­
tracts. Since the internal stand­
ard (m/e = 266.3) is equivalent 
to 50 jug, the above percentage 
values give an immediate indi­
cation of the relative amount of 
M M A  present in the volume of 
urine extracted. The upper line 
shows that the background in­
tensities prior to elution of 
M M A  are negligible
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P C  I B =  684- M b T G C  I = 2 5 0  °C
P S O U =  ! 1 3 n b T G C O =  3 5 . 5  °C
V E L E  = 7 0 . 1 V T G C S =  24-9 °C
C E M I = 0 . 6 0 nriP T  G C L  = 2 5 6  °C
V S E M =  1 7 8 0 V T S O U =  1 9 8  °C
#  N A S S T I M E I N T E M S I  T V
1 2 2 1 . 3 3 . 1 0-.  2  1 0 0
2 2 1 . 3 3 . 6 9 0 . 5  10  0
2  2 1 8 . 3 3 . 1 0 . 1  5 0
2 1 8  ; 3 3 . 6 1 0 4- . 7  1 1 5
3  2 4 - 7 . 3 3 . 1 0 . 0  0
2 4 - 7 . 3 3 . 6 1 0 7 . 2  1 1 8
4- 2 5 0 . 3 3 . 1 0 . 1  50
2 5 0 . 3 3 . 6 9 6 . 5  10  6
Fig. 13 El quantitative M IS  results for 
urine extract 2. Notice the close 
correspondence obtained be­
tween these results and those 
obtained under Cl conditions 
(refer Fig. 11)
Results and Discussion
The calibration curves obtained by E I/M IS  and 
C I/M IS  were straight lines with correlation co­
efficients obtained by the least-squares method of 
>0 .99  in each case (Fig. 9). The urinary excre­
tion of M M A  as determined by M IS  from a methyl­
malonic aciduria patient on vitamin B 12 therapy 
is presented in table 1. On the basis of the de­
crease in the daily M M A  excretion, patient 1 was 
diagnosed as being responsive to vitamin B 12. The 
results obtained for patient 2 indicate a near 
normal M M A  excretion rate.
C I/M IS  E I/M IS E I/M IS
Using 263/266 Using 247/250 Using 218/221
Patient T ¡jlq MMA/m l mg/day jug MMA/m l mg/day ¡JLg MMA/m l mg/day
Before B12 
injection
894 500 967 541 945 529
Day 10 after 
1st injection 
of B12
428 152 455 161 482 171
Patient 2 4.4 5.7 5.3 6.9 3.2 4.2
Table 1 M M A  excretion of 2 M M A  patients on Vitamin B12 therapy
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Instrument: M A T  44 digital G C /M S system
GC conditions: Open-coupled 25 m, SE-54
(Jaeggi) W COT column, 
0.3 mm I D
He flow rate: 2 ml/min
Injection split ratio: 1:10 
Column temperature:
(i) Calibration samples: 95 °C Isothermal
(ii) Urine extracts: 95 °C Isothermal for 4 mi­
nutes, then 230 °C for 4 
minutes
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Paper speed: 1 cm/min
M S conditions:
Source: 200 °C
Emission: 0.8 mA (El)
0.2 mA (Cl) 
e Energy: 70eV (E I )  
150 eV (Cl)
Sample preparation:
A  solution of [2H]3-M M A in acetone (50pi, 
1 mg/ml) was added to urine (50-1000 pi). The 
solution was saturated with sodium bicarbonate, 
extracted twice with ethyl acetate (2 ml) and the 
organic phase discarded. The aqueous solution was 
then acidified to pH1 extracted three times with 
ethyl acetate (2 ml) and the combined extracts 
dried over Na2S 0 4. The ethyl acetate solution was 
then evaporated to dryness and the dry residue 
heated with bis (trimethylsilyl)trifluoroacetamide 
(BSTFA) (50 pi) at 65 °C for 30 min.
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Abstract of paper presented at the inaugural meeting of The Human
Genetics Society of Australia,Held at Monash University,August 1977
M E T H Y L M A L O N I C  A C I D A E M I A  : R A I S E D  U R I N A R Y  L E V E L S  
D U R I N G  P R E G N A N C Y  I N  A N  O B L I G A T E  H E T E R O Z Y G O T E  W I T H  N O R M A L  F O E T U S
ft, Wilr.kon find C. Pull in
Oliver Latham Laboratory, 
N.S.W. Ileal I h Comm I an Inn , Sydney
*Department of Chemistry, 
University of Wollongong, N.S.W.
Methylmalonic acidaemia can readily be diagnosed prenatally. It has been 
suggested that the finding of raised urinary and/or amniotic fluid 
methylmalonic acid (MMA) levels in a pregnancy at risk for methylmalonic 
acidaemia could be used as an indication for therapeutic abortion, without 
waiting for enzyme studies.
Methylmalonic acidaemia due to methylmalonyl Coenzyme A apomutase deficiency 
was diagnosed in sisters' aged 3 and 4*$ years. The parents undertook a 
further pregnancy find maternal urinary MMA levels were monitored.
Amu I or ml c m  I m wan prrfmmcd at 1 r> weeks,
Urinary MMA was 3. !■!!> mg/G creatinine fit 13 weeks (normal), find ranged up 
to 11.8 mg/day, 12.7 mg/G creatinine at 33 weeks of pregnancy.
Tin* l iVO' I ' l  I I I  n u l l  I I I I  11 I < I I I WOIIIOII W l ' I O  l l l l do i  4 n«)*,/ < I -» v .
Amnlollr colls studies performed hy Dr. M.J. Mahoney 111« I I«wi I u«l norms I 
propionate ami vitamin B ^  metabolism in the foetus. further studies 
performed post-natally confirmed this. Maternal urinary MMA levels was 
8.6 mg/day at day 6, and 3.5 mg/day at 10 weeks postpartum.
In this obligate heterozygote for MMA due to apomutase deficiency, 
increased urinary MMA levels occurred during pregnancy with a normal 
foetus.
Abstract of paper presented at the inaugural meeting of The Human
Genetics Society of Australia,held at Monash University August 1977.
2.34 pm
A D I P I C  A C I D U R I A  :
A  P O S S I B L E  N E W  IN B O R N  E R R O R  O F  F A T T Y  A C I D  M E T A B O L I S M
R. Truscott. C. Pullin, B. Halpern 
Wollongong University, N.S.W.
B. Wilcken
Oliver Latham Laboratory, Sydney, N.S.W.
M. Silink, H. Griffiths, H. Kilham 
Royal Alexandra Hospital, Sydney, N.S.W.
and
F. Grunseit
Prince of Wales Childrens Hospital, Sydney, N.S.W.
Adipic acid and other short chain dicarboxylic acids occur in normal 
urine in tiny quantities. Larger amounts are found during moderate to 
severe ketosis.
Three unrelated hoys wore admitted to hospital aged 6 - 1 4  months. All 
had a history of 2 - 4 days vomiting and were semi-comatose. There was 
gross hepatomegaly. Serum transaminases were moderately elevated; 
blood ammonia level was normal in two, and moderately raised in one.
In all there was easily correctable hypoglycaemia and metabolic acidosis; 
urine and plasma amino acids were normal. Gas liquid chromatography of 
urine confirmed by mass spectrometry revealed no ketones, but massive 
adipic aciduria, with up to 6000 yg adipic acid/mg creatinine. In all 
cases recovery was rapid, hepatomegaly regressed, and there was no 
interval adipic aciduria.
F a s t i n g  f o r  s i x t e e n  h o u r s  r e p r o d u c e d  a m a rk e d  a d i p i c  a c i d u r i a  i n  tw o  
c a s e s ,  a d i p i c  a c i d  b e i n g  e x c r e t e d  i n  i n c r e a s i n g  a m o u n ts  f ro m  e le v e n  
h o u r s ,  b u t  h a d  n o  e f f e c t  i n  tw o  c o n t r o l  c h i l d r e n .  *
A d i p i c  a c i d u r i a  may b e  c a u s e d  b y  a n  i n b o r n  e r r o r  o f  f a t t y  a c i d  m e t a b o lis m  
i n  t h e s e  p a t i e n t s ,  i n  o n e  o f  whom t h e r e  i s  a h i s t o r y  o f  d e a t h  i n  i n f a n c y  
o f  tw o  s i b l i n g s ,  f ro m  u n k n o w n  c a u s e .
'thAbstract of paper presented at the 17 Annual Conference of the 
Australian Association Of Clinical Biochemists,AMP Building,Adelaide 
November 1978.
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DICARBOXYLIC ACIDURIA: A POSSIBLE DEFECT 
IN FATTY ACID METABOLISM
C . J .  P u lli n , R .J.W . T r u sc o tt, and B. Halpem  
U n iv e rsity  o f  Wollongong. N .S.W . 2500 
B. Wilcken
. O liv e r  Latham Laboratory, SYDNEY. N .S.W . 2000 
M. S i l i n k , H. G r i f f i t h s  and H. Kilham
Royal Alexandra H o sp ita l, SYDNEY. N .S.W . 2000 
F . Grunseit
Prince o f  Wales C h ild re n 's  H o sp ita l, SYDNEY. N .S.W . 2000
In v e s tig a tio n s w ill  be described on three unrelated males 
aged 6 - 1 4  months who presented in a semi-comatose sta te  with a 
h isto r y  o f  2 - 4 days vom iting and d iarrhoea. The ch ild ren  were 
characterized  by an e a s ily  co rrectab le  hypoglycaemia, mild metab­
o l i c  a c id o sis  and gross hepatomegaly with normal serum tr a n s­
aminases and amino a c id s .
GC/MS o f  urinary acid  e x tr a c ts  revealed large amounts o f  
a d ip ic , suberic and sebacic a cid s together with suberyl g ly c in e .
Only small amounts o f  l a c t i c  and 3-hydroxybutyric acid  were 
p re se n t. The above d ia g n o stic  GC pattern was not present when the 
ch ild re n  were w ell but could be provoked by fa s t in g .
A ge n e tic  d e fe c t is  suggested by the in fa n t ile  death o f  
two s ib lin g s  o f  one p a tie n t follo w in g a s im ila r  p attern  o f  i l l n e s s .  
We suggest th a t these p a tie n ts  may have a d e fe ct in short chain  
acy l CoA decarboxylase which when fa t  i s  the major energy source, 
leads to  increased u>-oxidation o f f a t t y  a cid s and a consequent 
ex cre tio n  o f  d ic a r b o x y lic  a c id s .
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